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Will the neurotrophin hypothesis sparkle on, long after the glitter of the firework is gone? 
 
Leaving aside the details of the discovery of BDNF by Yves-Alain Barde and his colleagues (1982) (some call 
it heroic experimentation [Reichardt 2006] others a fortunate accident [Y-A Barde, personal 
communication, 2012]), it does have a great legacy. Among this legacy is the neurotrophin hypothesis, 
which states that pathological conditions such as depression (partly) are secondary to an altered expression 
of BDNF. The theoretical and clinical possibilities of this hypothesis loom(ed) large, yet numerous hurdles 
are on the path towards definite inferences from it. We are still learning and answers may only come with 
time, new data, and alternative interpretations of the data that already are out there. This is what I tried to 
do over the course of the past few years and here I present the results of this exercise. And, do the results 
favor a sparkling future for the neurotrophin hypothesis? Well, they don’t as the findings of this thesis 
(solid work over novelty) detail inconsistencies on many fronts and make me contemplate that: ‘all that 
glitters is not gold (William Shakespeare, 1596-1598) – it can be fireworks as well’. 
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A classic example of the notion that new cultures often start with great discoveries is the discovery of Nerve 
Growth Factor (NGF), in the 1950s by Rita Levi-Montalcini, Stanley Cohen and Viktor Hamburger. Follow-up 
experiments on NGF, mostly performed by two of its discoverers; Levi-Montalcini and Cohen, convincingly 
showed that the signaling of this hormone serves at least two important functions: (I) the specific survival 
of neurons from a larger set of neurons (pruning, selective apoptosis) and (II) the maintenance of neuronal 
connections (Cohen et al., 1954; Levi-Montalcini, 1966; Levi-Montalcini, 1987). With these discoveries Levi-
Montalcini and Stanley Cohen paved their way to a Nobel Prize (Physiology or Medicine, 1986) and, 
importantly, to the understanding of many disease states such as developmental malformations, dementia 
and their treatment (the Nobel Committee, 1986). 
     Soon after its discovery it became apparent that NGF is not unique in its crucial functions for neuronal 
survival and maintenance but rather that it is a member of a family of related molecules. Subsequently 
were discovered, in order of appearance, Brain-Derived Neurotrophic Factor (BDNF; Barde et al., 1982), 
Neurotrophin-3 (NT3; Maisonpiere et al., 1990) and Neurotrophin 4/5 (NT4/5; Berkenmeier et al., 1991), all 
molecules with similar functions, yet different types of target receptors. Although NGF to date remains the 
most studied neurotrophin (11,884 published papers of which 4,412 in the past ten years [PUBMED, August 
2013]), BDNF (11,751 published papers [only 133 less than on NGF] of which 8,478 in the past ten years 
[4,066 more than on NGF]) has become a strong competitor in terms of allocation of research efforts 
devoted to it. The two Benjamin’s of the family, NT3 and NT4/5, clearly lag behind, with to date a summed 
up total of 2,751 published papers (of which 1,178 in the past ten years). So, BDNF related research has 
been on the rise. This rise may possibly be due to several features that are unique for BDNF, for instance its 
activity dependent secretion and function as a key regulator of neuronal function.  
 
Brain-Derived Neurotrophic Factor 
BDNF is a small dimeric hormone that consists of 247 amino acids with a total molecular weight of 27.8 kDa 
(Hohn et al., 1990). Barde and colleagues (1982) were the ones to discover the existence of this hormone 
and to show its neurotrophic properties in cultured sensory neurons. The molecular structure of BDNF is 
highly similar to that of the other neurotrophins and has remained homologues over species (i.e., 
vertebrates, rodents, non-human primates, and humans) suggesting that BDNF has a long evolutionary 
history (Hallböök, 1999).  
     BDNF is encoded by a gene located on the short arm of chromosome 11 where it extends 70 Kb. The 
structure and functioning of the BDNF gene is complex as it consists of 9 exons and 11 promotor sites that 
all code for the same BDNF peptide variant (Liu et al., 2005; Greenberg et al., 2009). The transcription of 
BDNF is mainly initiated by neuronal activity and DNA methylation. Besides, there are a number of extrinsic 









for a review). Down-regulation of BDNF transcription occurs directly at the transcription site through 
antisense BDNF, which also is coded by the BDNF gene (Pruunsild et al., 2007). 
     Two variants of BDNF peptides exist, a pro-form (pro-BDNF) and a mature form (mature BDNF, hereafter 
referred to as BDNF). After transcription, pro-BDFN is wrapped, packed in vesicles and transported into the 
Golgi-system. These vesicles can be spontaneously released, but unique for pro-BDNF is that its release also 
occurs in a stimulus dependent manner. This feature has been coined activity dependent secretion (Egan et 
al., 2003). Activity dependent secretion is believed to be an important feature because it may reflect the 
nature of the nervous system to respond and to form synaptic modulations based on experiences. And this, 
as several authors have brought forward, may be a cellular manifestation of memory and learning (Katz and 
Schatz, 1996; Lu 2003). Pro-BDNF is secreted in the larger part of the central nervous system, including the 
hippocampus, the amygdala, and the cerebral cortex (Reichardt 2006). Intra-cellular, pro-BDNF is cleaved 
into mature BDNF by furin and pro-convertases proteases. In the extra-cellular space cleaving occurs by 
plasmin and matrix metalloprotease-9 (Lee et al., 2001; Teixeira et al., 2010). Pro-BDNF binds with high 
affinity to the p75 receptor and this has been associated with programmed cell death (i.e., apoptosis; 
Boulle et al., 2012; Park and Poo, 2013). So, pro-BDNF has biological significance beyond acting as a 
precursor for mature BDNF.  
     Mature BDNF is, just as pro-BDNF, expressed throughout the brain but highest concentrations can be 
found in the hippocampus and the frontal cortex, brain regions that are of crucial importance in the 
regulation of emotion, learning, and memory (Lindsay et al., 1994; Park and Poo, 2013). BDNF interacts 
with several receptor systems but has highest affinity with the Tyrosine kinase B receptor system (TrkB; 
Chao 2003). The binding of BDNF with TrkB results in intracellular phosphorylation and activation of 
intracellular signaling cascades that lead to the activation of so called pro-survival pathways, inactivation of 
pro-apoptotic signaling, and with neurogenesis (Ullrich and Schlessinger, 1990; Park and Poo, 2013). Figure 




     It is useful to note that the mature BDNF variant also has some affinity with the p75 receptor system, the 
receptor that binds pro-BDNF with high affinity. Just as the coupling of pro-BDNF with p75, the coupling of 
mature BDNF with p75 is associated with apoptosis (Boulle et al., 2012). So, depending on receptor type, 
BDNF may have seemingly opposing effects on neuronal cell survival and viability. This dissociation has 
been coined the Yin-Yang hypothesis of neurotrophic functioning (Lu et al., 2005). Notwithstanding this, 
BDNF is regarded to be the key factor for initiating neurogenesis (the birth of new neurons), neuronal 
Figure 1. Overview of the signaling cascades that follow 
TrkB activation: (I) P13K/AKT (regulates translation 
initiation and neuronal survival); (II) MAPK (CREB 
phosphorilation); (III) PLC-y (CREB phosphorilation).  
 
Abbreviations:  
BDNF, Brain-Derived Neurotrophic Factor 
Ca2+, calcium 
ER, Endoplasmatisch Reticulum 
CREB, CAMP Response Element Binding  
P13K, MAPK, Mitogen Activated Protein Kinase 
Phosphatidylinositol 3 Kinase 
PLC-, Phospholipase α C 
TrkB, Tyrosine kinase receptor B 
 
Adapted from: Green and Craddock (2005) and Nagahara 
and Tuszynski (2011). 
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survival (the selective survival from a larger set of neurons), and axonal outgrowth (Reichardt 2006). 
Furthermore, there is an association between BDNF activity and the prevention of apoptosis (i.e., Kubo et 
al., 1995; Li and Liu, 2010).  
     Some of BDNF’s functions are dependent on developmental stage. It is for instance known that BDNF 
induces and supports the birth of new neurons early in development (Nagahara and Tuszynski, 2011) 
whereas in adulthood, BDNF is mostly associated with shaping the process of synaptic plasticity (Autry and 
Monteggia, 2012). An interesting perspective has begun to link the basal processes of apoptosis and 
neuronal plasticity to complex behavioral phenomenon, such as depression.  
 
Major depressive disorder  
With a lifetime prevalence of about 15 percent in community samples, depression is a common clinical 
disorder (Kessler et al., 2003). According to the World Health Organization (WHO 2004, 2008), depression is 
one of the leading causes of disease burden worldwide. Given its high prevalence and the large number of 
adverse personal and social consequences, depressive disorders bring enormous societal and economical 
costs (Greenberg et al., 1990; WHO 2008). Beyond this, the presence of depressive symptoms complicates 
the treatment of (other) chronic illnesses such as diabetes and it is, due to a related unhealthy life-style 
(e.g., a poor diet, smoking) and relatively high rates of completed suicides, strongly associated with poor 
general health and morbidity (Harris and Barraclough, 1998; Harris et al., 2006). Adding to the adverse 
consequences of being depressed is that the illness frequently co-occurs (and/or shares overlapping 
symptoms) with personality pathology and substance use- and anxiety disorders (Kessler et al., 2003, 2008; 
Kan et al., 2005). Box 1 ↓ lists the criteria that should be met to receive a diagnosis of a major depression.  
 
BOX I. The diagnostic criteria for a depressive episode as they are stated in the DSM-IV TR (APA 1994) 
A. Depression may be diagnosed if five (or more) of the following symptoms have been present during the same 2-week 
period and represent a change from previous functioning; at least one of the symptoms is either (I) or (II) 
I Depressed mood most of the day, nearly every day, as indicated by either subjective report (e.g., feels sad or 
empty) or observation made by others. Note: In children and adolescents, this can be irritable mood   
II Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as 
indicated by either subjective account or observation made by others) 
III Significant weight loss when not dieting or weight gain (e.g., a change of more than 5% of body weight in a 
month), or decrease or increase in appetite nearly every day   
IV Insomnia or hypersomnia nearly every day 
V Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of 
restlessness or being slowed down) 
VI Fatigue or loss of energy nearly every day 
VII Feelings of worthlessness or excessive or inappropriate guilt nearly every day (not merely self-reproach or guilt 
about being sick) 
IIX Diminished ability to think or concentrate, or indecisiveness, nearly every day 
IX Recurrent thoughts of death, or a suicide attempt or a specific plan for committing suicide 
B.  The symptoms do not meet criteria for manic features in the presence or the past 
C.  The symptoms cause clinically significant distress or impairment in important areas of functioning 
D. The symptoms are not due to the direct physiological effects of a substance or a general medical condition  
E.  The symptoms are not accounted for by bereavement and persist for longer than 2 weeks 
F.  The symptoms are not due to mood-incongruent delusions or hallucinations 
 
     The diagnostic criteria for major depression are set forth in the Diagnostic and Statistical Manual version 
IV Text Revised (DSM-IV TR 1994) of the American Psychiatric Association (APA). The core criteria for a 
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diagnosis of depression are having a depressed mood most of the day and a markedly diminished interest in 
almost all activities persisting for longer than two weeks. A diagnosis of depression can be established if an 
individual meets at least five of nine pre-specified symptoms. The indication of whether a symptom is 
present is provided verbally by the patient or, in some instances, by the impression of the clinician. The 
symptoms that make up the illness major depression are descriptive and by no means are meant to provide 
an etiological model of the illness. This is largely so because the exact etiology of depression is unknown, 
although it is generally acknowledged that genetic predisposition and stress exposure play an immensely 
important role in it (APA 1994; Kendler 2012). One of the major aims of current psychiatric research is to go 
beyond mere description and move to a hard medical model, that is, a model that takes the etiological 
mechanisms of the illness into account (Kendler 2012). 
     The most common treatments for depression include pharmacological treatments (e.g., antidepressants 
such as selective serotonin reuptake inhibitors), psychological therapies (e.g., cognitive behavioral therapy), 
and many alternatives such as running therapy, electric shock treatment, sleep deprivation, and treatment 
with bright light. All these treatments are at best modestly effective in alleviating the symptoms of 
depression as only about half of the patients respond well to them (Mann 2005). This, the modest efficacy, 
is partly the result of an incomplete knowledge on the exact mechanisms on which treatment should focus. 
The relatively poor treatment outcome, together with the high prevalence, high burden and economical 
and social impact, make that the pathophysiology of depression needs to be understood much more 
clearly. Research on this topic hence deserves a high level of priority.  
      Current research into the etiology, treatment, and prevention of depression encompasses a great deal 
of approaches (cognitive, psychodynamic, interpersonal, genetic, genomic, proteomic and combinations). 
Since the 1980s however, theories crafted on biology- are dominant in providing answers with regard the 
forthcoming and the treatment of this illness. Although the pathophysiology of depression can be stratified 
over several biological domains (see Penninx et al. [2013] for a recent review), the two most prevailing 
paradigms are the monoamine deficiency- and the neurotoxicity/stress hypothesis. These hypotheses sketch 
a picture of altered brain function due to mostly monoamine dynamics, stress and genetic predispositions 
that together affect brain functioning in such a manner that depression may emerge. Such an approach 
may appear reductionistic in understanding a complex medical/psychological phenomenon as depression, 
yet they explain some key clinical observations with regard to it.  
     The monoamine deficiency hypothesis, in its original form put forth by Joseph Schildkraut in 1965, 
sketches a neuroanatomical basis for depression in the form of a deficiency in the expression of serotonin 
and noradrenaline in the brain (Hirschfeld 2000; Bunny and Davis, 1965). This hypothesis has been, without 
doubt, very useful. For instance, it served as benchmark for the discovery of antidepressant agents such as 
selective serotonin reuptake inhibitors that increase the availability of monoamines in the brain (Mann 
2005). The theme of this hypothesis is elaborated in revised versions in which environmental events such as 
stress also are attributed to play an important role in illness initiation (e.g., Henninger et al., 1996; Caspi et 
al., 2003).  
     Stress exposure forms the point of departure of the neurotoxicity/stress hypothesis. It suggests that 
stress is translated into biological process in which the illness origin of depression is embedded (Sapolsky 
1990, 1996, de Kloet et al., 1998). Indeed, stress exposure, particularly early in life, has a substantial 
association with depression onset (Sapolsky 1996; Charney 2004; Spinhoven et al., 2010; Bogdan and Hariri, 
2012). Stress is perceived in the brain where the hypothalamus reacts with the release of corticotrophin 
releasing hormone. Corticotrophin releasing hormone is projected on pituitary receptors that respond with 
the secretion of adrenocorticotrophin hormone. This, in turn stimulates the adrenal cortex to produce 
cortisol (Pariante and Miller, 2001). Cortisol expression has a range of short- and long-term effects on the 
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body (e.g., sweating) and the brain (e.g., high vigilance). Hyperactivation of this so-called hypothalamic-
pituitary-adrenal axis is a consistent neurobiological abnormality in traumatized and depressed persons 
(Pariante and Miller, 2001) and not without effect, as structural brain damage may be a long-term 
cumulative effect of it (Videbech and Ravnkilde, 2004; van Harmelen et al., 2010; Kang et al., 2012). 
     Both the monoamine deficiency- and the neurotoxicity hypothesis received considerable support but 
they remain inadequate in some regards. For instance, the monoamine deficiency hypothesis has particular 
difficulties in explaining why it takes a number of weeks before the clinical efficacy of antidepressants kicks 
in and why in the larger part of persons (except maybe patients with a depressive disorder in the remission 
phase) a depletion of serotonin in the brain does not seem to produce depressive symptoms (Hirschfeld 
2000; Lacasse and Leo, 2005). Furthermore, some clinically efficacious antidepressants (e.g., tianeptine) 
actually are serotonin reuptake enhancers that, after ingestion, rapidly decrease the availability of 
serotonin in the synaptic cleft (Brink et al., 2006). The neurotoxicity hypothesis also has some weaknesses. 
For instance, according to the theory, a down-regulation of corticotrophin releasing hormone should show 
antidepressant properties, but it does not (Mann 2005). A particular convolution for the theory further is 
that many persons experience depression without being exposed to (psychosocial) trauma or severe stress.  
     So, few would dispute that there is the urgency to move beyond these two models if one wishes to 
understand depression more fully. The neurotrophin hypothesis is believed to be such a step ahead. In the 
section that follows I will introduce the principles of this hypothesis and show (explain) why it has become a 
prevailing model of depression. 
 
The neurotrophin hypothesis of depression 
The first hints that led to the formulation of the neurotrophin hypothesis of depression came, as they often 
do, from studies on rodents. Based on the functions of BDNF, Smith and colleagues (1995) hypothesized 
that impairment in the expression of this hormone could lead to depressive-like behavior in rats. Indeed, 
these authors found this to be the case. Siuciak and colleagues (1996) in turn tested, also in rats, whether 
increasing BDNF expression in the brain could produce an antidepressant-like effect. Also these authors 
could confirm their hypothesis. Duman, Heninger and Nestler linked these findings to everyday clinical 
practice and to the monoamine deficiency- and the neurotoxicity hypothesis. This led, back in 1997, to the 
formulation of what has become known as the neurotrophin hypothesis of depression.  
     The rational for the neurotrophin hypothesis of depression is quite straightforward: BDNF expression, 
that is supposed to be shaped by genetic and environmental influences, can determine neuronal faith and 
viability and subsequently behavior, including depressive like behaviors, learning, and memory (Duman and 
Monteggia, 2006). The two basal predictions from this hypothesis are that depression results from a stress-
induced decrease in BDNF expression and that antidepressants are efficacious because they normalize this 





The neurotrophin hypothesis: pre-clinical evidence 
The strongest evidence for involvement of the neurotrophic system in depression comes from animal 
studies. In a groundbreaking experiment, Malberg et al. (2000) showed that antidepressants increase 
adult hippocampal neurogenesis, a process that is under the direct influence of BDNF (Reichardt 2006). 
Similarly important was the finding by Santarelli et al. (2003) showing that if neurogenesis is blocked, 
the behavioral effects of antidepressants do not become evident. Here it should be noted that, only 
recently, compelling evidence has shown that substantial neurogenesis occurs throughout life in the 
adult human hippocampus (Spalding et al., 2013). Together, these observations led to the belief that 
antidepressants are effective by virtue of a second messenger system (Dranovsky and Hen, 2006). This, 
the involvement of a second messenger system could in theory also explain the latency of weeks 
before the clinical efficacy of antidepressant treatment becomes evident (Rush et al., 2006). 
Subsequent experiments could largely confirm the existence of such a system and it constituted, 
among others, out of BDNF expression (Zhao et al., 2008). In a similar manner, BDNF is assumed to 
play a mediating role in stress-induced hippocampal atrophy (Hoshaw et al., 2005; Kang et al., 2012). 
In line with this are pre-clinical studies that have shown that stress reduces the expression of BDNF 
mRNA (e.g., Prickaerts et al., 2006) and clinical findings that show that cortisol expression is 
abnormally high in severely depressed persons (Anacker et al., 2011).  
     Together these findings seem to suggest a common mechanism on depression initiation, 
progression, and treatment efficacy that goes beyond the neurotransmitter and receptor level. This 
mechanism is synaptic plasticity; the ability of neurons to connect or disconnect as a function of use or 
disuse (Park and Poo, 2013).  
 
The neurotrophin hypothesis: clinical studies 
A seminal advance for the neurotrophin hypothesis came from two studies on human subjects that 
were published in 2002 and 2003. Karege and colleagues (2002) were the first to show that serum 
BDNF concentrations are lower in depressed persons as compared to healthy control subjects. These 
authors further found that, within the group of depressed patients, serum BDNF concentrations were 
lower in the more severely depressed persons. A year later, Shimuzu et al. (2003) had a prime by 
showing an increase in serum BDNF concentrations in the course of antidepressant treatment. These 
findings that were thought of as being peripheral manifestations of the neurotrophic hypothesis 
greatly spurred the research activity on these topics. Replication attempts were subsequently 
published which served as input for two meta-analyses (Brunnoni et al. 2008; Sen et al. 2008). These 
Figure 2. A schematic representation of 
the neurotrophin hypothesis  
 
Abbreviations:  
BDNF, Brain-Derived Neurotrophic 
Factor 
TrkB, Tyrosine kinase B 
 





confirmed low serum BDNF concentrations in untreated depressed patients and normalization of this 
by antidepressant treatment.  
     In first stance, findings of abnormally low serum BDNF concentrations in depressed persons and 
normalization of this in the course of antidepressant treatment are seemingly important because they 
may help to parse out the pathophysiology of depression. In addition, a biological abnormality that is 
consistently reported and that is believed to be of relatively large effect-size may also be of value in 
clinical practice as a biomarker (i.e., an objective [non-invasive] parameter that may aid in the 
classification of a diagnostic condition or in the assessment of treatment efficacy). As mentioned 
above, depressive disorders are diagnosed based on subjective verbal assessments without any 
referent to underlying pathophysiology (APA 1994). This may come with disadvantages in that such 
assessments may be inaccurate and colored by the state a patient is in or by the clinical impression of 
the patient by the therapist. A biomarker may in such instance be of help, as based on the score on it, 
a large and heterozygous group can be stratified in homogenous subgroups with as advantage that 
patients can be assigned to treatment options that best fit their needs (Kapur et al., 2012).  
     An important question with regard to the above-presented findings relates to the sources of serum 
BDNF concentrations. A related question is whether peripheral differences in serum BDNF 
concentrations imply that there also are differences in the brain. Despite its name, BDNF is not solely 
derived from the brain. Other tissues, including several types of immune-, liver-, smooth muscle-, and 
vascular endothelial cells also serve as sources of BDNF (Cassiman et al., 2001). Nonetheless, there are 
indications that BDNF measured in peripheral tissues reflects BDNF activity in the brain. These 
indications include pre-clinical findings that BDNF crosses the blood-brain barrier (Pan et al., 1998) and 
positive correlations between peripheral and central BDNF concentrations (Klein et al., 2010). The 
human data on this topic is, unfortunately, limited to only one study. In this particular study, blood was 
simultaneously derived from high up the jugular veins and from arterial veins, showing that BDNF 
levels were higher in blood that was derived from the internal jugular veins as compared to arterial 
blood (Dawood et al., 2007). This indeed suggests that the source of BDNF in peripheral tissues can be 
found in the brain. For these reasons, it seems that neurotrophic functioning can be estimated from 
the periphery in a rather non-invasive manner. Corroborating this are human post-mortem studies 
that have indicated similar alternations in BDNF concentrations in the brains of persons who were 
depressed at the time of dying (e.g., Thompson Ray et al., 2011). Therefore, and given that for 
practical and ethical reasons data on central BDNF parameters is very hard to acquire, there is a great 
interest in peripheral BDNF measures in relation to depression and related phenotypes. 
     Besides the research on peripheral BDNF concentrations, other studies started to explore 
associations between variation on the gene that codes for BDNF and depression-related phenotypes. 
In the section that follows I will highlight some key studies that used this approach.  
 
The BDNF gene, depression and related phenotypes 
Of the 67,166 base pairs that make up the DNA sequence of the BDNF gene, one base pair clearly 
stands out with regard to the research attention that it received. This variant, known as BDNF val66met 
(rs6265), refers to a locus where adenine and guanine vary resulting in a valine to methionine insertion 
at codon 66 (Egan et al., 2003). This polymorphism comes in 3 variants: val homozygotes (val/val), 
heterozygotes (val/met), or met homozygotes (met/met; Petryshen et al., 2010). In a groundbreaking 
study, Egan and colleagues (2003) showed, in vitro, that the met allele is linked to a reduced activity-
dependent expression of BDNF in hippocampal neurons of rats. This finding has been replicated, in 
vivo, by Chen and colleagues (2006) and was further validated through animal studies using molecular 
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techniques such as knockout methods (Chourbaji et al., 2004; Pandey et al., 2008). Taking into mind 
the functions of BDNF, this finding of a functional variant on the BDNF gene sparked the interest of a 
lot of scientists, yielding a large output that I will summarize below. 
     In rodents it has been shown that the met variant at the val66met locus is associated with aberrant 
dendritic spine formation in the hippocampus, which according to the neurotrophin and the 
neurotoxicity hypotheses constitutes a correlate or risk factor for depression (Spencer et al., 2010). In 
line with this are recent findings by Bath and colleagues (2012) showing, in pre-clinical models, that 
the presence of a met allele is associated with greater anxiety- and depressive–like behavior. Some of 
these findings have been confirmed using data on human subjects. Highly relevant for the 
neurotrophin hypothesis were the findings of statistically significant associations between carrying a 
met allele and higher scores on depressive related traits (Montag et al., 2008; Beevers et al., 2009) and 
the DSM diagnosis of depression (Licinio et al., 2009; Lavebratt et al., 2010). Imaging studies have also 
provided evidence that is consistent with the neurotrophin hypothesis. Take for instance the findings 
by Pezawas et al. (2003) and Szeszsko et al. (2004) showing that carriers of a met allele have smaller 
hippocampal volumes (a phenotype associated with depression; MacQueen and Frodl, 2011; Spalding 
et al., 2013) as compared to persons who are homozygous for the val allele. Besides, some studies 
have shown that carriers of a met allele do worse on tasks measuring cognitive performance (e.g., 
Egan et al., 2003). Finally, some studies have reported that the met variant is associated with lower 
peripheral BDNF concentrations (e.g., Lang et al., 2009; Ozan et al., 2010). Based on the above (i.e., 
functionality, associations with behavior and neuroanatomy), BDNF val66met has become a very 
influential model to study neurotrophic functioning in a relatively non-invasive manner.  
 
The neurotrophin hypothesis – not all that glitters is gold 
As sketched above, the literature provides support for the notion that neurotrophic functioning may 
be at the heart of depression and related conditions such as anxiety. In addition, the literature largely 
is positive on (or at least gives ground for) the use of peripheral measures (notably serum BDNF 
concentrations) and certain genetic variants (notably BDNF val66met) as parameters or proxies for 
neurotrophic functioning in the brain. For an overview of the breakthroughs in the research into the 
neurotrofin hypothesis I refer to the timeline in Appendix I. 
     Despite the marvel of findings that seem to have successfully related these proxies to behavior and 
processes that are associated with neurotrophic functioning, there however also are is uncertainty 
regarding the predictions of the neurotrophin hypothesis. Two main sources of this uncertainty are: (I) 
a lack of knowledge on the basic determinants of serum BDNF concentrations and (II) unanswered 
clinical questions regarding the neurotrophin hypothesis. In this thesis I will address these issues and 
so try to provide a more refined model of (peripheral) neurotrophic functioning in in depressive (and 
related) disorders. 
 
Unexplored areas:  the basal determinants of serum BDNF concentrations  
One source of uncertainty regarding the predictions of the neurotrophin hypothesis is that next to 
nothing is known on the basal determinants/potential confounders of serum BDNF concentrations. We 
live in an associational world where phenomena cluster together. Because of this, characteristics (for 
instance behaviors or biochemical indices) may have a shared relation with a certain outcome without 
being genuinely associated to the outcome by itself (Smith and Ebrahimm, 2002). This has been coined 
as confounding; a phenomenon that complicates the interpretation of research findings and that easily 
can lead to erroneous inferences from the data and hitherto discordant facts. One solution in 
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minimizing the effects of confounding is to specify determinants because only then the opportunity 
arises to study independent associations. The first part of the prevailing thesis specifies the 
determinants of serum BDNF concentrations. 
 
Unanswered clinical questions regarding the neurotrophin hypothesis 
Another source of uncertainty is that some important clinical questions that are relevant in assessing 
the (construct and predictive) validity of the neurotrophin hypothesis remain unanswered. These 
questions include: (I) whether low BDNF concentrations persist beyond the clinical state of depression, 
(II) whether BDNF serum concentrations are related to the clinical characteristics of depression, such 
as its severity, (III) whether all types of antidepressants are equally associated with an upregulation of 
serum BDNF concentrations, and (IV) whether serum BDNF concentrations are also abnormally low in 
patients with an anxiety disorder. Here, I will try to answer these outstanding questions.  
     Furthermore, because the prominent role of stress and trauma exposure in the neurotrophin 
hypothesis and the etiology of depression, these factors need to be adequately explicated in BDNF 
related research, for instance by testing cross-term interaction effects among BDNF val66met and 
trauma exposure on outcomes of interest (e.g., hippocampal volume). To date, few studies have 
actually done this whilst it has been shown that such an approach can yield insight that otherwise 
would have remained hidden (see for instance Gatt et al., 2009).  
 
The purpose of this thesis  
With the above in mind we set out to outline the basal determinants of serum BDNF concentrations 
and to resolve some important clinical questions regarding the neurotrophin hypothesis.  
     A notable add-on of the current work is that is that in order to achieve reliable effect-size estimates 
on associations of interest this thesis will use well-powered single studies and meta-analyses. This is 
important because findings related to the neurotrophin hypothesis are not consistently replicated. In 
fact, for basically all evidence in favor of the neurotrophin hypothesis, null and even opposite findings 
have been reported (e.g., Elfving et al. [2012] for the finding that serum BDNF concentrations are low 
in depressed persons; Deuschle et al. [2013] for the finding that serum BDNF concentrations are up-
regulated in the course of antidepressant treatment; Terracciano et al. [2011] and Gerritsen et al. 
[2011] for the associations between val66met and serum BDNF concentrations and hippocampal 
volumes respectively). These discrepancies may be sample-related and for instance due to between-
study differences in patient recruitment, patient status, or antidepressant dosages. Other mundane 
reasons are methodological in nature and notably include the use of an underpowered study design 
(Button et al., 2013; Murad and Montori, 2013). Nothwitstanding the exact reason, the current thesis 
will provide reliable effect-size estimates through the use of well-powered single studies and meta-
analytical techniques to (dis)confirm the rigour of its own findings. 
     Through all this I hope to facilitate ongoing research into neurotrophic functioning in depression 
(and related illnesses). This, to my belief, is of eminent importance because it may add to the 
understanding of the pathophysiology of depression, a common and debilitating illness that needs to 
be better understood.  
 
Outline of this thesis 
The foregoing text broadly provided the theoretical background of this thesis. The chapters that follow 
go beyond description and are empirical in nature. The first aim of this thesis, on delineating the basic 
determinants of serum BDNF concentrations, is described in chapter 2 and 3. Chapters 4 till 9 are 
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devoted to the second aim of this thesis, that is to answer important clinical questions regarding the 
neurotrophin hypothesis 
     Chapter 2 provides a description of the basic determinants (sampling-, socio-demographic-, and life-
style characteristics) of serum BDNF concentrations. Chapter 3 describes seasonal entrainment of 
serum BDNF concentrations. Chapter 4 (a single study design) and chapter 5 (a meta-analysis) describe 
the author’s efforts to advance the understanding of the associations between serum BDNF 
concentrations and the illness major depression, its characteristics (e.g., the course illness), and the 
use of antidepressants. Chapter 6 evaluates whether abnormalities in serum BDNF concentrations are 
evident in persons diagnosed with an anxiety disorder. In chapter 7 I report a study on the effect of 
BDNF val66met on serum BDNF concentrations and whether this presumed effect is conditional upon 
exposure to childhood trauma. In chapter 8 and chapter 9 we extend our outcome measures beyond 
serum BDNF concentrations to the volume and the functioning of the hippocampus and to cognitive 
performance. Specifically, in chapter 8 we ascertain whether variation at the BDNF val66met locus, in 
interaction with stress exposure in child- and adulthood, is consistently associated with hippocampal 
volume and functioning and with cognitive performance. Chapter 9 contains a systematic review and 
meta-analysis on the association between BDNF val66met and hippocampal volume. Finally, in chapter 
10, I will aggregate and discuss our findings, address a vast array of pitfalls and limitations of our work 
and acknowledge objections to the way in which I interpreted the data. Finally, the possible 
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Determinants of serum BDNF concentrations 
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SIGNIFICANCE: In this study we sketch the basic determinants of serum BDNF concentrations. 
Herewith we offer an improved base to understand inter-individual differences in serum BDNF 





























Brain-Derived Neurotrophic Factor (BDNF) belongs to the neurotrophin family of growth factors and 
affects the survival and plasticity of neurons in the adult central nervous system. The high correlation 
between cortical and serum BDNF concentrations has led to many human studies on BDNF 
concentrations in various populations, however knowledge about determinants that influence BDNF is 
lacking. To gain insight into the factors that influence BDNF concentrations in humans, we measured in 
1,168 people aged 18 through 65, free of antidepressants and current psychiatric disease four 
categories of determinants (sampling, socio-demographics, lifestyle indicators and diseases) were 
measured as well as serum BDNF concentrations. We used univariable analyses and multivariable 
linear regression analyses in particular to determine which of the possible determinants significantly 
influenced serum BDNF concentrations. Our final multivariable regression analysis revealed that a non-
fasting state of blood draw, later measurement, longer sample storage and being a binge drinker all 
were associated with attenuated BDNF concentrations. This was in contrast to smoking and living in an 
urban area, which was associated with increased BDNF concentrations. Moreover we found that older 
subjects also had higher BDNF concentrations, but this only applied to women. Future studies on 
serum BDNF concentrations in humans should correct for the time of blood withdrawal, duration of 
































Brain-derived neurotrophic factor (BDNF) belongs to the neurotrophin family of growth factors and 
affects the survival and synaptic plasticity of neurons in the adult nervous system (Mossner et al., 
2007). BDNF binds with the TrkB tyrosine kinase receptor (Chao, 2003), which results in intracellular 
phosphorylation and activation of signaling cascades that lead to activation of pro-survival pathways 
(Ullrich and Schlessinger, 1990). BDNF is expressed throughout the central nervous system (Binder and 
Scharfman, 2004) and significant concentrations are also found in peripheral blood (Sen et al., 2008). 
BDNF crosses the blood-brain barrier by a saturable transport system (Pan et al., 1998). In animal 
models, cortical BDNF concentrations are highly correlated with peripheral serum BDNF 
concentrations (Sartorius et al., 2009), but evidence on the contrary has been reported as well (Elfving 
et al., 2010). Inconsistencies might be explained by the fact that BDNF-expression and its TrkB receptor 
is not specific for neuronal cells, but can also be found in endothelial cells in peripheral tissues 
(Esteban et al., 1995; Hiltunen et al., 1996; Donovan et al., 2000). The supposed importance of 
neuroplasticity in both the etiology and recovery of psychiatric disorders, has led to many studies 
linking serum BDNF concentrations to a wide variety of psychiatric and neurodegenerative diseases 
(Nakazato et al., 2003; Azoulay et al., 2005; Yasutake et al., 2006; Ciammola et al., 2007; Ikeda et al., 
2008). For proper interpretation of serum BDNF concentrations in humans, however, knowledge about 
determinants of serum BDNF concentrations is essential for adequate control of confounding factors.  
     As touched above, BDNF is not only considered to be a neurotrophin, but also an immunotrophin, 
epitheliotrophin and metabotrophin (Chaldakov et al., 2007). As of yet somatic conditions that have 
been correlated to BDNF mainly include cardiovascular disease or cardiovascular risk factors or disease 
(Ejiri et al., 2005; Fujinami et al., 2008; Hristova and Aloe, 2006; Suwa et al., 2006; Geroldi et al., 2006). 
For example, patients with acute coronary syndrome as well as patients with diabetes mellitus do have 
lower plasma concentrations of BDNF (Manni et al., 2005; Fujinami et al., 2008). However, spurious 
associations may be explained due to (unknown) confounding factors, since health indicators like 
alcohol use, smoking and physical exercise have also been linked to BDNF (Chan et al., 2008; Tang et 
al., 2008; Umene-Nakano et al., 2009). Even more basic determinants, like sampling characteristics 
have not specifically been examined regarding their association with serum BDNF concentrations. 
Although most human studies control for gender and age effects, reported effects of gender and age 
are contradictory. These mixed results may be explained by small sample sizes ranging from as low as 
10 (Marano et al., 2007) through a maximum of 465 participants (Ziegenhorn et al., 2007), as well as 
failure to control for potentially confounding factors (Aydemir et al., 2007). Finally, possible effects of 
sampling characteristics on serum BDNF concentrations have hardly been examined. The few studies 
available, however, do suggest a decrease of BDNF concentrations after longterm storage (Trajkovska 
et al., 2007) and a diurnal variation within individuals (Piccinni et al., 2008). Considering the broad 
interest in BDNF and the many factors associated with serum BDNF concentrations, it is surprising that 
no studies have been conducted to determine the effects of potential determinants of serum BDNF 
concentrations. Therefore, we examined the determinants (sampling characteristics, socio-
demographic variables, lifestyle indicators and [chronic] diseases) of serum BDNF in a large cohort of 
people without current psychiatric diseases.  
 
METHODS 
Data are from the baseline measurement of the Netherlands Study of Depression and Anxiety 
(NESDA). NESDA is a multisite naturalistic cohort study aimed to describe the 8-year course and 
consequences of depressive and anxiety disorders and to integrate biological and research paradigms 
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within an epidemiological approach. Recruitment took place in the general population, in general 
practices and in mental health organizations. The baseline sample consists of 2,981 participants aged 
18 through 65 years of which 2,625 were selected on the basis of a current or life-time history of 
depression and/or anxiety disorder, belonging to a high-risk group because of a family history or sub-
threshold depressive or anxiety symptoms, and 356 healthy controls. Patients with a primary 
psychiatric disorder not subject of NESDA, such as psychotic disorder, obsessive-compulsive disorder, 
bipolar disorder, or severe addiction were excluded as well as those not being fluent in Dutch. The 
Medical Ethics Commission of the participating institutes approved of this study and all respondents 
provided written informed consent. 
     All respondents received a structured diagnostic interview using the Composite International 
Diagnostic Interview (CIDI version 2.1) in order to assess current and lifetime DSM-IV diagnoses. The 4 
hour baseline assessment further included written questionnaires, interviews, a medical examination, 
and collection of blood and saliva samples, in order to gather extensive information about key (mental) 
health outcomes and demographic and clinical determinants. All measurements and interviews took 
place were carried out by our specially trained staff according to a previously determined protocol. For 
a detailed description of the objectives and methods of NESDA, see Penninx et al. (2008). Based on our 
previous study (Molendijk et al., 2010) showing that BDNF was associated with both current 
psychopathology and antidepressant usage, but not with trait psychopathology or sub-threshold 
symptoms, we excluded only participants with a current DSM-IV diagnosis of a depressive disorder or 
anxiety disorder in the last 6 months (n = 1,688) and those who were using any kind of antidepressant 
medication (n = 736). This resulted in a study population of 1,198 participants. Of these, 30 did not 
have serum BDNF assessment and 3 samples were below the detection limit. These persons therefore 
were excluded, leaving a final sample of 1,165 for the present study.  
 
BDNF assessment 
Blood was collected (between 06:20 and 12:30 h) after an overnight fast and immediately transferred 
to one of the five local laboratory-sites to start processing within 1 h. Serum samples for BDNF 
assessment were stored at  -85 C˚. After concluding the baseline assessment, serum samples were sent 
(ranging from 22 to 60 months after withdrawal) to the Department of Psychiatry and 
Neuropsychology in Maastricht (The Netherlands) for BDNF measurements. Serum BDNF protein 
concentrations were measured within 3 months after their receipt using the Emax Immuno Assay 
system from Promega according to the manufacturer’s protocol. The undiluted serum was acid 
treated, which in a dilution-dependent way reliably increased the detectable BDNF. Subsequently, 
serum samples were diluted 100 times and stored again at -85 C˚ for BDNF assay the next day. After 
dilution, the BDNF concentrations were well within the range of the standard curve. The assay 
sensitivity threshold was ascertained at 1.56 ng/ml reflecting the minimum level of BDNF in the serum 
that could be reliably determined. Three samples were below this threshold and deleted for all 
subsequent analyses (see also above). In our pilot study we had found that BDNF concentrations of 
acid-treated samples with subsequent dilution the day preceding the BDNF assay did not differ from 
the concentrations obtained in samples following acid treatment only on the preceding day, or from 
those derived after acid treatment conducted the day of the BDNF measurement. The serum samples 
used in our pilot study were stored samples of six individuals who did not participate in the present 
study. The samples’ coefficients of variance ranged from 2.9% to 8.1%. To gauge the intra-assay 
variance for the present study, we analyzed two of our current samples on two different plates on the 
same day. The resultant coefficients of variance of 0.1% and 3.1% were both well below the maximum 
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intra-assay variance of 8.8% as specified by the manufacturer. Greiner Bio-One high affinity 96-well 
plates were used and the resulting absorbance was read in duplicate using a Biorad Benchmark 
microplate reader at 450 nm. 
 
Potential determinants of BDNF 
Sampling variables 
The sampling variables that were tested consisted of time of blood withdrawal (minutes after 6.00 
a.m.), the number of minutes a sample was kept in a cool box before being processed in the local 




The socio-demographic variables that were tested consisted of gender (male/female), age (years), 
urbanicity of living environment of participant (urban/not urban) and years of education. An urban 
environment was defined according to the classification of the Dutch office for statistics (CBS) and 
dichotomized in more or less than 1000 addresses per square kilometer. As a previous study of our 
group suggested the presence of an age effect only in women (Bus et al., unpublished observations), 
we were also interested in the interaction between age and gender a priori. 
 
Health indicators 
The health indicators that were tested in this study included presence of metabolic syndrome, 
smoking, physical activity (met-minutes) and drinking (abstainer, mild, moderate, excessive) and body 
mass index (BMI). Metabolic syndrome was defined according to the updated Adult Treatment Panel 
III (ATP III) guidelines of the US national cholesterol education program (Grundy et al., 2005) in which 
metabolic syndrome is considered present if a participant meets at least three of the following criteria: 
(1) elevated waist circumference (men > 102 cm; women > 88 cm); (2) elevated triglycerides (> 150 
mg/dl); (3) reduced HDL cholesterol (men < 40 mg/dl; women < 50 mg/dl); (4) elevated blood pressure 
(> 130/85 mm Hg or use of medication for hypertension); or (5) elevated fasting glucose (> 5.6 mmol/l 
or use of medication for hyperglycemia). As a measure for physical activity we used Metabolic 
Equivalent of Task (MET)-minutes. A MET-minute is a ratio of the amount of energy expenditure during 
an activity to the expenditure at rest, which was calculated on the basis of the international physical 
activity questionnaire (Craig et al., 2003). Smoking was dichotomized into current smokers versus non-
smokers. In addition to current smoking, we also collected information on smoking status in the past 
(i.e., age of starting, age of quitting) and the average number of cigarettes smoked a day. The number 
of package years was calculated with one package year defined as smoking 25 cigarettes a day for the 
period of 1 year (= 9,125 cigarettes). The Fagerstrom questionnaire was used to measure the severity 
of nicotine dependence (Heatherton et al., 1991). Alcohol use was evaluated by creating four groups: 
abstainers, mild drinkers (drinking less than 7 units a week), moderate drinkers (drinking 8-13 units a 
week) and excessive (drinking ≥ 14 units a week). Alcohol categories were entered as dummy 
variables. In addition the AUDIT was used to measure alcohol dependence (Babor et al., 1989). BMI 
was calculated by dividing weight by the squared height and entered as a continuous variable. 
 
Disease indicators 
Based on previous associations with serum BDNF concentrations in humans, we evaluated the 
presence of Chronic Non- Specific Lung Disease (CNSLD; including asthma, chronic bronchitis and 
24 
 
chronic emphysema) and coronary artery disease (Fujinami et al., 2008). The latter was defined as self-
reported vascular events due to atherosclerotic disease (i.e., stroke, angina pectoris, myocardial 
infarction or a history of percutaneous transluminal coronary angioplasty or coronary artery bypass 
grafting). Stroke, myocardial infarction and angina pectoris were only considered present if supported 
by appropriately prescribed medication use.  
 
Statistical analysis 
Serum BDNF concentrations were normally distributed, with the exception of 12 (0.5%) positive 
outliers (i.e., level higher than 3 standard deviations (SD) above mean). Outliers were handled by 
trimming all serum BDNF concentrations above 3 SDs of the mean to the 3 SDs value. Univariable 
analyses were carried out using linear regression. We performed multiple linear regression analyses to 
assess independent determinants of BDNF. To facilitate the interpretation of the age-gender 
interaction, rather than taking absolute ages, we calculated and included the deviation from the mean, 
so that the participants’ ages were centered round the sample’s mean age. We generated 
multivariable models within each domain first by entering sampling characteristics, socio-demographic 
characteristics, health indicators and disease variables in four separate models. Subsequently, the 
independent predictors from all domain-specific models with P-values less than .15 were fitted into a 
final multivariate model. No collinearity or heteroscedasticity problems emerged. All tests were two-
sided. A P-value of 0.05 was considered statistically significant. All analyses were carried out using SPSS 
16.0 (SPSS, Chicago, IL, USA). 
 
RESULTS 
Sample characteristics  
The 1,165 participants had a mean age of 42.5 years (SD = 14.1) and 65.0% (757) were female. The 
mean BDNF level was 8.98 ng/ml (SD 3.1 mg/ml) with a range from 1.56 ng/ml through 18.50 ng/ml. 
Table 1 ↓ presents all further characteristics as well as the univariable associations of these 
characteristics with serum BDNF concentrations. As shown in Table 1 ↓, a lower serum BDNF level 
was associated with non-adherence to pretest fasting protocol (ß = 0.07; P = .01), sampling at a later 
day-time (ß = 0.07; P = .02), a longer time of storage (ß = 0.09; P = .002), high alcohol intake (excessive 
drinkers versus others (ß = 0.073; P = .020) and finally increased physical activity (ß = 0.06; P = .03). A 
higher BDNF serum level was found in older patients (ß = 0.21; P < .001), a higher degree of urbanicity 
(ß = 0.15; P < .001), current smokers (ß = 0.07; P = .01) and in patients suffering from the metabolic 
syndrome (ß = 0.06; P = .03) or coronary artery disease (ß = 0.08; P = .005).  
 
Multivariable analyses  
From the four models, categorized by variable type, we identified eleven significant determinants. 
Participants that had eaten prior to blood withdrawal had significantly lower serum BDNF 
concentrations (ß =0.07; P = .02). Sampling later during the morning resulted was associated with 
lower serum BDNF level (ß = 0.07; P = .01) as well as longer sample storage (ß = 0.08; P = .005). Serum 
BDNF concentrations in women significantly increased with age (ß = 0.23; P < .001), but also in men (ß 
= 0.10; P = .03). The age change was significantly different in women compared to men, as was 
indicated by the significant interaction between gender and age (ß = 0.08; P = .02). 
     Subjects who were living in a more urbanized area had higher BDNF concentrations (ß = 0.09; P = 
.002). Excessive drinkers had significantly lower serum BDNF concentrations compared with subject 
with more restraint drinking habits, as was indicated by the significant dummy variable (ß = 0.08; P = 
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.009). Current smokers had a significantly higher BDNF level compared to non-smokers (ß = 0.09; P = 
.003). Subjects with more physical activity had lower serum BDNF concentrations (ß = 0.06; P = .04). 
     Patients with cardiovascular disease had higher serum BDNF concentrations (ß = 0.08; P = .005). All 
these variables were entered in the final model. The presence of metabolic syndrome did not reach 
statistical significance (ß = 0.05; P = .12), but was entered into our subsequent model as well on the 
basis of a statistical significance at a P < .15 level. Our final multivariate regression analysis revealed 
that, when accounting for all potential determinants at once, having eaten prior to blood withdrawal 
(ß = 0.07; P = .01), measurement later on the day (ß = 0.06; P = .02), longer sample storage (ß = 0.08; P 
= .004), and being an excessive drinker (ß = 0.06; P = .03) all were associated with attenuated serum 
BDNF concentrations. This was in contrast to smoking (ß = 0.10; P = .001) and living in an urban area (ß 
= 0.11; P < .001), which resulted in increased BDNF concentrations. Moreover we found that older 
subjects also had higher BDNF concentrations, but this was only true for women (ß = 0.23; P < .001). 
The age change did not reach statistical significance for men (ß = 0.06; P = .26) and was significantly 
different from age change in women (ß = 0.10; P = .007)(see Table 2 ↓). 
 
Table 1. Sample characteristics (N = 1,165) and univariable associations with serum BDNF concentrations  
 Mean (SD) value or % (n) Linear regression 
  ß P-value 
Sampling variables    
   % fasting on withdrawal day  95.3  (n = 1,110) -0.07 0.01 
   Time of sampling (mean minutes past 0600 h)       168   (SD = 20) -0.07 0.02 
   Time in coolbox (mean minutes) 60      (SD = 43) 0.03 0.35 
   Duration of sample storage (#days) 1286 (SD = 228) -0.09 < 0.01 
Sociodemographics    
   % female  65.0   (n = 757) 0.02 0.42 
   Age (mean in years) 42.5   (SD = 14.1) 0.21 < 0.01 
   % living in urban area 85.9   (n = 1,001) 0.15 < 0.01 
   Education level (mean in years)  12.7   (SD = 3.1) 0.05 0.12 
Lifestyle indicators    
   % currently smoking 30.3   (n = 353) 0.07 0.01 
   % with metabolic syndrome 19.1   (n = 222) 0.06 0.03 
   Physical activity (#mean MET-minutes) 3708  (SD = 3108) -0.06 0.03 
   % abstinent of alcohol  44.8    (n = 522) Ref.  
   % mild drinker; <1U/day   34.2    (n = 399) -0.07 0.82 
   % moderate drinkers; 1-2U/day  5.9      (n = 69) -0.02 0.57 
   % excessive drinkers; >2U/day  3.6      (n = 42) -0.07 0.02 
  BMI (height/weight2) 25.3    (SD = 4.5) 0.04 0.22 
Disease    
   % with coronary artery disease  5.3     (n = 62) 0.08 < 0.01 
   % with CNSLD  10.0   (n = 117) < 0.01 0.98 
Abbrevations: SD = standard deviation; U = unit; BMI = body mass index; CNSLD = chronic non-specific lung disease; MET = metabolic 
equivalent of task 
 
Post-hoc analyses 
Significant associations in the univariable or multivariable analysis were analyzed in more depth by 
post hoc analyses using other definitions for the variable or including potentially explanatory variables. 





In order to further explore the gender differences, we assessed the influence of menopausal status 
and contraceptive pill use in women on BDNF concentrations. Since age and menopausal status are 
interwoven variables, we selected women in a narrow age range of 48-52 years of age. Since pre- and 
postmenopausal women were evenly dispersed (premenopausal n = 41; postmenopausal n = 40) in 
this age range, we minimized the confounding influence of age. The age variable was entered in a 
multiple regression together with a dichotomous menopausal status variable and the interaction 
between these two variables. We corrected for variables previously found to be of influence. 
Premenopausal women showed a significant increase in serum BDNF concentrations with age (ß = 
0.46; P = .02) and differed significantly (P = .03) from post-menopausal women who showed a non-
significant decrease (ß = -0.19; P = .43). Pre- and postmenopausal women’s BDNF serum 
concentrations did not significantly differ (ß = 0.12; P = .43) at the age of 50.1 years (mean age of this 
sample). To test whether contraceptive pill use influenced BDNF concentrations we selected all 
premenopausal women and entered the variable: yes versus no contraceptive pill use) in our final 
model. This, however, revealed a non-significant result for contraceptive pill use (ß = 0.03; P = .53). 
 
Table 2. Multiple linear regression analyses (per block and overall analyses) 
 Multivariate per block Final multivariate model 
Variables in four blocks B SE β P-value B SE  Β         P-value 
Sampling variables         
   Fasting on withdrawal day (0 = no, 1=yes) -10.03 0.443 -0.07 0.02 -10.01 0.43 -0.07 0.02 
   Time of sampling (minutes after 0600h) -0.01 < 0.01 -0.07 0.01 -0.01 < 0.01 -0.07 0.02 
   Time in coolbox (minutes) < 0.01 < 0.01 0.01 0.75 - - - - 
   Duration of sample storage (days) -0.001 < 0.01 -0.08 < 0.01 < -0.01 < 0.01 -0.08 < 0.01 
Sociodemographics         
   Gender (0 = female, 1 = male) 0.10 0.19 0.02 0.58 0.06 0.19 0.01 0.74 
   Age (years deviating from mean age) 0.05 < 0.01 0.23 < 0.01 0.05 < 0.01 0.23 < 0.01 
   Interaction age times gender -0.03 0.01 -0.08 0.02 -0.04 0.01 -0.10 < 0.01 
   Living in urban area (0 = no, 1=yes) -0.84 0.27 0.09 < 0.01 -0.98 0.26 0.11 < 0.01 
   Education level (years) 0.04 0.03 0.04 0.19 - - - - 
Lifestyle indicators         
   Current smoking (0 = no, 1 = yes) 0.599 0.20 0.09 < 0.01 0.66 0.19 0.10 < 0.01 
   Metabolic syndrome (n) 0.419 0.27 0.05 0.12 < 0.01 0.24 < 0.01 0.99 
   Physical activity (MET-minutes) < -0.01      < 0.01 -0.06 0.05 < -0.01 < 0.01 -0.05 0.07 
   Alcohol drinking dummy   (0 vs > 2U/day) -10.31 0.50 -0.08 < 0.01 -10.03 0.49 -0.06 0.04 
   Alcohol drinking dummy   (0 vs 1-2U/day) -0.58 0.40 -0.04 0.15 -0.477 0.40 -0.04 0.23 
   Alcohol drinking dummy   (0 vs < 1U/day) -0.21 0.21 -0.03 0.31 0.05 0.20 < 0.01 0.80 
   Body mass index (weight/height
2
) < 0.01 0.02 0.01 0.77 - - - - 
Disease         
  Coronary artery disease (0 = no, 1 = yes) 10.13 0.40 0.082 < 0.01 0.54 0.41 0.04 0.18 
  CNSLD (0 = no, 1 = yes)       < 0.01 0.30 < 0.01 0.99 - - - - 
 
Abbrevations: SD = standard deviation; SE = standard error; U = unit; CNSLD = chronic non-specific lung disease; MET = metabolic equivalent of task 
 
Smoking 
We created dummy variables for former and current smokers and subjects who have never smoked 
and entered these into our final model, thus correcting for potentially confounding factors. This 
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revealed that current smokers had significantly higher BDNF concentrations compared to those who 
have quit smoking (ß = 0.15; P < .001). However, no significant difference was found between current 
smokers and those who have never smoked (ß = 0.05; P = .11). Furthermore, no effect on serum BDNF 
concentrations was found of package years, actual number of cigarettes a day among smokers, as well 




In order to check whether the effect of alcohol intake on serum BDNF concentrations could be 
explained by the degree of alcohol dependence, we replaced the alcohol variables in our final model 
with the sum score of the AUDIT. No significant effect was found of the total AUDIT score on serum 
BDNF concentrations (ß = 0.05; P = .10). 
 
Cardiovascular disease 
Since the metabolic syndrome and cardiovascular disease were associated with serum BDNF 
concentrations in the univariable analysis, we further investigated this by repeating our multivariable 
analysis in a stepwise manner. We found that significance for both metabolic syndrome and 
cardiovascular disease was lost after the introduction of age as a variable. Moreover we investigated 
the individual components of metabolic syndrome, by adding these to our final regression model as 
described above. Only hyper-triglyceridemia significantly contributed to the variation in serum BDNF 
level (ß = 0.07; P = .018). The four other individual criteria did not reach statistical significance: low 
HDL cholesterol (ß = 0.01; P = .91), abdominal obesity (ß = 0.02; P = .44), hypertension ß = 0.01; P = 




Within a large cohort of people free from psychiatric disorders, we identified eight independent 
determinants of serum BDNF concentrations: time of blood withdrawal, time of storage, food intake 
before sampling, urbanicity, age, gender, smoking status and drinking behavior. Below we will discuss 
these determinants in more depth. 
 
Sampling variables 
Three sampling variables had an independent effect on serum BDNF concentrations in our study. First, 
although the overall decline was small, BDNF concentrations were significantly lower after long-term 
storage over a mean period of about 3.5 years. This is in line with previous results showing that serum 
BDNF had significantly decreased after 5 years of storage, but not yet after 12 months (Trajkovska et 
al., 2007). In our study, however, this decline of serum BDNF was far less pronounced. Most likely, this 
can be explained by storage temperature, which was much lower in our study (i.e., -85 C˚ compared to 
-20 C˚). It is important to know, especially for epidemiological studies taking blood samples outside the 
hospital that the time kept in a cool box before initial processing does not affect BDNF serum 
concentrations. Secondly, we found attenuated serum BDNF concentrations when blood was drawn 
later in the morning. Diurnal variation has been reported for plasma BDNF concentrations, but not for 
serum BDNF concentrations (Piccinni et al., 2008). Acknowledging the limited time-interval in which 
serum BDNF concentrations were measured in our study, a much larger diurnal variation in BDNF can 
be expected. This should be explored in more detail in subsequent studies. Finally, to our knowledge, 
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we are the first to show that food intake prior to sampling results in lower serum BDNF 
concentrations. Although we cannot exclude that these results were caused by selection bias, it does 
plead for taking this into consideration in future research. 
 
Socio-demographic variables 
In contrast with men, in whom change in BDNF concentrations by age is far less pronounced, in our 
sample of people aged between 18 and 65 years we found increasing serum BDNF concentrations in 
women with advancing age. In a previous study of our group among community-dwelling older people 
aged 50 through 72 years we found constant BDNF serum concentrations in men, whereas in women 
an age-related decrease was found. At a first glance, these results seem puzzling, but the difference 
between men and women, as well as the opposite age related effects in younger and older women, 
might be explained by gender-hormone differences between men and women. Post-hoc analyses 
found a significant interaction of age and menopausal state in women, with an age-related increase of 
serum BDNF concentrations in premenopausal women and an age-related decrease in 
postmenopausal women. As estrogen concentrations are significantly associated with BDNF 
concentrations (Monteleone et al., 2007), the postmenopausal drop in estrogen concentrations could 
possibly result in decreasing BDNF serum concentrations. These results thus suggest that in women 
serum BDNF concentrations peak at the climacteric age. However, since age and menopausal status 
are inextricably linked, it remains difficult to draw any conclusions in this cross-sectional approach, 
hence warranting future longitudinal research. Furthermore, participants living in an urban 
environment had significantly higher serum BDNF concentrations compared to their rural 
counterparts. The effect of urbanicity might be hypothesized to be an indirect effect mediated by 
different factors. On the one hand, one may expect decreased BDNF concentrations due to a higher 
exposure to stress factors (Godfrey and Julien, 2005) and higher frequency of psychopathology (Peen 
et al., 2009). On the other hand, one may expect increased BDNF concentrations due to a higher 
environmental enrichment, which has shown to induce BDNF gene expression (Kuzumaki et al., 2010). 
As we excluded participants with current psychopathology (and associated the highest stress 
concentrations), this latter effect might have outweighed the effect of stress and psychopathology. 
 
Health indicators 
Only two health indicators were associated with serum BDNF concentrations. First, current smoking 
was associated with higher BDNF concentrations. Interestingly, an opposite effect has been reported 
on plasma BDNF concentrations in two previous studies (Bhang et al., 2010). Assuming that previous 
results are not chance findings due to low patient numbers, these opposite effects might be explained 
by dysfunctioning platelets in smokers resulting in impaired BDNF-release from platelets, which would 
affect plasma but not serum concentrations of BDNF (Nowak et al., 1987). Despite the clear effect of 
current smoking, we neither detected a dose-response effect measured by package years (in smokers 
and ex-smokers) nor a dose-response effect measured by number of cigarettes a day (in current 
smokers). Different hypotheses seem valid. First these findings might indicate a direct toxic effect of 
smoking, as in animal research a direct relationship between nicotine and BDNF expression in the brain 
has been reported (Kim et al., 2007). 
     Secondly, the association might be caused by an underlying third factor related to serum BDNF 
concentrations as well as smoking habits (vulnerability for starting smoking or being able to quit when 
started), as preliminary evidence has found an effect of val66met polymorphism of the BDNF gene on 
smoking habits (Lang et al., 2007), although a replication was negative (Montag et al., 2008). 
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Moreover, in our sample we could not find an association between the degree of nicotine dependence 
and serum BDNF concentrations and previous studies (performed in plasma BDNF) showed that 
subjects had BDNF concentrations similar to non-smokers after 12 weeks of smoking cessation (Bhang 
et al., 2010). This evidence points towards a direct involvement of the inhalation of smoke in 
influencing BDNF concentrations. High alcohol intake, but not the severity of alcohol dependence, was 
associated with lower BDNF serum concentrations in our sample. BDNF has been hypothesized to be 
implicated in ethanol-induced neuro-degeneration in the adult brain, but to date, the role of BDNF in 
alcohol use disorders is still a matter of debate (Davis 2008). The only study of serum BDNF 
concentrations in patients with alcohol dependence found only diminished BDNF concentrations in 
case of co-morbid depression, but not in patients with alcohol dependence without co-morbid 
depression (Umene-Nakano et al., 2009). This picture becomes even more complicated acknowledging 
the possible role of the val66met polymorphism of the BDNF gene in relapse of alcohol use disorders 
(Wojnar et al., 2009). More research on the role of BDNF in alcohol use disorders is clearly warranted. 
Thus far, studies investigating BDNF outside the area of alcohol use disorder should exclude people 
who use more than 14 standardized units of alcohol a week. The small inverse relationship between 
physical activity and BDNF serum concentrations showed a tendency toward statistical significance. 
Previous studies reported increased serum BDNF concentrations directly after exercise (Tang et al., 




Although there is evidence that BDNF may play a role in the pathogenesis of cardiovascular disease 
(Chaldakov et al., 2004; Cai et al., 2006), BDNF serum concentrations were not associated with 
prevalent cardiovascular diseases or the metabolic syndrome. A closer look on previous studies of 
BDNF in cardiovascular disease suggests that positive results can be explained by methodological 
differences. First, some studies have reported an elevated expression of BDNF in atherosclerotic 
plaques (Ejiri et al., 2005), but to date it is not clear to what extent BDNF-expression in atherosclerotic 
plaques contributes to overall BDNF serum concentrations. Secondly, others have reported lower 
plasma BDNF concentrations in patients in the acute phase of coronary syndromes (Manni et al., 
2005), which may be explained by both the acute phase of the coronary syndrome as well as the 
differences between BDNF measurements in plasma versus serum. The lack of an association between 
BDNF serum concentrations and prevalent cardiovascular disease is relevant for future studies on the 
role of BDNF serum concentrations in late-life depression and neurodegenerative disorders in which 
cardiovascular diseases are highly prevalent. Lung diseases were not associated with BDNF level either. 
Elevated serum BDNF concentrations have been reported in patients with asthma (Lommatzsch et al., 
2005), but even when we investigated asthma and Chronic Obstructive Pulmonary Disease (COPD) 
separately, no effect was found (data not shown). 
 
Strengths and weaknesses 
Although we conducted the largest study to date on serum BDNF concentrations in human and 
included a large number of possible determinants, one important methodological issue has to be 
addressed for proper interpretation. This issue is that results for serum BDNF concentrations cannot 
be generalized to studies of BDNF in plasma or platelets. Because of the storage of BDNF in platelets, 
the concentration of BDNF in serum and plasma differs by a factor of 200 (Rosenfeld et al., 1995). As 
BDNF in platelets does not originate from mega-karyocytes or other precursor cells of the mature 
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platelet (Fujimura et al., 2002), it is likely that most of the BDNF in human platelets is sequestered 
from blood (Nakahashi et al., 2000). Furthermore, BDNF is released by platelets during the clotting 
process (Rosenfeld et al., 1995). This means that differences in platelet functioning, either by their 
ability to release BDNF or sequester BDNF from blood, may result in differences between serum and 
plasma BDNF concentrations. A possible disadvantage of measuring BDNF in serum may be a decline in 
BDNF concentrations after long-term storage of serum, which may not occur for BDNF stored in 
platelets (Trajkovska et al., 2007). In our study, serum was stored at -85 C˚ for a period varying 
between 22 and 60 months. Although we have found that serum BDNF concentrations significantly 
declines in long-term storage, this decline was relatively small and was corrected for. Furthermore, 
only one sample had a BDNF level below the lower detection limit. Therefore, we can conclude that 
reliable conclusions can be made after a long-term storage at -85 C˚. 
 
Final conclusions 
Future studies on serum BDNF concentrations in humans should correct for the time of day of blood 
withdrawal, storage, age, gender, urbanicity, smoking status and alcohol use. Although effect sizes are 
generally small and clinical relevance needs to be tested in subsequent clinical samples, we would 
suggest to exclude subjects who did not adhere to the pretest fasting protocol from clinical studies and 
to keep storage time limited. Moreover, for diseases with a diurnal variation, like mood disorders, it 
would be interesting to examine whether other parameters of BDNF serum concentrations (e.g., 
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SIGNIFICANCE: This study shows strong evidence for seasonality in serum BDNF concentrations. This 
unique finding provides avenues to understand those factors that regulate BDNF expression and they 



























Earlier findings show seasonality in processes and behaviors such as brain plasticity and depression that in 
part are regulated by Brain-Derived Neurotrophic Factor (BDNF). Based on this we investigated seasonal 
variation in serum BDNF concentrations in 2,851 persons. Analyses by month of sampling (monthly n’s > 
196) showed pronounced seasonal variation in serum BDNF concentrations (P < .0001) with increasing 
concentrations in the spring-summer period (standardized regression weight (ß) = 0.19, P < .0001) and 
decreasing concentrations in the autumn-winter period (ß = -0.17, P < .0001). Effect sizes (Cohen’s d) 
ranged from 0.27 to 0.66 for monthly significant differences. We found similar seasonal variation for both 
sexes and for persons with a DSM-IV depression diagnosis and healthy control subjects. In explorative 
analyses we found that the number of sunshine hours (a major trigger to entrain seasonality) in the week of 
blood withdrawal and the 10 weeks prior to this event positively correlated with serum BDNF 
concentrations (Pearson’s correlation coefficients ranged: 0.05 — 0.18) and this could partly explain the 
observed monthly variation. These results provide strong evidence that serum BDNF concentrations 
systematically vary over the year. This finding is important for our understanding of those factors that 
regulate BDNF expression and may provide novel avenues to understand seasonal dependent changes in 
behavior and illness such a depression. Finally, the findings reported here should be taken into account 
































The yearly orbit of the Earth around the Sun causes variability in the length of day. Many species are 
sensitive to this and exhibit biochemical and behavioral alternations as response. This has been termed 
seasonality (Walton et al., 2011). 
      Seasonality has become engrained in the field of psychiatry and clinical psychology through findings such 
as spring peaks in suicide rates (Postolache et al., 2010) and seasonal affective disorder (Rosenthal et al., 
1984, Lewy et al., 2006). Above this, subtle effects of season on depressive behaviors have been described. 
For instance, in periods in which there is relatively little daylight otherwise healthy individuals show reduced 
levels of activity, less interest in sex, and an increased urge for sleep (Kasper et al., 1989; Wehr and 
Rosenthal, 1989). Research at the pre-clinical level confirmed these findings by showing similar seasonal 
patterns in depressive-like behavior in rodents (Pyter and Nelson, 2006;; Prendergast and Kay, 2008) and, in 
addition, in brain plasticity (Pyter et al., 2005; Workam et al., 2009) that has been linked to the human 
depressed state (Castren et al., 2007). Taken together, these findings suggest that depressive behavior and 
related processes are sensitive to natural occurring environmental cues such as the length of the day.   
     Although the underlying mechanisms of seasonality in depressive behaviors could not be elucidated yet, 
some data point to variation in serotonin (5-hydroxytryptamine; 5-HT) expression as being the molecular 
mechanism that thrives this association (Lambert et al., 2002; Praschak-Rieder et al., 2008). Indeed, human 
studies show that central and peripheral 5-HT activity undergoes marked seasonal rhythmicity (Carlsson et 
al., 1980; Sarrias et al., 1989; Hanna et al., 1998; Neumeister et al., 2000; Praschak-Rieder et al., 2008; Luykx 
et al., 2012). Furthermore, 5-HT activity is positively related to the number of ambient sunshine hours 
(Lambert et al., 2002). However, although linked to depression, it has become increasingly clear that 5-HT 
alternations are not sufficient to cause the primary depressive phenotype (Nestler et al., 2002; Sharp and 
Cowen, 2011). So, seasonality in depressive behaviors might depend on changes in a pathway down-stream 
of 5-HT rather than directly through 5-HT signaling. Brain-Derived Neurotrophic Factor (BDNF) could serve 
as a component in such a pathway. BDNF is a signaling molecule that has a repertoire of regulatory 
functions on a related set of phenomena that are (partly) seasonal (e.g., energy balance and brain plasticity 
(Tapia-Arancibia et al, 2008; Liao et al., 2012)). It is well established that 5-HT and BDNF interact with each 
other and it has been suggested that these factors together have regulatory functions in neuronal 
functioning and neuronal plasticity (Mattson et al., 2004). Furthermore, the intertwined relationship 
between 5-HT and BDNF plays a fundamental role in the ‘neurotrophin hypothesis of depression’ (Duman 
and Monteggia, 2006). This hypothesis has become a leading model in the field of depression research by 
conceptualizing depressive disorders as being partly the consequence of deficiencies in mechanisms related 
to neuronal plasticity. Furthermore, the neurotrophin hypothesis predicts that BDNF and its receptor 
Tyrosine kinase factor B (TrkB) are targets of antidepressants because these factors modulate 
neuroadaptive changes that are believed to be essential for therapeutic change (Castren et al., 2007). 
     Given seasonality in 5-HT dynamics, the intrinsic relation between 5-HT and BDNF, and links between 
BDNF and processes and behaviors that occur according to a seasonal pattern, serum BDNF concentrations 
may also follow a seasonal pattern. A line of experimental work that has shown that light deprivation 
reduces BDNF mRNA and protein expression in the rat brain (Castren et al., 1992; Karpova et al., 2010) also 
gives ground to this idea. To date, however, no studies investigated seasonality in any BDNF parameter. 
Clarifying this issue is important in understanding the factors that influence BDNF expression, essential in 
evaluating research findings, and maybe helpful for a better understanding of seasonal variation in 
depressive-like behavior. Accordingly, we investigated seasonality in serum BDNF concentrations that are 
assumed to reflect central levels of BDNF (Pan et al., 1998; Klein et al., 2010). Since seasonality is entrained 
by environmental cues such as the number of sunshine hours, we also explored the relation between serum 
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BDNF concentrations and this variable. Here we hypothesized that BDNF concentrations will be positively 




Subjects were derived from the baseline sample of the Netherlands Study of Depression and Anxiety 
(NESDA). The NESDA is an ongoing cohort study among 2,981 persons who were recruited in mental health 
care, primary care and in the general population. Included in the NESDA were persons with a depressive 
and/or an anxiety disorder, persons with a depressive and/or an anxiety disorder in remission and persons 
without lifetime depressive or anxiety disorders. Exclusion criteria were evidence for psychotic-, bipolar I- 
or II-, or obsessive-compulsive disorder, severe alcohol use, and not being fluent in Dutch (see Penninx et 
al., 2008 for full details). For our present purposes, subjects were eligible on whom data on serum BDNF 
concentrations and date of blood withdrawal were available (N = 2,851, not eligible n = 130 [~ 4.5%]). 
Eligible and not-eligible persons did not differ with regard to gender, age and psychiatric diagnoses (all P 
values > .25). Ethical approval for the study was obtained from the Ethical Committees of the participating 
Institutes and all subjects gave their written informed consent. 
 
Demographical, behavioral, and clinical measurements 
Basic demographic and behavioral information on the sample was acquired through standard questions and 
procedures (see Penninx et al., 2008). Information on the amount of physical activity the participants 
engaged in was acquired by means of the International physical activity questionnaire and expressed as the 
number of met-minutes (i.e., the ratio of the amount of energy expenditure during activity to the energy 
expenditure at rest; Craig et al., 2003). Smoking was dichotomized in current smoker versus non-current 
smoker and alcohol use as abstainer versus non-abstainer. 
     Trained staff administered the Composite International Diagnostic Interview version 2.1 (CIDI; Wittchen 
et al., 1991) to establish lifetime and current (i.e., a diagnoses in the past 6-months) psychiatric diagnoses 
(Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV; American Psychiatric 
Association, 1994). The severity of depressive and anxiety symptoms was assessed using the Inventory of 
Depressive Symptoms (IDS; Rush et al., 1996) and Beck’s Anxiety Inventory (BAI; Beck et al., 1979). The use 
of antidepressants was assessed by means of self-report and drug container observation. Antidepressant 
use was defined as intake of minimally the daily dose as recommended by the World Health Organization 
(2008) on > 50% of the days during the last month.  
 
BDNF measurements 
Fifty ml of venous blood was withdrawn into vacuum tubes between 07:30 and 09:30 a.m. after an 
overnight fast (from August 2004 to March 2007). Serum was separated immediately and stored until 
assay. Serum BDNF concentrations were determined, in a laboratory of the University of Maastricht, the 
Netherlands, using the Emax Immuno Assay system from Promega according to the manufacturer’s 
protocol (Madison, WI, USA). Absorbency was read in duplicate using a Bio-Rad Benchmark microplate 
reader (Hercules, CA, USA) at 450 nm. Serum BDNF concentrations were expressed as ng/ml. The 
coefficients of variance ranged between 2.9% and 8.1%. Further information on the exact procedures (and 
their reliability and validity) that were used is provided elsewhere (Bus et al., 2011). 
 
Sunlight measurements  
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The number of sunlight hours was measured using pyranometers (World Meteorological Association 
(WMO; 1996), on a daily basis, at weather stations of the Dutch Royal Meteorological Institute (KNMI 2012; 
www.knmi.nl). The weekly number of sunlight hours was defined as the sum of all sub-periods in that week 
for which the solar irradiance exceeded 120 W/m2. Since NESDA gathered data at multiple sites in the 
Netherlands (i.e., Amsterdam, Groningen, and Leiden) data on the number of sunlight hours were collected 
from the weather stations that were most nearby the study sites (i.e., Schiphol weather station [latitude: 
52˚18’N] for the Amsterdam and Leiden areas [latitudes: 52˚31’N and 52˚09’N respectively] and Eelde 
weather station [latitude: 53˚08’N] for the Groningen area [latitude: 53˚12’N]).  
 
Statistical analyses  
Data were analyzed in SPSS 18.0 (Chicago, IL, USA) and are presented as the average ± standard deviation, 
unless otherwise indicated. Seasonal and monthly differences in demographical, behavioral, and clinical 
variables were analyzed using a χ2 (categorical variables) or Fisher’s exact test (continuous variables). 
Statistical significance was set at P < .05 (two-tailed). Effect sizes were reported as standardized Cohen’s d, 
standardized regression weights (ß), or eta-squared (η2) where appropriate. 
     Analysis of covariance was used to test for differences in serum BDNF concentrations by calendar month 
of sampling. The following covariates were included: gender, ethnicity, age, BMI, time of the day of blood 
draw, duration of serum storage, a current depression and/or anxiety diagnosis, antidepressant use, and 
sampling site because these variables have been shown to affect serum BDNF concentrations (Bus et al., 
2011; Molendijk et al., 2011). This was followed up by Bonferroni corrected post-hoc tests when required. 
In view of earlier findings (Bus et al., 2011; Molendijk et al., 2011), three additional sub-group analyses 
were performed with gender, psychiatric status, and antidepressant treatment status as additional 
grouping factors in order to assess potential interaction effects between these variables and month of 
sampling. In a similar manner we tested whether the earlier reported lower BDNF concentrations in 
antidepressant free depressed persons as compared to healthy control subjects, remitted depressed 
persons, and antidepressant treated depressed persons (Molendijk et al., 2011) remained statistically 
significant when month of sampling was controlled for. 
     Associations between the number of sunshine hours in the week of blood withdrawal and serum BDNF 
concentrations were explored using zero-order and partial Pearson’s product-moment correlation 
coefficients (r). For the latter, the variance due to the set of covariates (see above) was taken into account. 
We anticipated that sunlight related BDNF alternations could occur with some time delay and therefore we 
not only related BDNF concentrations to the number of sunshine hours in the week of blood withdrawal, 
but also to the number of sunshine hours in the weeks prior to blood withdrawal. Finally, the variables 
coding for the number of sunshine hours in the week of blood withdrawal and the 10 weeks prior to this 
event, were entered together in 1 block of a multiple stepwise regression analysis (the set of covariates was 
entered in a first block) to test the cumulative effect of the number of sunshine hours in the recent past on 
serum BDNF concentrations.  
 
RESULTS 
The overall sample (N = 2,851) had a mean age of 41.8 ± 13.1 years and included 1,827 women (66.5%). 
Table 1 ↓ shows the characteristics of the study participants by season of sampling (for a table on the 
characteristics of the study participants by month of sampling please contact Marc Molendijk; 
molendijkml@fsw.leidenuniv.nl). Subtle seasonal differences were observed in measures for psychiatric 
diagnoses and depression severity. These differences were similar to the findings reported by Winthorst et 
al. (2011) who studied seasonal variation of depressive and anxiety symptoms using, in part, the same data. 
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Shortly, there was a small rise in the winter season in the percentage of clinical diagnoses of depression and 
depression-anxiety and related to this, on average higher scores on the IDS and a slightly higher number of 
persons who used an antidepressant. Next to this, persons who were sampled in the winter tended to have 































Seasonality in serum BDNF concentrations 
We found strong indications for a seasonal pattern in serum BDNF concentrations (overall F = 11.32, P < 
.0001, η2 = 0.04, see Figure 1 ↓). The seasonal pattern was such that serum BDNF concentrations were, on 
average, lower in the months January to May and higher in the months June to December. For pair-wise 
comparisons by month of sampling see Table S2 in Appendix II. Effect sizes for monthly differences that 
were statistically significant after Bonferroni corrections ranged from small (d = 0.27, January versus 
August) to large (d = 0.66, March versus September). 
     A similar seasonal pattern in serum BDNF concentrations was observed for males and females, 
depressed and non-depressed persons, and for antidepressant treated (any antidepressant) and 




Mar 21–Jun 20          
(n = 693) 
Summer              
Jun 21–Sept 20 
(n = 663) 
Autumn                  
Sept 21–Dec 20 
(n = 815) 
Winter                 
Dec 21–Mar 20 
(n = 680) 
P-value 
Females                                 67.3% [466] 65.0% [431] 65.2% [531] 67.9% [462] = .54 
Age 41.5 ± 13.2 41.0 ± 13.3 42.5 ± 13.1 42.3 ± 12.5 = .08  
Northern European ancestry  95.7% [663] 94.3% [625] 94.1% [766] 95.1% [647] = .49 
Education (years) 12.3 ± 3.3 12.2 ± 3.3 12.1 ± 3.3 12.0 ± 3.2 = .40 
Body Mass Index 25.3 ± 4.5 25.7 ± 5.1 25.3 ± 5.1 26.1 ± 5.3 < .05   a 
Smoker                                       37.3% [258] 34.6% [229] 34.2% [279] 33.2% [226] = .43 
Physical activity 1   3.6 ± 3.1    3.7 ± 3.2    3.4 ± 3.1    3.4 ± 3.2 = .33 
Wake up time  06:56 ± 49.3 06:58 ± 40.5 06:59 ± 44.1 06:54 ± 48.1 = .11 
Time of blood draw  08:48 ± 17.4 08:47 ± 20.4 08:49 ± 33.3 08:59 ± 22.8 = .77 
Psychiatric status                                                                                                                                                     
    Healthy controls 2 43.9% [304] 45.2% [300] 47.1% [384] 36.7% [250] < .001 b 
    MDD 2 12.3%    [85] 12.2%    [81] 11.2%    [91] 16.0% [108] < .05   a 
    Anxiety 2, 3 20.5% [142] 18.3% [121] 17.5% [143] 21.0% [143] = .23 
    Comorbid anxiety 2, 3 23.4% [162] 24.3% [161] 24.2% [197] 26.3% [179] = .63 
Antidepressant medication 4                                     23.4% [162] 22.2% [147] 24.9% [203] 28.2% [192] = .05 
Depression severity, IDS 21.2 ± 14.5 20.1 ± 14.5     20.9 ± 15.0 22.8 ± 13.9 < .01   a 
Anxiety severity, BAI 12.1 ± 10.7 11.6 ± 10.5 12.0 ± 11.5 12.6 ± 10.5 = .52 
Alcohol Use 5                                                                                                                                                     
   Non-drinker                             46.4% [322] 50.9% [337] 52.2% [425] 49.5% [337] = .21 
   Drinker 0-1 unit   a day           37.2% [258] 36.7% [243] 36.4% [297] 37.6% [256] = .97 
   Drinker 1-2 units a day           10.6%   [73]    7.7%   [51]    7.1%   [58]   6.9%    [47] = .08     
   Drinker > 2 units a day              5.9%   [41]    4.8%   [32]    4.2%   [34]   5.9%    [40] = .44   
Abbreviations: BAI, Beck’s Anxiety Inventory; IDS, Inventory of Depressive Symptoms; MDD, Major Depressive Disorder.  
1 Mean met-minutes (i.e., ratio of energy expenditure during activity to energy expenditure at rest). 
2 Current (6 months diagnosis). 
3 
Included a diagnosis of social phobia, panic disorder, generalized anxiety disorder, and/or agoraphobia. 
4 
Included the use of SSRI, SNRI, TCA, NaSSA, and/or St. John’s worth for at least one month at regular dose. 
5 Beyond normal alcohol use, binge drinking (> 6 units at 1 occasion) was most often reported in the spring 
a Post-hoc tests showed higher levels in the winter as compared to the other seasons 
b Post-hoc tests showed higher levels in the summer as compared to the other seasons 
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antidepressant free persons (data not shown). The P-values for the interaction terms between the 
additional grouping factors and month of sampling were all > .10. Given our earlier findings showing that 
serum BDNF concentrations were highest in currently depressed persons on selective serotonin reuptake 
inhibitors or St John’s wort (Molendijk et al., 2011) we in addition tested for seasonality in serum BDNF 
concentrations in persons using these agents. A similar seasonal effect in serum BDNF concentrations was 
observed (η2 = 0.074) in this particular group. 
     Nadir (March) and peak (September) BDNF concentrations showed a correspondence with the end of 
the winter and the summer respectively. Even more, the pattern of BDNF concentrations over the year 
suggested an increase during the Dutch spring-summer period (equinox vernal, March 20 to September 22) 
and a decrease in the Dutch autumn-winter period (equinox autumnal, September 23 to March 19). Indeed, 
when decomposed by equinox, we observed a coherent pattern of increasing BDNF concentrations during 
the spring and summer (n = 1,356, ß = 0.19, P < .0001) and decreasing BDNF concentrations during the 
autumn and winter (n = 1,495, ß = -0.17, P < .0001, t = 9.87 [P < .0001] for the interaction equinox of 
sampling - consecutive week of sampling within the equinox; see supplementary Figure S1 in Appendix II).  
     Although somewhat attenuated, the earlier reported main effects (Molendijk et al., 2011) of lower serum 
BDNF concentrations in antidepressant free depressed persons as compared to healthy control subjects, 
remitted depressed persons, and antidepressant treated depressed persons remained statistically 
significant (P = .04, P < .001, and P = .04) in analyses in which diagnostic and treatment status were added 
as grouping factors next to month of sampling. 
 
 
Explorative analyses: sunshine hours and serum BDNF concentrations 
The number of sunshine hours per week throughout the year ranged from 2 hours per week to 131 hours 
per week. Exploratory analyses showed small positive correlations between the number of sunshine hours 
(in the week of blood withdrawal, and the 10 weeks prior to that) and serum BDNF concentrations ([zero 
order and partial] in the range: r = 0.04 — r = 0.18; see supplemental material Table S2 and Figure S2 in 
Appendix II). Correlations were largest for the number of sunlight hours 7 and 8 weeks prior to blood 
withdrawal. Together, the number of weekly sunlight hours in the week of sampling and in the 10 weeks 
prior to the week of sampling, positively predicted serum BDNF concentrations (entered in 1 block of a 
multiple stepwise regression analysis (the set of covariates was entered as a first block): ∆F = 11.22, 
multiple correlation = 0.21, P < .0001). The number of sunshine hours could partly explain the monthly 
differences in serum BDNF concentrations (i.e., η2 = 0.041, P < .0001 before and η2 = 0.011, P = .003 after 
the inclusion of the number of sunlight hours as covariates). Additional explorative analyses showed a 
similar pattern of correlations between the length of day (i.e., photoperiod) in the week of blood 
withdrawal, and the 10 weeks prior to that, and serum BDNF concentrations (data not shown). 
Figure 1. Mean serum BDNF 
concentrations by month of 
sampling.  
 
Error bars reflect the SEM.  
 
For pair-wise comparisons on 
serum BDNF levels by month 
of sampling I refer to 








The novel finding that emerges from this study is that of pronounced seasonal variation in serum BDNF 
concentrations. The seasonality that we observed followed a coherent pattern of increasing BDNF 
concentrations over the course of the spring and the summer and decreasing BDNF concentrations over the 
course of the autumn and the winter. Illustrative for the robustness of our finding was that the seasonal 
pattern was similar for both sexes and for conditions in which BDNF expression is altered, such as major 
depression (Duman et al., 2008). By means of covariate adjusted analyses we could exclude a range of 
potentially alternative explanations for our findings, including effects of for example physical activity and 
BMI that have been reported to be seasonal (Ma et al., 2006; Gordon et al, 1987) and that have been linked 
to serum BDNF concentrations as well (Currie et al., 2009; Golden et al., 2010). In addition, our results were 
of a relatively large magnitude with effect sizes (Cohen’s d) up to 0.66 for monthly differences. Together, 
these findings may have significant implications as discussed below.  
 
Seasonality in serum BDNF concentrations: mechanisms and theoretical implications 
What might explain the strong pattern of seasonality in serum BDNF concentrations? Differences in cAMP-
response element binding protein (CREB) activity could be an option. CREB is a transcription factor that 
binds to the promoter region of the BDNF gene and positively regulates BDNF transcription (Impey et al., 
2004). CREB activity is under the influence of 5-HT. Given that long day conditions give rise to a higher 5-HT 
expression (Lambert et al., 2002), seasonality in serum BDNF concentrations may be entrained by 5-HT 
induced CREB activation. This explanation would fit with observations that come from the field of 
antidepressant research. For example, increases in the transcriptional activity of BDNF in the course of 
treatment with a selective serotonin reuptake inhibitor are often observed but these only occur in the face 
of an increase in CREB activity (Conti et al., 2002). Also, antidepressants give rise to increased CREB activity 
but only if they are administered chronically (e.g., ≥ 21 days) (Conti et al., 2002). This appears to be in 
agreement with our observation that the correlations between BDNF concentrations and the number of 
sunshine hours were largest for the number of sunshine hours in 7 to 8 weeks prior to blood withdrawal. 
Furthermore, peak serum BDNF values were observed in the early autumn and nadir values in the early 
spring. So, the seasonality in BDNF expression seems to occur with a time-delay relative to the seasons and 
their corresponding weather characteristics.  
     Important for the interpretation of our results is the question whether peripheral differences in serum 
BDNF concentrations imply that there also are differences at the level of the Central Nervous System (CNS). 
As already shortly mentioned in the introduction part of our paper, it has been shown in rodents that BDNF 
crosses the blood-brain barrier (Pan et al., 1998) and that peripheral and central BDNF concentrations 
correlate positively (Klein et al., 2010). Therefore it is reasonable to assume that blood BDNF 
concentrations reflect BDNF concentrations in the CNS. Unfortunately the literature on this topic in humans 
is limited to only one study in which blood simultaneously was derived from high up the jugular veins and 
from arterial veins (Dawood et al., 2007). The results of this study showed that BDNF levels were higher in 
blood that was derived from the internal jugular veins as compared to arterial blood. This indeed is 
indicative for CNS production of BDNF that is obtained from peripheral tissues (Dawood et al., 2007). It 
should be noted though that some studies report null-findings with regard to an association between 
peripheral BDNF concentrations and more central parameters for BDNF activity, that is, the absence of 
correlations between plasma and cerebral spinal fluid concentrations of BDNF (Pillai et al., 2012).  
 
Seasonality in serum BDNF concentrations: practical implications 
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Notwithstanding some uncertainty with regard to the exact mechanisms underlying the seasonality in BDNF 
expression, our findings have immediate and important practical implications. First, our findings are of 
essential importance in the interpretation of results from longitudinal studies. That is, the results of trials 
that have serum BDNF concentrations as an outcome measure and that span several months, might be of 
little use unless detailed knowledge on seasonal effects is available. Second, and in agreement with the 
latter statement, our results stress the need to sample groups (e.g., depressed patients versus healthy 
control subjects) equally over the year in order to gain credibility and validity in research findings.  
 
Strengths, Limitations, and future studies 
Our study has strengths, notably reliability through a large sample size and validity through the adjustment 
for a range of confounders and subgroup analyses. However, there are also limitations. First, we used 
between-subject data whereas within-subject data with repeated samplings (monthly or more often) over 
at least 1 calendar year is more appropriate to establish seasonality. Second, there must have been some 
noise in the measurements related to the variables that coded for the hours of sun in the weeks prior to 
blood withdrawal. That is, we assigned each individual the number of sun hours that were recorded in the 
particular region these persons lived in under the assumption that they actually were in that particular 
region. However, we do not know this with certainty (e.g., participants may have been on vacation) and we 
also do not know whether they truly were exposed to the sun (e.g., participants may have stayed inside 
their houses). We assume that this resulted in random noise that decreased our ability to detect 
associations and thus that the true associations between sunlight hours and serum BDNF concentrations 
are likely to be of a larger magnitude than as reported here. Also, from our data we cannot conclude 
whether serum BDNF concentrations are kept in a certain homeostatic range over the year to serve a given 
function or whether we observed an epiphenomenon of some other physiological or (unmeasured) 
behavioral process that may be unrelated to central BDNF functioning. Finally, a limitation with regard to 
the Promega BDNF ELISA kit that was used is that it quantifies total amount of BDNF without distinguishing 
between the pro- and the mature BDNF forms (Lu et al., 2005; Yoshida et al., 2012 a). It could well be that 
the percentage of mature BDNF to total BDNF in serum may be altered as a function of season. Only since 
very recently it has been shown that such an important distinction can be made (Yoshida et al., 2012 a, b) 
and thus future studies could look into differences in pro-mature BDNF ratios over the seasons. 
     For future studies it further would be interesting to elucidate whether tryptophan, 5-HT, and/or CREB 
activity, truly have important roles, as hypothesized here, in the chain of events that in the end may lead to 
seasonality in serum BDNF concentrations. It also would be particularly interesting to study BDNF 
concentrations as a function of selected levels of (sun)light exposure. From our findings we would expect 
that serum BDNF concentrations will vary less in areas where the seasons, the number of sunlight hours, 
and/or the natural length of day vary less over the year (e.g., closer to the equator as compared to the 
Netherlands) or 12 hours light/dark regimens in laboratories. Finally, in the light of our findings that serum 
BDNF concentrations are correlated with the amount of ambient sunlight (and with the length of the 
photoperiod) an important area of investigation would be to investigate changes in serum BDNF 
concentrations in the course of treatment with bright light (Lieverse et al., 2011) in conditions that have 
been associated with an altered BDNF expression. 
 
Summary and conclusions 
Here we demonstrate that serum BDNF concentrations profoundly vary over the year and that this occurs 
according to a coherent pattern of increasing BDNF concentrations in the spring-summer period and 
decreasing BDNF concentrations in the autumn-winter period. In addition we show correlations between 
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serum BDNF concentrations and the number of sunlight hours. Although much remains to be understood 
with regard to these associations and notwithstanding some limitations, we believe that these results invite 
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SIGNIFICANCE: This paper reveals that low serum BDNF concentrations are a state characteristic of 
depression and that this normalizes following natural remission and in the course of antidepressant 
treatment. Critically however is that we show that the effect-sizes on these associations are small and 
that normalization of serum BDNF concentrations is not necessarily associated with a relief of 
























Recent evidence supports the neurotrophin hypothesis of depression in its prediction that Brain-Derived 
Neurotrophic Factor (BDNF) is involved in depression. However, some key questions remain unanswered, 
including whether abnormalities in BDNF persist beyond the clinical state of depression, whether BDNF 
concentrations are related to the clinical features of depression and whether distinct antidepressants affect 
BDNF concentrations equally. We addressed these questions and investigated serum BDNF concentrations 
in 962 depressed patients, 700 fully remitted persons (> 6 months) and 382 healthy controls. We found 
serum BDNF concentrations to be low in antidepressant-free depressed patients relative to controls (effect 
size, Cohen’s d) = 0.19, P < 0.01) and to depressed patients who were treated with an antidepressant (d = 
0.23, P < 0.01). BDNF concentrations of fully remitted persons (whether unmedicated or treated with an 
antidepressant) were comparable to those of healthy controls. Analyzing the sample of antidepressant-free 
depressed patients showed that BDNF concentrations were unrelated to the core clinical features of 
depression such as its severity or having a first versus a recurrent episode. The to antidepressant use 
associated up-regulation of serum BDNF concentrations in depressed patients was confined to selective 
serotonin reuptake inhibitors (d = 0.39, P < 0.01) and St John’s wort (d = 0.63, P = 0.03). Our results suggest 
that low serum BDNF concentrations are a state abnormality that is evident during depression and that 
normalizes during remission. Increases in serum BDNF concentrations during antidepressant treatment 
appear to be confined to some antidepressants and do not parallel clinical characteristics, such as the 






























Brain-Derived Neurotrophic Factor (BDNF) is a neurotrophin that has been linked to the viability of neurons 
in brain circuits that regulate emotion, memory, learning, sleep and appetite (Duman et al., 2000; Sutton 
and Schuman, 2006). The neurotrophin hypothesis of depression is based on these functions of BDNF and 
postulates that depression results from stress-induced decreases in BDNF expression and that 
antidepressants are efficacious because they increase BDNF expression (Duman et al., 1997; Duman and 
Monteggia, 2006). Consistent with this hypothesis are the findings that depression is accompanied by 
decreased central and peripheral concentrations of BDNF (Sen et al., 2008), and that antidepressants elicit 
an increase in BDNF concentrations in animal models for depression (Angelucci et al., 2005) and in 
depressed humans (Brunoni et al., 2008). Together with the latency of weeks before antidepressants 
become clinically effective (Nemeroff and Owens, 2002), these observations shaped the hypothesis that the 
efficacy of antidepressants depend on neuroadaptive changes that are brought about by changes in BDNF 
signaling (Duman and Monteggia, 2006). 
     Taken together, there is reason to believe that BDNF is involved in depression and in antidepressant 
action. Results inconsistent with the neurotrophin hypothesis, however, also have been reported. There 
are, for example, studies that did not detect alternations in BDNF in depressed persons or in the course of 
treatment with an antidepressant (Matrisciano et al., 2009). In addition, some questions remain 
unanswered so that the neurotrophin hypothesis is at best incomplete (Groves, 2007). A major question 
that needs to be answered is whether low BDNF concentrations persist beyond the clinical state of 
depression (Trajkovska et al., 2008). A second question is whether BDNF concentrations are related to the 
clinical features of depression, such as having a first versus a recurrent episode (Lee et al., 2007). Yet a third 
outstanding question is whether all classes of antidepressants affect BDNF concentrations equally. We 
therefore studied, cross-sectionally, serum BDNF concentrations of depressed patients, remitted depressed 
persons and never depressed persons. Our efforts had three concerns: (1) to compare serum BDNF 
concentrations of antidepressant-free and antidepressant treated current and fully remitted depressed 
patients and never depressed persons, (2) to explore the associations between some of the core clinical 
features of depression and serum BDNF concentrations and (3) to evaluate the association between the use 
of several distinct classes of antidepressants and serum BDNF concentrations. 
 
METHOD 
Patients and sample collection 
Patients were from the Netherland Study of Depression and Anxiety (NESDA). Full details on the rationale, 
objectives and protocol of NESDA are described in Penninx et al. (2008). In brief, NESDA is a prospective 
cohort study (N = 2,981) that recruited patients in mental health care, primary care and in the general 
population. Included were persons with a depressive and/or an anxiety disorder, persons with a depressive 
and/or an anxiety disorder in remission and persons without a history of these disorders. Persons who 
were diagnosed with a psychotic disorder, bipolar disorder (type I and II), obsessive-compulsive disorder, or 
severe alcohol use disorder were not eligible. Diagnostic and Statistical Manual of Mental Disorders, fourth 
edition (DSM-IV) diagnoses (APA, 1994) were assigned on the basis of responses to the Composite 
International Diagnostic Interview 2.1 lifetime version (CIDI 2.1; Wittchen et al., 1991) that was 
administered by trained interviewers. At baseline, participants provided blood samples, underwent a 
medical examination and gave written informed consent for the study that was approved by the Ethical 
Committees of the participating institutes.  
     Our study enrolled 2,044 persons (68.6% of the NESDA sample). On the basis of the assigned diagnosis, 
antidepressant use and the availability of BDNF data, we created five groups: antidepressant-free 
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depressed patients (n = 541), antidepressant-treated depressed patients (n = 421), antidepressant-free 
remitted depressed persons (n = 539), antidepressant-treated remitted depressed persons (n = 161) and 
healthy persons who served as controls (n = 382).  Depressed patients met the criteria for a depressive 
episode the last 6 months (n = 541). The majority of these patients had a current diagnosis of depression (n 
= 388), but some (n = 153) had a diagnosis of depression 1–6 months prior to baseline and did not fulfill all 
criteria in the past month. Persons who were in full remission of depression were diagnosed with major 
depression somewhere in their lives, but had been free of depression and anxiety for at least 6 months. 
Persons were included in the control group when they had: (1) no lifetime mood or anxiety disorders, (2) no 
documented family history of depression or anxiety and (3) a low score (< 14) on the Inventory of 
Depressive Symptoms (IDS; Rush et al., 1996). 
      Data on antidepressants use were acquired through drug container observation and self-report. Use of 
an antidepressant was defined as intake of minimally the daily dose as recommended by the WHO (2010) 
during the last month on at least 50% of the days. We coded for the use of selective serotonin reuptake 
inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), 
noradrenergic and specific serotonergic antidepressants (NaSSAs) and St John’s wort (Hypericum 
perforatum). The duration of antidepressant use was expressed in months. 
 
Clinical features of depression 
All patients were characterized on the symptom severity of depression using the IDS (Rush et al., 1996). 
Patient samples were further characterized on having a first or a recurrent depressive episode, the 
presence of comorbid anxiety, the age at onset of depression, the recency of depression, the chronicity of 
depression and on the presence of suicide ideation. The CIDI (Wittchen et al., 1991) served as source of 
information on the presence of a first- or a recurrent depressive episode, the presence of a comorbid 
anxiety, age at onset of depression (i.e., the age at which the first episode occurred) and the recency of 
depression (i.e., fulfilling criteria in the past month versus fulfilling criteria in the past 6 months but not in 
the past month). Depression was considered chronic if symptoms had been present for more than 24 
months during the last 5 years, which was assessed using the life chart method (Lyketsos et al., 1994). The 
scale for suicide ideation (Beck et al., 1997) was used to examine the presence of suicide ideation.  
 
BDNF measurements 
A measure of 50 ml of blood was withdrawn into vacuum tubes between 0730 and 0930 hours after an 
overnight fast. After blood collection, serum was separated and stored at -85 C˚ until it was assayed. BDNF 
protein concentrations were measured using the Emax Immuno Assay system from Promega according to 
the manufacturer’s protocol (Madison, WI, USA), in one laboratory by one technician who was blinded for 
the clinical diagnoses of the participants. Undiluted serum was acid treated as this reliably increased the 
detectable amount of BDNF in a dilution-dependent way. Greiner Bio-One high affinity 96-well plates were 
used. Serum samples were diluted 100 times, and the absorbency was read in duplicate using a Bio-Rad 
(Hercules, CA, USA) Benchmark microplate reader at 450 nm. The intra- and inter-assay coefficients of 
variation were found to be within 3 and 9%, respectively. Four persons had BDNF serum concentrations 
that were below the reliable detection threshold of 1.56 ng ml. These values were set at the lower 
detection limit. Positive outliers (mean > 3 SD, n = 6) were trimmed to the mean + 3 SD value. There were 
no differences between persons with missing and non-missing BDNF with regard to gender (P = 0.71), age 





Potential variance due to gender, age and educational level was controlled for in all analyses. In addition, 
we controlled for body mass index (BMI), physical activity and smoking as these variables are associated 
with BDNF (Suwa et al., 2006; Rojas-Vega et al., 2006) and mood (Simon et al., 2006; Harris et al., 2006; 
Kendler et al., 1993). Data on weight and height were collected, and BMI was calculated (weight/height2). 
Information on physical activity was gathered using the International Physical Activity Questionnaire (IPAQ; 
Craig et al., 1995) and expressed as the number of met-minutes (i.e., the ratio of the amount of energy 
expenditure during activity to the energy expenditure at rest). Smoking status was dichotomized as current 
versus non-smoker. Time of the morning blood withdrawal and duration of serum storage were controlled 
for since BDNF concentrations vary according to variation on these variables (Begliuomini et al., 2008; 
Trajkovska et al., 2007). 
 
Statistical analyses 
All computations were performed in SPSS version 17.0 (SPSS, Chicago, IL, USA). BDNF values were 
controlled for basic covariates in all analyses. Effect sizes on pair-wise comparisons were presented as 
Cohen’s d. (Cohen, 1988). A two-tailed P-level of 0.05 was used to determine statistical significance.       
     Analysis of variance (ANOVA) was used to compare BDNF concentrations of antidepressant-free 
depressed patients and antidepressant-treated depressed patients, antidepressant-free patients and 
antidepressant- treated persons who were in remission (< 6 months) and controls. Post-hoc tests were 
performed following a significant F-statistic using Tukey’s test.  
     A multivariable regression analysis was used to identify whether the clinical features of depression were 
associated with BDNF concentrations. Regression was performed in patient groups in which mean BDNF 
concentrations deviated significantly from the control group. Pearson correlation coefficients between 
predictors and BDNF concentrations were also calculated. Basic covariates were entered in the first step of 
regression. In the second step, the clinical features of depression were entered. The regression model was 
fit using method enter. Tolerance of the predictors and normality of error variances was verified.  
     To establish whether the use of an antidepressant effected BDNF concentrations equally in current and 
remitted depression, a 2 (currently depressed versus depression in (full) remission) times 2 
(antidepressants; yes versus no) ANOVA was performed. Potential antidepressant-specific associations 
between the use of SSRIs, TCAs, SNRIs, NaSSAs and St John’s wort and BDNF concentrations were evaluated 
by contrasting BDNF concentrations of persons who used one of these agents against the mean BDNF 
concentration of the antidepressant- free persons. Analyses were repeated with the severity of depressive 
symptoms and the duration of antidepressant use as covariates. 
 
RESULTS 
Demographics and clinical features 
Demographical and clinical features among the five groups are given in Table 1. ANOVA and χ2 tests showed 
that, compared with controls, depressed and remitted persons were more likely to be female, to be older, 
to have received fewer years of education and to smoke. BMI was higher in current and remitted 
antidepressant-treated depressed persons compared with controls and to antidepressant-free depressed 
and remitted persons. The amount of physical activity was low in the antidepressant treated currently 
depressed group relative to the other groups. Post-hoc comparisons on demographical and clinical features 
between the current and remitted depressed groups are given in Table 1 ↓. 
 
BDNF concentrations in persons with current or remitted depression and controls 
An ANOVA model showed a main effect of diagnostic status on serum concentrations of BDNF (F1, 1578 = 
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4.09, P = 0.01). Pair-wise comparisons (see Figure 1 ↓) indicated that serum BDNF concentrations were low 
in antidepressant-free depressed patients compared with controls (d = 0.19), antidepressant-free persons 
who were in full remission (d = 0.15), and antidepressant-treated depressed patients (d = 0.23). BDNF 
concentrations of antidepressant-free persons who were in full remission and depressed patients who were 
treated with an antidepressant were comparable to those of controls. 
 
Table 1. Demographic- and clinical characteristics (mean ± STD or percentages) of participants by depression diagnosis (never, current 
and remitted) and antidepressant use (no versus yes AD) 
 
Controls  
(n = 382) 
Depressed  
(n = 541) 
Depressed  
Antidepressant 
(n = 421) 
Remitted  
(n = 539) 
Remitted  
Antidepressants 
(n = 161) 
P-value 
Female (%) 61.0 66.7 67.0 71.1 70.8 < 0.05 
Age 45.7 ± 12.3 39.8 ± 12.6 42.6 ± 11.0 43.1 ± 12.9 45.4 ± 10.8 < 0.001 A,B 
Education (years) 13.4 ± 3.3 11.9 ± 3.2 11.7±3.3 12.6 ± 3.1 12.1 ± 3.3 < 0.001 
Body mass index 25.4 ± 4.6 25.5 ± 5.4 26.3±5.6 25.3 ± 4.6 26.6 ± 5.6 < 0.01   A,B 
Physical activity C 3.7 ± 3.0 3.5±3.3 3.2±3.3 3.8 ± 3.1 3.1 ± 2.8 < 0.01   B 
Smoker 16.5 38.7 46.0 35.5 34.3 < 0.001 A 
Alcohol dependent  5.4 23.3 20.0 17.0 13.7 < 0.001 
Depression severity 5.3 ± 3.5 29.6 ± 12.7 34.5 ± 13.1 16.8 ± 10.3 20.3 ± 10.6 < 0.001 A,B 
Age of onset of MDD NA 26.1 ± 12.3 27.4 ± 12.6 27.6 ± 12.2 28.2 ± 11.7     0.35 
Chronic depression D NA 27.5 38.3 11.1 18.7 < 0.001 A,B 
>1 episode NA 63.6 58.2 54.6 61.5 < 0.05   A 
Comorbid anxiety E NA 42.2 47.7 NA NA < 0.05 
Suicide ideation  NA 22.4 29.3 5.2 6.2 < 0.001 A 
 
Antidepressant medication 
 SSRI  NA NA 62.7 NA 65.8    0.27 
 SNRI  NA NA 16.4 NA 13.0    0.06 
 TCA  NA NA 8.1 NA 13.0    0.19 
 NaSSA  NA NA 8.6 NA 2.5 < 0.05 
 St John’s wort NA NA 4.3 NA 5.6     0.32 
 Duration of use F NA NA 7.5 ± 4.9 NA 10.9 ± 3.5 < 0.001 
Abbreviations:  NaSSA, noradrenergic and specific serotonergic antidepressant; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective 
serotonin reuptake inhibitor; TCA, tricyclic antidepressant 
 
A Indicates a significant difference between the antidepressant treated and antidepressant free current depressed groups 
B Indicates a significant difference between the antidepressant treated and antidepressant free remitted depressed groups 
C Mean met-minutes (that is ratio of energy expenditure during activity to energy expenditure at rest) divided by 1000 
D Symptoms were considered chronic if they were present for at least 24 months during the last 5 years 
E Included social phobia, panic disorder with and without agoraphobia, agoraphobia and generalized anxiety disorder 









BDNF and the clinical features of depression 
The exploration of the association between the clinical features of depression and serum BDNF was 
restricted to the antidepressant free currently depressed group, as BDNF concentrations in this group were 
low relative to controls. Pearson’s correlation coefficients indicated that female gender and being in the 
early remission phase of depression (1–6 months) versus having a current episode were negatively 
associated with serum BDNF. Age, BMI, age at onset of depression and the presence of co-morbid anxiety 
were positively associated to serum BDNF (Table 2 ↓). 
     Basic covariates were entered in the first step of the multivariable regression analysis, followed by the 
clinical features that were entered in step two. Tolerance of the predictors was high (all > 0.70), indicating 
that our individual predictors were not redundant with one another. Error variances were normally 
distributed. Results of the first step showed that gender and age were significant predictors of BDNF 
concentrations. Women had lower concentrations of BDNF compared with men (ß = -0.10, P = 0.02) and 
older patients had higher concentrations of BDNF (ß = 0.11, P = 0.002) compared with younger patients. 
Results of the second step showed that none of the clinical features (listed in Table 2 ↓) was significantly 
associated with serum BDNF. Gender and age preserved its significance. BMI emerged as a significant 
(positive) predictor of serum BDNF. Table 2 ↓ presents the results of the second step of the regression 
analysis. 
 
BDNF and the use of antidepressants 
A 2 (currently depressed versus depression in (full) remission) times 2 (antidepressant use; yes versus no) 
ANOVA showed that diagnostic status interacted with antidepressant use (F1, 1578 = 4.19, P = 0.03), indicating 
that the use of an antidepressant during a depressive episode was associated with higher BDNF 
concentrations, whereas in the remission phase, the use of an antidepressant did not show such an 
association (see also Figure 1 ↑). Main effects of diagnostic status and antidepressant use were not 
observed. To uncover potential differences between various classes of antidepressants, we compared BDNF 
concentrations of depressed patients who used SSRIs, SNRIs, TCAs, NaSSAs or St John’s wort among each 
other and those of antidepressant-free depressed patients. This analysis was restricted to the currently 
depressed group as the effect of the use of an antidepressant on serum BDNF concentrations was confined 
to this group. In this group, 67% (n = 282) used antidepressant for longer than 12 weeks. We observed a 
main effect of group (F5, 941 = 4.29, P < 0.001). Post-hoc comparisons showed that, relative to not using an 
antidepressant, the use of SSRIs (d = 0.39) and St John’s wort (d = 0.63) was associated with high 
** A, B 




Figure 1. Plotted are mean 
serum BDNF concentrations by 
diagnosis and antidepressant 
status. Error bars reflect the 
SEM. 
 
Serum BDNF concentrations are 
low in antidepressant-free 
depressed patients compared 
with controls (A: d = 0.19), 
antidepressant-free remitted 
persons (B: d = 0.15) and 
antidepressant-treated 
depressed patients (C: d = 
0.23).  
* Denotes statistical 
significance at P < 0.05.  
** Denotes statistical 






concentrations of BDNF. The use of a NaSSA was associated with low concentrations of BDNF relative to 
SSRI (d = 0.54) and St John’s wort (d = 0.85) use. Analyses were run with and without co-varying for the 
severity of depressive symptoms and for the duration of antidepressant use. These analyses revealed a 
similar pattern of results. Furthermore, serum BDNF concentrations were unrelated to treatment duration 
(r = -0.02, P = 0.65), which might suggest that our findings were not driven by the duration of 
antidepressant use. 
 
Table 2. Results of correlation and multivariable regression analyses of demographical and clinical characteristics with 
serum levels of BDNF in antidepressant free depressed patients (n = 541) 
 r 
A B 95% CI B β P-value 
Gender (1 = male, 2 = female) −0.13** −0.65 −1.24 to −0.06 −0.10 0.03 
Age (continuous, years)   0.17**   0.03   0.01 to 0.06    0.11 0.04 
Education (continuous, years) −0.04 −0.01 −0.09 to 0.08 −0.005 0.91 
BMI (continuous)   0.13**   0.06   0.01 to 0.10    0.09 0.04 
Physical activity (continuous per week) −0.02 −0.001 −0.01 to 0.01 −0.009 0.83 
Smoker (1=no, 2=yes) −0.02 −0.07 −0.04 to 0.02 −0.02 0.66 
Time of Blood withdrawal (continuous) 
B
 −0.04 −0.004 −0.12 to 0.02 −0.04 0.23 
Duration of serum storage (continuous)   0.02   0.14 −0.40 to 0.68    0.02 0.62 
Current (= 1) vs. early remitted (= 2)C −0.11* −0.15 −0.50 to 0.25 −0.04 0.52 
Severity (continuous)   0.03 −0.007 −0.04 to 0.02 −0.06 0.24 
Single (= 1) vs. recurrent episode (= 2)   0.01   0.05 −0.56 to 0.66    0.007 0.88 
Comorbid anxiety (1 = no, 2 = yes)   0.08*   0.31 −0.36 to 0.97    0.05 0.36 
Age at onset (continuous)   0.14**   0.08 −0.04 to 0.18    0.07 0.21 
Chronic depression (1 = no, 2 = yes)   0.07   0.19 −0.49 to 0.87    0.03 0.58 
Suicide ideation (1 = no, 2 = yes)   0.06   0.59 −0.13 to 1.33    0.07 0.12 
Abbreviations: BDNF, Brain-Derived Neurotrophic Factor; BMI, Body Mass Index; 95% CI, 95 percent Confidence Interval 
 
A Univariate correlation with serum levels of BDNF; Pearson's r for continuous variables and Spearman's ρ for variables 
B In minutes from 0600 hours 
C The presence of a current (1 month) versus an early remission (1–6 months of remission) diagnosis 
*   Denotes statistical significance at P < .05 
** Denotes statistical significance at P < .01 
 
BDNF and the use of antidepressants 
A 2 (currently depressed versus depression in (full) remission) times 2 (antidepressant use; yes versus no) 
ANOVA showed that diagnostic status interacted with antidepressant use (F1, 1578 = 4.19, P = 0.03), indicating 
that the use of an antidepressant during a depressive episode was associated with higher BDNF 
concentrations, whereas in the remission phase, the use of an antidepressant did not show such an 
association (see also Figure 1 ↑). Main effects of diagnostic status and antidepressant use were not 
observed. To uncover potential differences between various classes of antidepressants, we compared BDNF 
concentrations of depressed patients who used SSRIs, SNRIs, TCAs, NaSSAs or St John’s wort among each 
other and those of antidepressant-free depressed patients. This analysis was restricted to the currently 
depressed group as the effect of the use of an antidepressant on serum BDNF concentrations was confined 
to this group. In this group, 67% (n = 282) used antidepressant for longer than 12 weeks. We observed a 
main effect of group (F5, 941 = 4.29, P < 0.001). Post-hoc comparisons showed that, relative to not using an 
antidepressant, the use of SSRIs (d = 0.39) and St John’s wort (d = 0.63) was associated with high 
concentrations of BDNF. The use of a NaSSA was associated with low concentrations of BDNF relative to 
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SSRI (d = 0.54) and St John’s wort (d = 0.85) use. Analyses were run with and without co-varying for the 
severity of depressive symptoms and for the duration of antidepressant use. These analyses revealed a 
similar pattern of results. Furthermore, serum BDNF concentrations were unrelated to treatment duration 




Largely in accord with previous findings (Sen et al., 2008) and with the neurotrophin hypothesis of 
depression (Duman et al., 1997), our data showed that serum BDNF concentrations were low in 
antidepressant-free depressed patients compared with healthy controls. Our data further showed that 
BDNF concentrations were low in depressed patients who were not on antidepressant medication 
compared with antidepressant-free persons who were in full remission and that BDNF concentrations of 
this latter group were comparable to those of controls. Herewith, we establish as one of the first 
(Trajkovska et al., 2008) that low concentrations of BDNF in serum are a state characteristic of depression. 
In line with one study that reported low concentrations of BDNF in euthymic patients (Monteleone et al., 
2008), we found that patients who were in early remission (1 – 6 months) had serum BDNF concentrations 
that were comparable to those of currently depressed patients. Thus, serum BDNF concentrations remain 
low after clinical improvement has set in. This could indicate that low concentrations of BDNF are a 
consequence of depressive symptoms that persist into early remission. Alternatively, the low 
concentrations of BDNF during early remission might also represent a scar of a depressive episode. These 
explanations could not be fully elucidated in the current study and longitudinal designs clearly need to be 
performed to understand this issue. 
     We were unable to replicate the earlier findings that a higher depression severity (Karege et al., 2002; 
Shimuzu et al., 2003) having a recurrent compared with a first episode of depression (Lee et al., 2007) and 
the occurrence of suicide ideation (Deveci et al., 2007; Kim et al., 2007) are accompanied by lower 
concentrations of BDNF. In fact, we even found that the early remission phase, which was accompanied by 
a lower symptom severity of depression (mean IDS scores were 22.4 ± 11.4 versus 32.4 ± 12.1 in early 
remitted and currently depressed patients respectively), was associated with somewhat lower BDNF 
concentrations compared with the current depressive state. The other clinical features (that is age at onset 
of depression, the presence of comorbid anxiety and the chronicity of depression) also were unrelated to 
serum BDNF in multivariable analyses. These findings, given the size of the current cohort, give us 
confidence in excluding the clinical features of depression as potential correlates of serum BDNF 
concentrations. This might be an important conclusion, as it hints that other (than specifically depression 
related) factors may be at play in the relative fall of BDNF concentrations during a depressive episode. 
Interestingly, being male and BMI were found to be positively associated with BDNF among antidepressant-
free depressed patients. Although these findings were unsought, they parallel the results of some previous 
studies (Monteleone et al., 2005; Nakazato et al., 2003) and they give ground to interesting hypotheses. For 
example, as weight loss is a prime behavioral abnormality of depression (APA 1994) and often a residual 
symptom in early remission (Paykel 1985; Paykel et al., 1995) it could be that, alternations in BDNF 
concentrations are mediated by (transient) changes in eating behavior during, or in the aftermath of, a 
depressive episode. Likewise, weight gain is a documented side effect of antidepressant treatment (Kachur 
et al., 2005; Antilla and Leinonen, 2001) and thus the absence of weight loss could potentially explain the 
absence of a relative fall of BDNF in depressed patients during treatment with an antidepressant. 
Alternative factors that have been proposed to underlie the low concentrations of BDNF during depression 
are exposure to stressful life events. Two studies found that adverse life events are associated with lower 
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peripheral BDNF concentrations within a depressed and bipolar patient samples (Kauer-Sant’Anna et al., 
2007; Grassi-Oliveira et al., 2008). Therefore, it seems worthwhile to integrate a wider range of variables, 
notably (early) adverse life events, but also genetic variants and their interactions with environmental 
variables (Gatt et al., 2009) in models that study the link between BDNF and depression. 
     In addition, we found that serum BDNF concentrations were higher in antidepressant-treated patients 
compared with patients who were antidepressant free. This finding largely is in accord with previous 
findings (Sen et al., 2008). We were able to expand previous findings by showing that the use of an 
antidepressant is associated with increased serum BDNF during a depressive episode but not during 
remission. This suggests that antidepressant-induced increases in BDNF occur in a disease state when BDNF 
functioning might be defective and not in remission when BDNF functioning is normalized. In addition, we 
found the increase in serum BDNF concentrations to be a specific associate of the use of SSRIs and St John’s 
wort and not of the use of SNRIs, TCAs or NaSSAs. Although not directly confirmed, this finding might be 
explained by increased availability of extra-synaptic concentrations of serotonin. It is known that serotonin 
stimulates the expression of BDNF (Mattson et al., 2004; Martinowich and Lu, 2008). In line with this, we 
found the highest BDNF concentrations in patients who were treated with an agent that generally leads to 
an increase in the availability of serotonin, that is, SSRIs and St John’s wort (Mann, 2005; Gaster and 
Holroyd, 2000). Furthermore, we found the lowest concentrations of BDNF in patients who were treated 
with agents that have little or no impact on the availability of serotonin, that is, NaSSAs (Kent, 2000; Antilla 
and Leinonen, 2001). Nevertheless, this antidepressant-specific finding seems at odds with the prediction 
of the neurotrophin hypothesis, stating that increases in BDNF concentrations are a key mediator for an 
antidepressant response to occur (Duman and Monteggia, 2006). According to this prediction, one might 
expect that antidepressants that are known to be about equally efficacious in the treatment of the 
symptoms of depression (Gaster and Holroyd, 2000; Kent 2000; Berton and Nestler, 2006) would have 
similar effects on serum BDNF concentrations. Yet another finding that seems hard to reconcile with the 
neurotrophin hypothesis is that the group of depressed persons who used antidepressants (for prolonged 
period and on a frequent base) had the highest BDNF concentrations, but also the highest symptom 
severity of depression. This suggests, to our belief that increases in peripheral BDNF concentrations do not 
parallel clinical effectiveness, or at least have no direct effects on depression characteristics such as its 
severity. Such a conclusion on the absence of direct effects could also be drawn on the findings that the 
severity of a depressive episode was unrelated to serum BDNF concentrations and that persons who were 
in early remission had similar concentrations of BDNF yet a marked lower depression severity as compared 
to currently depressed patients. Caution, however, is warranted when interpreting these findings because 
our patients were not randomly assigned to the various drugs (or no drug) conditions. Thus, our findings 
might be confounded by indication. An additional limitation of our study is that we relied on data that were 
collected in a single wave, precluding any form of causality. Furthermore, we measured serum 
concentrations of BDNF and assume that these measurements mirror the amount of BDNF in the brain. This 
assumption is validated on preclinical work that showed that cortical and peripheral concentrations of 
BDNF are correlated (Sartorius et al., 2009; Klein et al., 2010) but remains complicated, because in addition 
to neurons, several other tissues serve as sources of BDNF in serum (Karege et al., 2002). Various strengths 
of our study also seem evident and these include the use of multivariable techniques and the large sample 
size (that relates positive to all previous studies and to two previous meta-analyses (Brunoni et al., 2008). 
     In conclusion, we believe that our data indicate that low concentrations of BDNF in blood serum are a 
state characteristic of depression and thus an abnormality that is evident during the clinical state and the 
early remission phase of depression but not when the symptoms of depression are in full remission. Our 
findings further suggest that some of the core clinical features of depression are unrelated to serum 
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concentrations of BDNF. Finally, increases in serum concentrations of BDNF appear to be a specific 
pharmacological effect of a subset of antidepressants that does not parallel depression characteristics such 




































































































          CHAPTER 5 
 
 
Serum BDNF concentrations as peripheral manifestations of depression  









Published as: Serum BDNF concentrations as peripheral manifestations of depression: evidence from 
a systematic 
review and meta-analyses on 179 associations (N = 9,484) 
Molecular Psychiatry AOP, doi: 10.1038/mp.2013.105 
 
SIGNIFICANCE: This systematic review and meta-analyses is noteworthy in that it confirms that 
alternations in serum BDNF concentrations are peripheral manifestations of depresion. Yet, the 
evidence for this is way slimmer as was initially thought. An important implication of the message 


























Meta-analyses, published in 2008/2010, have confirmed abnormally low serum BDNF concentrations in 
depressed patients and normalisation of this by antidepressant treatment. These findings are believed to 
reflect peripheral manifestations of the neurotrophin hypothesis, which states that depression is 
secondary to an altered expression of BDNF in the brain. Since the publication of these meta-analyses, 
the field has seen a huge increase in studies on these topics. This motivated us to update the evidence on 
the aforementioned associations and, in addition, to compile the data on serum BDNF concentrations in 
relation to the symptom severity of depression. Using a manifold of data as compared to earlier meta-
analyses we find low serum BDNF concentrations in 2,384 antidepressant-free depressed patients 
relative to 2,982 healthy controls and to 1,249 antidepressant-treated depressed patients (Cohen’s d = -
0.71 and -0.56, P-values < .0000001). When publication bias is accounted for, these effect-sizes become 
substantially smaller (d = -0.47 and -0.34 respectively, P-values < .0001). We detect between-study 
heterogeneity in outcomes for which only year of publication and sample size are significant moderators, 
with more recent papers and larger samples sizes in general being associated with smaller between-
group differences. Finally, the aggregated data negates consistent associations between serum BDNF 
concentrations and the symptom severity of depression. Our findings corroborate the claim that altered 
serum BDNF concentrations are peripheral manifestations of depression. However, here we highlight that 































The neurotrophin hypothesis, originally formulated in 1997 by Duman, Heninger and Nestler, characterizes 
major depressive disorder as being secondary to aberrant neurogenesis in brain regions that regulate 
emotion and memory. According to this hypothesis; aberrant neurogenesis is brought about by a (stress 
induced) lower expression of Brain-derived Neurotrophic Factor (BDNF). In addition, the neurotrophin 
hypothesis predicts that antidepressants are efficacious because they increase BDNF expression and 
herewith resolve aberrant neuronal plasticity (Duman and Monteggia, 2006; Park and Poo, 2013). A large 
pre-clinical literature, allowing for mechanistic insights, fits very well with these predictions. Taliaz and 
colleagues (2010) for instance, showed in rats that a reduction of BDNF in the dentate gyrus impairs 
neurogenesis and induces depressive-like behavior. Human post-mortem studies have indicated similar 
alternations in the brains of persons who were depressed at the time of dying (Thompson Ray et al., 2011). 
Further support for abnormalities in BDNF expression in depressed patients comes from clinical studies. 
Karege et al. (2002) as the first, found serum BDNF concentrations to be low in depressed patients as 
compared to healthy controls and lowest in persons with the highest levels of symptom severity. Shimuzu 
et al. (2003) were the first to show an increase in serum BDNF concentrations in the course of 
antidepressant treatment. 
     These findings generated a buzz of research activity and in 2008/2010 the clinical data were summarized 
in three meta-analyses (Sen et al., 2008; Brunoni et al., 2008; Bocchio-Chiavetto et al., 2010). These meta-
analyses, basically including the same 11 studies (N ~ 968) confirmed the finding of low serum BDNF 
concentrations in untreated depressed patients (effect size [Cohen’s d] ~ -1) and normalization of this by 
antidepressant treatment (d ~ 1) whilst suggesting that these associations were not hampered by between-
study heterogeneity or publication bias. Accordingly, the conclusion was: BDNF may have potential use as 
biomarker for psychiatric disorders or as a predictor of antidepressant efficacy (Sen et al., 2008; page 527). 
Since then, the field has seen an abundance of new data on these topics. Important is that this new data 
entails striking variation in outcomes across studies (see for instance Basterzi et al., 2009 or Elfing et al., 
2012). This, and the abundance of new data, motivated us to update the current state of knowledge by 
calculating pooled effect-size estimates on differences in serum BDNF concentrations among: 
 
 Antidepressant-free depressed patients and healthy controls subjects  
 Antidepressant-free- and antidepressant-treated depressed patients  
 Antidepressant-treated depressed patients and healthy controls subjects  
 
     An additional aim was to compile the data on the putative relation between serum BDNF concentrations 
and the symptom severity of depression in: 
 
 Antidepressant-free depressed patients 
 Antidepressant-treated depressed patients 
 Healthy control subjects 
 
     A final aim, made possible by a large amount of studies, was to learn on the potential influence that 
some relevant moderators might have on the outcomes of our interest.  
 
Method 
We adhered to the guidelines that are recommended by the preferred reporting items for systematic 
reviews and meta-analyses statement (Moher et al., 2009). The literature search, decisions on inclusion, 





We searched the PUBMED, Embase, and PsychInfo through April 1st 2013 to identify eligible human studies 
on serum BDNF concentrations in healthy controls, depressed patients or in both. These digital searches 
were supplemented by backward searches in which the references to the seminal papers of interest were 
screened (Karege et al., 2002; Shimuzu et al., 2003) and by examining the reference sections of the 
retrieved papers. 
     We included peer-reviewed human studies that reported data on serum BDNF concentrations in healthy 
controls, and antidepressant-free and treated depressed patients. Inclusion was independent of clinical- 
and the methodological characteristics of the sample or study. Non-empirical studies were excluded, as 
were studies that were not written in English, Dutch, German or Spanish. Papers that reported on 
overlapping samples were excluded except for the one that reported on the largest number of subjects.  
 
Data Extraction 
We extracted, as primary outcomes, mean serum BDNF concentrations and Standard Deviation (SD) as a 
function of diagnostic status and antidepressant use and/or indices on the relation between BDNF 
concentrations and the symptom severity of depression (e.g., Pearson’s r). When BDNF concentrations 
were assessed at multiple time points we extracted the data recorded at baseline and at the longest 
follow-up period.  
     We also extracted data on mean age, gender distribution, depression severity, antidepressant use 
(subdivided by SSRIs, TCAs, and SNRIs), duration of antidepressant use, and the number of subjects in the 
study. Where records did not provide sufficient information, corresponding authors were contacted and 
the required data was requested. In those cases where non-significant results were reported in a paper 
(e.g., P > .05) and authors did not reply to our request, we assigned an estimated effect-size of zero. 
 
Quality Assessment 
We used the Newcastle-Ottawa Scale (NOS; Wells et al., 2013) to assess the quality of the included studies. 
Overall quality score was defined as the frequency of criteria that were met by the particular study. We 
excluded NOS items 4 and 7 because these are meaningless in the context of the current paper. Mean-
quality score of the included studies was 3.18 (Standard Deviation [SD] = 0.14). The agreement between 
the independent raters was excellent (Cohen’s Kappa = 0.89, Standard Error [SE]  = 0.03). 
 
Statistical analysis 
All calculations were performed using comprehensive meta-analyses 2.0 (Borenstein et al., 2009). Random 
effects models were applied to calculate pooled Cohen’s d (Cohen 1988) on between-group differences in 
serum BDNF concentrations. Pooled correlation coefficients were calculated on the relation between 
serum BDNF concentrations and the symptom severity of depression. All outcomes were weighted using 
inverse variance methods (Mosteller and Golditz, 1996). Statistical significance of the pooled effect-sizes 
was assessed using a Confidence Interval (CI) of 95%. The I2 measure was used to quantity the amount of 
between-study heterogeneity and considered to be high when I2 > 50% (Higgins and Thompson, 2002). 
Statistical significance of heterogeneity was assessed using the Q-statistic (Borenstein et al., 2009).  
     Through meta-regression analyses the possible moderating effects of between-study differences on 
outcomes was evaluated. We considered the number of subjects included in the study, year of publication, 
mean age, symptom severity of depression of the patient sample, gender distribution, and the NOS score 
as potential moderators for all outcomes of interest. The severity rating scales that were used differed 
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between studies. These instruments use different values to quantify severity (e.g., Hamilton 1960 or Rush 
et al., 1996) that do not necessarily equate to each other. Therefore, we used the validated severity 
categories: none, mild, moderate, severe, and very severe that can be derived from the continuous scores 
on each of these instruments as potential moderating variable. The moderation analysis on the difference 
in serum BDNF concentrations between healthy controls and antidepressant-treated depressed patients in 
addition included variables coding for the class of antidepressant and the duration of treatment. For the 
meta-analysis on antidepressant-free and treated depressed patients, the set of moderators was extended 
with a variable coding for change in depression severity over treatment defined as the percentage of 
improvement on the depression rating scale that was used.  
     Publication bias was assessed by inspection of funnel-plots and the Egger test (Egger et al., 1997). The 
trim-and-fill procedure, a validated manner to estimate an effect-size after bias has been taken into 
account (Duval and Tweedie, 2000; Peters et al., 2007), was performed in case of publication bias. Power 
and sample size calculations were performed using G*Power (Faul et al., 2009). Stability of our results was 
evaluated by sensitivity analyses in which each study was excluded from analyses at a time. 
 
Results 
Our initial search generated 730 papers of which 55 fulfilled the inclusion criteria for at least one of our 
meta-analyses. From these papers we could extract 124 between-group effect-size estimates and 55 
correlation coefficients. For details on the search strategy we refer to the flow chart (Figure 1 ↓). Table 1 
↓ lists in which meta-analysis the papers were included and provides demographic and clinical 




Figure 1. Flow-chart of the search strategy and results                                                                                                                                                                         
Abbreviations: BDNF; Brain-Derived Neurotrophic Factor; HC; Healthy Controls, MDD; Major Depressive Disorder.                                                                                                                            
A 192 records reported on the BDNF gene, 193 records were reviews, perspectives, comments or hypotheses, 36 records reported on animal data, 14 records were post-
mortem studies, 12 records were in vitro studies, and 111 records did not rapport on BDNF. 
B 2 records reported overlapping data, 3 records reported on the BDNF gene, 64 records reported on plasma BDNF concentrations, 3 records were reviews, 43 records 
did not reported on serum BDNF concentrations in illnesses other than depression and did not indicate that depression related assessments were performed. 
C




Table 1.  Summary of study characteristics of included studies (studies are sorted by year and month of publication) 
 















   n c 
 
severity  
Karege et al., 2002       (1)(5)   B-S     60    50 37    HC 
   Depressed + 
    30 
    30 
   MADRS 
Shimuzu et al., 2003 (1)(2)(3)(5)(6)   both      83    43 43    HC 
   Depressed - 
   Depressed + 
    50 
    16 
    17 
   HAMD 
Gervasoni et al., 2005 (1)(2)(3)(4)   both      52    54 40    HC 
   Depressed - 
   Depressed +  
    26 
    26 
    26 
   MADRS 
Gonul et al., 2005 (1)(2)(3)(4)(5)   both      46    71 36    HC 
   Depressed - 
   Depressed + 
    18 
    28 
    28 
   HAMD 
Karege et al.,  2005 (1)(4)    B-S      78    56 34    HC  
   Depressed - 
    35 
    43 
   MADRS 
Aydemir et al., 2005 (1)(2)(3)   both      20    80 36    HC 
   Depressed - 
   Depressed +  
    10 
    10  
    10 
   HAMD 
Zanardini et al., 2006 (6)   W-S      16    69 56    Depressed +      16    HAMD 
Lommatzsch et al.,  2006 (1)(5)   B-S      80   100 28    HC 
   Depressed - 
    62 
    18 
   EPDS 
Ayedemir et al., 2006 (1)(2)(3)   both      40   100 35    HC 
   Depressed - 
   Depressed + 
    20 
    20 
    20 
   HAMD 
Bocchi-Chiavetto et al., 2006 (6)   W-S      12    70 53    Depressed +     12    MADRS 
Lang et al., 2006 (4)   B-S      24    NK 46    Depressed - 
   Depressed +  
      8 
    16 
   MADRS  
Aydemir et al., 2007 (1)    B-S      50    74 33    HC 
   Depressed- 
    26 
    24 
   HAMD 
Yoshimura et al., 2007       (1)(2)(3)(4)   both      72    65 46    HC 
   Depressed - 
   Depressed + 
    30 
    42 
    42 
   HAMD 
Ziegenhorn et al., 2007 (1)(5)   B-S    465    48 85    HC 
   Depressed- 
  259 
     91 
   HAMD 
Hellweg et al., 2007 (3)   W-S      40    71 51    Depressed -  
   Depressed + 
     40 
     40 
   HAMD 
Okamoto et al., 2008 (6)   B-S      18    50 61    Depressed +      18    HAMD 
Stanek et al., 2008 (4)   B-S      34    56 73    HC      34    PRIME 
Huang et al., 2008 (1)(2)(3)   both    218    72 33    HC 
   Depressed - 
   Depressed + 
   107 
   111 
     79 
   HAMD 
Piccini et al., 2008 (1)(2)(3)   both      30    83 42    HC 
   Depressed - 
   Depressed + 
     15 
     15 
     15 
   HAMD 
 
Matrisciano et al., 2009 (1)(2)(3)   both      41    51 37    HC 
   Depressed - 
   Depressed + 
     20 
     21 
     21 
   HDRS 
Basterzi et al., 2009 (1)(2)(3)   both     58    67 33    HC 
   Depressed - 
   Depressed + 
     15 
     43 
     43 
   HAMD 
Gorgulu et al., 2009 (1)(2)(3)   both      72    69 36    HC 
   Depressed - 
   Depressed + 
     31 
     41 
     22 
   HAMD 
Grønli et al., 2009 (6)   B-S     15    60 70    Depressed +      15    HAMD 
Umene-Nakano et al., 2009 (1)(5)   B-S     40    25 44    HC 
   Depressed - 
     20 
     20 
   HAMD 
Fernandes et al., 2009 (2)(6)   B-S     40    60 42    HC 
   Depressed + 
     30 
     10 
   HAMD 
Lee et al., 2009 (1)   B-S    132    61 74    HC 
   Depressed - 
     98 
     34 
   GDS 
Ozan et al., 2010 (1)   B-S    122    70 34    HC 
   Depressed - 
     56 
     66 
   HAMD 
Diniz et al., 2010 (1)(4)    B-S     71    83 70    HC 
   Depressed - 
     42 
     29 
   HAMD 
Eker et al., 2010 (1)(4)     B-S     47    75 31    HC 
   Depressed - 
     22 
     25 
   HAMD 
Bocchi-Chiavetto et al., 2010 (1)(4)   B-S      84    81 43    HC 
   Depressed - 
     59 
     25 
   MADRS 









Table 1 continued 
 















    n 
 
severity  
Hu  (1)   B-S     84    73 43    HC 
   Depressed a - 
   Depressed b - 
     28 
     28 
     28 
HAMD 
Zhou et al., 2011 (1)    B-S   123    NK NK    HCa 
   HCb 
   Depressed - 
     30 
     58 
     35 
   HAMD 
Su et al., 2011 (1)   B-S     52      0 23    HC 
   Depressed - 
     21  
     31  
   NK 
Rojas et al., 2011 (3)   B-S     34    71 42    Depressed - 
   Depressed +  
     34 
     34 
   HAMD 
Yoshimura et al., 2011 (3)(4)    W-S   132    60 51    Depressed  – 
   Depressed + 
   132 
   132 
   HAMD 
Wolkowitz et al., 2011       (1)(2)(3)    B-S      57    36 39    HC 
   Depressed - 
   Depressed + 
     28 
     29 
     25 
   HAMD 
Kobayakawa et al., 2011 (1)   B-S    162    30 65    HC 
   Depressed - 
     81 
     81 
   HADS 
Terraciano et al., 2011 (5) 
 
  B-S 2,099    62 51    HC 
   Depressed - 
1,661 
   438 
   CES-D 
Molendijk et al., 2011 (1)(2)(3)(4)(5)(6)   B-S 1,344    65 42    HC 
   Depressed - 
   Depressed + 
   382  
   541 
   421  
   IDS 
 
Toups et al., 2011 (6)   B-S       70    80 47    Depressed +       70    HAMD 
Satomura et al., 2011 (2)(4)(5)   B-S    272    63 53    HC 
   Depressed + 
   163 
   109 
   HAMD 
Sasaki  et al., 2011 (1)(2)(3)(5)(6)   B-S       52    56 13    HC 
   Depressed - 
   Depressed + 
      22 
      19 
      11 
   CDRS-R 
Sozeri-Varma  et al.,  2011 (1)(4)    B-S       70    73 37    HC 
   Depressed - 
      40 
      30 
   HAMD 
Bus et al., 2012 (4)   B-S 1,230    50 61    HC 1,230    BDI 
Gedge et al., 2012 (5)   W-S       29    69 45    Depressed +       29    HAMD 
Gazal et al., 2012 (1)   B-S       72  100 25    HC 
   Depressed - 
      36 
      36 
   BDI 
Birkenhäger et al., 2012 (6)   W-S       42    43 47    Depressed -       42    HAMD 
Deuschle  et al., 2012 (1)(2)(3)(4)   W-S       70    72 52    HC 
   Depressed - 
   Depressed + 
      14 
      56 
      56 
   HAMD 
Harvey  et al., 2012 (1)(5) 
 
  W-S    200    49 44    HC 
   Depressed - 
      89 
   111 
   PHQ-9 
Oral et al., 2012 (1)(5)   B-S      79    68 27    HC 
   Depressed - 
      40 
      39 
   BDI 
Karlovic et al., 2012 (1)   B-S    264    50 46    HC 
   Depressed - 
   142 
   122 
   HAMD 
Jeon et al., 2012 (1)(2)(3)(4) 
  
  W-S    155    71 44    HC 
   Depressed - 
   Depressed + 
     50 
   105 
   105 
   HAMD 




  B-S    147    56 38    HC 
   Depressed + 
     78 
     69 
   SIGH-D 
Elfving et al., 2012 
 
(1)(2)   B-S    406    81 46    HC 
   Depressed - 
   Depressed + 
   289 
   117 
      45 
   ICD-10 
Papakostas et al., 2013 (1)   B-S      79   52 36    HC 
   Depressed - 
      43 
      36 
  HAMD 
Abbreviations: HC, Healthy controls; Depressed -, antidepressant free; Depressed +, antidepressant treated; NK, Not Known. 
A This column indicates in which meta-analysis the study that is indicated in the corresponding row is included: (1) HCs vs. depressed -; (2) HCs 
vs. depressed +; (3) Depressed - patients vs. MDD+; (4-6) regard meta-analyses on continuous associations between serum BDNF concentrations 
and depression severity scores: (4) in HC’s; (5) in depressed -; (6) in depressed +.  
B This column, design, indicates whether Within-Subjects data (W-S), a Between-Subjects data (B-S), or a combination of these types of data 
(both) is used by the study that is indicated in the corresponding row. 
C Note that the numbers in the column n do not add to the numbers as they are given in the column N. This is because the numbers in column n, 




Random-effects meta-analyses showed that antidepressant-free depressed patients had lower BDNF 
concentrations as compared to healthy controls (d = -0.71, 95% CI = -0.89 ― -0.53, P < .0000001; 46 
comparisons, n = 5,203; see Figure 2 ↓) and to those of antidepressant-treated depressed patients (d = -
0.56, 95% CI = -0.77 ― -0.35, P < .00001, 28 comparisons, n = 4,204). Repeating this latter analysis using 
only studies that reported pre- and post-treatment BDNF concentrations gave a somewhat higher effect-
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size estimate (d = -0.74, 95% CI = -1.04 ― -0.45, P < .0000001, 23 comparisons, within-subjects data on 711 
patients pre- and post-treatment). Differences in BDNF concentrations among healthy controls and 
antidepressant-treated depressed patients were not observed (d = 0.07 P = .52; 24 comparisons, n = 
3,720). Forest plots (except Figure 2 ↓) are provided as supplementary materials (Figure S1–S3) in 
Appendix III of this thesis. 
 
 
Figure 2. Forrest plots for random effect meta-analyss on differences in serum BDNF concentrations between healthy  
control subjects and antidepressant-free depressed patients. The sizes of the squares are proportional to sample size. 
 
A meta-analysis aggregating 30 associations (n = 1,807) on the relation between BDNF concentrations and 
the symptom severity of depression in antidepressant-free depressed patients yielded a statistically 
significant, negative correlation (r = -0.19; 95% CI = -0.28 ― -0.10, P < .00001). There was no evidence for a 
relation between serum BDNF concentrations and depression severity in antidepressant-treated depressed 
patients (r = -0.02; P = .36, 20 associations, n = 1,820) or in healthy controls (r = -0.02; P = .41, 5 
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associations, n = 2,276). Forest plots are provided as supplement (Figure S4–S6) in Appendix III of this 
thesis. 
 
Between–study heterogeneity and moderation analyses 
A large amount of between-study heterogeneity in outcomes was identified in all meta-analyses that 
yielded significant outcomes (55% < I2 < 87%, for I2-, Q-, and P-values we refer to Table 2 ↓). 
 





No. of subjects Heterogeneity Publication bias 
   HC Depressed- Depressed+    I
2 
 Q P Egger’s t P 
Group-wise comparisons          
  HC                 vs  depressed - 41  2,911 2,292 NA    86.1% 287.6 < .001    4.2 < .001 
  HC                 vs  depressed+ 24  2,591 NA 1,129    84.6% 150.2 < .001    1.4    .16 
  Depressed- vs depressed + 27   NA 2,955 1,249    84.4% 165.1 < .001    2.5 < .05 
  Depressed- vs depressed + W-S 1 23   NA     711     711  83.9% 136.8 < .001    2.6 < .05 
Continuous associations          
  HC    5 2.276 NA NA    14.8%      4.7     .32    1.0    .15 
  Depressed -  29   NA 1,807 NA    67.9%   87.2 < .001    2.5 < .05 
  Depressed+  19    NA NA 1,820    18.3%    48.9      .36    0.6    .53 
Abbreviations: HC, Healthy controls; depressed-, antidepressant free; depressed+, antidepressant treated; NA, Not Applicable; W-S, Within-Subjects 
data 
1 Here, only associations were included that were derived using a within-subjects designs (i.e., treatment studies) 
 
In a series of meta-regression analyses, we aimed to identify sources of heterogeneity in outcomes. We 
observed that differences in serum BDNF concentrations among antidepressant-free depressed patients 
and healthy control subjects could partly be explained by sample size (r = −0.33, R2 = 0.11, P = 0.03) and by 
year of publication (r = −0.30, R2 = 0.09, P = 0.04), with larger samples and more recently reported papers 
in general reporting smaller between-group differences. In the meta-analysis on changes in serum BDNF 
concentration over the course of antidepressant treatment, we found that a larger decrease in symptom 
alleviation was accompanied by a larger increase in BDNF concentrations (r = −0.48, R2 = 0.22, P = 0.01). 
Other moderators, including NOS score, were not observed (see Table 3 ↓ for all coefficients). Moderation 
analyses were not performed when between-study heterogeneity was not detected. 
 
Publication bias and power 
Visual inspection of the funnel plots suggested that there was evidence for publication bias in all meta-
analyses that yielded a significant outcome. Egger’s tests confirmed this (t-values in the range 2.5 – 4.2, P-
values all < .05, see Table 2 ↑ for exact values).  
     Trim-and-fill estimations were used to assess the impact of publication bias. The meta-analysis on 
differences in BDNF concentrations among healthy controls and untreated depressed patients suggested 
that 9 studies had to be imputed to result in a symetric funnel plot. Imputation led to a smaller, yet 
significant, effect-size (d = -0.47, 95% CI = -0.64 ― -0.27, P < .000001). The pattern of publication bias was 
similar in the meta-analyses comparing group differences among antidepressant-free and treated subjects, 
where 5 (all data) and 4 studies (within-subjects data) needed to be imputed to yield a symetric funnel 
plot. Also here, imputation led to smaller effect-size estimates (d = -0.54 and -0.34 respectively, P-values < 
.001). Likewise, for the meta-analyses on the continous association between serum BDNF concentrations 
and the symptom severity of depression in untreated depressed persons, the trim-and-fill estimations 
suggested that 5 studies had to be imputed to result in a symetric funnel plot pattern. Herewith, the effect-
size estimate (r = -0.07) was no longer statistically signinicant. Funnel plots are provided in Appendix III 




Table 3. Associations (Pearson’s correlation coefficients for continuous- and Spearman’s Rho correlation coefficients for categorical 
variables) between study characteristics and study effect size (by meta-analysis)  
Group differences HC vs. depressed-  HC vs. depressed+ Depressed- vs. depressed+  Depressed- vs. depressed+ W-S 
 41 effect-sizes 
n = 5,203 
24 effect-sizes 
n = 3,720 
27 effect-sizes 
n = 4,204 
23 effect-sizes 
n = 1,422 
Gender (percentage female)        0.16        0.11        0.06        0.08 
Age (mean, years)        0.13       -0.11        0.08        0.11 
Depression severity (cat.)      -0.17       -0.10       -0.21       -0.07 
Percentage SSRI        NA         0.29       -0.35 
#
       -0.34 
Percentage TCA        NA       -0.21        0.13        0.11 
Percentage SNRI        NA       -0.10        0.17        0.17 
Percentage NaSSA        NA       -0.14        0.14        0.15 
Duration of treatment (weeks)        NA       -0.34        0.04        0.04 
Clinical response on treatment         NA        NA        NA      -0.48 * 
Sample size (n)        0.33 *       -0.15        0.25        0.21 
Year of publication        0.30 *       -0.16        0.18        0.18 
Study quality (criteria met)        0.04        0.06        0.35 
#
        0.34 
Abbreviations: HC, Healthy controls; depressed-, antidepressant free; depressed+, antidepressant treated; NK, Not Known; W-S, Within-
Subjects data only (i.e., associations were that were derived using a within-subjects design. 
1 Given that there was no evidence for between-study heterogeneity, moderation analysis was not performed in these sub-groups. 
* Statistically significant at P < .05  # Trend-like finding at P < .10 
 
      We calculated the numbers of subjects that are needed to detect differences with a power of 0.80 at an 
α-level of .05 (one-sided). Hereto we used the pooled effect-size estimates that were corrected for 
publication bias. These calculations suggested that 57 subjects in each group would be neccesary to 
reliably detect differences in serum BDNF concentrations between healthy controls and antidepressant 
free depressed subjects. For differences in serum BDNF concentrations among antidepressant-free and 
treated persons, this number would be 108. Based on this, the majority of the included samples was not 
sufficiently powered (observed median sample size = 36). Sample-size calculations were not performed for 
continuous associations between serum BDNF concentrations and the symptom severity of depression 
since these were not statistically significant.  




Here we confirm, based on a manifold of data as compared to previous meta-analyses (Sen et al., 2008; 
Brunoni et al., 2008; Bocchio-Chiavetto et al., 2010) that serum BDNF concentrations are low in untreated 
depressed patients and normalized by antidepressant treatment. The moderate to large effect-sizes that 
we rapport on these differences (random-effects meta-analyses, d = -0.71 and -0.56 respectively) are 
similar to the ones that were reported in the seminal studies (Karege et al., 2002; Shimuzu et al., 2003) and 
in previous meta-analyses. These findings are not new. The novelty of our work, instead is that our 
analyses highlight a large amount of unexplained between-study heterogeneity in outcomes and 
publication bias that together may call for a critical interpretation of the claim that altered serum BDNF 
concentrations are related to, and a clinical useful marker for, the illness depression. 
     We find a large amount of between-study heterogeneity in outcomes and none of the theoretically 
relevant variables that we tested  (e.g., the symptom severity of depression or gender distribution of the 
sample) was associated with this. Understanding the sources of the observed heterogeneity is essential 
and obviously, it may have come from between-sample characteristics that were not tested in our study, 
such as alcohol consumption and smoking (Bus et al., 2011), sleep problems (Giese et al., 2013), 
seasonality (Molendijk et al., 2012), or exposure to trauma (Elzinga et al., 2011). Given that depression is a 
63 
 
heterogeneous illness (Rush 2007), heterogeneity in outcomes may also have come from diversity in 
clinical characteristics of patient samples. The severity of depression, however, did not explain it. 
Unfortunately, we did not have the opportunity to test many of the other clinical characteristics because 
most of the included studies did not report on these variables.  
     We did find an artificial base for the heterogeneity in outcomes. First, a large part of the studies 
included in our meta-analysis was underpowered. Given that a low level of power increases the false 
versus true positive ratio (Sterne and Smith, 2001), some overly positive findings may have been among 
the studies that we included, causing heterogeneity in outcomes. Second, we found that sample size and 
year of publication were significant predictors of between-study heterogeneity, with larger samples and 
more recently published findings being associated with smaller between-group differences. This indicates 
publication bias; a particular threat to the validity of a meta-analysis (Dickersin 1990). We indeed found 
evidence for publication bias in funnel-plots (Egger et al., 1997) and we applied validated trim-and-fill 
procedures to provide effect-size estimates that account for this (Peters et al., 2007). These yielded 
attenuated effect-size estimates that were about half as large as those reported in previous meta-analysis 
(Sen et al., 2008; Bocchio-Chiavetto et al., 2010) and of moderate magnitude at best (d = -0.47 through -
0.34). The often discussed association between serum BDNF concentrations and the symptom severity of 
depression (e.g., Karege et al., 2002), for which we initially found some evidence, even lost its statistical 
significance after correcting for publication bias and thus likely does not exist. Given that the relevance of a 
diagnostic biomarker (i.e., a variable that is able to distinguish between diagnostic groups; Kapur et al., 
2012) depends on the magnitude of an effect-size (and not on statistical significance per se; Kapur et al., 
2012), we conclude that serum BDNF concentrations are likely to be of little clinical use (as has been 
suggested in two earlier excellent reviews Groves 2007; Gass and Hellweg, 2010). Complicating this even 
more is that low serum BDNF concentrations have been reported in persons diagnosed with schizophrenia 
(Green et al., 2011), bipolar disorder (Fernandes et al., 2011), eating disorders (Montleone et al., 2005), 
and anxiety (Molendijk et al., 2012) indicating that serum BDNF concentrations are not specific enough to 
differentiate among diagnoses. Multiple-assay methods may serve a role as biomarker better, as recently 
has been shown (Papakostas et al., 2013). 
     Although limited in scope with regard to clinical utility, our findings do not dismiss the possibility that 
abnormalities in BDNF expression reflect the pathophysiological processes that may underlie depressive 
illnesses (Duman et al., 1997; Duman and Monteggia, 2006). Even more, the associations that we report 
on, also when adjusting for publication bias, stand out as being strong when compared to other biological 
abnormalities in depression, for instance blood markers for immune dysregulation (e.g., CRP and IL-6 [d = 
0.15 and 0.25 respectively]) or HPA-axis activity (e.g., adrenocorticotropin hormone [d = 0.28] for a review 
on these abnormalities see Penninx et al., 2013).  
     A difficulty that remains however is that we studied peripheral BDNF concentrations. There are 
indications that BDNF concentrations measured in serum reflect BDNF activity in the brain (e.g., Dawood et 
al., 2007; Klein et al., 2010). However, it has never been proven that peripheral BDNF concentrations 
directly reflect or influence the pathophysiology of depression. A complication is  that other tissues than 
the brain, including immune-, liver-, smooth muscle-, and vascular endothelial cells serve as sources of 
BDNF (Cassiman et al., 2001; Karege et al., 2002b). The lower peripheral BDNF concentrations in 
depression and up-regulation of this in the course of antidepressant treatment therefore may be an 
epiphenomenon resulting from an altered BDNF expression (or metabolism) by these peripheral organs. 
Therfore, the alternations that we rapport on do not neccesarly indicate that similar alternations occur at a 




Strengths and limitations 
The work presented herein has as obvious strength that it is based on a large amount of data (total N = 
9,484), yielding in general accurate effect-size estimates (Ioannidis 2005). Another strength is that through 
sensitivity- and moderation analyses we addressed the potential influence of single studies and sources of 
heterogeneity. Notwithstanding this, our work carries limitations that need to be reflected upon.  
     Some limitations regard the methods that we used. First, we relied on funnel-plot assymetry and trim-
and-fill estimations to assess publication bias. These methods are limited in that one never knows whether 
asymmetry in a funnel-plot is due to publication bias or to unmeasured differences between studies 
(Munafo and Flint, 2004) and whether the most extreme effect-sizes are the ones that are left unpublished 
(Peters et al., 2007). Second, in at least some regards the methods that we used were limited with regard 
to their ability to detect associations. The meta-regression analyses, for instance, may have been 
underpowered. Besides, P-values were not adjusted for multiple comparisons. Also important is that there 
may have been noise in our assessment of individual study quality. The NOS scale that we used to this end, 
although recommended by the Cochrane Collaboration (www.cochrane.org) is not rigorously validated and 
therefore our quality assessments may have been unreliable (Sanderson et al., 2007). Together, this may 
have limited our ability to detect true associations (i.e., false negatives) or may have led to the detection of 
associations that in reality do not exist (i.e., false positives). Finally, our findings are limited in scope in that 
they cannot be directly generalized to other BDNF parameters such as plasma or whole blood BDNF 
concentrations since there is no one–to–one relationship among these measures (see for instance 
Terracciano et al., 2010). 
 
Future work 
There are several issues that deserve future research attention. First, our finding of a greater increase in 
serum BDNF concentrations in the course of antidepressant treatment is associated with a larger decrease 
in depression symptom severity may fuel work into the temporal dynamics between BDNF expression and 
treatment efficacy. It would be interesting if future studies could address early changes in the course of 
(non-)pharmacological treatment, a notion for which some evidence exists (Lang et al., 2006; Machado-
Vieira et al., 2009; aan het Rot et al., 2012). Besides, the prediction of how successful a given treatment 
will be, based on changes in serum BDNF concentrations (i.e., a treatment biomarker) is clinically relevant 
(see for instance Schmidt et al., 2011). In our meta-analysis we did not have the possibility to address this 
because most of the included studies reported on pre- and post BDNF concentrations only. Another venue 
for future investigations regards the distinction between the pro- and the mature BDNF variant. The ELISA 
kits that currently are in use to quantify BDNF are not sensitive enough to make this distinction. Given the 
proposed opposing effects of these two BDNF variants (proBDNF is believed to induce apoptosis; Park and 
Poo, 2013) it would be interesting to study pro/mature BDNF ratios and whether these differ among 
diagnostic groups. The tools hereto were only recently developed and validated (Yoshida et al., 2012).  
     With regard to future work on peripheral BDNF concentrations we finally wish to note that analyses 
would gain credibility if they were controlled for relevant confounding factors and performed using data 
(preferably within-subject) on a sufficiently large sample (N ~ 150, according to our power-analyses). 
 
Concluding remarks  
Our meta-analyses (aggregating 179 effect-size estimates; N = 9,484) initially yielded support for the claim 
that alternations in serum BDNF concentrations are peripheral manifestations of depression. This is not 
new. The important contribution of our work however is that we clearly show that between-study 
heterogeneity, underpowered designs, and publication bias are at play that together give rise to inflated 
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effect-size estimates. Together this suggest that the evidence base for the claim that altered serum BDNF 
concentrations are peripheral manifestations of depression is slimmer as was initially thought and amidst a 
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SIGNIFICANCE: Anxiety disorders mimic depression to a great extent, so it was expected that serum 
BDNF concentrations would be low in the patients with such an illness. In this well-powered study 
we could not confirm this expectation, exepct for somewhat lower BDNF concentrations in female 
patients. This gender specific finding may suggest that BDNF is involved in the pathophysiology of 



























Whereas animal models indicate that Brain-Derived Neurotrophic Factor (BDNF) plays a role in anxiety-
related behavior, little is known about BDNF in patients with an anxiety disorder. We therefore tested the 
hypothesis that serum BDNF concentrations are low in patients with an anxiety disorder as compared to 
healthy controls. We further examined the associations of gender and some of the clinical characteristics of 
anxiety with serum BDNF concentrations. Hereto, serum BDNF concentrations were determined in 393 
unmedicated patients with social anxiety disorder, panic disorder, agoraphobia, and generalized anxiety 
disorder (66.7% females) and in 382 healthy controls (62.0% females). Overall, there were no differences in 
BDNF concentrations among patients and controls, regardless of type of anxiety disorder. Analyses 
stratified by gender, however, revealed that female patients had lower concentrations of BDNF relative to 
female controls (P < 0.05, effect size (Cohen’s d) = 0.19), which was stronger in female patients with > 1 
anxiety disorder (P < 0.01, d = 0.32). BDNF concentrations were similar among male patients and male 
controls and unrelated to the clinical characteristics of anxiety. Our results mirror preclinical findings 
indicating that gender plays a role in the association between BDNF and anxiety and suggest that BDNF 


































Brain-derived neurotrophic factor (BDNF), a neurotrophin that regulates neuronal survival and plasticity 
(Bramham and Messaoudi 2005), has been attracting growing attention in relation to major depressive 
disorder. The neurotrophin hypothesis of depression predicts that aberrant support by BDNF is associated 
with neuronal atrophy and an increased risk of depression (Duman et al., 1997; Duman and Monteggia 
2006). Consistent with this neurobiological concept on depression are the replicated findings that BDNF 
concentrations are low in central and peripheral tissues during a depressive episode (Dwivedi et al., 2003; 
Molendijk et al., 2010). Depression is often accompanied by anxiety and it is believed that these disorders 
share similarities in their etiology and pathophysiology (Kendler et al., 1992, 1995; Klaassen et al., 1998; 
Maron et al., 2004; David et al., 2009). Therefore, some authors sought to extend the neurotrophin 
hypothesis of depression to the anxiety disorders. The first attempts to investigate the link between BDNF 
and anxiety used rodent models for anxiety-like behavior. Chen et al. (2006) for example genetically 
manipulated male mice so that the secretion of BDNF from neurons got depleted, which was associated 
with behavior that resembled human anxiety. Findings of Monteggia et al. (2007) on the other hand, seem 
to indicate that the conditional knockout of BDNF is associated with decreased anxiety-like behaviour in 
female mice, while having no effect on anxiogenic behavior in male mice. Finally, Govindarajan et al. (2006) 
reported that an enhanced expression of BDNF had a facilitatory effect on anxiety-like behavior in male 
mice. Thus, these data, although intriguing, remain inconclusive with regard to whether the neurotrophin 
hypothesis also applies to anxiety like-behavior. However, the data do support sex differences with regard 
to the association between BDNF and anxiety-like behavior. Data on BDNF protein concentrations in 
humans with an anxiety disorder is limited to two relatively small-scale studies in patients with panic 
disorder. The evidence from these studies is conflicting. The first of these studies found similar BDNF 
concentrations in 42 patients with panic disorder as compared to 31 controls (Kobayashi et al., 2005), 
whereas the second found lower BDNF concentrations in 12 patients with panic disorder as compared to 12 
controls (Strohle et al., 2010). Data on the associations between BDNF and other anxiety disorders than 
panic disorder, such as social anxiety disorder or generalized anxiety disorder, are not available. Such data, 
however, are relevant because it could increase our understanding of the pathophysiology that may 
underlie anxiety (Martinowich et al., 2007). Here we addressed this important issue and determined serum 
BDNF concentrations in 393 unmedicated patients (66.7% females) with social anxiety disorder, panic 
disorder, agoraphobia, and generalized anxiety disorder, or a combination of these disorders and in 382 
healthy controls (62.0% females). All patients were currently free of depression. We tested the hypothesis 
that serum BDNF concentrations are low in patients with an anxiety disorder as compared to controls in 
analyses that were controlled for a range of demographical and behavioral confounders. We further 
performed analyses on gender differences with regard to serum BDNF concentrations. Finally, in our 
patient sample, we tested whether and to what extent the type of anxiety disorder, the severity of anxiety, 





The data analyzed are from the Netherlands Study of Depression and Anxiety (NESDA; see Penninx et al., 
2008 for an overview). Briefly, the NESDA is a prospective cohort study on 2,981 persons (66.4%female, 
aged 18 through 65) who were recruited in specialized mental health care, primary care, and in the general 
population. Included in NESDA were persons with a current or a remitted anxiety and/or mood disorder 
and persons without a lifetime diagnosis of an anxiety or mood disorder. Persons with a psychotic, bipolar, 
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obsessive–compulsive or severe addiction disorder were not eligible. Diagnoses of anxiety disorders (i.e., 
Social Anxiety Disorder (SAD), Panic Disorder (PD), Generalized Anxiety Disorder (GAD), and Agoraphobia 
(Agr), and depressive disorders (i.e., major and minor depressive disorder and dysthymia) were determined 
on the basis of responses to the Composite International Diagnostic Interview 2.1 (CIDI) life-time version 
(Wittchen et al., 1991) according to the criteria set forth in the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition (DSM-IV; APA 1994). The CIDI is a commonly used diagnostic instrument and has a 
high reliability (Wacker et al., 2006) and validity (Wittchen et al., 1991). At baseline, participants also 
underwent a medical examination and provided blood samples. All subjects gave written informed consent 
for the study that was approved by the Ethical Committees of the participating institutes. The sample that 
was examined here consisted of NESDA participants who were diagnosed with PD, SAD, Agr, GAD, or a 
combination of these disorders within the last 6 months and of healthy controls. To allow a study on the 
association of BDNF with anxiety without the confounding effects of depression and psychotrophic 
medication use (associations that our group previously confirmed, see Molendijk et al., 2010) we selected 
patients who were currently free of depression and who were untreated with anxiolytics (ATC code N05B) 
and antidepressants (ATC codes N05B, N06A, and N06AX; WHO 2010) and St John's Wort. Healthy controls 
were eligible for inclusion if they were free of life-time anxiety and mood disorders, not at high risk for 
these disorders because of a documented family history of these illnesses, and if they scored low on Beck's 
Anxiety Inventory (BAI; < 10; Beck et al., 1988) and on the Inventory of Depressive Symptoms (IDS; < 14; 
Rush et al., 1996). We included a total of 393 patients and 382 lifetime healthy controls. 
 
BDNF protein measurements 
Serum samples were obtained before 10:00 h after an overnight fast and stored at –85 C˚. Serum BDNF 
protein concentrations were measured, in duplicate, using the Emax Immuno Assay system from Promega 
according to the manufacturer ' s protocol (Madison, WI, USA) by one technician who was blind to clinical 
diagnoses. Measurement procedures are described in detail elsewhere (Bus et al., 2011). In brief, serum 
samples were diluted 100 times, and the resulting absorbency was read in duplicate using a Bio-Rad 
(Hercules, CA, USA) Benchmark microplate reader at 450 nm. The intra- and inter-assay coefficients of 
variation were within 3 and 9% respectively. 
 
Clinical characteristics 
Four clinical characteristics were examined with regard to their association with serum BDNF 
concentrations. These included the severity of anxiety symptoms, the chronicity of anxiety, the age at onset 
of anxiety, and a history of MDD. Continuous scores based on BAI (Beck et al., 1988) were used as a 
measure for the severity of anxiety symptoms. BAI is a 21-item self-report measure that has good validity 
(Kabacoff et al., 1997) and test–retest reliability (Beck et al., 1988). The measure for the chronicity of 
anxiety was based on the life chart interview, a commonly used method to describe the course of 
psychopathology (Lyketos et al., 1994). The life chart refreshes memory by determining life events that 
occurred during the last 4 years and based on these “memory anchors” subsequently assesses the presence 
of anxiety symptoms during this interval. This yields a score in the range 0 – 48 months with avoidance 
behavior and/or panic attacks during the past 4 years. The CIDI interview (Wittchen et al., 1991) served as 
source of information on the age at onset of anxiety (i.e., the age in years when the first episode of anxiety 





Previously we described that age, body mass index (BMI), smoking, alcohol intake, physical activity, time of 
the day of blood draw (in minutes from 06:00 h), and number of months of serum storage are associated 
with serum BDNF concentrations (Bus et al., 2010; Molendijk et al., 2010). Therefore, we took the possible 
confounding role of these variables into account by including them as covariates in all analyses. Data on 
age, BMI (weight/height2), smoking (dichotomized as smoker versus non smoker), and alcohol use (coded 
as non-drinker, 0–1 units a day, 1–2 units a day, and > 2 units a day) were collected using standard methods 
(Penninx et al., 2008). Information on physical activity was gathered using the international physical activity 
questionnaire (Craig et al., 2003) and expressed as number of met-minutes (i.e., the ratio of the amount of 
energy expenditure during activity to the energy expenditure at rest). Together, this set of variables will be 
referred to as the set of basic covariates. 
 
Statistical analysis 
Demographical and clinical characteristics between patients and controls were compared using analyses of 
variance and Students t-tests for continuous data and χ2 tests for categorical data.  
     Analysis of variance (ANOVA) with correction for the set of basic covariates was performed to assess 
differences in serum BDNF concentrations between all patients with an anxiety disorder and healthy 
controls. This analysis was repeated with diagnosis and gender as factors (2 times 2 ANOVA: any anxiety 
diagnosis versus controls and gender) to explore whether serum BDNF concentrations were comparable 
among female and male patients and controls and to test a possible interaction between diagnosis and 
gender. Next, a multiple linear regression analysis was performed to investigate whether serum BDNF 
concentrations differed between the subtypes of anxiety diagnoses (i.e., SAD, PD, Agr, GAD, or > 1 anxiety 
disorders) and controls. In this analysis the set of basic covariates was entered in a first step of regression 
and dummy variables coding for the presence of each of the anxiety disorders were entered in a second 
step. The control group served as reference category.  
     In the patient sample, a regression analysis, corrected for the basic covariates, was performed to assess 
whether serum BDNF concentrations were associated to the severity-, the chronicity-, and the age at onset 
of anxiety and a history of a depressive episode. Computations were performed in SPSS 18.0 (Chicago, IL). A 
P-value of < 0.05 (two-tailed) was considered as the threshold for statistical significance. Effect sizes on 
between-group comparisons were presented as standardized Cohen's d (Cohen 1988). Standardized 
regression weights (β values) were used as an index of the strength and the direction of the associations 
that were obtained in the regression analyses. Tolerance of the predictors and normality of error variances 
was verified in all regression models. 
 
RESULTS 
Sociodemographic and clinical characteristics 
Table 1 ↓ displays the demographical and clinical characteristics of patients and controls. Patients were on 
average younger, received fewer years of education, and were more likely to smoke and to use alcohol as 
compared to controls.  
 
Serum BDNF concentrations in patients and controls 
ANOVA (any anxiety diagnosis versus controls) revealed no main effect of diagnosis (mean BDNF anxiety = 
9.31, SD = 3.38 versus healthy controls = 9.49, SD = 3.18, P = 0.49). This analysis was repeated with gender 
as additional factor (2 times 2 ANOVA: any anxiety diagnosis versus controls times gender) to explore 
whether serum BDNF concentrations were comparable among female and male patients and controls and 
to test an interaction between diagnosis and gender. Adding the factor gender to the analysis revealed a 
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diagnosis-gender interaction (F 1,754 = 4.02, P = 0.05) apart from a main effect of gender (F 1,753 = 4.24, P = 
0.05), with males having higher serum BDNF concentrations than females. Pair-wise comparisons on least 
square differences revealed that female patients had lower concentrations of BDNF (mean = 8.90, SD = 
3.24) relative to female controls (mean BDNF = 9.49, SD = 3.20; t 485 = 2.02, P = 0.05, d = 0.19) and to male 
patients (mean BDNF = 9.94, SD = 3.44; t 376 = 3.16, P = 0.01, d = 0.30). Male controls had BDNF 
concentrations (mean = 9.51, SD = 3.10) that were comparable to those of female controls (P = 0.95) and to 
male patients (P = 0.28). Importantly, possible confounds that might have had occurred because of 
between-group differences in age, educational attainment, smoking, and alcohol use were statistically 
controlled for. Mean corrected BDNF concentrations are plotted in Figure 1 ↓ for persons with an anxiety 
disorder and healthy controls by gender. 
 
Table 1. Demographic and clinical characteristics (mean ± standard deviation or percentages) by diagnosis and gender 




(n = 262) 
Male 
(n =  131) 
Female 
(n = 237) 
Male 
(n = 151) 
 
Age   40.1 ± 13.2   43.1 ± 12.9   44.1 ± 12.3   48.3 ± 11.9 < .001 a, b, c, d 
Education (years)   12.0 ± 3.2   12.2 ± 3.3   13.3 ± 3.2   13.5 ± 3.5 < .001 c, d 
Body Mass Index   24.7 ± 5.0   25.9 ± 4.4   24.8 ± 4.8   26.3 ± 4.1   .41    a, b 
Smoker                                       %         39.8         36.5         14.1         20.1 < .001 a, c, c 
Physical activity 1      3.6 ± 2.9      3.8 ± 3.4     3.8 ± 2.9     3.8 ± 3.2    .94 
Alcohol Use  
   Non-drinker                           %         51.3          31.9        60.5        48.2 < .01    a, b, c, d 
   Drinker 1-2 units a day        %         45.5          55.7        38.5        46.8 < .01    a, b, c, d 
   Drinker > 2 units a day        %           3.2          12.4          1.0          5.0 < .01   a, b, d 
Social anxiety disorder           %          52.2           48.9         NA          NA   .47 
Panic disorder 2                       %          46.2           38.9         NA          NA   .17 
Generalized anxiety                       %          17.6           22.1         NA          NA   .27 
Agoraphobia                            %          17.2           14.5         NA          NA   .34 
> 1 anxiety disorder               %          17.6           22.1         NA          NA   .12 
 Anxiety characteristics               
    Anxiety severity, BAI  15.2 ± 9.3   12.4 ± 8.8 2.7 ± 2.9   1.6 ± 2.2 < .001 a, b, c, d 
    Age at onset of anxiety     20.1 ± 12.6    21.9 ± 13.3             NA          NA   .15 
    Chronicity of  anxiety 3                22.6 ± 20.1    20.6 ± 20.2             NA          NA   .12 
   History of depression          %          45.0           32.1         NA          NA < .01 
BDNF (ng/ml)      8.9 ± 3.2      9.9 ± 3.4     9.5 ± 3.2     9.5 ± 3.1 < .05    b, c 
Abbreviations: BAI; Beck’s Anxiety Inventory, BDNF: Brain-Derived Neurotrophic Factor 
1 Mean met-minutes (i.e., ratio of energy expenditure during activity to energy expenditure at rest) 
2  Percentages do not add up to 100% due to  comorbidity among the anxiety disorders. 
3  Number of months with anxiety symptoms in the past 4 years 
4  
Mean BDNF levels, corrected for the basic covariates (see Method section) 
a
 Indicates a statistical significant difference (P < .05) between female and male controls 
b Indicates a statistical significant difference (P < .05) between female and male patients 
c Indicates a statistical significant difference (P < .05) between female controls and female patients 






The role of gender (indicated by the main effect of gender and the diagnosis–gender interaction) was 
ascertained by modeling all subsequent analyses separately for female and male subjects as well as for the 
whole sample. Using multivariable regression analyses, with correction for the basic covariates, we 
investigated whether BDNF concentrations differed between the subtypes of anxiety diagnoses (i.e., SAD, 
PD, Agr, GAD, or > 1 anxiety disorder) versus healthy controls. Tolerance of the predictors was close to 1 
(range: 0.91 – 0.97), indicating no redundancy among the predictors. Furthermore, error variances were 
normally distributed. Overall, there were no differences in serum BDNF concentrations between each of 
the types of anxiety diagnoses versus controls (see Table 2 ↓). In analyses stratified for gender it appeared 
that BDNF concentrations were low in female patients with > 1 anxiety diagnosis as compared to female 
controls (P < 0.05). BDNF concentrations of male patients with > 1 anxiety diagnosis, instead, were 
somewhat higher as compared to male controls (P = 0.10). The differences among female patients and 
female controls and among female and male patients in serum BDNF concentrations, as they were found in 
analysis of covariance, thus were largely driven by patients who had > 1 anxiety diagnosis. Indeed, effect 
sizes for the comparison of corrected BDNF concentrations among female patients versus female controls 
(d = 0.19) became larger when comparing BDNF concentrations of female patients with > 1 anxiety 
diagnosis versus female controls (d = 0.32). Similarly, the difference among female and male patients (d = 
0.30) also became more apparent when comparing BDNF concentrations of female patients with > 1 
anxiety diagnosis versus male patients with > 1 anxiety diagnosis (d = 0.66).  
 
Table 2. Results of univariable correlation and multivariable regression analyses on serum BDNF levels in patients with an 
anxiety disorder contrasted versus healthy controls (n = 775) 
    Whole sample (n = 393)           Female (n = 262)          Male (n = 131) 
 r 1 B ± SEM ß 
 
r 1 B ± SEM ß r 1 B ± SEM ß 
  Social phobia   -.04  -0.28 ± 0.27  -0.04   -.08*  0.78 ± 0.54   0.10    .03   0.11 ± 0.48   0.02 
  Panic disorder   .02   0.14 ± 0.30  -0.02    .03  0.50 ± 0.53   0.07    .12*    0.77 ± 0.52   0.09 
  Agoraphobia    .01  -0.16 ± 0.44   0.01   -.02  0.62 ± 0.72   0.06    .06   0.64 ± 0.79   0.05 
  Generalized anxiety   -.01  -0.01 ± 0.40  -0.01   -.03  0.19 ± 0.81   0.02    .04   0.40 ± 0.64   0.04 
1 Spearman’s rho with variables coded as: 1 = not present, 2 = present. 
* Statistical significance at P < .05 
Note. The healthy controls served as the reference category in the multivariable model. B’s and ß’s thus represent the association of the specific 
anxiety disorders versus having no anxiety disorder 
 
Figure 1. Plotted are mean serum 
BDNF concentrations by diagnosis 
and gender. Error bars reflect the 
SEM. 
Serum BDNF concentrations are 
low in female patients with an 
anxiety disorder as compared 
with female controls (A: d = 0.19) 
and male patients with an anxiety 
disorder (B: d = 0.30). 
The diagnosis-gender interaction 
effect is significant at P < .05.  
* Denotes statistical significance 
at P < 0.05.  
** Denotes statistical significance 
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Additional regression analyses, corrected for the set of basic covariates were run to elucidate whether 
variation in some of the clinical characteristics of anxiety or a history of depression could account for 
variation in serum BDNF concentrations. The clinical characteristics correlated among each other (ranging 
from –0.04 to 0.28), yet the tolerance of the individual predictors was close to 1 (range: 0.80 to 0.98) 
indicating no redundancy among the predictors. Furthermore, error variances were normally distributed. 
The regression showed no association of the severity and chronicity of anxiety, and having had an episode 
of major depression with serum BDNF concentrations (see Table 3 ↓). Age at onset of anxiety was 
positively associated with serum BDNF in univariable analyses, which seemed to be largely driven by the 
male patients in the sample (see Table 3 ↓). However, also in male patients this association did not reach 
full statistical significance and in multivariable analyses only a trend-like finding (P = 0.09) was observed. 
Finally, the difference between female patients and male patients in serum BDNF concentrations was 
observed in all regression models. Hence the gender difference in serum BDNF concentrations could not be 
attributed to between-gender differences in the demographical, behavioral, and clinical variables on which 
we focused in the current study. 
 
Table 3. Results of univariable correlation and multivariable regression analyses on the association of the clinical facets of  
anxiety with serum BDNF levels in patients with an anxiety disorder (n = 393) 
    Whole sample (n = 393)           Female (n = 262)          Male (n = 131) 
 r 1 
 














Anxiety characteristics 1          
  Anxiety severity   -.01  -0.01 ± 0.02  -0.01   -.01 -0.01 ± 0.02  -0.02   .07    0.01 ± 0.04   0.02 
  Age at onset    .11*   0.02 ± 0.02   0.06     .06 -0.01 ± 0.02  -0.02   .16*    0.06 ± 0.03   0.22* 
  Chronicity of anxiety    .07   0.02 ± 0.01   0.09    .06  0.01 ± 0.01   0.08   .09    0.01 ± 0.02   0.06 
  >1 anxiety disorder 2  -.07  -0.02 ± 0.41  -0.05   -.12* -0.84 ± 0.01  -0.12†   .11    0.98 ± 0.81   0.12 
  History of depression 2  -.03  -0.02 ± 0.35  -0.02     .01  0.01 ± 0.08   0.01  -.07  -0.05 ± 0.15  -0.03 
1 Pearson’s r when continuous variables are involved and Spearman’s rho if dichotomous are involved 
2  Dichotomous variables are coded as: 1 = not present, 2 = present 
†  Indicates a trend at P = .07. * Statistical significance at P < .05 
 
DISCUSSION 
The primary goal of this study was to test the hypothesis that serum BDNF concentrations are low in 
patients with an anxiety disorder as compared to healthy controls. Our results, controlled for a range of 
demographical and behavioral variables, did not confirm this hypothesis as overall no differences between 
patients with an anxiety disorder (i.e., social anxiety disorder, panic disorder, agoraphobia, and generalized 
anxiety disorder) and healthy controls were found in the amount of BDNF in blood serum. Given these data, 
it seems unlikely that BDNF is involved in the pathophysiology of anxiety disorders per se. Nevertheless, 
additional analyses on gender differences in serum BDNF concentrations revealed that female patients with 
an anxiety disorder had low serum BDNF concentrations as compared to female controls and to male 
patients. BDNF concentrations in male patients tended to be slightly higher as compared to male controls. 
BDNF concentrations among female and male controls were similar. Thus, our gender specific finding, 
showing lower concentrations of BDNF only in female and not in male patients with an anxiety disorder, 
might point in the direction that BDNF is related to the pathophysiology of anxiety in female but not in 
male patients. Other than the here reported data, very little is known on the relation between BDNF and 
human anxiety. As referred to in the introduction, to date, only two studies addressed this issue and these 
studies present conflicting results. Kobayashi et al. (2005) found no differences in serum BDNF 
concentrations between patients with panic disorder and healthy control subjects. Our analyses that were 
run in the whole sample confirmed this finding. Strohle et al. (2010) on the other hand did find lower 
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concentrations of BDNF in patients with panic disorder as compared to healthy control subjects. The 
sample that was studied by Strohle et al. however consisted mostly of females (75%). Therefore it could be 
that the large proportion of females drove the results that were reported in this particular paper.  
     Interestingly, our findings are in agreement with the observation that anxiety in female mice is more 
susceptible to changes in BDNF than in males (Monteggia et al., 2007). Of note is that the methods that 
were used to manipulate BDNF expression in these preclinical studies were rigorous (e.g., a complete 
knockout or ~ 10-fold over-expression of BDNF; Govindarajan et al., 2006; Monteggia et al., 2007). 
Therefore, the outcomes of these studies might lack the necessary ecological validity to be directly 
comparable to the outcomes of studies using human subjects (Groves 2008). However, our gender-specific 
findings also compare well with some studies in patients with depressive disorders showing lower 
concentrations of BDNF in female depressed patients as compared to male depressed patients (Karege et 
al., 2002a; Huang et al., 2008). The origins of our gender specific findings are unknown. Here, and also in a 
previous study on depressed subjects (Molendijk et al., 2010) we found that the differences in serum BDNF 
concentrations between female and male patients were not driven by demographical (e.g., age), behavioral 
(e.g., smoking), or clinical (e.g., severity) variables. In the current study, we further found that the 
difference between female and male patients could not be attributed to a specific subtype of anxiety. A 
general deduction from this, and from our finding that serum BDNF concentrations are similar among 
female and male controls, is that the origins of our gender-specific findings may lie in a female specific 
associate of anxiety. One interesting candidate that might serve as an explanation for our gender specific 
findings is an explanation in terms of alternations in the expression of the ovarian hormone estrogen in 
females during the state of anxiety. The expression of estrogen typically is low in females with an anxiety 
disorder (Seeman, 1997; Almeida et al., 2005; Walf and Frye, 2006) and this might be of relevance here 
since estrogen is a signaling molecule upstream of BDNF that triggers the expression of BDNF (Scharfman 
and MacLusky, 2004; Begliuomini et al., 2007). Furthermore, estrogen has been shown to have therapeutic 
effects in psychiatric conditions such as major depression and schizophrenia (see for example Kulkarni et 
al., 2008; Young and Korszun, 2010), disorders in which peripheral BDNF concentrations also are low, as 
confirmed by recent meta-analyses (Sen et al., 2008; Green et al., 2010). Therefore, the interaction of 
estrogen with BDNF might be of importance in our understanding of low BDNF concentrations in female 
patients in general.  
     In addition to gender-specific findings we found that serum BDNF concentrations are similar across the 
subtypes of anxiety disorders and thus peripheral BDNF measurements do not have the specificity to 
categorize anxiety disorders. Furthermore, it should be noted that peripheral BDNF measurements lack 
specificity to categorize psychiatric disorders outside the spectrum of anxiety (see also Gass and Hellweg, 
2010 for a review) as low concentrations of BDNF have been shown in depression (Karege et al., 2002a), 
schizophrenia (Green et al., 2010), and eating disorders (Nakazato et al., 2003). Interestingly, the number of 
anxiety disorder, on the other hand, did show associations with serum BDNF concentrations. In female 
patients serum BDNF concentrations tended to decrease as the number of anxiety disorders increased, 
whereas in male patients serum BDNF concentrations tended to increase as the number of anxiety 
disorders increased. Interestingly, some studies using predominantly female patients have shown a worse 
clinical course and a greater impairment in patients who suffer from multiple anxiety disorders (Bruce et 
al., 2005; Kroenke et al., 2007) and thus having multiple anxiety disorders might be considered an 
indication of anxiety severity. However, our findings that a higher symptom severity of anxiety or a more 
chronic course do not go along with lower concentrations of BDNF seems to suggest that no associations 
exist between BDNF and the severity of anxiety. In addition, a later age at anxiety onset appeared to be 
associated with higher concentrations of BDNF, particularly in male patients. However, in multivariate 
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analyses this association did not reach full statistical significance. Finally, we found a history of depression 
to be unrelated to serum BDNF concentrations in patients with a current anxiety disorder, which is in line 
with our previous finding that BDNF concentrations are low during a depressive episode but return to 
normal in the course of depression remission (Molendijk et al., 2010).  
     A salient strength of our study is that we report on a large sample of various anxiety disorders that 
allowed for analyses stratified by gender. Moreover, all analyses were controlled for possible confounding 
effects of various demographical and behavioral variables, showing that the current findings could not be 
explained by such factors. Moreover, we could eliminate the confounding effects of depression and the use 
of psychotrophic medication. Thus, we believe that our results advance the understanding of the role of 
BDNF in anxiety. Notwithstanding this, we do wish to emphasize some limitations of our study. First, we 
evaluated correlative associations and therefore we do not know whether our main finding of low 
concentrations of BDNF in female patients with an anxiety disorder are causally involved in anxiety or 
whether they are merely a consequence of being anxious. Furthermore, although some between-group 
differences in the current study reached statistical significance, the effect sizes on these associations 
typically were small leading to the question whether or not our findings are of any clinical relevance. Yet 
another limitation might be that we studied easily accessible serum BDNF concentrations and can only 
assume that these measurements mirror the amount of BDNF in the brain (Sartorius et al., 2009; Klein et 
al., 2010). This, however, only is an assumption since there are many possible other sources of BDNF in 
blood serum (Karege et al., 2002b). Given that especially platelets constitute a source of peripheral BDNF 
concentrations, it might be worthwhile to control for platelet count in future studies on between-group 
differences in serum BDNF concentrations (Karege et al., 2005; Ziegenhorn et al., 2007). Finally, we studied 
BDNF concentrations in isolation of other hormones, neurotransmitters, and receptors that might interact 
with BDNF and as such could have explained the associations that we observed (Kapczinski et al., 2010).  
     In sum, this large-scale study in patients with anxiety disorders shows that serum BDNF concentrations 
are low in female patients with an anxiety disorder but not in male patients with an anxiety disorder. These 
results were not driven by differences in demographical, behavioral, or clinical variables and thus suggest 
that low concentrations of BDNF might be specifically related to the pathophysiology of anxiety in females. 
Future research is needed to clarify whether these lower concentrations of BDNF in females contribute to 
anxiety or whether they are merely a consequence of having one or more anxiety disorders. Furthermore, 
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SIGNIFICANCE: The axiom that prevails in explaining depression related alternations in BDNF 
expression is trauma/stress exposure. We do not find evidence for this except for a negative 
correlation between recent stress exposure and serum BDNF concentrations, explaining only ~ 1 
percent of the variance. We do find a val66met - trauma interaction effect on serum BDNF 
concentrations, which in contrast to expectations had no effect on behavior. The extent to which 
























Recent findings show lowered Brain-Derived Neurotrophic Factor (BDNF) concentrations in major 
depressive disorder. Exposure to stressful life events may (partly) underlie these reductions in BDNF, but 
little is known about the effects of early or recent life stress on BDNF concentrations. Moreover, the effects 
of stressful events on BDNF concentrations may in part be conditional upon a common variant on the BDNF 
gene (val66met; rs6265), with the met allele being associated with a decrease in activity dependent 
secretion of BDNF compared to the val allele. We investigated in 1,435 adults with lifetime MDD the impact 
of childhood abuse and recent life events on serum BDNF concentrations and assessed whether the impact 
of these events was moderated by the BDNF val66met polymorphism. Overall, BDNF met carriers had 
reduced serum BDNF concentrations when exposed to childhood abuse in a dose-dependent way. Exposure 
to recent life events was also associated with decreases in BDNF concentrations, but this was independent 
of BDNF val66met. Moreover, when not exposed to childhood abuse, met carriers had higher BDNF 
concentrations than the val/val individuals, who did not show decreases in BDNF associated with childhood 
abuse. Finally, these findings were only apparent in the depressed group without comorbid anxiety. These 
gene–environment interactions on serum BDNF concentrations suggest that met carriers are particularly 
sensitive to early stressful life events, which extends previous findings on the moderating role of the BDNF 
































Major depression is one of the most common psychiatric disorders, which involves dysregulation of affect, 
motivation, appetite, sleep, and cognitive dysfunctions, resulting in impairments in several aspects of life. 
An accumulating body of research indicates that depression is often the result of the interplay between 
genetic vulnerability and environmental factors (Kendler, 2005). In particular, childhood abuse is a 
significant etiological factor in the development and persistence of depression across the life cycle 
(Charney, 2004; Heim and Nemeroff, 2001; McLaughlin et al., 2010; Spinhoven et al., 2010). Moreover, 
exposure to stress during adulthood (for example, divorce or job loss) often precipitates or exacerbates 
depressive symptoms (Kendler et al., 1999). In some instances, stressful events in adulthood interact with 
stressful events that occurred early in life to contribute to the process of stress sensitization (Post 2007).  
     Given its major contribution to the burden of disease, it is important to identify underlying biological 
mechanisms that might lead from stress exposure to depression. One of the neurobiological changes that 
may be triggered by both chronic and acute stress is a down-regulation of Brain-Derived Neurotrophic 
Factor (BDNF). The neurotrophin BDNF is a critical regulator of the formation, plasticity, and integrity of 
neurons in brain circuits that regulate emotion (Angelucci et al., 2005). In animals, exposure to stress early 
in life (e.g., maternal separation) has been found to induce a relative decrease in the expression of BDNF 
and to subsequent neuronal atrophy and degeneration in the hippocampus and the cortex, which can 
persist into adulthood (Smith et al., 1995; Roceri et al., 2004; Song et al., 2006). According to the 
neurotrophic hypothesis of depression, reductions in BDNF expression may account for the pathophysiology 
of depression (Duman and Monteggia, 2006). Consistent with this idea, several studies found decreased 
central (Karege et al., 2005) and peripheral concentrations of BDNF (Molendijk et al., 2011) in depressed 
patients. More specifically, in line with this, one study found lowered plasma BDNF in depressed women 
with a history of childhood neglect compared to non-abused depressed women and controls (Grassi-
Oliveira et al., 2008). A study among bipolar patients reported similar reductions in serum BDNF 
concentrations in patients exposed to stressful life events (Kauer-Sant’Anna et al., 2007).  
     A common Single-Nucleotide Polymorphism (SNP) on the BDNF gene is val66met. Val66met refers to a 
valine (val) to methionine (met) insertion at codon 66 (Egan et al., 2003). This SNP affects intracellular 
processing and secretion of BDNF, with the met allele being associated with a decrease in activity-
dependent secretion of BDNF compared to the val allele (Egan et al., 2003). Most studies have compared 
carriers of a met allele (val/met) with individuals who are homozygous for the val allele (val/val) because 
individuals who are homozygous for the met allele (met/met) are rare in Caucasians (~ 4%). In general, 
these studies have shown that met carriers have lower hippocampal gray matter (Pezawas et al., 2004; 
Bueller et al., 2006) and poorer episodic memory performance (Egan et al., 2003) compared to individuals 
homozygous for the val allele. Moreover, several studies have reported that met carriers are more 
vulnerable to the effects of childhood abuse compared to individuals who are homozygous for the val allele 
in terms of depressive symptoms (Kaufman et al., 2006; Wichers et al., 2008) and hippocampal gray matter 
(Gatt et al., 2009). Whereas variations on the BDNF gene seem to play an important role in depression, 
little is known on how variations on the BDNF polymorphism val66met may influence serum BDNF 
concentrations of individuals who have been exposed to childhood abuse and/or recent negative life 
events. A closer examination of the impact of childhood abuse and recent life stress and the moderating 
role of variations on the BDNF polymorphism val66met on blood-derived BDNF concentrations may help to 
elucidate the neurobiological changes that underlie the susceptibility of developing depression after 
exposure to stressful life events. Therefore we investigated, cross-sectionally, the impact of childhood 
abuse and recent life events on serum BDNF concentrations in a large sample of individuals with lifetime 
depression and assessed whether the impact of these stressful life events was moderated by variations on 
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the BDNF val66met polymorphism. Based on findings in animals and humans, we hypothesized that 
childhood abuse and recent life events would reduce serum BDNF concentrations, particularly in met 
carriers of the BDNF val66met polymorphism. 
 
METHOD 
Patients and sample collection 
Participants were derived from the NESDA (for details on the design, objectives, and protocol see Penninx 
et al., 2008). In brief, NESDA is a prospective cohort study (N = 2,981) that recruited subjects with a current 
depression and/or an anxiety disorder, patients with depression and/or an anxiety disorder in remission, 
and healthy controls without a history or current depression or anxiety disorder in specialized mental 
health care, primary care, and the general population. A general inclusion criterion was an age of 18 
through 65 years. Excluded were individuals with a primary diagnosis of psychotic, obsessive compulsive, 
bipolar, or severe addiction disorder (requiring care in specialized addiction clinics). A second exclusion 
criterion was not being fluent in Dutch. At baseline, participants provided blood and underwent a medical 
examination. The study protocol was approved by the Ethical Review Board of the VU University Medical 
Center and by local review boards of each participating institute. After full information about the study was 
provided, written informed consent was obtained from all participants. From the NESDA baseline sample, 
we selected 1,435 participants (48.1%), with a mean age of 42.2 years (± 12.4) and 30.7% (n = 440) males. 
To investigate individuals with a vulnerability to depression, our selection was based on the following 
criteria: (1) participants had to have a current or lifetime diagnosis of depression; (2) genomic data, data on 
serum BDNF concentrations, and measurements of childhood abuse and recent stress had to be available; 
and (3) participants had to be of North-European descent. DSM-IV diagnoses (APA, 1994) of major 
depression and anxiety disorders (generalized anxiety, social phobia, panic with or without agoraphobia, or 
agoraphobia) were determined by means of the Composite Interview Diagnostic Instrument (CIDI; Wittchen 
et al., 1991) that was administered by trained research staff. The CIDI has high reliability (Wacker et al., 
2006) and validity (Wittchen et al., 1991). Depression symptom severity was assessed using the Inventory 
of Depressive Symptoms Self-Report version (IDS; Rush et al., 1996). The use of antidepressants was 
gauged on by self-report and drug container observation. 
     Childhood abuse was assessed retrospectively using a semi-structured childhood trauma interview, 
previously used in the Netherlands Mental Health Survey and Incidence Study (de Graaf et al., 2004a, b). In 
this interview, participants were asked whether they had experienced before the age of 16 years one of the 
following types of trauma: emotional neglect, psychological, and physical and/or sexual abuse. After an 
affirmative answer, details on the frequency of these events and the perpetrators involved were asked for. 
Because of the large overlap between emotional neglect and emotional abuse, the two types of abuse were 
merged together as emotional abuse. Answers were coded as zero, one, two, or three reported types of 
childhood abuse. The mean number (± Standard Deviation [STD]) of childhood abuse types was 1.12 ± 1.15, 
with 42.7% (n = 613) reporting no childhood abuse, 21.6% (n = 310) reporting one type of childhood abuse, 
17.1% (n = 246) reporting two types of childhood abuse, and 18.5% (n = 266) reporting three types of 
childhood abuse. For the main analysis of variance (ANOVA), the presence of childhood abuse was defined 
as 0 versus ≥ 1 type of CA. For dose–response analyses, individuals were divided into three categories: 
individuals reporting no childhood abuse, one type of childhood abuse, and two or more types of childhood 
abuse.  
     The occurrence of 12 recent stressful life events (‘recent stress’) was assessed using the List of 
Threatening Events Questionnaire (LTE-Q; Brugha et al., 1985; Brugha and Cragg, 1990). These events 
reflect the presence of life stressors during the past year, such as serious illness and injury, death of close 
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friend or relative, unemployment, major financial loss, and loss of important relationships. The LTE-Q has 
good test–retest reliability, high agreement between participant and informant ratings, and good 
agreement with interview-based ratings (Brugha and Cragg, 1990). Answers were coded as the total 
number of life events. The mean number (± STD) of reported stressful life events was 0.68 (± 1.0), with 
58.4% (n = 838) reporting no life events, 23.6% (n = 338) reporting one event, 12.1% (n = 173) reporting two 
events, 4.5% (n = 64) reporting three events, 0.6% (n = 9) reporting four events, 0.6% (n = 9) reporting five 
events, 0.2% (n = 3) reporting six events, and 0.1% (n = 1) reporting seven events. For the main analyses, 
recent stress was defined as 0 versus ≥ 1 incident(s) of (a) stressful life events during the preceding year, 
whereas for the dose–response analyses, individuals were divided into three groups: individuals reporting 
no life event, one life event, and ≥ 2 life events in the past year.  
 
Genotyping  
For detailed descriptions on the procedures according to which genotyping was performed, we refer to 
Boomsma et al., (2008). The val66met polymorphism (Dibisnp RS6265) was extracted from whole genome 
data using PLINK software (http://pngu.mgh.harvard.edu/~purcell/plink). Val66met was in the equilibrium 
as stated by Hardy and Weinberg (P = .28). Moreover, genotype frequencies (val66val 65.5%, val66met 
32.5%, and met66met 2%) were similar to those reported in previous studies on Caucasian populations (Gatt 
et al., 2009; Lang et al., 2009). Individuals who were homozygous for the met allele were merged with the 




Fifty milliliters of blood was withdrawn into vacuum tubes between 07:30 a.m. and 09:30 a.m. after an 
overnight fast. Following blood collection, serum was separated and stored at −85° C until it was assayed. 
BDNF protein concentrations were measured using the Emax ImmunoAssay system from Promega 
according to the manufacturer’s protocol (Madison, WI, USA). Greiner Bio-One high-affinity 96-well plates 
were used. Serum samples were diluted 100 times, and the absorbency was read in duplicate using a Bio-
Rad Benchmark microplate reader at 450 nm. Serum BDNF protein concentrations were expressed in 
nanograms (ng) per milliliter. The intra-assay and inter-assay coefficients of variation were within 3% and 
9%, respectively. Prior to analyses, BDNF values that were three SD above the mean (n = 5, 0.35%) were 
trimmed to a value of the mean plus three SD’s. One BDNF value (0.07%) was below the reliable detection 
limit of the ELISA kit of 1.56 ng/ml and was set at the lower detection limit of 1.56 ng/ml. 
 
Statistical analysis 
Ancova’s and χ2 tests were used to determine between-group differences in demographical and clinical 
features. Estimates of the main and interaction effects of childhood abuse, recent stress, and val66met on 
serum concentrations of BDNF were performed using 2 (childhood abuse: yes/no) times 2 (recent stress: 
yes/no) times 2 (val66met: val/val versus met carriers) ancova. Childhood abuse and recent stress were 
entered as dichotomous variables in order to have a maximal number of subjects in each cell. Since gender, 
age, years of education, symptom severity of depression, presence of current depression versus remitted 
depression, presence of a current co-morbid anxiety disorder, use of an antidepressant, exact time of 
morning blood withdrawal, and the duration of serum storage have been discussed as potential sources of 
between-subject variation in BDNF concentrations (Trajkovska et al., 2007; Begliuomini et al., 2008), we 
statistically controlled for their possible confounding effects by adding these variables as covariates to the 
analysis. Significant interactions were followed up by independent t-tests.  
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     Secondly, because recent studies suggest that the symptomatology and causal pathways for depression 
without co-morbid anxiety disorder may be quite distinct to those for depression with co-morbid anxiety 
disorder(s)(see Gatt et al., 2009), we repeated the same 2 (childhood abuse: yes/no) times 2 (recent stress: 
yes/no) times 2 (val66met: val/val versus met carriers) ancova in participants with (lifetime) depression 
without co-morbid anxiety (depression − anxiety, n = 401) and individuals with (lifetime) depression and co-
morbid anxiety disorders (depression + anxiety, n = 1,033), separately. Finally, to asses dose–response 
relationships between childhood abuse and recent stress and BDNF concentrations, additional Ancovas 
were conducted in the case of significant main effects of childhood abuse and/or recent stress or 
interactions with val66met, based on three categories (no childhood abuse or recent life events versus one 
type of childhood abuse or recent life event versus two or more types of childhood abuse or recent life 
events). Computations were performed in PASW version 18.0 (PASW, Chicago, IL, USA). Statistical 




Table 1 ↓ shows the demographical and clinical characteristics by val66met, reported history of CA, and 
recent stressful life events. Exposure to childhood abuse and recent stressful life events was independent 
of BDNF genotype (P = .13 and P = .74, respectively). Exposure to recent stressful life events tended to be 
reported somewhat more often in individuals with a history of childhood abuse (P = .07). Individuals who 
were homozygous for the val allele had more years of education compared to individuals who carried a met 
allele. Individuals who reported childhood abuse were of older age and more likely to be female, to have a 
current episode of depression, to have more chronic depression, to have greater symptom severity of 
depression, and co-morbid anxiety and alcohol use disorders compared to individuals who did not report 
childhood abuse. Individuals reporting recent life events were of younger age, had less years of education, 
and were more likely to smoke, to have a current episode of depression, and to have chronic depression, 
greater symptom severity of depression, and a co-morbid anxiety disorder (see Table 1 ↓). No other main 
effects or val66met times childhood abuse, val66met times recent stress, val66met times childhood abuse 



















Table 1. Demographic and clinical characteristics (mean ± STD or percentage) by val66met and exposure to childhood abuse and recent 
stressful events (N = 1,435) 
   val66val (n = 940)                            val66met (n = 495) 
                             No abuse (n = 388)                           Abuse (n = 552)                           No abuse (n =225)                           Abuse (n =270 ) 
 No recent 
stress 
(n = 237) 
Recent stress 
(n = 151) 
No recent 
stress 
(n = 309) 
Recent stress 
(n = 243) 
No recent 
stress 
 (n = 138) 
Recent stress           
(n = 87) 
No recent 
stress           
(n = 154) 
Recent stress 
(n = 116) 
P-value 
Male                                   38.0 32.5 25.9 26.3 31.2 37.9 31.8 27.6 < .05 B 
Age (years)                                 42.3 ± 12.8 38.5 ± 13.7 44.1 ± 11.4 42.2 ± 11.8 41.8 ± 13.3 39.5 ± 12.7 44.4 ± 11.7 41.7 ± 12.5 < .01 B,C 
Education (years)                12.3 ± 3.1 12.1 ± 3.2 12.2 ± 3.4 11.8 ± 3.3 12.1 ± 3.0 11.2 ± 3.1 12.0 ± 3.1 11.4 ± 3.3    .06   A,C 
Body Mass Index  26.2 ± 4.9 25.1 ± 4.4 25.7 ± 5.3  26.0 ± 5.3 25.3 ± 4.9 25.4 ± 4.8 26.5 ± 5.4 25.7 ± 5.6    .23       
Smoker                               31.3 42.9 38.0 41.8 34.1 48.8 3.3 48.2 < .01  
C
 
Alcohol dependent            13.9 13.6 22.0 23.9 18.8 14.9 20.8 29.3 < .01    B 
Emotional abuse                NA  NA  93.8 94.8  NA  NA  94.4 96.3     .79
      
 
Physical abuse                   NA  NA  27.8 34.9 NA  NA  27.1  40.4  < .05        
Sexual abuse                      NA  NA  38.2  29.3  NA  NA  29.2 38.5    .09
       
 
> 1 event of abuse              NA NA 63.1 64.2 NA NA 53.9 67.2    .10       
> 1 event of recent stress   NA 47.7 NA 43.2 NA 58.6 NA 32.8 < .05  B         
Current depression  46.4  54.3  57.9  68.3 59.4 54.0 54.5 69.8 < .01 B,C 
Chronic MDD 
1
 24.3 22.7 28.1 33.2 21.5 28.2 24.6 37.4 < .05
  B,C
 
Depression severity  22.1 ± 12.8 24.3 ± 12.4 27.7 ± 13.2 31.2 ± 12.4 24.0 ± 13.5 23.2 ± 13.5 26.7 ± 13.1 29.7 ± 11.6 < .01 B,C 
Comorbid anxiety 
2
            30.0 28.5 41.4 49.8 33.3 33.2 35.1 46.6 < .01
  B,C
 
Antidepressant use 3                35.0 33.1 39.3 42.8 30.4  26.4  39.6 44.0 < .05  B 
Abbreviations: BMI: Body Mass Index 
1  Included a diagnosis of social phobia, panic disorder with and without agoraphobia, agoraphobia, or generalized anxiety disorder. Comorbid anxiety was 
assessed using the CIDI interview 
2  Included the use of noradrenergic and specific serotonergic antidepressants, serotonin and norepinephrine reuptake inhibitors, selective serotonin 
reuptake inhibitors, St  John’s wort, and tricyclic antidepressants 
A There is a statistically significant difference between the val66val group and val66met group 
B There is a statistically significant difference between the no abuse group and the abuse group 
C There is a statistically significant difference at between the no recent stress group and the recent stress group 
 
Impact of childhood abuse, recent stress, and val66met on serum BDNF concentrations  
Using a 2 (childhood abuse: yes/no) times 2 (recent stress: yes/no) times 2 (val66met: val/val versus met 
carriers) Ancova on serum BDNF concentrations, we found no main effect of childhood abuse (P = .38) nor a 
main effect of val66met on BDNF concentrations (P = .33), but BDNF val66met moderated the effects of 
childhood abuse on serum BDNF concentrations (F1, 1,416 = 5.57, P = .01, see Figure 1 ↓). Met carriers 
reporting childhood abuse had significantly lower concentrations of BDNF compared to met carriers that 
did not report childhood abuse (F1, 506 = 4.19, P = .04, d = 0.19), whereas individuals reporting childhood 
abuse who were homozygous for the val allele had similar concentrations of BDNF compared to 
homozygous val carriers without childhood abuse (P = .12). Furthermore, in individuals reporting no 
childhood abuse, met carriers had higher concentrations of BDNF compared to homozygous val carriers (F1, 
629 =3.88, P = .04, d = 0.19), while in the childhood abuse group, met carriers had similar concentrations of 
BDNF compared to homozygous val carriers (P = .22). Exposure to recent stressful life events did not affect 
BDNF concentrations (P = .79). No other interaction effects were found (all P-values > .10). 
 
Dose–response associations between childhood abuse and BDNF 
To investigate a dose–response association between CA and BDNF concentrations, an additional 3 
(categories of childhood abuse: no childhood abuse [n = 613], one type of childhood abuse [n = 310], or two 
or more types of childhood abuse [n = 512]) times 2 (val66met: homozygous val/val versus met carriers) 
ANOVA was conducted. An interaction was found between CA categories and val66met (F2, 1,418 = 2.99, P = 
.05). Post-hoc comparisons showed that BDNF concentrations were only low in met carriers when 
participants reported two or more types of childhood abuse compared to no childhood abuse (P = .032), 
but not when they reported one type of childhood abuse (P = .51), while in homozygous val carriers, no 
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main effect of childhood abuse categories was found (P = .29, data not shown).  
 
Depression without comorbid anxiety 
We repeated the 2 (C childhood abuse: yes/no) times 2 (recent stress: yes/no) times 2 (BDNF val66met: 
val/val versus met carriers) Ancova on serum BDNF concentrations in individuals with an (lifetime) 
depression without a co-morbid anxiety disorder (n = 402). In this group, recent stress did affect BDNF 
concentrations (F1, 383 = 7.19, P = .008, d = 0.29), indicating lower BDNF concentrations in individuals 
reporting one or more recent stressful life events (8.24 ± 3.20) compared to those who did not report 
negative life events (9.16 ± 3.06). Moreover, the interaction between childhood abuse and val66met was 
also present in the depression - anxiety group (F1, 383 = 9.77, P = .002), with met carriers who reported 
childhood abuse having significantly lower serum concentrations of BDNF compared to met carriers who 
did not report childhood abuse (F1, 138 = 10.03, P = .002, d = 0.44), whereas individuals reporting childhood 
abuse who were homozygous for the val allele even had somewhat higher concentrations of BDNF 
compared to homozygous val carriers without childhood abuse (F1, 258 = 3.82, P = .05, d = 0.23). Moreover, 
met carriers with a reported history of childhood abuse showed lower BDNF concentrations compared to 
homozygous val carriers with reported childhood abuse (F1, 173 = 7.45, P = .007, d = 0.45), while met carriers 
reporting no childhood abuse had higher BDNF concentrations compared to the non-abused homozygous 
val carriers (F1, 223 = 5.34, P = .02, d = 0.23). There were no other main or interaction effects in this group. 
 
Dose–response associations between recent stress and BDNF in depression with comorbid anxiety 
To evaluate whether there was a dose–response association between the number of reported recent life 
events and BDNF concentrations, an additional ancova was conducted on the three categories of recent 
stress: no (n = 232) versus one recent life event (n = 92) versus two or more life events (n = 78), which 
confirmed the effect of recent stress (F2, 388 = 3.17, P = .04). However, post hoc comparisons showed that 
BDNF was not affected in a dose-dependent way: whereas individuals reporting one life event had lower 
BDNF concentrations (8.19 ± 3.09) than those reporting no life event (9.11 ± 3.06; P = .02; d = 0.30), the 
group reporting two or more life events (8.53 ± 3.35) did not differ from the group reporting no or one life 
event (both P-values > .10). 
 
Dose–response associations between childhood abuse and BDNF in depression with comorbid anxiety 
To investigate a dose–response association between childhood abuse and BDNF concentrations in met 
carriers versus the homozygous val group, a 3 (no childhood abuse [n = 225], one type of childhood abuse 
[n = 81], or two or more types of childhood abuse [n = 96]) times 2 (val66met: homozygous val/val versus 
met carriers) Ancova was conducted (Figure 1 ↓). An interaction was found between childhood abuse 
categories and val66met (F3, 383 = 6.47, P < .0001), indicating that BDNF concentrations decrease in met 
carriers with an increasing umber of types of childhood abuse exposure (F3, 132 = 5.00, P = .003), while in the 
homozygous val carriers, no main effect of childhood abuse categories was found (P = .11). Post-hoc 
comparisons showed that BDNF concentrations were low in met carriers when participants reported two or 
more types of childhood abuse compared to no childhood abuse (P = .001, d = 0.63), but not when they 
reported one type of childhood abuse (P = .11). Moreover, met carriers had lower BDNF concentrations 
when reporting two or more types of CA compared to the val/val group that reported two or more types of 
childhood abuse (P = .006, d = 0.66), but not when reporting one type of childhood abuse (P = .46). 
Furthermore, a main effect of val66met also emerged (F3, 383 = 5.56, P = .02), with met carriers having lower 






Depression with comorbid anxiety 
The results of the same ancova in the depression with comorbid anxiety group showed a main effect of 
recent stress on BDNF concentrations (F1, 1,014 = 4.14, P = .04, d = 0.16). In contrast to the findings in the 
MDD − anxiety group, recent stress exposure was associated with elevated BDNF concentrations (9.26 ± 
3.8) compared to not being exposed to recent stressful events (8.47 ± 3.4). Moreover, recent stress tended 
to interact with val66met (F1, 1,014 = 3.04, P = .08). No other main or interaction effects were significant in the 
depressed with comorbid anxiety group.  
 
Dose–response associations between recent stress and BDNF in depression with comorbid anxiety 
To evaluate whether there was a dose–response association between reported life events in the val/met 
versus the val/val, an additional 3 (categories of recent stress: no [n = 606], one recent life event [n = 246], 
or two or more life events [n = 181]) times 2 (BDNF val66met: val/val versus met carriers) anova was 
conducted. Here, only a trend for life events categories was found (F2, 1,016 = 2.33, P = .09) and no interaction 
with val66met (P = .29). When comparing the means for the three recent stress groups post hoc, only 
individuals reporting one life event (9.58 ± 4.00) had higher BDNF concentrations than those reporting no 
life events (8.98 ± 3.42; P = .03), whereas the group reporting two or more life events (9.14 ± 3.42) did not 
differ from the group reporting 1 or no life event (both P’s > .10). 
 
DISCUSSION 
The main new result of this study is that the impact of childhood abuse on serum BDNF concentrations 
appears to be dependent on variations on the BDNF val66met polymorphism, at least in individuals with 
(lifetime) depression without co-morbid anxiety. In BDNF met carriers, exposure to childhood abuse was 
associated with reduced serum concentrations of BDNF, and these differences were most pronounced in 
met carriers who also reported negative life event(s) in the past year. In addition, these BDNF reductions 
associated with childhood abuse were linear in nature, so that BDNF concentrations were lowest in met 
carriers reporting two or more types of childhood abuse. Moreover, these associations were not accounted 
for by the presence of a current depression or by other potentially confounding factors, such as gender or 
the use of an antidepressant, as these factors did not differ between the homozygous val/val and the met 
carriers. The val/val group, on the other hand, did not show reductions in BDNF concentrations related to 
childhood abuse, and in the depressed group without co-morbid anxiety, BDNF concentrations were even 
higher in val/val participants reporting childhood abuse. Taken together, these findings are in line with the 
idea that met carriers are more sensitive to stress induced down-regulation of BDNF. 
     A second main finding is that exposure to stressful events that occurred in the past year reduced BDNF 
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Figure 1. Mean serum BDNF 
concentrations by exposure 
to the number of childhood 
abuse types and val66met. 
Error bars reflect the SEM. 
* denotes statistical 
significance at P < .05; ** 
denotes statistical 
significance at P < .01; ## 
denotes statistical 
significance at P < .01 when 
comparing the val/met 
group with 2 or more types 
of childhood abuse with the 





concentrations, independent of variation on the val66met polymorphism, at least in the depressed group 
without co-morbid anxiety. These results extend the finding of two previous studies showing lowered BDNF 
concentrations in bipolar patients reporting negative life events (Kauer-Sant’Anna et al., 2007), and in 
women with high risk of depression reporting recent life events (Trajkovksa et al., 2008). In the group with 
co-morbid anxiety, recent stress exposure was associated with increased BDNF concentrations, however. 
Moreover, while childhood abuse was associated with reduced BDNF in the met carriers, BDNF 
concentrations were not associated with childhood abuse in the co-morbid group. These findings seem to 
suggest that a co-morbid anxiety disorder may counteract the down-regulation of BDNF associated with 
childhood abuse and recent stressful events. So far, it is unclear how this relates to the symptomatology of 
depression with and without co-morbid anxiety, particularly because childhood abuse has specifically been 
linked to co-morbidity of depression and anxiety disorders (Hovens et al., 2009). Moreover, some studies 
have associated the val/val polymorphism with anxiety, rather than with depression (Gatt et al., 2009), but 
in the group with co-morbid anxiety disorders, we did not find any indications that val/val individuals have 
lower BDNF concentrations.  
     Although it should be taken into account that this is a cross-sectional study, preventing causal inferences 
about the impact of childhood abuse, it is remarkable that exposure to childhood abuse, which occurred in 
many individuals more than 25 years ago, is associated with decreased BDNF concentrations, at least in met 
carriers without co-morbid anxiety disorders. These reductions of serum BDNF concentrations in individuals 
with reported childhood abuse suggest that exposure to chronic stress during childhood may lead to a long-
lasting down-regulation of the neurotrophic system, which might be further reduced by recent stressful 
events. These results extend the findings of previous studies showing lower concentrations of BDNF in 
patients with current depression and a history of childhood abuse (Grassi-Oliveira et al., 2008). Since 
variation at the val66met locus were not taken into account in this study, it remains unclear whether the 
effects of childhood abuse were mainly driven by met carriers, as might be expected on the basis of our 
results. 
     The finding of reduced BDNF concentrations in met carriers is also of interest when considered in the 
context of previous findings, indicating that met carriers are particularly vulnerable to the impact of 
childhood abuse with respect to depressive symptoms (Kaufman et al., 2006; Wichers et al., 2008) and 
enhanced loss of hippocampal prefrontal gray matter (Gatt et al., 2009), given that low BDNF 
concentrations are associated with depression (Sen et al. 2008). Moreover, reductions in BDNF expression 
can have a direct impact on neuronal growth and plasticity in fronto-hippocampal networks (Murakami et 
al., 2005; Song et al., 2006). It should be noted that, in our sample, no associations were found between 
met carriers and higher depression severity after childhood abuse, however, which is consistent with some 
recent studies (Aguilera et al., 2009; Nederhof et al., 2010). Definitely, longitudinal studies are needed to 
further unravel the developmental trajectories relating exposure to childhood abuse and recent life events 
to low BDNF concentrations and altered brain structures and functioning. 
     One other interesting observation is that variations on the BDNF val66met polymorphism itself were not 
directly associated with variations in BDNF concentrations even though, among individuals reporting no 
childhood abuse, met carriers had higher BDNF concentrations compared to homozygous val carriers. Very 
few studies in humans investigated the association between the val66met and serum BDNF concentrations. 
One study in psychological healthy individuals also reported enhanced serum BDNF concentrations in met 
carriers compared to val/val individuals (Lang et al., 2009). Two other studies did not find an association 
between the val66met polymorphism and variations in peripheral BDNF concentrations, not in a sample of 
depressed patients (Duncan et al., 2009) nor among healthy twins (Vinberg et al., 2009).  
     Taken together, findings regarding associations between the val66met polymorphism and variations in 
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peripheral BDNF concentrations in humans are mixed. This could be due to the fact that, in previous 
studies, neither childhood abuse nor exposure to recent stressful events has been taken into account. 
Furthermore, this might also be related to the fact that the direct associations between val66met and BDNF 
concentrations in blood serum, if anything, appear to be rather small in individuals reporting no childhood 
abuse (in our study d = 0.19) and thus can only be detected in large samples. In sum, this study has shown 
that childhood abuse is associated with reduced BDNF concentrations in met carriers with lifetime 
depression (without comorbid anxiety), whereas serum BDNF concentrations of val/val carriers do not 
seem to be affected by exposure to childhood abuse.  
     A number of limitations should be taken into account when evaluating these findings. First, the reliability 
of participants’ recall of events from childhood may vary, given the long time gap between occurrence and 
recall. Self-reported childhood abuse requires caution when interpreting the results, although Goodman et 
al. (1999) observed good reliability among psychiatrically ill women. Related to this, one cannot rule out 
that the association between childhood abuse or recent stress and low BDNF concentrations in individuals 
with lifetime depression could (in part) be spurious, in the sense that individuals with a current depressed 
mood might have low BDNF concentrations and also experience life events in a (more) negative way, 
without these factors being directly related to each other. We do not consider this possibility very likely, 
however. First of all, we have previously shown that the association between negative life events and 
depression is independent of current mood state (Spinhoven et al., 2010). Moreover, in all analyses we 
added current versus remitted depression as a covariate, and the associations between life events and 
BDNF remain statistically significant when taking current mood state into account. A longitudinal design 
would be optimal to assess whether pre-differences versus post differences in serum BDNF are directly 
affected by stressful events. Another limitation is that we assessed serum BDNF concentrations, which may 
not be a direct measure of central BDNF, even though previous studies in animals showed that BDNF can 
cross the blood–brain barrier in both directions (Pan et al., 1998) and a strong association has been 
reported between central and peripheral BDNF concentrations (Karege et al., 2002). A third limitation is 
that we only assessed the val66met variant, whereas there are more loci on the BDNF gene that might be 
associated with variations in serum BDNF concentrations. Moreover, gene-gene interactions, in particular 
interactions with the 5HTT polymorphism, were not addressed in this study, whereas these interactions 
have been shown to be relevant in predicting depression in combination with childhood abuse in some 
studies (e.g., Kaufman et al., 2006; Wichers et al., 2008), although not in others (Gatt et al., 2009). 
     Despite the considerations mentioned above, we provide new and important evidence to suggest that a 
chain of events, commencing with gene-environment interactions and their impact on (set points of) BDNF, 
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SIGNIFICANCE: In this study we further the understanding of the association of BDNF val66met with 
hippocampal volume/functioning and cognitive performance. Critically, we take trauma/stress 
exposure into account. We find a small effect of val66met on hippocampal volume and that trauma 
exposure in childhood accounts for individual differences in hippocampal encoding activity. This 
latter effect seems to manifests itself differently as a function of val66met. These findings, although 
in need for replication, raise the question whether met carriers show abnormal brain response on 
emotional laden stimuli. This message comes with the notion that again, no effects no behavioral 




















The val66met polymorphism on the BDNF gene has been reported to explain individual differences in 
hippocampal volume and memory related activity. These findings, however, have not been replicated 
consistently and no studies to date controlled for the potentially confounding impact of early life stress, 
such as childhood abuse, and psychiatric status. Using structural and functional MRI we therefore 
investigated in 126 depressed and/or anxious patients and 31 healthy control subjects the effects of 
val66met on hippocampal volume and encoding activity of emotional laden and neutral words, while taking 
into account childhood abuse and psychiatric status. Our results show slightly lower hippocampal volumes 
in carriers of a met allele (n = 54) relative to val/val homozygotes (n = 103; P = 0.02, Cohen’s d = 0.37), 
which appeared to be independent of childhood abuse and psychiatric status. For hippocampal encoding 
activity we found a val66met–word valence interaction (P = 0.02) such that carriers of a met allele showed 
increased levels of activity in response to negative words. This, however, was only evident in the absence of 
childhood abuse, as abused val/val homozygotes showed hippocampal encoding activity for negative words 
that was comparable to that of carriers of a met allele.  Neither psychiatric status nor memory accuracy did 
account for these associations. In conclusion, BDNF val66met appears to have a small, yet significant, impact 
on hippocampal volume independently of childhood abuse and psychiatric status. Furthermore, early 
adverse experiences such as childhood abuse account for individual differences in hippocampal encoding 






























INTRODUCTION   
Brain-Derived Neurotrophic Factor (BDNF) regulates the sprouting of axons and dendrites in the 
hippocampus, a key structure for emotion and memory processing (Murer et al., 2001; Komulainen et al., 
2008). Rodent studies, for example, have shown that BDNF modulates hippocampal neuronal 
differentiation (Taliaz et al., 2010) and hippocampal dependent memory (Choi et al., 2010). Moreover, 
human studies have reported a positive relation between BDNF concentrations, hippocampal volume, and 
memory performance (Gunstad et al., 2008; Erickson et al., 2010). 
     Studies focusing on a single nucleotide site in the DNA sequence of the BDNF gene; val66met (a valine 
[val] to methionine [met] insertion at codon 66) have partly confirmed the associations of BDNF protein 
expression with neurobiological and behavioral abnormalities. Egan and colleagues (2003) showed in vitro 
that the met allele is linked to a reduced activity-dependent expression of BDNF in hippocampal neurons of 
rats, a finding that was replicated by Chen et al. (2004). In addition, studies have shown that in the 
hippocampus the met allele is associated with diminished levels of N-acetyl-aspartate, a putative marker 
for neuronal integrity (Stern et al., 2008). In line with these findings, some studies have shown that the met 
allele is associated with impaired episodic memory (Egan et al., 2003) and executive functioning 
(Rybakowski et al., 2003; Erickson et al., 2008). Structural and functional Magnetic Resonance Imaging 
(MRI) studies further suggest that carriers of a met allele have smaller hippocampal volumes relative to 
val/val homozygotes (Pezawas et al., 2004; Frodl et al., 2007) and altered hippocampal activity during the 
encoding of stimuli (Egan et al., 2003). 
     Nevertheless, these findings have not been consistently replicated (Schofield et al., 2009; Benjamin et 
al., 2010; Lau et al., 2010; Gerritsen et al., 2012) which might be due to the inclusion of small samples and 
task characteristics such as the emotional valence of the stimuli. Furthermore, the occurrence of early 
trauma such as childhood abuse and psychiatric status represent sources of variation in hippocampal 
volume and function (reviewed in Bremner et al., 2007; MacQueen and Frodl, 2011) that have not been 
taken into account in previous studies. In addition, gene-environment interactions have been reported 
between BDNF val66met and abuse on brain structure and activity (Gatt et al, 2009; Juhasz et al., 2010). As a 
consequence, the earlier reported associations between BDNF val66met and hippocampal structure and 
function might be (partly) dependent on a history of childhood abuse or on psychiatric status. 
     The goal of this study, then, was to evaluate the effects of val66met on hippocampal volume and on 
encoding related hippocampal activity while taking into account the potential influence of childhood abuse 
and diagnostic status. Given earlier conflicting findings we further aimed to extend previous findings by 
examining the effects of neutral, positive, and negative emotional stimuli on hippocampal activity.  
 
MATERIAL AND METHODS 
Subjects 
The data analyzed are from the imaging sample of the Netherlands Study of Depression and Anxiety 
(NESDA; Penninx et al., 2008; van Tol et al., 2010). Included in the sample were 301 subjects of whom 233 
were patients with a current depressive and/or anxiety disorder and 68 healthy control subjects. Genetic 
and high-quality functional and structural MRI data were available for 157 persons of whom 126 were 
depressed and/or anxious patients and 31 were healthy controls. Subjects in the current study did not 
differ from subjects in the NESDA imaging sample (N = 301) with regard to age (P = .98), gender (P = .22), 
and current diagnosis (P = .07). 
     Subjects underwent imaging at three different locations in the Netherlands: Academic Medical Center 
(AMC), University of Amsterdam, University Medical Center Groningen (UMCG), and Leiden University 
Medical Center (LUMC). To be eligible subjects had to be between 18 to 57 years of age and fluent in Dutch. 
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Exclusion criteria were having an Axis-I disorder other than a depressive and/or anxiety disorder (Diagnostic 
and Statistical Manual of Mental disorders fourth edition (DSM-IV; APA 1994), being on antidepressant 
treatment other than SSRIs at a stable dose (WHO 2008), a history of a major internal or neurological 
disorder, dependency on alcohol and/or drugs, smoking > 5 cigarettes a day, or hypertension (> 180/130 
mmHG). The protocol and procedures were approved by each of the Ethical Committees of participating 
institutes and all subjects signed an informed consent.  
     Diagnoses of depressive and anxiety disorders were established according to the criteria set forth in the 
DSM-IV (APA, 1994) on the basis of responses to the Composite International Diagnostic Interview 2.1 
(CIDI) lifetime version (WIttchen et al., 1991), a reliable and validated diagnostic tool (Wacker et al., 2006). 
The severity of depressive and anxiety symptoms was assessed with the Montgomery Åsberg Depression 
Rating Scale (MÅDRS; Montgomery and Åsberg; 1979) and the Beck Anxiety Inventory (BAI; Beck et al., 
1988;) which both have been shown to have excellent psychometric characteristics (Davidson et al., 1986; 
Kabacoff et al., 1997).  
     Childhood abuse was assessed retrospectively using a semi-structured childhood trauma interview de 
Graaf et al., 2004 a, b). In this interview, participants were asked whether they had experienced emotional 
neglect or psychological abuse, physical abuse, and/or sexual abuse before the age of 16 years. After an 
affirmative answer, subjects were asked for details on the frequency of the events. Based on the sum and 
the frequency of abusive events an index (range 0-8) was calculated for each subject (for details see 
Wiersma et al., 2009).  
 
Genotyping 
For a detailed description of the procedures we refer to Boomsma et al. (2008). In sum, variation at the 
val66met locus was extracted from whole-genome data using PLINK software version 1.07 
(www.pngu.mgh.harvard.edu). In our sample, 103 subjects were val/val homozygotes (65.6%) and 54 
subjects carried a met allele (34.4%). Two subjects (1.3%) with the met/met genotype were merged with 
heterozygous subjects into a group of met allele carriers. Genotype counts were 82 val66val, 42 val66met, 
and 2 met66met in the patient group and 21 val66val, 10 val66met, and 0 met66met in the healthy control 
group. Patient and healthy control samples did not differ with regard to genotype distribution (P = .77). 
Allele frequencies were in Hardy-Weinberg equilibrium in the GAIN-MDD sample in which the genotyping 
was performed (N = 3,530, χ21 = 0.62, P = .43) and in the sub-sample on which we present data (n = 157, χ
2
1 
= 2.66, P = .10). 
 
Memory Paradigm 
In the scanner subjects performed a subject-paced, event-related encoding task, similar to the paradigm 
described by Daselaar et al. (2003) and known to reliably activate the hippocampus. The task is described in 
detail elsewhere (van Tol et al., 2011). Briefly, during the encoding phase of the task 120 words (40 of 
neutral valence, 40 of positive valence, and 40 of negative valence) were presented in pseudo-randomized 
order. Subjects were instructed to classify these words according to valence. After a 10-minute retention 
interval, subjects were asked to complete a word recognition task. Subjects were instructed to indicate 
whether they had seen the word or whether the word was new. Discriminant accuracy was calculated as 
the proportion correctly recognized words minus the proportion false alarms (van Tol et al., 2011). 
 
Image acquisition and data handling 
Image acquisition and data handling are detailed elsewhere (van Tol et al., 2011, 2012). In sum, imaging 
data were collected using Philips 3-Tesla MRI scanners (Best, The Netherlands) using SENSE-6 and 8 channel 
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head coils (AMC and UMCG/LUMC respectively). Echo-planar images were obtained using a T2*-weighted 
gradient echo sequence with repetition time 2300 ms, a 30 ms echo time (UMCG 28ms), a matrix size of 96 
× 96 (UMCG 64 × 64), producing 35 axial slices of 3 mm thickness direction interleaved, 2.29 × 2.29 mm in-
plain resolution (UMCG 3 × 3). Anatomical imaging included a sagittal 3-D gradient-echo T1-weighted 
sequence with a repetition time of 9 ms and a 3.5 ms echo time producing slices with a voxel size of 1 × 1 × 
1 mm. Imaging data were preprocessed with SPM5 (Statistic Parametric Mapping, London, UK; 
www.fil.ion.ucl.ac.uk/).  
     Preprocessing of the data included reorientation of the functional images to the anterior commissure, 
slice time correction, image realignment, registration of the T1-scan to the mean image, warping to 
Montreal Neurological Institute (MNI) space as defined by the SPM5 T1-template, reslicing to 3 × 3 × 3mm 
voxels, and spatial smoothing using an 8 mm FWHM Gaussian kernel. Haemodynamic responses to each 
stimulus were modeled with a delta function convolved with a synthetic haemodynamic response function 
and modulated using response times.  
     Contrast images for subsequent hits versus baseline were calculated for the neutral, positive, and 
negative word condition per subject on a voxel-by-voxel basis, based on subsequent recognition success 
and entered in a 2 (group: val/val homozygotes versus met carriers; independent factor) by 3 (condition: 
neutral, positive, negative (> baseline); dependent factor) Mancova with age, education and scan center as 
covariates. Mean BOLD signal change during successful encoding in the left and right hippocampus was 
extracted per condition (neutral/positive/neutral > baseline) using the MARSBAR toolbox (Brett et al., 
2002). The hippocampal masks of the Automated Anatomical Labeling software package, implemented in 
the WFU Pick Atlas toolbox (Maldjian et al., 2003) were used to define the left and right hippocampal 
region.    
     Anatomical images were processed using an optimized Voxel Based Morphometry approach, following 
the Diffeomorphic Anatomical Registration Through Exponentiated Lie algebra (DARTEL; Ashburner, 2007) 
using SPM5 software implemented in Matlab 7.1.0 (The MathWorks Inc., Natick, MA, USA). For details see 
van Tol et al. (2011, 2012). To test for differences in regional brain volume, an independent samples t-test 
was set up for a voxel-wise comparison of the grey matter density images of the val/val homozygotes and 
met carriers, with age, scan center and total gray matter volume as covariates. Following a similar approach 
as for signal change extraction, the mean volume of the left and right hippocampus was additionally 
extracted. Data were exported to SPSS 18.0 (Chicago, IL, USA) for further analysis. 
 
Statistical analyses 
Computations were performed in SPSS 18.0. A P value of < .05 (2-tailed) was considered as the threshold 
for statistical significance. Demographical and clinical characteristics between groups were compared using 
Student’s t-tests for continuous- and χ2-tests for categorical data.  
     Main effects of val66met on right, left, and total hippocampal volume were calculated using a Repeated 
Measures (RM) Ancova with left versus right hippocampal volume as the within-subjects factor and age, 
gender, number of years of education, SSRI use, alcohol use, scan site, and total gray matter volume as 
covariates. Ancova’s were used to assess the effects of val66met on memory accuracy and hippocampal 
activity during the encoding of neutral, positive, and negative words. To address val66met–valence 
interaction effects on memory accuracy and hippocampal encoding activity we ran RM Ancova’s with word 
valence (positive versus neutral and negative versus neutral) as within-subject factor and age, gender, 
number of years of education, SSRI use, alcohol use, scan site, hippocampal volume, memory accuracy, and 
handedness as covariates. If indicated by between-group differences in memory accuracy, accuracy scores 
were included as covariates in the analyses on hippocampal encoding activity. 
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     Possible interaction effects of val66met with abuse and diagnosis (dummy variables coding for healthy, 
depressed, depressed-anxious, and anxious) on hippocampal volume, memory accuracy, and hippocampal 
encoding activity were evaluated using hierarchical stepwise regression analyses if indicated by statistically 
significant associations in the above described analyses. Regression analyses consisted of three steps: (I) 
covariates, (II) val66met, childhood abuse, and diagnosis, and (III) the interaction terms val66met × abuse 
and val66met × diagnosis. Analyses were rerun with lifetime instead of current diagnosis. Tolerance of the 
predictors and normality of error variances were verified.  
     To assess regional specificity of val66met within the hippocampus, voxel-wise analyses were repeated on 
the gray matter density maps and contrast maps reflecting encoding related activity using SPM5, with the 
threshold set at P < .001, uncorrected. For regions outside the hippocampus, a threshold of P < .05, FWE 
corrected was set.      
 
RESULTS 
The overall sample (N = 157) had a mean age of 37.39 ± 10.08 years and included 100 women (63.7%). 
Demographical and clinical characteristics of the sample are given in Table 1 ↓ by BDNF genotype. There 
were no statistically significant differences between the genotype groups in terms of demographical and 
clinical variables. Furthermore, val66met was not differentially associated with exposure to childhood abuse 
(dichotomous nor with exposure to the specific types of childhood abuse (all P-values > .75).  
 
Table 1.  Demographic and clinical characteristics (mean ± STD or percentages) by BDNF genotype 
             val66val 
           (n = 103) 
         val66met 
          (n = 54) 
P-value 
Females                                                      %                 64.1                63.0 = .89 
Age           37.1 ± 10.0          37.9 ± 10.4 = .65  
Education (years)           12.4 ± 3.0          12.6 ± 3.3 = .70  
Smoker                                                       %                 33.0                23.2 = .14     
Alcohol use                                               %                 56.2                  60.0 = .58 
SSRI use                                                     %                 30.1                20.4 = .19 
Right handed                                            %                 91.3                94.4 = .48 
Childhood trauma index range 0 -8)                1.6 ± 2.0             1.7 ± 2.3 = .87  
Diagnostic status    = .78 1 
   Healthy controls                                   %                 20.4                18.5 = .78 
   Depression                                             %                 22.3                25.9 = .61 
   Anxiety 2                                                 %                 20.4                14.8 = .39 
   Depression and anxiety 2                   %                 20.4                24.1 = .59 
Depression severity, MÅDRS           11.6 ± 8.8          13.6 ± 11.6 = .23  
Anxiety severity, BAI           11.7 ± 9.1          13.3 ± 11.2 = .84  
Abbreviations: BAI, Becks Anxiety Inventory; MADRS, Montgomery Åsberg Depression Rating Scale; SSRI, Selective Serotonin Reuptake Inhibitor 
1 Chi-square test (3 df) for differences in distribution of the val and the met allele over diagnoses 
2 
Included a diagnosis of social phobia, panic disorder, generalized anxiety disorder, and/or agoraphobia 
 
BDNF val66met and hippocampal volume    
Total hippocampal volume was smaller in carriers of a met allele relative to val/val homozygotes (F1,180 = 
5.33, P = .02; standardized Cohen’s d = 0.38; see Figure 1 ↓ and Table 2 ↓ for covariate adjusted means on 
total, right, and left hippocampal volume ± Standard Error [SE]). No interaction of val66met × right versus 
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left hippocampus was observed (P = .63). BDNF val66met had no effect on total gray matter volume (P = 
.60). Voxelwise analyses of the hippocampus confirmed these findings, with the peak voxel located in the 
posterior part of the hippocampus (MNI coordinate: Right hippocampus: [x = 18 y = -33 z = 8 and x = 21 y = -
30 z = -4], Z = 3.61/3.42, k = 29/17, PFWE-ROI = .018; Left hippocampus: [x = -18 y = -36 z = 8], Z = 3.17, k = 4, 
PFWE-ROI = .062).  
     Regression analyses were used to evaluate whether the smaller hippocampal volume in met carriers as 
compared to val/val homozygotes were moderated by the effects of abuse or diagnostic status. Main 
effects of childhood abuse and psychiatric status, and interaction effects of val66met with childhood abuse 
and psychiatric status on hippocampal volume were not observed (all P’s > .10). The main effect of val66met 
remained statistically significant after the inclusion of childhood abuse and psychiatric status in the model 
(B = -0.13, 95% Confidence Interval [CI] = -0.24 to -0.02, P = .02). Similar results were obtained in analyses 
with lifetime instead of current diagnosis and in analysis in which continuous measures for childhood abuse 
and depression severity were included as predictors (data not shown). No effect of BDNF val66met was 





Table 2 Cerebral and hippocampal volumes and hippocampal related encoding activity (mean ± SEM) by BDNF genotype and word 
valence (neutral, positive, and negative) 
 val66val  
 (n = 103) 
val66met  
(n = 54) 
P value 
Total grey matter volume 1      736.57 ± 5.35      731.66 ± 7.45 = .60 
Hippocampal volume 1, 2                                   
   Total           6.45 ± 0.03          6.31 ± 0.04 = .02 
   Right           3.06 ± 0.02          2.99 ± 0.02 = .01 
   Left           3.39 ± 0.02          3.31 ± 0.02 = .05 
Hippocampal encoding activity 1, 3    
   Neutral words           0.15 ± 0.04          0.16 ± 0.06 = .97 
   Positive words           0.15 ± 0.05          0.23 ± 0.07 = .30 
   Negative words           0.20 ± 0.05          0.36 ± 0.06 = .04 
1 All mean values are corrected for gender, age, years of education, SSRI and alcohol use, and site of scanning 
2 Mean values are additionally corrected for total cerebral grey matter volume 
3 Mean values are additionally corrected for total hippocampal volume 
 
Figure 1. Hippocampal volume by val/val and val/met genotype. 
Data are covariate adjusted (see the method section).  
 






BDNF val66met and task performance 
Persons who were val/val homozygotes did not differ from met carriers with regard to the discriminant 
accuracy of neutral, positive, and negative words (all P’s > .35). There also were no overall differences in 
discriminant accuracy as a function of genotype (covariate adjusted means ± SE: val/val homozygotes = 
0.57 ± 0.01 versus met carriers = 0.58 ± 0.02; P = .85). Interaction effects of val66met and word valence on 
memory accuracy were not observed (all P’s > .10). Furthermore, memory accuracy was unrelated to 
hippocampal volume (Pearson’s r = 0.13; P = .10) and to hippocampal encoding activity (r = 0.04; P = .66). 
 
BDNF val66met and hippocampal activity    
Main effects of val66met and word valence on hippocampal activity during the encoding of neutral and 
positive words were not observed (see Table 2 ↑). However, val66met interacted with neutral versus 
negative word valence (P = .02) such that hippocampal activity was higher in carriers of a met allele in the 
negative word condition relative to hippocampal activity in the neutral word condition (Bonferroni 
corrected P = not significant). This was not observed in val/val homozygotes (see Figure 2 ↓ and Table 2 ↑ 
for covariate adjusted means ± SE by word valence). No val66met-neutral versus positive word valence 
interaction effect on encoding activity was found (P = .17). Effects of lateralization were not observed. 
Voxel-wise analyses located the peak voxel of the interaction between negative versus neutral encoding 
times val66met cluster at the left posterior hippocampus ([x = -21 y = -27 z = -6], F1, 461 = 14,11, Z = 3.55, 




Exploratory voxel-wise whole brain analyses showed no statistical significant effects of val66met and 
val66met-word valence interactions in brain areas other than the hippocampus at the a priori set threshold 
of P < .05, FWE corrected. 
    Regression analyses were used to evaluate whether the higher hippocampal activity during the encoding 
of negative words were moderated by the effects of abuse or diagnostic status. Hippocampal encoding 
activity in response to words of negative valence was higher in abused subjects as compared to non-abused 
subjects (B = 0.16, 95% CI = 0.05 to 0.28, P = .007). In addition we found a val66met-childhood abuse 
interaction effect (B = -0.10, 95% CI = -0.17 to -0.02, P = .01) showing that childhood abuse predicted 
increased hippocampal activation in response to negative words in val/val homozygotes (P = .009) but not 
in carriers of a met allele (P = .34) (see Figure 3 ↓). Effects of psychiatric status (lifetime and current) and 
val66met by psychiatric status interaction effects were not observed (all P’s > .10). Adding memory accuracy 
as a predictor to the model did not change our results (data not shown) making it unlikely that these results 
are accounted for by genotype differences regarding attention or effort.  




Figure 2. Plotted are covariate 
adjusted mean total 
hippocampal activity levels 




(val/val n = 103; val/met n = 54). 
Error bars reflect the SEM.  
 
* denotes statistical significance 










We addressed the effects of val66met on hippocampal volume and function while taking into account the 
possible confounding effects of childhood abuse and psychiatric status.  
     In line with some previous studies (Szeszko et al., 2005; Bueller et al., 2006; Frodl et al., 2007) but not all 
(e.g., Gerritsen et al., 2012) we find smaller hippocampal volumes in carriers of a met allele relative to 
val/val homozygotes. This effect has generally been explained by abnormal intracellular trafficking and 
impaired activity secretion of BDNF, and by extension aberrant (trophic support in carriers of a met allele 
relative to the val/val homozygotes that have been shown in in vitro experiments (Egan et al., 2003; Chen 
et al., 2004). But since atrophy of the hippocampus has also been associated with (early) stress and/or 
current or remitted depression (MacQueen and Frodl, 2011) it is crucial to exclude the possible 
confounding effects of these variables. Our data suggests that the association between the met allele and 
hippocampal volume is independent of childhood abuse. This finding is at odds with those of Gatt and 
colleagues (2009) who modeled the interaction of early life stress and val66met in the prediction of 
hippocampal volume and found that the combination of carrying a met allele and being exposed to early 
life stress was associated with smaller hippocampal volumes in healthy adults. It could be that the observed 
discrepancy between the results of Gatt et al. (2009) and ours might be explained by a broader definition of 
early life stress by Gatt and colleagues (2009) who included for example also illness and exposure to natural 
disasters as stressful events whereas we focused on childhood abuse including physical, sexual, and 
emotional abuse. Furthermore, the study subjects of Gatt et al. (2009) were all healthy control subjects (N = 
89) whereas we studied mostly patients. However, exactly how these differences between the studies 
could have led to a different pattern of results is unclear. In line with Frodl and colleagues (2007), we show 
that lifetime and current psychiatric status does not thrive the val66met genotype effect on hippocampal 
volume, providing evidence for a direct association between the met allele and small hippocampal volume 
that further appears to be specific to the hippocampus.  
     In addition to reduced hippocampal volume, we show that val66met interacts with word valence such 
that encoding activity is increased in carriers of a met allele during the negative word condition and not in 
the neutral or positive word condition. This effect was not observed in other brain areas than the 
hippocampus and is consistent with some studies in which emotional stimuli were used (e.g., Dennis et al., 
2010). We could not replicate the finding of higher hippocampal activation in carriers of a met allele in 
response to neutral stimuli that was reported in the seminal study by Egan et al. (2003). On the basis of a 
recent study that showed that negative affectivity increased more in response to social stress in met 
carriers as compared to val/val homozygotes (Wichers et al., 2008) one may speculate that carriers of a met 
Figure 3. Plotted are covariate 
adjusted mean total hippocampal 
activity levels during the encoding of 




Error bars reflect the SEM.  
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met – childhood abuse 
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* denotes statistical significance at P 
< .05. 
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 denotes statistical 
significance at P < .05 for the 
difference between abused and non-















allele are more sensitive or reactive to negative stimuli. Owing to a possible relation between higher 
hippocampal activity and psychopathology (Thomaes et al., 2009) this finding might concur with studies 
that show a link between the met allele and depression (reviewed in Verhagen et al., 2010).  
     We further found, in line with some studies that childhood abuse predicts higher levels of hippocampal 
encoding activity (Werner et al., 2009; Heim et al., 2010). However, from our data it appears that childhood 
abuse is associated with a relative increase in hippocampal activity in val/val homozygotes only and not in 
carriers of a met allele. Although speculative, an interpretation may be that higher levels of hippocampal 
activity after exposure to childhood abuse in val/val homozygotes reflect a higher sensitivity for 
emotionally negative stimuli in that in carriers of a met allele is present regardless of exposure to childhood 
abuse. This idea is in line with studies that report hippocampal dysfunction in various severe psychiatric 
illnesses, particularly if exposure to childhood abuse is documented (Thomaes et al., 2009; Heim et al., 
2010; MacQueen and Frodl, 2011).  
     Despite differences in hippocampal volume and activity between val/val homozygotes and carriers of a 
met allele we did not find differences in memory accuracy and clinical variables (e.g., depression severity) 
as a function of BDNF genotype. This may suggest that our findings are relevant for both healthy individuals 
and patients and also is pertinent to the debate on the relationship between hippocampal volume and 
function with behavioral performance. However, with regard to the absence of associations between 
hippocampal volume, hippocampal function, and memory performance, a recent review on 80 studies 
showed, in line with our findings, that the model: a bigger brain structure  greater brain response  
better performance may not reflect reality (Eyler et al., 2010). 
     A notable strength of our study is that the findings are derived from a genetically homogeneous sample 
making it unlikely that our results are devoid by population stratification (Cardon and Palmer, 2003). 
Furthermore, we studied the effects of val66met in the context of childhood abuse and emotional valence of 
stimuli, and our results clearly highlight the importance of including such variables. A few weaknesses of 
our study also merit attention. Obviously, we cannot exclude the possibility that other polymorphisms on 
the BDNF gene or on other genes, notably those that constitute the neurotrophic pathway (e.g., CREB1 and 
NTRK2; see for example Juhasz et al., 2010) might have contributed to the effects that we observed. With 
regard to our self-reported measurement of childhood abuse it should be noted that the validity and 
reliability of recall might vary by diagnosis and time since abuse took place. Furthermore, in the face of 
negative findings statistical power is important to take into account. Overall we had a comparatively large 
sample size, but our analysis on psychiatric status might have been underpowered because patient samples 
may have been too small (e.g., only 31 healthy control subjects) to detect main effect sizes that are 
reported to be moderate at best (Campbell et al., 2004; Videbech et al., 2004). Finally, although we 
speculate that carriers of a met allele are more reactive to emotionally negative laden stimuli as compared 
to val/val homozygotes we are not able to confirm this because we have no subjective ratings of the stimuli 
by our participants. 
     In sum, our results suggest that BDNF val66met has a small effect on hippocampal volume and this effect 
appears to be independent of childhood abuse and psychiatric status. Furthermore, gene-environment 
interactions between val66met and childhood abuse account for individual differences in hippocampal 
encoding activity of negative stimuli. Important venues for future research are to delineate the exact 
mechanisms, in vivo, through which the met allele produces its effect on hippocampal volume and function. 
In addition, it remains to be investigated, in longitudinal designs, whether or not the effects of val66met on 
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SIGNIFICANCE: Over the years, the finding that met carriers at the BDNF val66met locus have a 
relatively low hippocampal volume is a pillar under the neurotrophinn hypothesis to which basically 
all paper on the genotype refer (total number of citations for the first paper on this issue [Pezawas et 


























Inconsistenties have been reported with regard to an association between val66met, a single nucleotide 
polymorphism on the BDNF gene, and hippocampal volume. We performed a systematic review and a 
meta-analysis to determine the magnitude and direction of this putative association and estimated the 
potential influence of demographical, clinical, and methodological characteristics of studies. Tests of 
publication bias and time-related trends were performed and statistical power of the included studies 
was calculated. The literature search for MRI studies on differences in total hippocampal volume as a 
function of BDNF val66met returned twenty-five records that fulfilled our criteria (total N = 3,620). Meta-
analysis showed that carriers of a met allele had lower hippocampal volumes relative to val/val 
homozygotes (d = 0.13, P = .02). Between-study heterogeneity in effect size estimates was substantial 
and this could not be explained by demographical, clinical, and methodological differences across 
studies. Funnel plot inspection and trim-and-fill estimations suggested evidence for publication bias and 
effect sizes decreased substantially over the years (Pearson’s r = -0.54, P < .01). All included studies were 
underpowered. This meta-analysis suggests that carriers of a met allele have lower total hippocampal 
volumes relative to val/val homozygotes. However, the effect sizes on this association converged closer 
to null with virtually each attempt at replication and were based on underpowered studies. Together our 
findings may suggest that the reported association between BDNF val66met and hippocampal volume is 































Brain-Derived Neurotrophic Factor (BDNF) has been implicated in the pathophysiology of major depressive 
and bipolar disorder, and schizophrenia (Krishnan and Nestler, 2010). BDNF is a neuronal growth factor 
that has an array of functions including the induction of neuronal sprouting and differentiation (Poo, 2001). 
The role of BDNF is particularly evident in the hippocampus where it regulates processes such as learning 
(Lu and Gottschalk, 2000; Tapia-Arancibia et al., 2008). Besides, by acting on hippocampal networks, BDNF 
is believed to be a moderator of mood (Taliaz et al., 2009).  
     An intriguing feature of the expression of BDNF is that it is, unlike other neurotrophins, not only 
secreted constitutively but also in response to neuronal activity (i.e., activity dependent secretion; Egan et 
al., 2003). Interestingly, in vitro experiments have shown that the activity dependent secretion of BDNF is 
dependent on a single nucleotide site on the BDNF gene; val66met, a valine into methionine insertion at 
codon 66 (Egan et al., 2003; Chen et al., 2004). Congruent with this is the finding that transgenic mice that 
carried a met allele had less dendritic complexity in the hippocampus and a reduced hippocampal volume 
(Magarinos et al., 2010). Furthermore, in in vitro experiments the met allele has been linked to diminished 
neuronal integrity (Egan et al., 2003; Stern et al., 2010). Finally, human data are suggestive for an 
association between the met allele and the incidence of mood disorders (Verhagen et al., 2008), 
schizophrenia (Gratacos et al., 2007), and bipolar disorder (Rakofsky et al., 2011). Taken together, these 
data add considerably to the idea that BDNF expression contributes to psychopathological characteristics 
and that this might be mediated by variation at the val66met locus (for a critical review see Groves 2007). 
     In line with this idea, two high impact papers (Pezawas et al., 2004; Szeszko et al., 2005), using Magnetic 
Resonance Imaging (MRI) techniques, showed lower hippocampal volumes in carriers of a met allele 
relative to val/val homozygotes. This message inspired many and the association between val66met and 
hippocampal volume became an area of interest, not at least because the hippocampus is considered to be 
a clinically relevant phenotype (MacQueen and Frodl, 2011). However, subsequent data with regard to this 
association is heterogeneous (e.g., Dutt et al., 2009). Reasons for this might be that the effect of val66met 
on hippocampal volume is small and that therefore some studies may have lacked the necessary statistical 
power to detect it (i.e., false negatives) or that the two pioneering papers may have overestimated the 
true effect (i.e., a winners curse). Alternatively it could be that heterogeneity in findings is caused by 
demographical, clinical, or methodological differences across studies. 
     When faced with non-uniform findings it is useful to aggregate data over studies in order to learn about 
the most plausible nature of an association (Lohmueller et al., 2003). Hence, we determined the magnitude 
of the putative association between BDNF val66met and total hippocampal volume by means of a meta-
analysis. The potential moderating influence of demographical, clinical, and methodological characteristics 




Using the terms: val66met OR rs6265 AND hippocampus and val66met OR rs6265 AND hippocampal volume 
two of us (BB and MM) searched the database PUBMED (www.ncbi.nlm.nih) through February 1st 2012 for 
human MRI studies on differences in hippocampal volume as a function of BDNF val66met. The digital 
search was supplemented by a backward search in which all the references that were made to the 2 
seminal papers were screened and by examining the reference sections of the retrieved records. We 
selected for inclusion human MRI studies that reported on differences in total hippocampal volume 
between val/val homozygotes and carriers of a met allele. Inclusion was independent of demographic (e.g., 
gender), clinical (e.g., diagnostic status), and methodological characteristics (e.g., Voxel-Based Morphology 
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[VBM] or actual volume measurements) of the sample and the study. Our search yielded 81 papers of 
which 25 records (k) fulfilled our inclusion criteria (total N = 3,620). For detailed information on the search 




Figure 1. Flow-chart of the search for papers on the association of val
66
met with hippocampal volume 
 
Data Extraction 
We extracted mean total hippocampal volume and Standard Deviation (SD) (or t and P values and the 
direction of the effect) as a function of BDNF val66met genotype. These outcomes were weighted using 
inverse variance methods (Borenstein et al., 2009) and converted to standardized Cohen’s d metrics 
(Cohen, 1988). Here, a positive value of this metric indicated larger hippocampal volumes in val/val 
homozygotes relative to carriers of a met allele. In those cases where non-significant results were reported 
without the necessary statistics to calculate Cohen’s d (2 records: Karnik et al., 2010; Gerritsen et al., 
2011), we assigned the strength of the difference between val/val and carriers of a met allele in 
hippocampal volume an estimated effect size of 0. Where non-significant results were reported with 
sufficient information to calculate an effect size, but not the direction of the effect (1 record: Agartz et al., 
2006), we assigned the association a Cohen’s d that was, with regard to its direction, concordant with the 
study hypothesis. To indicate whether effect size imputation was associated to different effect sizes, we 
constructed a binary variable indicating whether imputation had taken place. In a meta-regression 
framework this variable was tested for association with Cohen’s d. Two of the included records reported 
longitudinal data (Koolschijn et al., 2010; Millan Sanchez et al., 2012). We included the baseline data of 
these studies since more subjects were available at baseline compared to follow-up.  
     In addition to hippocampal volumes and genotype, we extracted data on (I) demographical 
characteristics: mean age, percentage females, ethnicity, Minor Allele Frequency (MAF), and genotype 
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frequencies of the sample; (II) clinical characteristics: psychiatric status (i.e., percentage of the sample with 
current depression, schizophrenia, or bipolar disorder and the percentage healthy controls of the sample) 
and psychotrophic medication use (percentage of the sample that used antidepressants, antipsychotics 
and/or mood stabilizers); and (III) methodological characteristics of the study: method of hippocampal 
volume extraction (VBM versus actual volume measurements), Hardy-Weinberg equilibrium, and whether 
the hippocampus was traced manually or automatically.  
 
Quality Assessment 
We used the criteria set forth by the Strengthening Reporting of Genetic Association Studies (STREGA; 
Little et al., 2009) and the Strengthening Reporting of Observational Studies in Epidemiology (STROBE; von 
Elme et al., 2007) checklists using the 11-item list adaption from Karg et al. (2011) to evaluate the 
methodological quality of the included studies. Overall quality score was defined as the frequency of 
relevant criteria that were met by each individual study. Independent quality assessments were performed 
by AK and MM. Agreement among the raters proved to be excellent (Cohen’s Kappa=0.83, Standard Error 
(SE) = 0.04). Overall, the quality of the included studies was good (mean = 0.86, SD = 0.14, range 0.56 - 
1.00). Quality ratings of the studies are presented in Table S1 in Appendix IV of this thesis. 
 
Statistical analysis 
Meta-analytical calculations were performed using Comprehensive Meta-Analyses version 2.0 (CMA 2.0; 
Borenstein et al., 2009) with statistical significance set at P < .05.  
     A random effects model was applied to calculate Cohen’s d (± 95% Confidence Interval (CI)) on the 
difference in total hippocampal volume between val/val homozygotes and carriers of a met allele. 
Heterogeneity between studies was assessed using the Q statistic (Borenstein et al., 2009). Given the 
possible impact of psychiatric diagnoses on hippocampal volume (MacQueen and Frodl, 2011) meta-
analyses and heterogeneity assessments were repeated stratified by psychiatric diagnosis (no diagnosis 
versus any diagnosis). The difference in effect-sizes that were acquired in these analyses was assessed 
using a z difference statistic. 
     In a series of meta-regression analyses the possible moderating effects of demographical, clinical and 
methodological differences across studies on Cohen’s d were evaluated. The first of these analyses was 
carried out to test the effects of demographical and methodological characteristics and was run using the 
data from all included studies. In addition, we tested the clinical characteristic: healthy controls versus any 
disorder in this analysis. In a second analysis the moderating effects of the demographical and 
methodological characteristics were assessed using the data from healthy control samples only. This was 
done to exclude the noise that might have been caused by diagnostic or psychotrophic treatment status of 
the patient samples. A third analysis was conducted in patient samples to specifically test the moderating 
effects of psychiatric status (depression versus no depression, schizophrenia versus no schizophrenia, and 
bipolar disorder versus no bipolar disorder) and psychotrophic medication use (yes versus no). In case of 
>1 statistically significant moderator, meta-regression analyses were followed up by multivariable 
regression analysis (SPSS Inc, Chicago, Ill) including the significant moderators in order to learn about their 
relative contributions to Cohen’s d.  
     Publication bias was assessed by funnel plot asymmetry inspection and the Egger test (Egger et al., 
1997). In case of publication bias, a trim-and-fill procedure was performed. The trim-and-fill procedure is a 
procedure that provides an estimation of the effect size after potential bias has been taken into account 
(Duval and Tweedie, 2000; Peters et al., 2007). Tests of time-related trends were performed by correlating 
year of publication with weighted Cohen’s d. Time-related trends were visualized by means of a cumulative 
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meta-analysis (a meta-analysis that calculates an aggregated effect size for each study that is added to the 
literature) and scatter-plots. A posteriori power and sample size calculations were performed using 
G*Power (Faul et al., 2009). 
 
RESULTS  
Description of samples 
The number of subjects of the included studies ranged from n = 34 to n = 572 (mean = 145, SD = 122). In 14 
out of the 25 studies (56%) the majority of subjects was female. Mean age of the samples ranged from 23 
years to 72 years (mean = 40, SD = 14). Eleven of the 25 included studies (44%) reported data on healthy 
subjects only (n = 1,784). The remaining 14 studies (56%) reported data on both healthy subjects (14 
subsamples, n = 981) and patients with a diagnosis of a psychiatric ilness (depression [7 subsamples, n = 
431], Schizophrenia or psychosis [6 subsamples, n = 345], bipolar disorder [2 subsamples, n = 50], and 
anxiety [1 subsample, n = 29]). Some studies (Benjamin et al., 2006 and Gruber et al., 2011) did not provide 
sufficient information to calculate Cohen’s d separately for the healthy and the patient samples. Because 
of this, these studies were not included in the stratified meta-analyses and meta-regression analyses. The 
numbers in these analyses, therefore, do not add up to the total of N = 3,620. Table 1 ↓ shows basic 
information on the included records. 
 
Meta-analysis 
The results of the meta-analysis over all studies (k = 25, N = 3,620) showed that carriers of a met allele had 
lower hippocampal volumes as compared to val/val homozygotes (d = 0.13 ± 0.06, 95% CI = 0.03 to 0.24, z 
= 2.41, P = .02; see Figure 2 ↓, panel A for a forest-plot). Analyses stratified by psychiatric diagnosis (no 
diagnosis versus any diagnosis) revealed similar point estimates for non-patient (d = 0.16 ± 0.06, 95% CI = 
0.04 to 0.27, z = 2.57, P = .01, k = 23, n = 2,542) and patient samples (d = 0.17 ± 0.11, 95% CI= -0.05 to 0.38, 
z = 1.54, P = .12, k = 12, n = 692)(Pdifference = .96). Substantial heterogeneity across studies was identified in 
the analyses that were run on the data of all samples (Q = 54.47, P < .001) on the data of healthy samples 


































































Table 1. Summary of characteristics of studies measuring total hippocampal volume differences between val/val homozygotes and carriers 
of a met allele at the val66met locus presented by year of publication 
Author, year N % female age  ethnicity   % of N MAF  patient status  % of N 
Pezawas et al., 2004       111 50% 34 a Caucasian              100% NK healthy controls 100% 
Szeszko et al., 2005        44 45% 27 Caucasian              100% 0.19 healthy controls   
schizophrenia 
  67% 
  43% 
Agartz et al., 2006 101 30% 42 a Caucasian              100% 0.19 a healthy controls   
schizophrenia 
  51% 
  49%  
Bueller et al., 2006              36 61% 27 Caucasian                
African American    
Asian 
  67% 
  19%                      
  14% 
0.21 healthy controls 100% 
Frodl et al., 2007               120 48% 43 NK   NK 0.19 healthy controls    
depression 
  50% 
  50%      




 Caucasian                    100% 0.19 
a
 healthy controls 100% 
Takahashi et al., 2008   62 40% 25 Asian                     100% 0.39 healthy controls   
schizophrenia 
  53% 
  47% 
Chepenik et al., 2009              34 53% NK Caucasian                




  82% 
    8% 
  10% 
0.20 healthy controls 
bipolar disorder 
  47% 
  53% 
Dutt  et al., 2009                383 50% 43 Caucasian              100% NK healthy controls 
unaffected relatives 
psychosis 
  16% 
  50% 
  33% 
Gatt et al., 2009                  89 51% a 36 a Caucasian 100% 0.20 a healthy controls  
Jessen et al., 2009 163 56% 43 Caucasian 100% NK healthy controls 
depression   
  48% 
  52% 
Joffe et al., 2009              113 48% a 37 a Caucasian 100% 0.21 healthy controls 100% 
Schofield et al., 2009 161 47% 32  NK   NK 0.22 healthy controls 100% 
Toro et al., 2009                331 52% NK Caucasian 100% 0.20 healthy controls 100% 
Benjamin et al., 2010            173 65% a 69 a Caucasian 
 
100% NK healthy controls    
depression 
  67% 
  33% 
Karnik et al., 2010             129 54% 49 Caucasian 
African American 
  90% 
  10% 
0.17 healthy controls 100% 
Koolschijn et al., 2010           177 28% 
 
37 Caucasian 100% 0.20 healthy controls   
schizophrenia 
  51% 
  49% 
Cole et al., 2011 188 55% 40 Caucasian 100% 0.22 healthy controls    
depression 
  59%  
  41% 
Gerritsen et al., 2011 572 63% 23 Caucasian 100% 0.23 healthy controls 100% 
Gonul et al., 2011                73 66% 32  Caucasian 100% 0.25 healthy controls    
depression 
  55% 
  45% 
Gruber et al., 2011                105 47% 38  Caucasian 100% 0.23 healthy controls 
schizophrenia             
bipolar disorder 
  37% 
  32% 
  30% 
Kanellopoulos et al., 2011              56 63% 72 Caucasian 100% 0.27 healthy controls    
depression 
  59% 
  41% 
Richter et al., 2011  138 67% 25 Caucasian 100% 0.27 healthy controls 100% 
Milan Sanchez et al., 2012   43   7% a 57 a Caucasian 100% 0.24 a healthy controls 100% 
Molendijk  et al., 2012 157 67% 37 Caucasian 100% 0.18 healthy controls 




  20% 
  61% 
  19% 
Abbreviations: MAF, Minor Allele Frequency; NK, Not Known; e-pub, e-pub ahead of print. 
a
 Estimated from larger sample 
b
 Not further specified ethnicity, but not Caucasian, African American, or Asian 
c Included a diagnosis of depressive disorder (n = 43, 45%) or comorbid depressive/anxiety disorder (n = 52, 55%) 




Figure 2. Forrest plot of a conventional meta-analysis (panel A, left side of the Figure) and a cumulative meta-analysis (panel B, 
right side of the Figure) 
 
Meta-regression analysis 
We evaluated the potential moderating effects of demographical, clinical, and methodological differences 
across studies in a series of 3 meta-regression analyses. Analyses were conducted separately using the data 
from all included studies, using the data from healthy control samples only, and using the data from 
patient samples only. Table 2 ↓ provides the coefficients that were obtained in these analyses. In sum, 
mean age of the sample explained a significant amount of variance in weighted d (r = -0.43, R2 = 0.18, P < 
.05), but most pronounced in the data that were derived from healthy samples. This effect was such that 
effect sizes were lower in healthy samples in which the subjects were older. Effects of other 
demographical, clinical, and methodological moderators were not observed. Imputation of effect size (3 
records: Agartz et al., 2006; Karnik et al., 2010; Gerritsen et al., 2011) and methodological quality of the 
included studies also were unrelated to weighted effect size. 
 
Publication bias, and time-related trends, and Sample size calculations 
Visual inspection of the funnel plot suggested evidence for publication bias. Egger’s test confirmed this 
(Egger’s Intercept = 1.71, 95% CI = 0.16 to 3.26, t = 2.29, P = .02). A trim-and-fill estimation suggested that 
the addition of 2 small and non-significant studies that had to be trimmed and filled would be sufficient to 
result in a non-significant agregated Cohen’s d (random effects model) of 0.09 (95% CI = -0.02 to 0.22, not 
statistically significant; see Figure 3 ↓ for the funnel-plot with observed and imputed values). 
     Test of time-related trends showed a significant correlation between year of publication (2004 to 2012) 
and Cohen’s d (r = -0.54, R2 = 0.29, P < .01). This effect was consistently found in healthy control samples (r 
= -0.49, R2 = 0.24), patient samples (r = -0.55, R2 = 0.30), and mixed healthy–patient samples (r = -0.55, R2 = 
0.30). The observation that effect sizes decreased over the years is illustrated in Figure 1, panel B ↑ (a 
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cumulative meta-analysis) and in Figure 4 ↓ (a scatter-plot on the relation between year of publication 
and effect size).  
 
Table 2. Correlations of demographical, clinical, and methodological study characteristics with Cohen’s d on the relation 
between val66met and hippocampal volume 
 All samples  
(k = 25, N = 3,620)  
HC samples  
(k = 23,  n = 2,542) a 
Patient samples    
(k = 12, n = 692) a 
Demographical/Study characteristics 
   Gender (percentage female)   0.04 -0.01 -0.19 
   Age (mean, years)  -0.36 -0.43*
 b
 -0.35 
   Ethnicity (1 = mixed, 2 = Caucasian)  -0.29 -0.33 -0.40 
   Minor allele frequency  -0.08 -0.08 -0.14 
   Sample size  -0.31 -0.31 -0.40 
   Study quality (frequency of criteria met)   0.12 -0.04  0.45 
Clinical characteristic 
   Psychiatric diagnosis (1 = no, 2 = yes)   0.18 NA  NA 
   Major depressive disorder (1 = no, 2 = yes)  NA NA -0.29 
   Bipolar disorder (1 = no, 2 = yes)  NA NA  0.39 
   Schizophrenia (1 = no, 2 = yes)  NA NA  0.15 
   Psychotropic drugs (1 = no, 2 = yes)  NA NA -0.22 
Methodological characteristics 
  VBM (1 = no, 2 = yes)   0.12  0.24  0.01 
  Magnetic strength (1 = 1.5 Tesla, 2 = 3 Tesla) c  -0.09 -0.13 -0.07 
  Manual hippocampal measurement (1 = no, 2 = yes)   0.31  0.28  0.20 
Abbreviations: HC, Healthy Control; NA, Not Applicable; VBM, Voxel Based Morphology.  
a Note. Numbers do not add up to the total N of 3,620. This is because some studies (Benjamin et al., 2006 and Gruber et al., 2011) did not 
provide sufficient information to calculate Cohen’s d separately for the healthy sample and the patient sample. 
b Mean age did not remain a statistically significant predictor of Cohen’s d in a multivariable regression analysis in which year of publication 
also was added as a predictor variable, whereas the latter did.  
c One study measured at 1 Tesla [Toro et al., 2009] and was coded as 1.5 Tesla. Excluding this study from analysis did not change the results. 





Figure 3. Funnel plot and trim-and-fill 
estimation showing the typical pattern 
of publication bias. Filled and open data 
points depict observed and imputed 
values respectively. The filed diamond 
depicts the aggregated point estimate 
(d = 0.13, P = .02) and the open 
diamond the aggregated point estimate 
after imputation of two studies (d = 









Given that year of publication and age both were significantly associated with effect size these variables 
were analyzed together in a multivariable regression model. Results of this analysis showed that the effect 
of year of publication on weighted d remained statistically significant (B = -0.07, 95% CI = -0.14 to -0.01, β = 
-0.43, P = .03) whereas the effect of age disappeared (B = -0.01, 95% CI = -.02 to 0.01, β = -.35, P = .08).  It 
should be noted though that the multivariable statistics should be interpreted with caution when using 
meta-analysis data because the risk of over-fitting and spurious results (Sterne et al., 2001). Also in our 
data, if we corrected the standard error for the use of meta-analytic data this relation lost its statistical 
significance. Notwithstanding this, through data inspection we recognized that the negative association 
between mean age and Cohen’s d that we observed in univariable tests, might have been driven by null 
associations in 2 recently published studies in samples with the relatively high mean ages (~ 70 years; 
Benjamin et al., 2010; Kanellopoulos et al., 2011). Indeed, if these studies were excluded from the meta-
regression, the effect of year of publication remained similar (r = -0.47, P < .05) whereas the effect of mean 
age of the sample lost its significance (r = -0.29, P = .17) 
     Based on the aggregated effect size we calculated the sample size that is needed to detect a relation 
between variation at val66met (with the MAF being 0.25) and total hippocampal volume with a power of 
0.80 at an α-level of .05. This calculation suggested that 1,900 subjects (1,086 val/val homozygotes and 814 
carriers of a met alle) would be neccesary to detect an association of the met allele with total hippocampal 
volume. Statistical power of the included studies ranged from ~ .07 for the study with the smallest sample 
size (Chepenik et al., 2009 [n = 34] reported effect size d = 1.20) to ~ 0.30 for the largest sample size 




The main goal of this paper was to determine, by meta-analysis, the magnitude and direction of the 
relation between BDNF val66met and hippocampal volume. Our results, based on 25 samples and a total of 
3,620 subjects, suggest that carriers of a met allele have slightly lower total hippocampal volumes (d = 
0.13) relative to val/val homozygotes. This finding has a plausible biological basis as it can be derived by 
the findings that BDNF regulates the sprouting and survival of neurons in the hippocampus (Lu and 
Gottschalk, 2000) and that the met allele is associated with abnormal activity of BDNF in hippocampal 
neurons (Egan et al., 2003). Hence, the lower hippocampal volume in met carriers is mediated through 
aberrant trophic support by BDNF. Notwithstanding meta-analytical significance and concordance with 
biological knowledge, several outcomes of the meta-analyses indicate that the lower hippocampal volume 
in met carriers is not a genuine biological effect of the met allele but likely has an artificial basis. 
Figure 4. Scatter plot showing the relation 
between year of publication and standardized 
Cohen’s d (weighted by the inverse of the 
variance) on the association of val
66
met and 
total hippocampal volume (Pearson’s r = -0.54, 
P < .01). Dashed bordered circles indicate 
studies that included healthy subjects only (r = -
0.49). Solid bordered circles indicate studies 
that included both healthy control subjects and 
patients (i.e., depression, schizophrenia, and 







     Between-study heterogeneity in outcomes in genetic imaging studies may, in general, be due to 
associations that exist in some populations but not in others or might stem from between-study 
differences in methodology. Given heterogeneity in a number of characteristics across the studies, it may 
not be surprising that the reported effect sizes were variable as well (i.e., 7 positive and statistically 
significant studies and 18 statistically inconclusive positive and negative studies). Through stratified meta-
analyses and meta-regression analyses we aimed to identify the sources of this heterogeneity. This is an 
important venue to pursue as identifying factors that explain variance in outcomes may hint to possible 
mechanisms that thrive an association. Both types of  analyses, however, gave little reason to suspect that 
heterogeneity in demographical, clinical, and methodological characteristics across studies was 
systematically related to heterogeneity in effect-sizes. Specifically, we would like to add that manual versus 
automatic hippocampal volume measurements and the use of 1.5 Tesla versus 3 Tesla also were not 
associated, structurally, with differences in effect-sizes. An evaluation of the relation between 
methodological quality of each of the included studies and imputation of effect size similarly showed no 
relation with Cohen’s d. This lack of association is an important observation because it justifies the broad 
set of inclusion criteria that was applied here. However, it should be noted that the use of meta-regression 
analysis might be hazardous with regard to the occurrence of false positive and negative findings because 
the number of data-points on which the results of these analyse are based ussualy is rather small (i.e., the 
number of studies that are included in a meta-analysis; Munafo and Flint, 2004).  
     Between-study heterogeneity may have artificial sources as well. We detected two such sources in the 
aggregated data set. First, we consistently observed, over the mixed healthy-patient samples, healthy 
samples, and patient samples that effect sizes converged closer to null with virtually each subsequent 
attempt at replication. Second, clear evidence for publication bias was identified. Publication bias typically 
results from negative studies that are left unpublished and/or from selective outcome reporting (Ioannidis 
2011). Together, the decrease in effect size estimates over the years and the publication bias suggest that 
the observed aggregated effect size (d = 0.13) is an overestimation for the true or most plausible effect size 
on the association of interest.  
     Yet another finding from this meta-analysis is that the studies included in our meta-analysis were all 
underpowered. In fact, a posteriori power calculations revealed that the power of the included studies 
ranged from as low as ~ 0.07 to only ~ 0.30 to detect an effect of the met allele on hippocampal volume. 
Given that a low level of power increases the ratio of false to true positives (Sterne and Davey Smith, 2001), 
it seems likely that some false positive findings were among the studies that we included. It should be noted 
that evidence for increases in the ratio of false to true positives could not directly be extracted from our 
aggregated data. We did, however, find moderate negative correlation coefficients (albeit non-significant) 
for the relation between the number of subject in a study and effect size (range: -0.31 to -0.40), that is, 
larger samples tended to yield smaller effects.  
     There are some limitations with regard to the methods that were used to detect publication bias. A core 
problem with regard to the interpretation of funnel-plot asymmetry is that one never knows whether the 
funnel plot asymmetry is truly due to publication bias or whether it is due to unmeasured differences 
between studies (Munafo and Flint, 2004). Indeed, heterogeneity in effect-sizes may have come from 
sources that were not tested in our study, such as the duration or dose of psychotrophic medication use, 
disease severity, and exposure to stress (MacQueen and Frodl, 2010). Also the key assumption of the trim-
and-fill method that the most extreme effect sizes are the ones that are left unpublished has been 
questioned. However, simulation experiments have shown superiority of the trim-and-fill method above 
other methods to quantify publication bias when between-study heterogeneity in outcomes is present 
(Peters et al., 2007). 
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      A limitation that we would like to add is that we could not test the hypothesis of differences in 
hippocampal volumes between subjects who were homozygous for the met allele (i.e., met/met) and 
heterozygote val/met subjects, that is a potential dose-dependent effect of the met allele. The frequency of 
occurrence of the met/met variant is particularly low, at least in Caucasian samples (Petryshen et al., 2011), 
and none of the included studies reported outcome estimates for this particular variant. Related, the 
majority of subjects in the studies that were included in our analyses were Caucasian from origin, except 
for 1 study that reported a positive non-significant effect in an Asian sample (Takahaski et al., 2008). Thus 
our results might be less applicable for subjects who are of ethnic backgrounds other than Caucasian. In 
addition, it could be that variation at the val66met locus of the BDNF gene is important for hippocampal 
morphology only in interaction with childhood trauma exposure for which some evidence exists (Gatt et al., 
2009) although 2 of the in this meta-analysis included records (Gerritsen et al., 2011; Molendijk et al., 2012) 
could not replicate this phenomenon. Another limitation of our study might be that we focused on total 
hippocampal volume whereas the morphology of the hippocampus is complex and can, for example, be 
subdivided in a head, a body and a tail (Maller et al., 2007). It could be that the effect of the met allele is 
limited to morphologically specific sites of the hippocampus (see Montag et al., 2009). 
     In sum, we carried out a systematic review and meta-analysis on the association between val66met and 
total hippocampal volume. The results that are reported here indicate that carrying a met allele at the 
BDNF val66met locus is associated with lower hippocampal volumes. So, one might conclude that the met 
allele has an effect on hippocampal morphology. However, we observed that effect size estimates 
converged closer to null with virtually each attempt at replication and that all studies on the subject matter 
were largely underpowered. Furthermore, we found evidence for publication bias inflating the association 
reported in the literature. Altogether, this not only suggests that the effect is inherently smaller than 
reported here (d = 0.13) but also calls into question whether the observed effect is a biological effect of the 
met allele or whether it is an artifact of underpowered studies. We therefore conclude that variation at the 
BDNF val66met locus is not likely to account for individual differences in hippocampal volume but rather 
that the association is subject to a winners curse, with large effect sizes found in a few early studies and 



























The overarching purpose of this thesis was a better appreciation and a more refined model of (peripheral) 
neurotrophic functioning in depressive (and related) disorders. The empirical data of the prevailing thesis 
are presented in the previous eight chapters. The next chapter consists of an aggregation and a discussion 
of these data. This will be done first for the findings on the determinants of serum BDNF concentrations, to 
be followed by the clinical findings that are reported herein. Strengths and weaknesses will be discussed on 
the spot and additionally in a paragraph dedicated to this important subject. The discussion will continue 
with the possible implications of our findings and based on the current state of knowledge the main open 
questions will be stipulated. A summary in English, Dutch, German, and Spanish closes up this thesis. 
 
Determinants of serum BDNF concentrations 
Each empirical chapter in this thesis explored an area that either is directly relevant for our understanding 
of neurotrophic functioning in psychiatric illness, notably depression, or laid a basic to this end. Chapters 2 
and 3 are examples of the latter as here the determinants of serum BDNF concentrations were explored.  
     In line with a conceptualization of serum BDNF concentrations as being dependent on a myriad of 
factors, a long-list of variables was discovered that systematically are associated with serum BDNF 
concentrations. Table 1 ↓ summarizes this list next to the main null findings that are reported in the 
chapters 2 and 3. 
 
The Basic Determinants of serum BDNF concentrations 
Chapter 2 addressed four categories of variables with regard to their association with serum BDNF 
concentrations. These categories were sampling-, socio-demographic-, lifestyle-, and disease variables.  
     Of the sampling variables (four were tested; time of blood withdrawal, the number of minutes that a 
sample was kept in a cool box before being processed, the duration of sample storage, and adherence to 
the fasting protocol) it was found, in multivariable analyses, that participants who were sampled later in 
the morning and those who did not adhere to the fasting protocol had lower serum BDNF concentrations. 
Longer sample storage of blood serum before BDNF determination took place also was associated with 
lower serum BDNF concentrations. Thus with time, even when stored at -85 C˚, the BDNF protein 
deteriorates. Herewith we replicate the findings of a Danish group (Trajkovska et al., 2005) that addressed 
this topic for storage at -20 C˚.  
     The socio-demographic variables that were tested included gender, age, degree of urbanicity of living 
environment, and years of formal education. Of these, age was positively associated with serum BDNF 
concentrations. An age–gender interaction effect further specified this association and indicated that the 
increase in serum BDNF concentrations related to age was more strongly evident in females as compared 
to males. This finding was somewhat more complicated as the age related increase in serum BDNF 
concentrations in women seemed to end when the menopausal stage set in (around 50 years of age; 
Voorhuis et al., 2011). A possible explanation for this will be provided in a latter part of this discussion. 
Living in a more urban area was associated with increased serum BDNF concentrations. With regard to the 
112 
 
lifestyle indicators (i.e., smoking, alcohol consumption, the amount of physical activity, and body mass 
index) it was found that being an excessive drinker was associated with lower-, whereas smoking was 
associated with higher serum BDNF concentrations.  
 
Table 1. Determinants of serum BDNF concentrations  
Category Variable Relation to BDNF 1  
Sampling variables 
(chapter two,  N = 1,168) 
 
 
- time of morning blood draw  
 
- sample in cool box before processing  
 
- duration of sample storage  
 
- fasting at times of blood draw   




↓ when longer stored 
 
↓ when non-fasting 
Socio-demographic variables  




- age (years) 
  
- level of urbanicity  
 
- years of education 
no association 
 
↑ when higher age 
 
↑ in urban areas 
 
no association 
Lifestyle indicators  
(chapter two,  N = 1,168) 
- physical activity  
 
- alcohol consumption  
 
- smoking  
 
- body mass index  
no association 
 
↓ in excessive-drinkers 2 
 




(chapter two,  N = 1,168) 
- metabolic syndrome  
 
- chronic lung disease  
 







(chapter three,  N = 2,851) 
- season of blood sampling 
 
- month of blood sampling 
 
- ambient sunlight hours 
↑ in late summer and early fall 
 
↑ in September and October 
 
↑ following sunny periods 
1 ↑, ↓: statistically significant higher or lower serum BDNF concentrations respectively 
   no association: no statistically significant association between serum BDNF concentrations and the  variable that is  
   indicated in the corresponding row 
2  excessive-drinking is defined as > 14 units per week 
 
     None of the disease related variables, including the presence of chronic non-specific lung- and coronary 
artery disease, were associated with serum BDNF concentrations. These null findings were not expected 
based on the literature (see for instance Golden et al., 2010). A possible explanation for this may be the 
overall health status of the sample and, as a result, a lack of variation in the occurrence of these illnesses 
and thus low statistical power. 
 
Seasonality in serum BDNF concentrations 
Chapter 3 assessed seasonality, a broad concept that refers to biochemical or behavioral alternations as 
response to variability in the length of day (Walton et al., 2011), in serum BDNF concentrations. A drive to 
study this topic was that in rodents seasonality has been observed in neuronal plasticity, a process that is 
regulated by BDNF (Workman et al., 2009). A further motivation was that molecular events, upstream of 
BDNF have been shown to undergo seasonal rhythmicity (Lambert et al., 2002). Finally, depression 
presumably is related to serum BDNF concentrations (Sen et al., 2008) and this illness occurs to some 
extent according to a seasonal pattern (Lewy et al., 2006). So, seasonality in serum BDNF concentrations 
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was expected. And indeed, particular strong evidence for our expectation was found: serum BDNF 
concentrations increased in the spring-summer period and decreased in the autumn-winter period. This 
effect was independent of potential confounders such as having a DSM-IV depression diagnosis. 
Importantly, the observed effect-size estimates for monthly differences in serum BDNF concentrations 
were substantial (up to a Cohen’s d of 0.60). Explorative analyses further showed that the number of 
sunshine hours (a major trigger to entrain seasonality; Walton et al., 2011) in the weeks prior to blood 
withdrawal positively correlated with serum BDNF concentrations and this partly explained the observed 
monthly variation. It was also found, and this may not come as a surprise now, that the length of day 
correlated in a similar manner with serum BDNF concentrations as the number of ambient sunshine hours 
did.  
     The findings on the determinants of serum BDNF concentrations have significant implications, as will be 
discussed in the part that follows. 
 
Determinants of serum BDNF concentrations: implications 
Knowledge on the determinants is of importance. Smith and Ebrahim (2002, page 1438) wrote that we live 
in an associational world where people who differ in some regard from others, often differ systematically in 
other regards as well (e.g., persons who are depressed are more likely to smoke [Kendler et al., 1993]). So, 
characteristics cluster together and as such they may have shared relationships with certain outcomes. 
Confounding is said to occur then when one element of a cluster is associated with a given outcome, 
whereas this relation is due to another element of the cluster. Confounding is the most likely cause of 
spurious associations (Smith and Ebrahim, 2002) and as such a stand in the way of (research) progress. 
Gaining detailed insight into determinants or the confounding structure of certain traits, biological 
alternations or behavior is a means to avoid this because it can provide a scaffold for the exploration of 
independent associations. The findings in the first two chapters of this thesis provide such a scaffold. 
 
Determinants of serum BDNF concentrations: methodological implications 
First, given that the time of the day of blood draw and non-fasting protocol are associated with serum 
BDNF concentrations, a stringent sample protocol is warranted to obtain valid results. In this protocol a 
narrow time range should be defined in which blood sampling should take place (e.g., between 07:00 and 
07:30 a.m.) and it should be specified and controlled for that participants are sober at the time of blood 
draw.  
     Next, since the duration of sample storage impacts on serum BDNF concentrations, when studying 
differences among diagnostic groups, one needs to make sure that the groups that are compared do not 
differ in a systematic manner. Let me provide an (oversimplified) example for why this is/becomes 
(increasingly) important. The US army stores blood from all its soldiers since the start of the first Gulf war in 
1991 (Nature News, July 2013) to answer relevant questions with. Say, one wishes to learn whether 
veterans who were sent to Iraq and who did and did not develop post-traumatic stress disorder differ from 
non-soldier controls with and without PTSD with regard to serum BDNF concentrations. Data on the soldier 
group comes from the US army database whereas those on the control group need to be gathered after the 
research question is formulated (let’s say June 2014). Given that BDNF levels decrease about 1/10 of a 
standard deviation each year as a function of storage time (chapter 2) the amount of BDNF in the serum of 
the soldiers (sampled in 1991) would at least be 2 standard deviations lower compared to those of the non-
soldier controls (sampled in 2014). Concluding that soldiers who develop post-traumatic stress disorder 
have lower serum BDNF concentrations as compared to healthy controls with PTSD obviously wouldn’t be 
valid as the between-group difference is due to storage duration.  
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     The discovery of seasonality in serum BDNF concentrations (chapter 3) is important for methodological 
reasons alike. One, it is crucially important when interpreting the results from longitudinal studies. In fact, 
trials that span months and that have serum BDNF concentrations as an outcome, may be of little use 
unless detailed knowledge on seasonal effects is taken into account (in the protocol and/or the 
statistically). Likewise, there is the need to sample groups (e.g., depressed versus healthy controls) equally 
over the year in order to gain credibility in research findings. Given the seasonal patterns in the occurrence 
of mood disorders (Lewy et al., 2006) this is quite difficult. I will illustrate this with an example that applies 
to one of the main findings that is presented in this thesis; the lower serum BDNF concentrations in 
depressed persons as compared to healthy controls (chapter 4, to be discussed in a next part). In the 
NESDA sample, persons who are depressed are more likely to be sampled in the winter (42 percent of the 
participants) as compared to the summer (36 percent of the participants). This 6 percent difference may 
not seem that large but it is statistically significant (P-value for the difference  = .001) and given the large 
sample-size of the NESDA a difference of a few percent involves several dozens of persons. Just as the 
prevalence of depression, serum BDNF concentrations differ as a function of season, with higher 
concentrations in persons who are sampled in the summer as compared those who are sampled in the 
winter (d = 0.47, P < .001, see chapter 3). Together this already suggests that controlling for season of 
sampling may make a difference. This indeed is so. Our data shows that the differences in serum BDNF 
concentrations between depressed patients and healthy control subjects is statistical significant (P = .007) 
and has an effect size of d = 0.19. When this analysis is rerun controlled for seasonality, the direction of the 
effect and its statistical significance hold, yet the latter shifts upwards to P = .04 and importantly, the 
strength of the association is attenuated by about 40 percent to d = 0.11. This is illustrative for the 
importance of accounting for determinants. Please note that large sample size is more robust with regard 
to deleterious effects of confounding as compared to studies that conclude on the basis of a smaller sample 
(Lenth 2001). Therefore the effect-size estimates derived from small-scale studies may be hampered by 
confounding to a larger extent and thus the results that these yield may not only be less reliable but also 
less valid.  
     Concluding from the above, a stringent sample protocol and/or statistical control for a range of relevant 
variables seem warranted in BDNF related research in order to come to valid results. I gladly noticed that, 
based on our findings, several authors have picked in their studies on serum BDNF concentrations (e.g., Ball 
et al., 2013). What the above-presented findings obviously do not bring is insight into how exactly serum 
BDNF concentrations vary as a function of different levels of determinant exposure. this however was not 
the intention of this thesis and the epidemiological nature of the data that were used gave little room for 
studying this. Still, some of the findings herein do hint to mechanisms that govern BDNF expression. Given 
that I consider such hints important in generating future hypotheses, I do not want to simply jump over 
them. Two illustrative examples therefore are discussed below: (I) the interaction effect between age and 
menopausal stage and serum BDNF concentrations (chapter 2) and (II) the delayed positive linear 
relationship between the number of ambient sunlight hours and serum BDNF concentrations (chapter 3). 
Please note that we did not formally test the hypotheses that are brought forward in the following section. 
 
Gender specific associations: estrogen and BDNF  
Chapter 2 reports a larger to age related, increase in serum BDNF concentrations in women as compared to 
men. Given the large number of participants that formed the base for this result (757 women, 408 men), 
this is not likely to be a chance finding. In addition, we could convincingly exclude that behavioral- or illness 
characteristics were the source of this association. What could have caused it? Hormonal differences 
between the two genders seem a viable explanation. In accord with this was that the age related rise in 
115 
 
serum BDNF concentrations in women occurred until the menopausal stage (~ 50 years of age; Voorhuis et 
al., 2011) and not thereafter. In fact, in female participants it was observed that from ~ 50 years on, age 
was not associated with serum BDNF concentrations. So, serum BDNF concentrations peak at the 
climacteric age in women. This is interesting because (I) there are studies that have established positive 
correlations among peripheral estrogen and BDNF concentrations (e.g., Monteleone et al., 2007) and (II) 
estrogen expression drops sharply in females in the menopausal stage (Genazzani et al., 1999). Based on 
this, we hypothesized that the association between age and serum BDNF concentrations could be 
dependent on menopausal stage and by extension, maybe, on estrogen expression. To probe this further, 
women in the age range 48 to 52 years were selected and the interaction between age and menopausal 
status on serum BDNF concentrations was modeled. This analysis showed that in premenopausal women 
BDNF concentrations increased as a function of age whereas in post-menopausal such a relation was not 
observed. This corroborates, although not proves, the idea that in women serum BDNF concentrations are 
under the influence of estrogen expression. This may have clinical implications in that the transition into 
the menopause is associated with increased odds on depression (Judd et al., 2012) and a relatively large 
drop in cognitive performance (Farrag et al., 2002), which, according to the neurotrophin hypothesis, are 
both under the influence of BDNF (Duman et al., 1997). Interestingly, and in line with this idea, is that in 
chapter 6 we find that anxious women have lower serum BDNF concentrations as compared to healthy 
women, whereas in male patients with an anxiety disorder this effect was not observed. This gender 
specific association could, in theory, also be explained by estrogen because the expression of this hormone 
is low in anxious women (Walf and Frye, 2006). Some pre-clinical studies suggest the potential importance 
of this on the level of the central nervous system by showing that estrogen - BDNF interactions are 
associated with dendritic growth and synaptogenesis in the cerebellum (Haraguchi et al., 2012). So, 
estrogen and BDNF interactions may be of importance in understanding age and gender related changes in 
behavior (e.g., depression) and abilities (e.g., cognitive performance). Of course, a manifold of changes 
occur during the menopausal transition that were not controlled for so alternative explanations loom. 
Besides, estrogen does not explain some other observations of our studies (e.g., the increase in serum 
BDNF concentrations as a function of age in males).  
 
Let the sun shine bright: serotonin and BDNF  
Our study described in chapter 3 also yielded some results that hint to mechanisms that govern BDNF 
expression. Here, I point to the positive relationship between the number of ambient sunlight hours and 
serum BDNF concentrations. Interestingly, this effect was observed with a delay; where the number of 
ambient sunlight hours in the weeks prior to blood draw (for up to 7 to 8 weeks before this event) 
correlated positively with serum BDNF concentrations, the number of sunlight hours in the week of the 
blood draw itself were not. Importantly, also for this finding we could exclude a range of confounding 
factors such as the time of the day of blood draw and the study that yielded this finding was well powered.  
     A possible explanation for this effect can be gained through a comparison with an observation from the 
treatment setting. Preclinical and clinical studies have shown that antidepressants upregulate the 
transcriptional activity of BDNF (Duman and Monteggia, 2006) but only after long-term administration (e.g., 
≥ 21 days; Conti et al., 2002). The gist on why the increase in BDNF expression occurs with a lag time is that 
antidepressants first increase the availability of monoamines, notably serotonin, to set in CREB activity 
(Castren et al., 2007). CREB, a general transcription factor (Guilloux et al., 2012), binds to the promoter 
region of the BDNF gene and this positively regulates transcription (Impey et al., 2004). Therefore it seems 
likely that (serotonergic) antidepressants act on CREB through an increase in the availability of serotonin 
(Impey et al., 2004). Just like treatment with pharmacological antidepressants, long day conditions give rise 
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to a higher expression of serotonin (Lambert et al., 2002). This increase is very likely to occur through a 
direct effect of light on the expression of L-Tryptophan. L-Tryptophan is known to increase 5-Hydroxy-
tryptophan and serotonin expression, leading in turn a higher level of CREB activity and BDNF expression 
(Castren et al., 2007). Therefore it seems likely that also the delayed increase in serum BDNF 
concentrations following relatively sunny periods is entrained by increased CREB activation that is induced 
by a larger availability of biological active serotonin and its precursors L-tryptophan (Cappielo et al., 1996) 
and 5-hydroxy-tryptophan (Wehr et al., 2001).  
     An final note on the finding of seasonality in serum BDNF concerns that, although here described as a 
confounder, it in theory also could be regarded as a mediator linking season and depression.  This mediator 
role could not be excluded in our studies, although it may not seem that likely given the lag-time with 
which the change in BDNF occurred and the absence of a depression diagnosis times season interaction 
effect on serum BDNF concentrations. 
 
The determinants of serum BDNF concentrations – recapitulating  
In my view, the data that the first two chapters of this thesis bring improve the base to understand inter-
individual differences in serum BDNF concentrations. Besides, the acquired knowledge will facilitate 
ongoing research into neurotrophic functioning in depression (and related illnesses). It allowed us to test, 
largely independent, some predictions from the neurotrophin hypothesis, which is the topic of the next 
part of this discussion. 
 
The neurotrophin hypothesis of depression and our work 
The rationale for the neurotrophin hypothesis of depression is straightforward: BDNF expression, shaped 
by genetic and environmental influences, determines neuronal faith and viability and subsequently 
behavior, including depression (Duman et al., 1997). The two basal predictions from this hypothesis are 
that depression results from a stress-induced decrease in BDNF expression and that antidepressants are 
efficacious because they normalize this (Duman and Monteggia, 2006).  The overarching purpose of this 
thesis was to evaluate the validity of these predictions using peripheral BDNF parameters and a genetic 
variant that is presumed to be associated with neurotrophic functioning. In the section below I will discuss 
the studies that were performed to this end. 
 
Serum BDNF concentrations in depressive illness 
Chapter 4 and 5 advanced the understanding of the associations between serum BDNF concentrations and 
the illness major depression. Chapter 4, a single study, reports in accord with previous findings (Sen et al., 
2008) and the neurotrophin hypothesis (Duman et al., 1997) that serum BDNF concentrations are low in 
depressed patients as compared to healthy controls (d = 0.19). Importantly, this study also shows that 
serum BDNF concentrations are low in depressed patients as compared to persons who are in full remission 
and that serum BDNF concentrations of this latter group are comparable to those of controls. Thus, low 
serum BDNF concentrations are a state characteristic of depression; an abnormality that is evident during 
depression and that normalizes during remission. 
     Chapter 5, a meta-analysis on the same subject, establishes the robustness of this association as it 
shows, based on 2,384 depressed patients and 2,982 healthy controls that serum BDNF concentrations are 
low in the depressed state (d = -0.47, 95% CI = -0.64 ― -0.27). Herewith the neurotrophin hypothesis is 
corroborated in its prediction that serum BDNF concentrations are abnormally low in depressed patients. 
What may be the cause of this between-group difference? The axiom that has been brought forward by the 




Serum BDNF concentrations and trauma/stress exposure 
The axiom that for over a decade has been brought forward in explaining depression related alternations in 
BDNF expression is early life trauma- (such as childhood abuse) or stress exposure in adulthood (Duman et 
al., 1997; Duman and Monteggia, 2006). Some preclinical and clinical evidence exists for this idea (see for 
instance Groves 2007). In contrast, the well-powered and well-controlled studies in this thesis show that 
trauma exposure is not associated with BDNF concentrations (chapter 7). In fact, with regard to stress 
exposure we only could show a negative correlation between recent stress exposure (e.g., a divorce) and 
serum BDNF concentrations. Given that this association only explained ~ 1 percent of the variance in serum 
BDNF concentrations it probably does not constitute a sufficient explanation for alternations in 
neurotrophic functioning in stress related illnesses. The relationship between trauma exposure and BDNF, if 
it is truly there, probably is more complex and for instance dependent on the presence of a moderator (see 
chapter 7 in which a val66met - trauma interaction effect on serum BDNF concentrations was established). 
This will be discussed in a later part of this discussion. Nothwitstanding a lack of knowledge on moderators, 
I wish to state that the findings regarding trauma- and stress exposure largely, as they appear to be now 
(i.e., largely negative) are not in line with the neurotrophin hypothesis. So, maybe other explanations need 
to be sought for the lower BDNF concentrations in stress related illnesses such as depression. Some 
findings in this thesis suggest on such mechanisms, other then stress. These putative mechanisms, 
alongside some some findings that show a lack of fit with the predictions of the neurotrophin hypothesis, 
will be the topic of the section below. 
 
Serum BDNF concentrations and the early remission phase: reverse causation? 
In chapter 4 we found that patients who were in the early remission phase of their depressive episode, and 
thus largely free of symptoms, had serum BDNF concentrations that were lower as compared to those of 
currently depressed patients. Thus, serum BDNF concentrations remain low, or even become somewhat 
lower, after clinical improvement has set in. Explanations for this could not be elucidated in this thesis and 
longitudinal designs with frequent samplings need to be performed to understand this issue. Albeit the lack 
of a clear explanation, the finding of low levels of BDNF in the early remission phase is not in line with the 
prediction of the neurotrophin hypothesis that low neurotrophic support endangers a person to become 
depressed (Duman and Monteggia, 2006). In fact, it seems to plead for reverse causation in that the lower 
serum BDNF concentrations do not endanger a person to become depressed but rather are a consequence 
of being depressed. Why would serum BDNF concentrations be particularly low in the early remission 
phase of depression? Two hypotheses will be formulated here that potentially can explain it: (I) to 
depression related changes in body-weight and (II) to depression related changes in levels of oxidative 
stress. These hypotheses will be discussed below. 
     In chapter 4 we find that BMI is positively associated with serum BDNF concentrations in depressed 
patients (note that such a correlation was not observed in healthy control subjects, see chapter 2). 
Although this finding was unsought, it parallels the results of some previous studies (Nakazato et al., 2003; 
Monteleone et al., 2005) and they give ground to an interesting hypothesis. As weight loss is a prime 
behavioral abnormality of depression (APA 1994) and often a residual symptom in early remission (Paykel 
1985; Paykel et al., 1995) it could be that alternations in serum BDNF concentrations are mediated by 
(transient) changes in eating behavior during, or in the aftermath of a depressive episode. The mechanism 
would then simply be that a decrease in intake of the building blocks for the protein BDNF could lower the 
expression of it or in this case particular, a higher metabolism of BDNF and consequently lower BDNF 
concentrations. Likewise, weight gain is a documented side effect of antidepressant treatment (Kachur et 
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al., 2005). And this, or better the absence of weight loss could potentially explain the absence of a relative 
fall of serum BDNF concentrations in depressed patients who are treated with an antidepressant (the 
associations among antidepressants and serum BDNF concentrations will be discussed in a latter part of 
this discussion).  
     Another explanation for the abnormally low serum BDNF concentrations in the early remission- and the 
active depression phase is mediation by oxidative stress. Depressive disorders are accompanied by a 
decreased antioxidant status (Maes et al., 2011). The antioxidant status of a person refers to the capacity 
to protect against reactive oxygen species. An imbalance of the oxidative status generates toxic reactive 
oxygen species and this causes damage to membrane lipids, to DNA and consequently disturbs the 
functioning and stability of proteins (Sarandol et al., 2007). So, oxidative stress causes oxidative imbalance 
with accompanying protein damage and also BDNF functioning may be negatively affected by it. 
Alternations in oxidative stress homeostasis set in during the depressed state (probably due to behavioral 
alternations such as a changed eating pattern and less physical activity). Therefore also the lowering of 
BDNF functionning, if it truly is affected by oxidative stress, may only set in during the depressed state 
(critically, not prior to the depressed state as the neurotrophin hypothesis suggests). Given that the 
disturbed oxidative stress homeostasis may linger on into early remission (Barnham et al., 2004), BDNF 
levels consequently may remain low in this phase. There is one study in human subjects that confirmed the 
idea on the role of oxidative stress on neurotrophic functioning to some extent. This study by Kapczinski et 
al. (2008) showed a negative correlation (r = -0.58) between serum thiobarbituric acid reactive substances 
and BDNF concentrations in bipolar patients (in whom serum BDNF concentrations in general are low; 
Fernandes et al., 2011). This is suggestive for the notion that alterations in oxidative stress homeostasis 
may be mechanistically associated with alternations in the expression/metabolism of BDNF. There are 
some preclinical studies that support this idea. Already in 1996, Kirschner and her colleageaus showed, in 
vivo, that neuronal damage and decreased BDNF expression can be induced by chemical hypoxia. This, 
however, could be attenuated by BDNF administration. Interestingly, some authors have suggested that 
antidepressants may affect oxidative stress homeostasis in a positive manner (Khanzode et al., 2003). 
Therefore, normalization of oxidative status may complementary explain the absence of abnormally low 
serum BDNF concentrations in antidepressant treated depressed persons. Finally, is notable that several 
studies show that oxidative stress is associated with processes that typically are governed by BDNF, such as 
neuronal functioning (Barnham et al., 2004).  
     Whatever the mechanism that is involved in the lowering of serum BDNF concentrations in the 
depressed and the early remission phase, chapter 4 suggests that the effect-size on these differences are 
small in absolute sense (i.e., a standardized mean difference of ~ 0.2) and also when compared to those 
reported by earlier small scale studies and meta-analyses (see for instance Sen et al., 2008). Small effect-
sizes indeed were confirmed in the meta-analysis, the way to converge to the true effect-size, in chapter 5. 
The findings of this chapter and the implications that they may have are discussed below.  
 
Serum BDNF concentrations and depression diagnosis – small effect-size estimates 
Chapter 5, a large-scale meta-analysis, shows lower serum BDNF concentrations in untreated depressed 
patients as compared healthy controls. This finding is not new (see above). The novelty of the work instead 
is that it highlights a large amount of between-study heterogeneity in outcomes. Importantly, none of the 
theoretically relevant variables that we tested (e.g., gender distribution of the sample) was associated with 
the between-study heterogeneity. Obviously, it may have come from between-sample characteristics, such 
as heterogeneity in clinical characteristics of patient samples. However, for this idea, meta-regression 
analyses could find no evidence whatsoever. In contrast, these analyses showed an artificial base for the 
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heterogeneity in outcomes. First, a large part of the studies that were included was underpowered. Given 
that a low level of power increases the false versus true positive ratio (Sterne and Smith, 2001), some 
overly positive findings may have been among the studies that we included, causing heterogeneity. Second, 
we found that sample size and year of publication were significant predictors of between-study 
heterogeneity, with larger and more recently published studies reporting smaller between-group 
differences. This points to publication bias – which is a threat to the validity of the literature and besides a 
cause of hererogeneity. Analyses that accounted for publication bias yielded an attenuated effect-size 
estimate that was about half as large (i.e., d = 0.47) as the one reported in previous meta-analysis that was 
based on 8 times less data (Sen et al., 2008). Of course, small-effect sizes do not attest the validity of a 
hypothesis. In fact, the effect-size estimate remained statistically significant and thus corroborates it. What 
this finding does attest however is that the data, for reasons of publication bias and overestimations of 
effect-sizes, should be critically interpreted. A consequence of this is that the evidence for the neurotrophin 
hypothesis is slimmer as was initially thought. This is in line with more recent work showing that, using 
longitudinal designs, serum BDNF concentrations are not, or only marginally, predictive for depression 
related psychopathology (e.g., Vinberg et al., 2013; Bus et al., submitted). Furthermore, the findings in this 
thesis on the lack of an association between serum BDNF concentrations and the clinical features of 
depression and all major types of antidepressants use (chapters 4 and 5) also suggest that the evidence for 
the neurotrophin hypothesis is not so strong as was initially thought. This will be discussed in below.  
 
Serum BDNF concentrations and the clinical features of depression 
The putative association between serum BDNF concentrations and the symptom severity of depression has 
been brought forward as a pillar of the neurotrophin hypothesis (e.g., Karege et al., 2002). This makes 
sense because when you predict that serum BDNF concentrations play a role in the pathophysiology of 
depression as the neurotrophin hypothesis does (Duman and Monteggia, 2006) you may expect that BDNF 
levels are are particularly low in more severely depressed patients. The findings reported in chapter 4 and 5 
however are not in line with this expectation. The single study reported in chapter 4 could not replicate the 
association between depression symptom severity and serum BDNF concentrations in unmedicated 
depressed persons (r = 0.03, P = 0.23, N = 541) neither could the meta-analysis in chapter 5. The meta-
analysis added a layer of certainty to this, as it showed that the studies that did find evidence for this 
association are outliers and likely false positives. So, the dose-response association between serum BDNF 
concentrations and the symptom severity of depression probably does not exist. This further is exemplified 
by the finding in chapter 4 that the early remission phase is accompanied by a much lower symptom 
severity of depression (mean depressive symptom severity scores were 22.4 ± 11.4 versus 32.4 ± 12.1 (P < 
.000001) in currently depressed patients) alongside lower BDNF concentrations as compared to the current 
depressed state. 
     Regarding the other clinical characteristics of depression, chapter 4 also could not confirm the findings 
that having a recurrent compared with a first episode of depression (Lee et al., 2007) and the presence of 
suicide ideation (Deveci et al., 2007; Kim et al., 2007) are accompanied by lower concentrations of BDNF. 
Age at onset of depression, the presence of comorbid anxiety and the chronicity of depression also were 
shown to be unrelated to serum BDNF concentrations (see chapter 4). Because most of the studies in the 
literature did not report on these variables there was no opportunity to confirm the null-findings regarding 
these clinical characteristics through meta-analysis. Notwithstanding this, together these findings, given the 
samples-sizes that were used to come to them, give confidence in excluding the clinical features of 
depression as potential correlates of serum BDNF concentrations. This is an important conclusion, as it 
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hints that other factors than specifically to depression related phenomenon, such as weight gain and loss, 
may be at play in the relative fall of BDNF concentrations during/around a depressive episode. 
Serum BDNF concentrations and antidepressant treatment 
A core prediction of the neurotrophin hypothesis is that antidepressants are clinically efficacious because 
they normalize neurotrophic functioning and with this aberrant brain functioning (Duman and Monteggia, 
2006). In the chapters 4 and 5 we find some evidence for this prediction.  
     Within the context of a large-scale single study (chapter 4) we found evidence that serum BDNF 
concentrations normalize in the course of antidepressant treatment. This finding largely is in accord with 
previous findings (Brunoni et al., 2008). It should be noted though that the effect-size on this association is 
considerably smaller (i.e., d = 0.23) as compared to the effect-sizes that previous studies report on. Still, in 
chapter 5 the reliability of this finding was confirmed through meta-analysis, albeit this analysis also yielded 
a considerably smaller effect-size estimate  (i.e., d = 0.34) as compared to those in previous studies (i.e., d = 
0.80; Sen et al., 2008). Besides, we were able to expand previous findings by showing that the use of an 
antidepressant is associated with increased serum BDNF during a depressive episode but not during 
remission. This suggests that antidepressant-induced increases in BDNF occur in a disease state when BDNF 
functioning might be defective and not in full remission when BDNF functioning is normalized (see chapter 
4).  
     Interesting was that the increase in serum BDNF concentrations appeared to be specifically associated 
with the use of SSRIs and St John’s wort and not with the use of SNRIs, TCAs or NaSSAs (chapter 4). 
Although not directly confirmed, this finding might be explained by increased availability of extra-synaptic 
concentrations of serotonin, as it is known that serotonin stimulates the expression of BDNF (Martinowich 
and Lu, 2008). In line with this, we found the highest BDNF concentrations in patients who were treated 
with agents that generally lead to an increase in the availability of serotonin; SSRIs and St John’s wort 
(Gaster and Holroyd, 2000). Furthermore, the lowest concentrations of BDNF were found in patients who 
were treated with NaSSAs that are known to have little or no impact on the availability of serotonin (Antilla 
and Leinonen, 2001). Noteworthy is that this observation, and its putative explanation in terms of the 
availability of serotonin fits very well with the findings on seasonality in serum BDNF concentratons (see 
chapter 3). The antidepressant specific effect on serum BDNF concentrations however could not be 
replicated in the meta-analysis reported in chapter 5. This could be due to a lack of statistical power as in 
this analysis it had to be assessed through a meta-regression that used the number of included study as 
data-points and this number was only 28.  
     Notwithstanding the findings that seem to confirm the neurotrophin hypothesis, the results that were 
described in chapter 4 and 5 do not all recapitulate it. First, the antidepressant-specific effect on serum 
BDNF concentrations (already mentioned above) seems at odds with the specific prediction of the 
neurotrophin hypothesis that increases in BDNF concentrations are a key mediator for an antidepressant 
response to occur (Duman and Monteggia, 2006). According to this prediction, one might expect that 
antidepressants that are known to be about equally efficacious in the treatment of the symptoms of 
depression (Berton and Nestler, 2006) would have similar effects on serum BDNF concentrations. Clearly, 
this is not the case.  
     A second finding that seems hard to reconcile with the neurotrophin hypothesis is that the group of 
depressed persons who used antidepressants (for prolonged period and on a frequent base) had the 
highest BDNF concentrations, but also the highest symptom severity of depression (chapter 4). This 
suggests that increases in peripheral BDNF concentrations do not parallel clinical effectiveness, or at least 
have no direct effects on depression characteristics such as its severity. Thus, the temporal dynamics as 
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predicted from the neurotrophin hypothesis do not seem to be correct. Furthermore, epiphenomena for 
the finding that antidepressants are associated with serum BDNF concentrations cannot be excluded. 
Interestingly, among these epiphenoma are those that also could explain differences among untreated 
depressed persons and healthy control subjects (i.e., to depression and treatment related weight gain and 
loss and oxidative stress levels). Finally, chapter 5 reports, along a similar line as the findings regarding 
differences among diagnostic groups, that a large amount of unexplained between-study heterogeneity in 
outcomes and publication bias is evident in the literature on the association between antidepressants and 
serum BDNF concentrations. This also indicates that the effect of antidepressants on serum BDNF 
concentrations is not that large as they initially were thought to be. 
    Relevant to the above-presented discussion on lower BDNF concentrations in persons diagnosed with 
depression are the findings reported in chapter 6. In this chapter serum BDNF concentrations were 
evaluated in persons diagnosed with an anxiety disorder. Given that the anxiety disorders mimic 
depressions to a great extent (David et al., 2009), abnormalities in serum BDNF concentrations were 
expected. This putative association is the topic of the section that follows. 
 
Serum BDNF concentrations and anxiety 
Based on animal models (e.g., Monteggia et al., 2007), some small-scale human studies (Strohle et al., 
2010), and the neurotrophin hypothesis (Duman and Monteggia, 2006) there is a strong a priori reason to 
expect that serum BDNF concentrations are low in persons who suffer an anxiety disorder. However, robust 
evidence for this belief is absent. Chapter 6 filled this gap and explicitely tested the hypothesis that serum 
BDNF concentrations are low in patients with an anxiety disorder as compared to healthy controls. The 
results of this study, controlled for a range of demographical and behavioral variables and derived from a 
sufficiently powered design however did not confirm this hypothesis as overall no differences in serum 
BDNF concentrations between patients with an anxiety disorder and healthy controls were found. So, it 
seems unlikely that BDNF is involved in the pathophysiology of anxiety disorders per se.  
     Given that the preclinical literature gives ground to test for gender differences in the relation between 
anxiety and BDNF (Govindarajan et al., 2006), we assessed gender differences as well. Analyses stratified by 
gender revealed that female patients had somewhat lower BDNF concentrations relative to female controls 
(d = 0.19), whereas BDNF concentrations were similar among male patients and male controls. This gender 
specific finding could point in the direction that BDNF is related to the pathophysiology of anxiety in female 
but not in male patients. Remarkable is that this finding compares well with some studies from the 
depression literature, which have shown lower concentrations of BDNF in female depressed patients as 
compared to male depressed patients (Karege et al., 2002a; Huang et al., 2008; and chapter 4). 
     The origins of this gender specific finding are unknown. Here, and also in depressed subjects (see 
chapter 4) we found that the differences in serum BDNF concentrations between female and male patients 
were not driven by demographical (e.g., age), behavioral (e.g., smoking), or clinical (e.g., severity) variables. 
In chapter 6 it further was shown that the difference between female and male patients could not be 
attributed to a specific subtype of anxiety. A general deduction from this, and from the finding that serum 
BDNF concentrations are similar among female and male controls, is that the origins of it may lie in a 
female specific associate of anxiety. One interesting candidate that might serve as an explanation is the 
expression of the ovarian hormone estrogen, which in women with an anxiety disorde typically is low 
(Seeman, 1997; Almeida et al., 2005; Walf and Frye, 2006). This is of relevance here because estrogen is a 
signaling molecule that triggers the expression of BDNF (Scharfman and MacLusky, 2004; Begliuomini et al., 
2007). This explanation relates to the observation in chapter 2 that in women serum BDNF concentrations 
seem to peak at the climateric age (which already is discussed in an earlier part of this discussion). 
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Alternatively, and also not unlikely, the lower BDNF concentrations in female patients may be a female 
specific artifact of being anxious that is (causally) unrelated to the disease state itself. Therefore, and 
because of the findings that males did not show anxiety related lower serum BDNF concentrations, I 
conclude that it is unlikely that BDNF is involved in the pathophysiology of anxiety disorders per se. This 
conclusion is in contrast to the neurotrophin hypothesis (Duman and Monteggia, 2006) that patients with 
to depression related conditions exhibit abnormally low neurotrophic support. A final finding from chapter 
6 that deserves to be noted is that a history of depression seems unrelated to serum BDNF concentrations 
in patients with a current anxiety disorder, which corroborates our finding that low serum BDNF 
concentrations are a state characteristic of depression (see chapter 4).  
     The gender specific association and the low effect-size estimates that are reported in this thesis bring me 
to the topic of clinical utility. Studies into neurobiological abnormalities in psychiatric illness, BDNF in the 
prevailing thesis, may serve two functions: (I) they may help to parse out the pathophysiology of a certain 
illness condition and (II) they may add in the classification of a diagnostic condition or in the prediction of 
how successful a given treatment will be. The second function, clinical utility, will be discussed in some 
detail in the section that follows.  
 
Clinical utitlity: diagnostic and treatment biomarkers 
I will start this section with a short introduction on the concepts biomarker, moderation and mediation. 
     As stipulated in an earlier part, depressive disorders nowadays are diagnosed based on subjective 
assessments. This comes with disadvantages, as they may be inaccurate and/or colored by the state a 
patient is in. Therefore it is generally believed that an objective biological marker could improve the 
diagnostic process (i.e., a diagnostic biomarker; Schmidt et al., 2011). In addition, a biomarker could help to 
reduce heterogeneity by classification in a finite number of illness subtypes, which could have as advantage 
that patients can be assigned to treatment options that best fit their needs (Schmidt et al., 2011). This 
latter distinction can be regarded as a treatment moderator; a differentiation that is used to decide for 
whom a certain treatment will work: depression type A  antidepressant X  depression alleviation versus 
depression type B  antidepressant Y  depression alleviation. Several biological markers have been 
studied in relation to depression (e.g., cytokines, metabolic markers; see Kapur et al., 2012), yet so far 
without success in that none of them have led to true clinical gain. A well-known example of this is the 
dexamethasone suppression test, which in the 1970/80s had initial promise in predicting relapse into 
depression. After extensive and sufficiently powered studies, this test however appeared to have a rather 
low sensitivity (~ 40-50%) and specificity (~ 70%)(APA taskforce on laboratory tests in psychiatry, 1987) and 
therefore could not be translated in clinical utility. 
     The concept of treatment mediator can be described along a similar line. A mediator however is 
different from a moderator in that it describes a mechanism by which a treatment may work (i.e., a 
treatment mediator: depression  treatment  increase in biomarker X  depression alleviation). 
Information on treatment mediators also would be of clinical help in that objective assessment early in the 
course of treatment may be used as a marker for (early or future) treatment success and hence may 
improve drug efficacy (Schmidt et al., 2011) and the understanding of the mechanisms that underlie 
antidepressant action.  
 
BDNF as biomarker 
Could serum BDNF concentrations possibly serve a biomarker function? Around the time that I started my 
thesis (2008) the answer on this question was yes. Sen et al. (page 527) for instance, concluded their 2008 
meta-analyses on 748 subjects of whom 366 were depressed that serum BDNF concentrations may have 
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use as a biomarker for major depressive disorder or antidepressant efficacy. The effect-sizes on which this 
conclusion was based (i.e., Cohen’s d ~ 0.80) made their conclusion seemingly valid. However, and looking 
fairly at an effect size of 0.80, what does it tell us and can it be applied to distinguish between-groups in a 
diagnostic setting? Yes, it can, but only to a certain extent (i.e., probability that an individual is correctly 
classified based on it (only) is 0.66 [Coe 2002]). 
     We report in chapter 4 and 5 effects sizes on between-group differences that are considerably smaller 
(e.g., for the difference between untreated depressed persons and healthy controls the best estimate is d = 
-0.47 (95% CI = -0.64 ― -0.27). How well can a person be assigned to a group based on such an estimate? 
Not so well. In fact, the probability of correct classification is .59. Please note that an effect size of 0.00 
would yield a .50 correct classification. Given that the relevance of a diagnostic biomarker depends on the 
magnitude of an effect-size (and not on statistical significance), I conclude that serum BDNF concentrations 
are lof little, if any, clinical use.  
     What is more is that lower BDNF concentrations have been reported in persons diagnosed with 
schizophrenia, with bipolar disorder, with eating disorders, etcetera. In Table 2 ↓ (next page) the most 
reliable evidence (i.e., derived from the largest single study or from meta-analysis) for alternations in serum 
BDNF concentrations in some psychiatric and neurological illnesses is presented. From this table it becomes 
clear that low serum BDNF concentrations are not specific enough to differentiate among diagnoses. So 
arguably, these values are very little informative in the clinical setting. Another reason why the issue of 
BDNF as a diagnostic biomarker may need a nuanced approach is that basically all the findings are acquired 
from between-subjects designs and therefore the data apply to groups and not to individuals. Furthermore, 
for the clinical use of BDNF parameters the detailed knowledge on the myriad of factors that influence 
BDNF concentrations also should be taken into account, making the assessment of BDNF concentrations 
pretty complex. 
     Although limited in scope with regard to clinical utility, our findings on between-group differences do 
not necessarily dismiss the possibility that abnormalities in BDNF expression reflect a pathophysiological 
process that may underlie depression (Duman et al., 1997). Even more, the magnitude of the difference in 
serum BDNF concentrations between depressed patients and healthy control subjects that we report on 
(e.g., d = -0.47 for depressed persons versus healthy controls) stands out as strong when compared to 
other biological abnormalities in depression, for instance blood markers for immune dysregulation (e.g., 
CRP [d = 0.15]) or HPA-axis activity (e.g., adrenocorticotropin hormone [d = 0.28] see Penninx et al., 2013). 
Furthermore, in the meta-analysis reported in chapter 5 we find that a greater increase in serum BDNF 
concentrations in the course of antidepressant treatment is associated with a larger decrease in depression 
symptom severity. This finding may fuel work into the theoretically and clinically relevant topic on the 
temporal dynamics between BDNF expression and treatment efficacy. It would be interesting if future 
studies could address early changes in the course of (pharmacological) treatment, a notion for which some 
evidence exists (Lang et al., 2006; Machado-Vieira et al., 2009) and on which Maryna Polyakova (Max 











Table 2.   Alternations in serum BDNF concentrations in other psychiatric/neurological illnesses than depression (in alphabetical order). 
Magnitude of the difference is expressed as standardized Cohen’s d versus a healthy control group 
Disorder, author, year Design Finding 
ADHD                                    
Corominas-Roso et al. (2013) 
single study  BDNF concentrations are low in patients with ADHD  (n = 54)[d = -0.80] 
Alcohol dependency           
Huang et al. (2011) 
single study  BDNF concentrations are low in alcohol dependent patients (n = 65)[d = -1.24] 
Alzheimer’s disease       
Yatsutake et al. (2006) 
single study  BDNF concentrations are low in patients with Alzheimer’s disease (n = 60) [d = -0.77] 
Autism                                   
Hashimoto et al. (2006) 
single study  BDNF concentrations are low in patients with autism (n = 18)[d = -1.58] 
Bipolar Disorder         
Fernandes et al. (2011) 
meta-analysis 
 
BDNF concentrations are low in patients with bipolar disorder (n = 548) in the manic- 
and depressed state [[d = -0.8, 95% CI = -1.1 — -0.5] and d = -0.94, 95% CI = -1.72 — -
0.53 respectively] 
Eating disorders        
Monteleone et al. (2011) 
single study  BDNF concentrations are low in patients with anorexia nervosa (n = 27) and bulimia 
(n = 24)[d = -1.54 and -1.26 respectively] 
Huntington’s disease   
Ciammola et al. (2007) 
single study  BDNF concentrations are low in patients with Huntington’s disease (n = 42)[d = -1.71] 
Schizophrenia                       
Green et al. (2010) 
meta-analysis BDNF concentrations are low in schizophrenic patients (n = 1,114)[d = -0.53, 95% CI = 
-0.81 — -0.18].   
Abbreviations: ADHD, Attention-Hyperactivity Disorder; BDNF, Brain-Derived Neurotrophic Factor 
 
     Noteworthy in this context, and of high importance for future progress, is a recent argument by Steve 
Hyman (Broad Institute, Cambridge) who said in Nature news (May 10, 2013) that It’s a fool’s errand to try 
to find a biomarker for a diagnosis with little basis in nature … such efforts waste human capital and 
governmental and industry funds. This makes a lot of sense: the broad nosological categories that in 
general are used in psychiatric research pose serious limitations in the possibilities to detect (biological) 
abnormalities (Casey et al., 2013) because they are not valid. Searching for associations beyond the 
boundaries of diagnostic categories therefore may be worth considering as an important innovation. It 
could for instance be considered whether single, or less broad, and more carefully defined domains that 
may constitute the illness depression (e.g., motivation or reward) in particular are correlated with BDNF. 
With my colleague Boudewijn Bus (Radboud University Nijmegen, The Netherlands) and others I have tried 
to make some advance in this (Bus et al., 2013). This enterprise however yielded little additional insight. 
So, and given that BDNF alternations are observed in many psychopathological conditions (see Table 2 ↑), 
studies could relate alternations in BDNF to trans-diagnostic phenomena (e.g., rumination; Beevers et al., 
2009; oxidative stress; Kapczinski et al., 2008, sleep; Giese et al., 2013, weight gain and loss; Monteleone et 
al., 2007), or the research domain criteria (Casey et al., 2013).  
 
Two know more than one 
Given that the above feed my concerns on the relevance of serum BDNF concentrations with regard to 
depression (either as a biomarker or a factor contributing to its pathophysiology) and debate on these 
issues in the literature I decided to ask the opinion of colleagues on this issue. Heretoo, I ran a poll in which 
I asked 100 researchers (who were corresponding author for published papers that had BDNF and 
depression (n = 50) or cognitive/interpersonal and depression (n = 50) [the latter group was included to 
reduce bias] in their title) about this. The results of this poll are described in detail in Appendix V. The 
majority of researchers that responded (n = 60) either agreed (43 percent) with the proposition that serum 
BDNF concentrations are relevant with regard to depression or expressed the belief that the future will 
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inform us on this issue (42 percent). Only 15 percent explicitly disagrees with the notion that serum BDNF 
concentrations relevant with regard to depression. In this sense, the poll was helpful in that most authors 
see either relevance in the use of serum BDNF concentrations as parameters for depression or suggests 
that more research will bring definite answers.  
 
Recapitulating our work on serum BDNF concentrations in relation to the neurotrophin hypothesis 
Table 3 ↓ gives an overview of the findings on serum BDNF concentrations and how these relate to the 
predictions from the neurotrophin hypothesis. Conclusions will follow in a later part of this discussion. 
 
Table 3.  Summary of the research findings in this thesis on serum BDNF concentrations and how they fit with the neurotrophin 
hypothesis (confrimative versus non-confirmative) 
Confirmative 
 1. Serum BDNF concentrations are low in depressed patients relative to healthy controls (chapter 4 [N = 923] and chapter 5 [N = 5,203]). 
2. Serum BDNF concentrations are normalized in the course of depression remission (chapter 4 [N = 1,080] and chapter 5 [N = 4,204]). 
3. Serum BDNF concentrations are normalized in the course of antidepressant treatment (chapter 4 [N = 1,080]; chapter 5 [N = 4,204]). 
4. A larger increase in serum BDNF concentrations is associated with a larger decrease in depressive symptoms over the course of 
    antidepressant treatment (chapter 5 [N = 1,422]) 
5. Serum BDNF concentrations are low in female patients with an anxiety disorder relative to female controls (chapter 6 [N = 499]). 
6. Exposure to recent stressful events is associated with lower serum BDNF concentrations (chapter 7 [N = 1,435]). 
Non-confirmative 
1. Serum BDNF concentrations are low in the early remission phase of depression as compared to the depression state  (chapter 4 [N = 
    541]) 
2. Serum BDNF concentrations are normalized in the course of treatment with an antidepressant but this is not associated with remission 
    (chapter 4 [N = 421]). 
3. Equally effective pharmacological antidepressants are differently associated with serum BDNF concentrations (chapter 4 [N = 421]) A 
4. Clinical characteristics (notably depression severity) are not associated with serum BDNF concentrations (chapter 4 [N = 541] and 
    chapter 5 [N = 9,484]). 
5. The differences in serum BDNF concentrations as a function of diagnostic and treatment status are overestimated and are of a  
     small effect-size at best (chapter 5 [N = 9,484]). 
6. Serum BDNF concentrations are normal in male patients with an anxiety disorder relative to male controls (chapter 6 [N = 276]). 
7. Childhood trauma exposure is not associated with serum BDNF concentrations (chapter 7 [N = 1,435]). 
A Note that the possibility exist that different types of antidepressants may be clinically efficacious through different mechanisms (Mann 
  2005) and that therefore this finding is not neccesarly non-corfirmative with te neurotrophin hypothesis.  
 
     Besides our studies on serum BDNF this thesis explored associations between variation on the gene that 
codes for BDNF (val66met) and depression-related phenotypes. These explorations are discussed in the 
following section.  
 
BDNF val66met and the neurotrophin hypothesis 
The genetic studies in this thesis focused on one particular polymorphism on the BDNF gene: val66met. The 
reason for this focus is fully described in the introduction of this thesis. In sum, the interest in val66met was 
fuelled by two studies that showed that this polymorphism has functional properties. Egan and colleagues 
(2003) showed a reduced activity dependent expression of BDNF in cultured hippocampal neurons (in vitro) 
that carried a met allele. These authors extended this finding by showing worse cognitive functioning and 
altered hippocampal memory activity in human met carriers as compared to val/val homozygotes. In a 
paper published in Science (2006), Chen and colleagues confirmed these findings (in vivo).  
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     Based on these groundbreaking findings, variation at the BDNF val66met locus has become one of the 
most influential models to study BDNF functioning and it is generally believed that the field benefitted by 
the identification of the presumed functionality of this polymorphism (Lu et al., 2013). For human studies it 
seems particular interesting to assess variation at the val66met locus in relation to several phenotypes 
because it is believed that variation at this locus mirrors individual (chemical) differences in BDNF 
functioningin the brain. In line with this presupposition are some human studies that apparently reproduce 
the animal findings (e.g., phenotypic hallmarks of depression such as lower hippocampal volumes in met 
allele carriers as compared to val/val homozygotes [Pezawas et al., 2004]).  
     In a series of three studies, we addressed the relevance of this polymorphism with regard to: BDNF 
serum concentrations, DSM-IV depression and anxiety diagnoses, depression- and anxiety symptom 
severity, cognitive functioning, and hippocampal functioning and morphology. As an important add-on, we 
incorporated trauma and stress exposure in our studies to model inter-individual differences in outcomes 
due to these factors and their potential interaction with BDNF val66met. This is imperative for the reasons 
that: (I) strong inter-individual differences exist in the degree of how detrimental the effects of 
trauma/stress exposure on mental health are and this may be driven by individual genetic make-up (see for 
example Caspi and Moffitt, 2006) and (II) trauma/stress exposure is a central theme in the neurotrophin 
hypothesis (Duman and Monteggia, 2006).  
     The expectations were that established correlates of depression would be related to the genotypic 
variant that is associated with lower neurotrophic support (i.e., the met variant) particularly in the face of 
trauma- or stress exposure. Some of our explorations yielded results that were in line with this expectation. 
Many, however, also were not. Below these findings are discussed.  
 
BDNF val66met – trauma/stress exposure and serum BDNF concentrations 
In Chapter 7 we addressed whether variation at the val66met locus influences serum BDNF concentrations. 
The main effects of exposure to childhood abuse (i.e., sexual-, physical-, or emotional abuse exposure 
before the age of 16 years), recent negative life events (i.e., stressful events such as a divorce in the year 
before measurements) and their potential cross-term interactions with val66met were also assesed. Our 
focus on the cross-term interactions among BDNF val66met and stress exposure followed specifically from 
studies that reported that met allele carriers are more vulnerable to the effects of stress exposure as 
compared to individuals who are homozygous for the val allele when considering depressive symptoms 
(Wichers et al., 2008), hippocampal volume (Gatt et al., 2009), and cognitive functioning (Gatt et al., 2009).  
     The well-powered and controlled study reported in Chapter 7 rendered some interesting findings. First, 
in the absence of main effects of trauma exposure and val66met it was found that the impact of childhood 
abuse on serum BDNF concentrations was dependent on variation at the val66met. Specifically, in met 
carriers, trauma exposure was associated with reduced serum BDNF concentrations, whereas in the val/val 
group BDNF concentrations were even higher when trauma exposure was reported (i.e., a cross-over 
effect). The BDNF reductions that were associated with childhood abuse in met carriers were linear in 
nature, so that BDNF concentrations were lowest in met carriers reporting exposure to multiple types of 
trauma. These findings follow the neurotrophin hypothesis to some extent. Yet it should be noted that they 
were not in total agreement, as no associations were found between being met carrier and higher 
depression severity or the presence of a DSM-IV depression diagnosis, also not when exposed to childhood 
abuse. Maybe the conjunct of the here observed effect on serum BDNF concentrations and on 
psychopathology is not mandatory in order for the neurotrophin hypothesis to be valid, but it would have 
strenghtened the model.  
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     A second exciting finding described in chapter 7 was that exposure to stressful events that occurred in 
the past year was associated with reduced serum BDNF concentrations. This effect was, in contrast to that 
of childhood abuse, independent of variation at the val66met locus. This result directly replicates earlier 
findings (e.g., Trajkovksa et al., 2008). The finding of lower serum BDNF concentrations following stress 
exposure also corroborate with a body of knowledge derived from animal studies (see for instance et al., 
2012) and obviously also with the neurotrophin hypothesis. Interestingly, the decreased serum BDNF 
concentrations following recent stress exposure were, as may be expected, associated with relatively high 
levels of depression symptom severity. It is tempting to link these two findings, but note that these results, 
remarkable as they may seem, are only correlation in nature. It further should be mentioned that although 
statistically significant, the effect was small as it only explained ~ 1 percent of the variance in serum BDNF 
concentrations. 
     Together the findings described in chapter 7 suggest (notwithstanding considerations as the use of 
cross-sectional data) that a chain of events, commencing with gene-environment interactions, may lead to 
low serum BDNF concentrations. It would be interesting if longitudinal studies could further unravel the 
developmental trajectories towards psychopathology that follow trauma and/or stress exposure and 
whether these may run through individual genetic make-up and neurotrophic functioning.  
 
BDNF val66met – trauma/stress exposure and the hippocampal formation 
In chapter 8 we used functional and structural MRI techniques in order to test associations between the 
val66met variant and the structure and function of the hippocampal formation, a critical brain structure in 
the pathophysiology of depression (MacQueen and Frodl, 2011). For similar reasons as provided previously, 
we took trauma- and stress exposure into account. The study yielded the following results. First, and in line 
with earlier studies, we find slightly smaller hippocampal volumes in carriers of a met allele relative to 
val/val homozygotes. This effect has been explained as being the result of abnormal intracellular trafficking 
and impaired activity secretion of BDNF in carriers of a met allele (Chen et al., 2006). Since atrophy of the 
hippocampus has also been associated with (early life) stress exposure and/or a having (had) a depressive 
episode (MacQueen and Frodl, 2011), it is crucial to exclude the possible confounding effects of these 
variables. In previous studies, stress exposure and depression diagnosis have largely not been taken into 
account (with the exception of Frodl et al., 2007 and Gatt et al., 2009). We did explicitly model these 
interactions. It turned out, however, that the association between the met allele and lower hippocampal 
volume was independent of trauma/stress exposure and current/lifetime depression. This null finding is at 
odds with the findings reported by Gatt et al. (2009), who found that the combination of carrying a met 
allele and being exposed to early life stress was associated with particular small hippocampal volumes (and 
a large number of other hallmarks of depression such as poor cognitive functioning). The observed 
discrepancy between the results of Gatt et al. (2009) and ours may be due to a broader definition of early 
life stress by Gatt and colleagues (2009) who included for example also illness as stressful event whereas 
we specifically focused on childhood abuse including physical, sexual, and emotional abuseIt remains 
unclear how this between-study difference could have led to a different pattern of results, assuming that 
neither one is due to chance. With regard to the latter it should be noted that a recent large-scale study 
(568 healthy participants; Gerritsen et al., 2012) also could not replicate the findings by Gatt et al. (2008). 
The issue of non-replication will be discussed in a next part.  
     In addition to on average slightly reduced hippocampal volumes, we show in chapter 8 that val66met 
interacts with (emotional) word valence on hippocampal encoding activity. This effect is such that 
hippocampal related encoding activity is increased in carriers of a met allele when presented with negative 
words and not when presented with neutral or positive words as compared to val/val homozygotes. This 
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effect was not observed in other brain areas and seems to be consistent with some studies in which 
emotional stimuli were used (e.g., Dennis et al., 2010 or Lau et al., 2010). Although intriguing, it is 
imperative to mention that, as in chapter 7 (note that the sample in chapter 8 is a sub-sample of the much 
larger sample that was used in chapter 7), despite effects on neurobiological measures (in this case brain 
morphology and neuronal activity) also in this study there were no corresponding effects of the same 
constellation of predictor variables on psychopathology outcomes (e.g., depression diagnosis, illness 
severity). A critical point here is that this particular study with a total N of only 157 may have lacked the 
necessary statistical power to detect between-group differences that may be small at best.In addition, with 
regard to the absence of associations between hippocampal volume, hippocampal function, and memory 
performance, a recent review showed, in line with our findings, that the model: ‘a bigger brain structure  
greater brain response  better performance’ may not reflect reality (Eyler et al., 2010). 
     Notwithstanding the above, the chapters 7, 8, and 9 also yielded some findings that were not in line with 
the expectations as they can be derived from the neurotrophin hypothesis. These inconsistent findings are 
the topic of the section that follows. 
 
BDNF val66met – inconsistent findings 
I would like to start with the finding from chapter 9 because the study in this chapter turned out to be a 
defining one.  
     Chapter 9 reports a systematic review and meta-analysis on the association between val66met and total 
hippocampal volume. This study was undertaken because inconsistenties have been reported with regard 
to this association (see for instance the difference in outcomes between Szeszko et al., 2005 and Dutt et al., 
2009). The potential influence of demographical, clinical, and methodological characteristics of studies was 
also assessed. Meta-analysis confirmed that carriers of a met allele had lower hippocampal volumes 
relative to val/val homozygotes, yet with a very small effect-size  (d = 0.13, P = .02; k = 25, total N = 3,620). 
However, between-study heterogeneity in effect size estimates was substantial and this could not be 
explained by demographical, clinical, and methodological differences across studies. Funnel plot inspection 
and trim-and-fill estimations suggested evidence for publication bias and effect sizes decreased 
substantially over the years (Pearson’s correlation coefficient on the relation between year of publication 
and effect-size was -0.54). When publication bias was taken into account the association between val66met 
and total hippocampal volume was no longer statistical significant. A further striking finding was that all 
included studies were largely underpowered. Altogether, this shows that variation at the val66met locus is 
not likely to account for individual differences in hippocampal volume but rather that the association is 
subject to a winners curse, with large effect sizes found in a few early studies and increasingly smaller effect 
sizes in later (better-powered) studies. 
      This finding does not stand on its self. When taking a close look at the best evidence in the current 
literature a trend becomes clear. Mandelman and Grigorenko for instance (2012) pooled the data on the 
association between val66met and general cognitive ability, memory and executive functioning (k = 23, total 
N = 7,095) and found, despite promising initial studies (i.e., Egan et al., 2003), no association between 
val66met and cognitive functioning. Another recent meta-analysis by Kambeitz and colleagues (2013) 
showed, when publication bias is taken into account, that the val66met polymorphism has no effect on the 
neuronal systems underlying the encoding of information into episodic memory (hippocampal and para-
hippocampal encoding activity; 16 comparisons N = 2,985). This finding also is in contrast to what was 
previously claimed (e.g., Montag et al., 2009). A final example is a study by Gyekis and colleageaus (2013) 
showing, using the largest number of subjects to date, no evidence for an association of val66met with the 
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diagnosis depression (k = 26, total N = 17,426). This is notable since previous meta-analyses (e.g., Verhagen 
et al., 2009) have suggested that the met allele was associated with a depression diagnosis.  
     The pattern is clear: the evidence for associations between BDNF val66met and depression relevant 
phenotypes is waning. Based on this I conclude that the val66met polymorphism has little, if any, prediction 
accuracy regarding depression related phenotypes. Another consideration in formulating this conclusion is 
that BNDF val66met was not associated (again in spite of earlier evidence) with psychopathology outcome 
(chapter 7 and 8), serum BDNF concentrations (chapter 7), cognitive performance (chapter 8), nor with 
hippocampal volume (chapter 9). So, albeit knowing the (presumed) functionality of a polymorphism 
(through preclinical work) the studies in this thesis show (and a large literature from other groups as well) 
that this is not neccesarily associated with sampled outcomes in humans. Imperative for the interpretation 
of the above (and also for the earlier confirmative findings) is the recent finding that many genetic variant, 
deletions, and copy number variants are found in neuronal cells that do not correspond with those found in 
non-neuronal cells (McConnel et al., 2013). Therefore, our findings regarding BDNF val66met, that were 
based on the genotype of non-neuronal cells, may be limited in that the exact correspondence between 
these cells and neuronal cells is not known. This issue should be acknowledged in future (single-cell) 
studies. 
 
Recapitulating our work on BDNF val66met in relation to the neurotrophin hypothesis 
Table 4 ↓ gives an overview of the findings in this thesis that regard BDNF val66met and how these relate to 
the predictions from the neurotrophin hypothesis. Conclusions will follow in a next part.  
 
Table 4.  Summary of the research findings in this thesis on BDNF val66met and how they fit with the neurotrophin hypothesis 
(confrimative versus non-confirmative) 
Confirmative 
1. Carriers of a met allele seem to be more vulnerable with regard to childhood trauma exposure when serum BDNF concentrations are 
    taken as an outcome (chapter 7 [N = 1,435]). 
2. Carriers of a met allele locus have somewhat lower hippocampal volumes as compared to val/val homozygotes (chapter 8 [N = 157]) 
3. Carriers of a met allele locus show higher hippocampal activity in response to words of negative emotional valence as compared to 
    val/val homozygotes (chapter 8 [N = 157]). 
Non-confirmative 
1. Variation at the BDNF val66met locus is not associated with serum BDNF concentrations, depression diagnosis, and depression 
    symptom severity (chapter 7 [N = 1,435]). 
2. Variation at the BDNF val66met locus is not associated with cognitive performance and the brain functioning (chapter 8 [N = 157]). 
3. Lower hippocampal volumes are not associated with carrying a met allele at the BDNF val66met locus [chapter 9 [N = 3,620]). 
 
 
The neurotrophin hypothesis and our work – recapitulating  
Before I will start to contemplate on the strengths and limitations of the studies reported herein and state 
my conclusions, please see Table 5 ↓ (next page) for a summary of all the findings in this thesis and how 









Table 5.  Summary of research findings and how they fit with the neurotrophin hypothesis (confrimative versus non-confirmative) 
Confirmative 
 1.  Serum BDNF concentrations are low in depressed patients relative to healthy controls (chapter 4 [N = 923] and chapter 5 [N = 5,203]). 
2.   Serum BDNF concentrations are normalized in the course of depression remission (chapter 4 [N = 1,080] and chapter 5 [N = 4,204]). 
3.   Serum BDNF concentrations are normalized in the course of antidepressant treatment (chapter 4 [N = 1,080]; chapter 5 [N = 4,204]). 
4.   A larger increase in serum BDNF concentrations is associated with a larger decrease in depressive symptoms over the course of 
      antidepressant treatment (chapter 5 [N = 1,422]) 
5.   Serum BDNF concentrations are low in female patients with an anxiety disorder relative to female controls (chapter 6 [N = 499]). 
6.   Exposure to recent stressful events is associated with lower serum BDNF concentrations (chapter 7 [N = 1,435]). 
7.   Carriers of a met allele seem to be more vulnerable with regard to childhood trauma exposure when serum BDNF concentrations are  
       taken as an outcome (chapter 7 [N = 1,435]). 
8.   Carriers of a met allele locus have somewhat lower hippocampal volumes as compared to val/val homozygotes (chapter 8 [N = 157]) 
9.   Carriers of a met allele locus show higher hippocampal activity in response to words of negative emotional valence as compared to 
       val/val homozygotes (chapter 8 [N = 157]). 
Non-confirmative 
1.  Serum BDNF concentrations are low in the early remission phase of depression as compared to the active phase of depression 
     (chapter 4 [N = 541]) 
2.   Serum BDNF concentrations are normalized in the course of treatment with an antidepressant but this is not associated with 
      remission (chapter 4 [N = 421]). 
3.   Several classes of equally effective pharmacological antidepressants are differently associated with serum BDNF concentrations 
      (chapter 4 [N = 421]). A 
4.   Clinical characteristics (most notably depression severity) are not associated with serum BDNF concentrations (chapter 4 [N = 541]). 
5.   The differences in serum BDNF concentrations as a function of diagnostic and treatment status are overestimated and are of a  
       small effect-size at best (chapter 5 [N = 9,484]). 
6.   Serum BDNF concentrations are normal in male patients with an anxiety disorder relative to male controls (chapter 6 [N = 276]). 
7.   Childhood trauma exposure is not associated with serum BDNF concentrations (chapter 7 [N = 1,435]). 
8.   Variation at the BDNF val66met locus is not associated with serum BDNF concentrations, depression diagnosis, and depression 
      symptom severity (chapter 7 [N = 1,435]). 
9.   Variation at the BDNF val66met locus is not associated with cognitive performance and the brain functioning (chapter 8 [N = 157]). 
10. Lower hippocampal volumes are not associated with carrying a met allele at the BDNF val66met locus [chapter 9 [N = 3,620]). 
A Note that the possibility exist that different types of antidepressants may be clinically efficacious through different mechanisms (Mann  
  2005) and that therefore this finding is not neccesarly non-corfirmative with te neurotrophin hypothesis. 
 
Conclusion 
What is the final word on this? I do not think that we are on the verge of understanding depression through 
peripheral BDNF measurements or genetic variants that are supposed to be associated with neurotrophic 
functioning. The lack of universality of findings on BDNF alternations in depression that is brought forward 
in this thesis (and also by other research groups in recent years) suggest that attributing behavioral 
differences to peripheral BDNF parameters and genetic variants is overreaching. There is simply too much 
clinical data that do not corroborate, or are even tangential to, the predictions of the neurotrophin 
hypothesis. Of course, and taking for instance the heterogeneity of depression into mind, inconsistencies 
do not necessarily reject the neurotrophin hypothesis for all depressed patients. Besides, some predicted 
associations from the neurotrophic model appear to be established (e.g., abnormally low serum BDNF 
concentrations in the depressed state). Nonetheless, in these instances the meaning of them often is not 
that clear (e.g., reverse causation in which low neurotrophic support does not endanger a person to 
become depressed but rather are a consequense of being in the depressed state). In fact, reverse causation 
largely is my theory. 
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     Furtermore, what this thesis illustrates clear is the value of well-powered studies, as it shows that some 
of the core observations on which the neurotrophin hypothesis rests are less evident, and sometimes even 
absent, when well-powered studies are used. This was particularly evident in our work  on val66met.  
      So, in my view the conventional wisdom that existed at the time of the start of my PhD tract that 
peripheral BDNF parameters and genetic variants are relevant in the pathophysiology of depression is too 
far fetched. In fact, from the above I conclude, whilst taking limitations into account and acknowledging 
that the results herein are largely contingent upon peripheral measurement that the neurotrophin 
hypothesis should no longer be credited in its original form.  
 
Methodological (and other) considerations and future work 
Strengths 
The studies that form the heart of this thesis have salient strengths. First of all, in basically each individual 
study, results are derived from a large single sample or from data that come from multiple studies and 
together add up to a large sample. This safeguards against false positive- and negative findings and 
provides effect-size estimates that are accurate with regard to their magnitude (Ioannidis 2005). The proof 
of this principal became evident in the pooled effect-sizes that were derived from the meta-analyses that 
we performed, as these converged closer to those that were reported in studies that used a relatively large 
sample size as compared to those studies that used a relatively small sample size. A second notable 
strength of our work is that most analyses were adjusted for a range of possible confounding factors and 
that we were able to perform subgroup and moderation analyses. This allowed us to infer on (largely) 
independent associations, which increases, although not guarantees, the likelihood of valid findings. 
Validity was also achieved through the use of standardized diagnostic tools to assess current and lifetime 
psychopathology and the use of a control group (although the latter not necessarily eliminates all possible 
confounders; Prasad and Jena, 2013). Furthermore, for the interpretation of our findings we did not solely 
rely on P-values (Johnson 2013) as, where appropriate, we reported effect-size estimates and their 
respective confidence levels as well.  
     Notwithstanding strengths in design, method and reporting, I am well aware of the limitations that carry 
our work. The main limitations, besides those already mentioned, are discussed below. 
 
Limitations 
Table 6 ↓ lists the main limitations of the work in this thesis. These limitations are discussed in the section that follows.  






Not sufficiently persuasive to prove causality 2-9 (mostly) 
Non-random allocation 
 
Not sufficiently persuasive to prove causality 2-9 (mostly) 
Generalization of findings 
 
Our study findings do not (directly) generalize to all populations 2-9 (mostly) 
A multitude of tests and power Large data-sets do not protect against multiple testing  
 
Some effects may be so small that they are hard to detect even when using a large 
sample 
 









A limitation of most of the work in this thesis is that it relies on data that were collected in a single wave. 
This is a limitation because data that is gathered in such a manner does not allow for conclusions that 
delineate the time course of event, let alone matters of causality. Take for instance our finding that serum 
BDNF concentrations are abnormally low in the depressed state. This finding could be explained so that a 
low expression of BDNF predisposes or endangers a person to an episode of depression (i.e., the temporal 
precedence of a cause–effect relation). Indeed, this could be so. However, we cannot infer from our data 
that alternate explanations are false. For instance, it could be that the low serum BDNF concentrations in 
the depressed state are a consequence of being depressed (as has been discussed above). Note though that 
a lack of clarity with regard to temporal precedence is not a limitation for all cross-sectional findings that 
we reported. Take for instance the correlation between the amount of ambient sunshine and serum BDNF 
concentrations (chapter 3) where the presumed cause can be placed before the event, as it is not very likely 
that BDNF in blood causes the sun to shine. The findings regarding stress exposure and serum BDNF 
concentrations can be interpreted along a similar line. Yet, also for these particular cases, repeated 
sampling on each individual would have been more persuasive. 
 
Non-random allocation 
Another obvious limitation is that due to the epidemiological nature of the NESDA data, of which we made 
extensive use, none of the participants were randomly allocated to the conditions, such as medicated 
versus non-medicated. Therefore, our work lacks the experimental nature that is needed for causal 
inferences. Take for example our finding that distinct classes of antidepressants seem to have a differential 
effect on serum BDNF concentrations (chapter 4). The patients in this study were not randomly assigned to 
the particular antidepressant condition. Hence, a priori differences may have existed between persons who 
used a different kind of antidepressant. For instance, persons who were treated with TCA’s, which is not a 
first-choice antidepressant, may have represented a clinically distinct group, consisting of a large number of 
non-responders on treatment with SSRI’s, which typically is a first-choice antidepressant (Mann 2005). 
Thus, what we labeled as being an antidepressant-specific effect on serum BDNF concentrations may 
actually have been the effect of being a non-responder to treatment with a SSRI. Although we did test for a 
great number of possible confounders and actively explored alternative explanations, still some between-
group differences may have gone undetected. Thus, because of non-random allocation, our work does not 
prove causality. 
 
Generalization of findings 
Other limiting factors regard the exact extent to which it can be generalized to the population at large or to 
specific subgroups within the population. The clinical scope of the work in this thesis is broad, as the age 
range of the NESDA sample is wide (18 to 65 years of age), and NESDA includes patients from several 
sources (i.e., primary care and out-patient clinics). Notwithstanding this, in the NESDA sample no 
children/adolescents or elderly persons are included and the persons with depressive and anxiety disorders 
are all outpatients with in general modest levels of symptom severity. Also, most of the participants that 
were enrolled in our studies are from a Caucasian descent. So, generalizations from our findings to the 
young and the old, the severely ill (e.g., patients who receive intra-mural care), and to persons who are not 
from a Caucasian background may not be straightforward. This also holds for our findings that were derived 
from meta-analyses, since the studies that were included also enrolled mostly persons from a Caucasian 




Multiple testing and power 
In an earlier part of this section, the use of large samples was heralded as a strong point of our work. A 
large sample indeed comes with advantages. However, it does not protect against the testing of a 
multitude of hypotheses. Given that in this thesis a substantial number of hypotheses were tested (using a 
single large data set) our work may have yielded some false positive findings. Second, some effects are so 
small that they cannot be reliably detected even when large numbers of subjects are included. The null-
findings that were derived from our studies on the presumed relationship between val66met and cognitive 
functioning (see chapter 8) may be a good example of this.  
     While considering this, statistical power is just as important to take into account when faced with 
positive findings (Christley 2010). Again, although overall we performed analyses using comparatively large 
sample sizes, at times we performed sub-group analyses that may have lacked sufficient statistical power. 
Likewise, the meta-regression analyses, reported in the chapters 5 and 9, may have been underpowered 
since these were based on the rather small number of studies. Our search for moderators therefore may 
have yielded significant associations that have different effect-sizes or actually are non-existing.  
 
Measurement: you can never have enough precision 
We measured, analyzed and concluded on BDNF concentrations in serum derived from peripheral veins. 
Although there are inherent advantages to this method (i.e., easily accessible, only minimal invasive, and 
reliable with regard to intra- and inter assay variability) some points of concern should be stated.  
     First of all, an assumption that we had is that peripheral BDNF measurements reliably mirror the amount 
of BDNF in the brain. The data that underlies this assumption rely for the larger part on positive 
correlations between BDNF concentrations in the central nervous system and the periphery (Klein et al., 
2010) and active transport of BDNF through the blood-brain barrier (Pan et al., 1998) that have been shown 
in non-human animal studies. Furthermore, some rodent studies have shown that peripheral 
administration promotes the regeneration of spinal cord injury (Krishna et al., 2013) and has an effect on 
depressive-like behavior (Schmidt and Duman, 2010). However, there is no clear consensus on this issue 
and criticism and uncertainty remain. There are good reasons for this. One, in the brain, the expression of 
BDNF is locally and time specific (Bennet and Lagopoulos, 2013). Animal studies have shown, for instance, 
that antidepressant treatment increases the expression of BDNF in some brain regions (e.g., the ventral 
tegmental area; Taliaz et al., 2012) but not in others (e.g., the hippocampus; Lanz et al., 2012; Taliaz et al., 
2012). A second reason is that there are complexities in assigning the exact sources of BDNF in peripheral 
tissues (Bejot et al., 2011). The brain-derived part in the name BDNF suggests that all BDNF that is active in 
an organism has its origin in the brain. This however is at least a little misleading (Gass and Hellweg, 2010; R 
Hellweg, personal communication, 2013; B Bus, personal communication, 2009 through 2013) as several 
types of immune-, smooth muscle-, and endothelial cells serve as sources of BDNF as well (Karege et al., 
2002). Thus, the BDNF concentrations that we measured are likely not to have come from the brain for a 
100 percent. In fact, given that serum BDNF concentrations are much higher in serum as compared to that 
in cerebro spinal fluid (> a 1000 fold) they may largely reflect peripheral synthesis (Pillai et al., 2010). A 
consequence of this is that alternations in peripheral BDNF may not reflect (disturbed) central pathways 
but epiphenomenon of some other physiological or behavioral- and/or peripheral process that is not 
necessarily related to central BDNF functioning (as has been discussed above).  
     So, the serum BDNF measures may not more than a summed-up net, crude parameter of central BDNF 
functioning. Besides, some other issues regarding the measurement of serum BDNF should be 




Serum BDNF concentrations versus other peripheral BDNF parameters 
BDNF concentrations in serum are just one of several peripheral measures to gauge on neurotrophic 
functioning in the brain. Other available non-invasive options include BDNF concentrations in whole blood, 
blood plasma, and blood platelets. Since there are some studies that assayed a multitude of these 
parameters there is knowledge on how these parameters relate. In general, studies report statistically 
significant, yet mostly modest associations among these measures (e.g., correlations between plasma and 
serum BDNF concentration in the range r = 0.21 and r = 0.26 (Terracciano et al., 2011; Jeon et al., 2012) to r 
= 0.71 (Yoshimura et al., 2010)]. Thus, the measures that are used in the literature to gauge on the process 
of neurotrophic functioning in the brain relate, but far from perfect. Our findings derived from serum 
therefore are limited in scope in that they cannot be directly generalized to other peripheral BDNF 
parameters. Besides, this raises the question which parameter serves best as a mirror for neurotrophic 
action in the brain. Some authors have brought forward that leukocyte BDNF mRNA content, because of its 
short half-life, could more closely reflect central BDNF dynamics (Gass and Hellweg, 2010) and therefore 
perhaps may be less subject to (peripheral) confounding factors. In addition, it has been argued that a 
combination of peripheral BDNF indices may have advantages above a single one. Assessing both platelet 
and serum BDNF concentrations could be in particular relevant. Blood platelets store BDNF and release 
BDNF during the clotting process and by agonist simulation (Rosenfeld et al., 1995; Fujimura et al., 2002). 
Therefore it could be that inter-individual differences in serum BDNF concentrations are mediated by a 
lower activity of blood platelets caused by medications (notably here antidepressants) or pathological 
conditions (notably depression; Karege et al., 2002).  
 
Pro- versus mature BDNF 
Besides the limitations of measuring in the periphery, there are some other drawbacks regarding the 
methods that we used to quantify BDNF. One is that the ELISA kit that was used in our studies could not 
make the distinction between the pro- and the mature BDNF variant (Lu et al., 2005). Thus, what we have 
quantified are total BDNF concentrations in serum without any regard to whether it was the pro- or the 
mature form. Given that the two BDNF variants are functionally different (see the introduction part for 
this), it would have been interesting to study whether pro-mature BDNF ratios differed, for instance, 
among diagnostic groups. The antibody that is sufficiently specific to make this distinction, however, was 
developed only recently by Yoshida et al. (2012a) and therefore not applied in the studies that make up this 
thesis.  
 
Between-study differences and the golden standard 
A final disadvantage is that large between-study differences are reported in mean serum BDNF 
concentrations. This has even been shown for BDNF concentrations that are assessed by the same research 
group, among similar diagnostic groups, using the same ELISA kit (e.g., Karege et al., 2002 and 2005: mean 
serum BDNF = 22.6 ± 3.4 versus 10.1 ± 2.3 respectively). These differences probably are the result of 
different laboratory procedures and for within-study comparisons and meta-analyses they are not likely to 
constitute a limiting factor. An unfortunate consequence however is that there is no such thing as an 
accepted reference value that defines an individual BDNF value to be high or low. Because of this, only 
within-study differences can be interpreted reasonably. Standardization of measurements would be of 
great value here. 
     Summarizing the previous section, as with basically all constructs, the ability to conclude on a construct 
depends largely on how well the construct can be measured. Serum BDNF concentrations can be reliably 
measured, yet with error and with noise. Besides, the correspondence between peripheral and central 
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BDNF functioning is far from clear and therefore the meaning that can be assigned to (largely all) peripheral 
measurements is only limited. 
 
Future work – what is worth studying and what is worth changing? 
In the part that follows I discuss some options to overcome the limitations that are sketched above. These 
options are listed in Table 7 ↓. 
 
Table 7. Areas of future interest  
I.   Acquire mechanistic understanding on what exactly alters neurotrophic functioning in depression 
II.  Single studies versus teamwork and large scale data-sharing 
III. Measure and study beyond single BDNF parameters and use within-subject data 
IV. Present convergent evidence from multiple research levels (e.g., man and mice data in conjunct) and leave broad  
      diagnostic categories 
 
Mechanistic understanding 
Now, and despite large interest, there is no consensus on what exactly causes altered neurotrophic 
functioning in depression, let alone whether it is of functional significance for (mental) health. Learning 
about this should be the greatest aspirational goal for the field because based on such knowledge the 
question whether pathological processes or epiphenomena are at play could be answered. From our 
studies it appears that the axiom that to depression related alternations in BDNF expression are due to 
trauma- or stress exposure (Duman and Monteggia, 2006) likely does not hold. Probably the relation is 
more complex and moderated by other factors (see chapter 7). Besides, there are hints on mechanisms 
other than stress-exposure that may regulate altered neurotrophic functioning in the depressed state. 
Some of these are also discussed in this thesis (e.g., menopausal stage and estrogen expression). 
Additionally, although not empirically pinned down, I formulated two explicit hypotheses that could thrive 
inter-individual differences in serum BDNF concentrations in depression and in the course of treatment for 
this illness (i.e., oxidative stress and [to depression and treatment related] changes in body-weight). Note 
that these hypotheses rather suggest reverse causation (i.e., depression  low BDNF instead of low BDNF 
 depression).  
 
Single studies and ultimate answers -- teamwork matters 
In the literature it is common practice to report single study findings. For several reasons I wish to argue 
that the relevance of future efforts would greatly increase when other approaches were used.  
     Most importantly, the ever-expanding individual study results should be placed in the quantitative body 
of knowledge that already exists. The need for integration is bigger than ever. Data integration is important 
for the reason that single studies do not provide ultimate answers. See for instance chapter 5 where we 
through data integration show that serum BDNF concentrations are not associated with the symptom 
severity of depression, whilst this belief initially existed (Karege et al., 2002). A similar example can be 
found in chapter 9 where we show, also in contrast to what was generally believed (see e.g., Pezawas et al., 
2004), that the val66met polymorphism is not associated with hippocampal volume. A data-sharing network 
could be the approach to answer, with rigor, many of the outstanding questions. Actually and since I truly 
belief in it, I am trying to launch such a project. Wide support is necessary for this, so I sought and am 
seeking international collaboration, with among others, Brisa Fernandes (Hospital de Clinicas, Porto Alegre, 
Brasil), Maryna Polyakova (Max Planck Institute, Leipzig, Germany), Kenji Hashimoto (Chiba University, 
136 
 
Chiba, Japan), and Rainer Hellweg (Charite University, Berlin, Germany) to come to this end. Evidently a 
dating-sharing network (of existing data) comes at low costs. 
 
Beyond a single BDNF measurement 
The literature to date, obviously including our own work, largely materializes on single cross-sectional 
measurements. Instead I would like to promote to: (I) measure and study beyond single BDNF 
measurements, (II) gather longitudinal (instead of between-subject) data, and (III) provide convergent 
evidence.  
     The common practice nowadays is to extract a single BDNF parameter from blood whilst other 
hormones, neurotransmitters, and receptor systems are not taken into account. This is problematic 
because herewith those factors that may interact with BDNF, and in theory could explain observed 
associations, are neglected. My eyes therefore are on studies that in conjunct to BDNF measure for 
instance the enzymes that convert pro-BDNF to mature BDNF or cortisol-, tryptophan-, and serotonin blood 
levels. A particular good example this is the recent study by Zhou et al. (2013) in which pro- and mature 
BDNF concentrations alongside their respective receptor systems: p75 and Trk-B, were assessed in serum 
and lymphocytes. The data from this study showed the welcome evidence that proBDNF and p75 receptors 
were lower in depressed patients as compared to healthy controls whereas the opposite was observed for 
the mature BDNF variant and its receptor Trk-B.  
     Next, studies should rely less on data that are collected in a single wave but instead on within-subject 
data. This is a more appropriate manner since it excludes a large amount of between-subject variance and 
an accompanying increase in the possibility to detect meaningful associations. In this thesis an example for 
this can be found in chapter 5 where we show that effect-size estimates are largest when they are derived 
from (pure) within-subject designs. Related, it is desirable that future studies should actively control for 
relevant confounders (see chapter 2 and 3) and are sufficiently powered (see chapter 5 and 9 for some 
recommendations on this). 
 
An ideal: convergent evidence 
What for me represents a general low-point in the literature is that the preclinical and clinical work on the 
neurotrophin hypothesis disconnect: the first uniformly reports a causal role for BDNF in the development 
of depressive-like behavior whereas the latter reports many null findings (including, importantly, from 
meta-analysis [e.g., the chapters 5 and 9] and many other examples, e.g., Kambeitz et al. [2012] or Dodds 
et al. [2013]). There are clashes: preclinical researchers take the stance that clinical workers do not 
measure the right BDNF parameters and clinical workers the one that preclinical workers do not measure 
depression or manipulate BDNF functioning with too much rigor (e.g., completely knock it down or 
overexpress it a manifold of times). This leaves the neurotrophin hypothesis as a theory beyond testability. 
Changing cultures is necessary here.  
     It seems hard to directly weigh the relevance of the preclinical versus the clinical evidence. In humans 
the knowledge on neurotrophic functioning is largely contingent upon peripheral parameters (except 
maybe the studies that focus on val66met, imaging- and post-mortem studies). A salient detail here is that 
the one study that cdme closed to neurotrophic functioning in the human brain (on the amount of neuronal 
proliferation) by Reif et al. (2006) reports negative results. Preclinical studies, instead, measure BDNF in 
central tissues and they provide more spatial (and temporal) precision. Such studies are indispensable 
(albeit maybe they come with little pathological validity [Krishnan and Nestler, 2010]). It can therefore be 
suggested that the methods that are used in the greater part of the human studies are just not the right 
ones. Taking this stance should push me to reframe the title of my thesis into something like: will the 
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neurotrophin hypothesis with its predictions on depressive disorders in humans sparkle on, long after the 
glitter of the firework is gone?  But no, this is too long of a title (Mentink A. 2013, personal communication). 
Besides, I am interested in human depression per se and there are claims that preclinical studies are too 
lofty and oversold (e.g., manipulations that lack ecological validity) with regard to the human template they 
model (Couzin-Frankel 2013). Yet, progress in understanding the neurobiology of depression is contingent 
upon a combination of preclinical models, human cellular models and human biological studies (Hyman 
2014). Besides, critical is the research evidence that comes from multiple levels (see for instance Tripp and 
colleagues [2013] for a good example and also that from our group, in a recent collaborative work with 




































































SUMMARY AND CONCLUSIONS 
 
The role of BDNF in Depression 
Will the neurotrophin hypothesis sparkle on, long after the glitter of the firework is gone? 
 
BACKGROUND 
Neurotrophic support is ubiquitous in the brain where it is believed to be essential for the normal 
functioning of neuronal plasticity, memory and learning. The neurotrophin Brain-Derived Neurotrophic 
Factor (BDNF) is the main mediator of neurotrophic support and it has been stated repeatedly that by 
understanding it’s regulation, the understanding of several psychiatric conditions can be increased. 
According to the neurotrophin hypothesis, depressive disorders arise from aberrant neurotrophic support 
by BDNF in brain areas that regulate emotion. Over the years, this hypothesis has gained steady steam. 
Furthermore, there is ground for the belief that peripheral measures (notably BDNF concentrations in 
blood) and certain genetic variants (notably BDNF val66met) can serve as windows for neurotrophic 
functioning in the brain). 
      However, amid a lot of excitement, uncertainty regarding the predictions of the neurotrophin 
hypothesis remains. Sources of uncertainty are a lack of knowledge on the basic determinants of serum 
BDNF concentrations and unanswered clinical questions. In this thesis I tried to provide a more refined 
model of (peripheral) neurotrophic functioning in depressive (and related) disorders by addressing these 
two sources of uncertainty.  
     The empirical data that forms the hart of this thesis and a discussion on it are presented in the foregoing 
chapters. A detailed summary will be presented in the following section. 
 
RESULTS 
Below, the results of our empirical studies are presented (by chapter) alongside the significance that I 
believe that they may have. The first aim of this thesis, to delineate the basic determinants of serum BDNF 
concentrations, is reported in chapter 2 and 3. The chapters 4 through 9 answer clinical questions 
regarding the neurotrophin hypothesis. 
 
PART I: Determinants  
Chapter 2 provides a detailed description of the basic determinants of serum BDNF concentrations. It 
shows, in persons who were untreated with antidepressants and free of a current psychiatric illness, that a 
non-fasting state at the time of blood draw, later measurement on the day, longer sample storage, and 
being a binge drinker all were associated with attenuated serum BDNF concentrations. This was in contrast 
to smoking and living in an urban area, which both were associated with increased BDNF concentrations. 
Finally, older subjects had higher serum BDNF concentrations, but this mostly applied to women (i.e., a 
gender-age interaction effect).  
     The significance of this paper is that it sketches the basic determinants of serum BDNF concentrations. 
Herewith, it provides an improved base to understand inter-individual differences in serum BDNF 
concentrations and knowledge that is essential in preventing erroneous inferences from data. 
 
In chapter 3 we studied seasonal entrainment of serum BDNF concentrations. Analyses by month of 
sampling (monthly n’s all > 196) showed pronounced seasonal variation. Serum BDNF concentrations 
increased linearly over the spring-summer period (i.e., equinox vernal) and decreased linearly over the 
autumn-winter period (i.e., equinox autumnal). Explorative analyses showed that the natural length of day 
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and the number of ambient sunshine hours (major triggers to entrain seasonality) in the weeks prior to 
blood withdrawal correlated with serum BDNF concentrations.  
     These findings add to the literature as they provide avenues to understand those factors that regulate 
BDNF expression. Besides the findings reported herein are of vital importance in the design- and evaluation 
of studies on BDNF. 
 
PART II: the neurotrophin hypothesis of depression 
In the 4th chapter we advance the understanding of the associations between serum BDNF concentrations 
and depression. Using data on 962 depressed patients, 700 remitted depressed persons and 382 healthy 
controls we found serum BDNF concentrations to be low in antidepressant-free depressed patients relative 
to controls and to depressed patients who were treated with an antidepressant. Serum BDNF 
concentrations of fully remitted persons were comparable to those of healthy control subjects. Analyzing 
the sample of antidepressant-free depressed patients showed that BDNF concentrations were unrelated to 
the core clinical features of depression such as its severity.  
     This paper reveals that low serum BDNF concentrations are a state characteristic of depression that 
normalizes in the course of natural remission and antidepressant treatment. Critically is that in this paper 
we show that the effect-sizes on these associations are small and that normalization of serum BDNF 
concentrations is not necessarily associated with a relief of depressive symptoms. 
 
Chapter 5 reports the findings of meta-analyses on differences in serum BDNF concentrations in 
antidepressant-free depressed patients versus healthy control subjects and antidepressant-treated 
depressed persons. The paper shows low serum BDNF concentrations in 2,384 antidepressant-free 
depressed persons relative to 2,982 healthy controls and to 1,249 antidepressant-treated depressed 
patients. When publication bias was accounted for, these effect-sizes became small to medium at best. This 
paper further shows, in contrast to prior belief, that serum BDNF concentrations and the symptom severity 
of depression are not related. 
     This paper is noteworthy, not in that it confirms that alternations in serum BDNF concentrations appear 
to be peripheral manifestations of depresion but that it shows that the evidence for this is slimmer as was 
initially thought. An important implication of this message is that serum BDNF concentrations probably are 
of little clinical use. 
 
In chapter 6 we evaluated serum BDNF concentrations in 393 patients with an anxiety disorder and in 382 
healthy control subjects. We found no overall differences in serum BDNF concentrations among patients 
and controls. A gender-diagnosis interaction on serum BDNF concentrations however was detected 
indicating that female patients with an anxiety disorder had lower serum BDNF concentrations relative to 
female controls. This was not observed in males. Serum BDNF concentrations were unrelated to the clinical 
characteristics of anxiety.  
     Anxiety disorders mimic depression to a great extent, so it was expected that serum BDNF 
concentrations would be low in patients with such an illness. Except for somewhat lower serum BDNF 
concentrations in female patients, this paper does not confirm the expectation. This may suggest that BDNF 
is involved in the pathophysiology of anxiety in women or, not unlikely, that the somewhat lower serum 
BDNF levels in anxious women are a female specific artifact of being anxious. 
 
The 7th chapter addressed the presumed effect of BDNF val66met on serum BDNF concentrations and 
whether it, if there, is conditional upon exposure to childhood trauma or other forms of stress. Overall, met 
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carriers had reduced serum BDNF concentrations when exposed to childhood abuse. This effect was dose-
dependent. Moreover, when not exposed to childhood abuse, met carriers had higher BDNF concentrations 
than val/val individuals (i.e., a val/met-abuse interaction effect). Exposure to recent life events was 
associated with a small decrease in BDNF concentrations.  
     Trauma- or stress exposure is, according to the neurotrophin hypothesis, the axiom that prevails in 
explaining depression related alternations in BDNF expression. This paper largely does not confirm this 
idea. The paper does report a val66met – childhood trauma interaction effect on serum BDNF 
concentrations. The extent to which this interaction may be important (on various levels of functioning) 
remains elusive. 
 
In chapter 8 we unravel whether the volume and functioning of the hippocampus and cognitive 
performance are related to variation at BDNF val66met. Structural and functional MRI data on depressed 
and/or anxious patients and healthy control subjects was used to elucidate this. Our results showed slightly 
smaller hippocampal volumes in carriers of a met allele relative to val/val homozygotes. For hippocampal 
encoding activity we find a val66met–word valence interaction such that carriers of a met allele showed 
increased levels of activity in response to emotional laden words.  
     This paper furthers the understanding of the association of BDNF val66met with hippocampal 
volume/functioning and cognitive performance. Critically, it takes trauma/stress exposure into account. We 
find a small effect of val66met on hippocampal volume and that childhood abuse accounts for individual 
differences in hippocampal encoding activity. This latter effect manifests itself differently as a function of 
val66met. These findings, although in need for replication, raise the question whether met carriers show 
abnormal brain response on emotional laden stimuli. This message comes with the notion that no 
behavioral effects were observed alongside the neurobiological differences. 
 
Chapter 9 contains a review and meta-analysis on the association between BDNF val66met and hippocampal 
volume. The results showed that carriers of a met allele had somewhat lower hippocampal volumes relative 
to val/val homozygotes. Between-study heterogeneity in effect size estimates was substantial and this 
could not be explained by demographical, clinical, and methodological differences across studies. We found 
strong evidence for publication bias and effect sizes decreased substantially over the years. This all led to 
the conclusion that lower hippocampal volumes are not a genuine biological effect of the met allele but 
rather a methodological artifact.  
     The finding of low hippocampal volumes in met carriers has become a pillar for the neurotrophinn 
hypothesis (total citations for the first paper on this association [Pezawas et al., 2005] is > 500). The meta-
analysis on this subject however shows that this association is non-existent and probably an artifact due to 
the use of underpowered studies.  
 
METHODS  
Before I present the highlights of the discussion and my conclusions, I shortly present the main strengths 
and limitations of the methods that were used in this thesis because these need to be reflected upon when 
interpreting the way in which I gave meaning to the findings herein. 
     A salient strength is that basically all studies in this thesis were extremely well powered. Herewith this 
thesis provides reliable effect-size estimates (Big Data Notable Fidelity). Another strength is that a high 
level of validity was achieved through adjustment for potential confounding factors and through subgroup- 
and moderation analyses. Besides, I actively sought to determine how reliable our research findings were 
by conducting meta-analyses. 
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     Notwithstanding this, I am well aware of the limitations of the studies in the prevailing thesis. First, our 
conclusions are contingent on peripheral measures to gauge on the central process of neuronal plasticity. 
Second, this thesis mostly elaborated on cross-sectional data and in none of the studies the subjects were 
randomly allocated to the conditions in which they were. Thus the reported findings are not sufficiently 
persuasive to prove causality. Finally, the findings of this thesis do not (directly) generalize to all 
populations, notably not to the young, the old and the severely ill. 
 
DISCUSSION 
This thesis accomplishes two things: (I) it outlines the determinants of serum BDNF concentrations and (II) 
it resolves some important clinical questions regarding the neurotrophin hypothesis. Together these 
accomplishments have significant methodological and theoretical implications that are summarized below. 
I will start with the findings on the determinants of serum BDNF concentrations. 
 
Part I: determinants 
Gaining detailed insight in determinants or the confounding structure of certain traits is the best strategy to 
avoid spurious associations and therefore worthwile. The knowledge on this issue was only rudimentary 
when I started this thesis trajectory back in 2008. 
     In line with a conceptualization of serum BDNF concentrations as being dependent on a complex myriad 
of factors, a long-list of variables was discovered that systematically showed association with serum BDNF 
concentrations. On this list were many variables that could have easily confounded the results of studies 
that test the predictions from the neurotrophin hypothesis. An example that illustrates this well is 
seasonality. It is established that the prevalence of depression is higher in the winter- as compared to the 
summer months (Lewy et al., 2006). In chapter 3 I report profound seasonality in serum BDNF 
concentrations. Together this suggests that controlling for season could change the magnitude of some 
associations with a prime interest of the neurotrophin hypothesis, for instance the difference in serum 
BDNF concentrations among depressed patients and healthy controls. This turns out to be so, as the data in 
chapter 3 shows that the effect-size on this association is attenuated by about 40 percent when seasonality 
is taken into account.  
     In this thesis, our group has begun to make progress in understanding the factors that systematically 
influence serum BDNF concentrations. The focus was on methodological issues, that is: how to avoid 
confounding. This was achieved as the findings that are reported in chapter 2 and 3 invite for a perspective 
on BDNF related research in which the basal determinants and seasonality are engrained. Herewith, we 
contribute timely to the literature 
 
Part I: the neurotrophin hypothesis 
The chapters 4 through 7 set out to explore serum BDNF concentrations in relation to psychiatric illness, 
notably depression. Explicitly tested was whether: (I) patients with depressive disorders (and related 
conditions) consistently exhibit abnormally low serum BDNF concentrations, (II) serum BDNF 
concentrations are related to the characteristics of depression (e.g., the severity of symptoms), (III) 
antidepressant use accounts for variance in serum BDNF concentrations, and (IV) etiological risk factors for 
depression (trauma and stress exposure) account for variance in serum BDNF concentrations. 
 
Serum BDNF concentrations - confirmative findings 
In line with what was expected, chapter 4 and 5 show that serum BDNF concentrations are low in 
antidepressant-free depressed patients relative to controls and to depressed patients who were treated 
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with an antidepressant. The data from chapter 4 and 5 further indicate that serum BDNF concentrations of 
fully remitted persons are comparable to those of healthy controls. So, low serum BDNF concentrations are 
a state characteristic of depression: evident during the depressed state and normalized in full remission. 
Also in line with what was expected is that serum BDNF concentrations normalize in the course of 
antidepressant treatment. All these findings are robust since they were derived from the largest (and most 
reliable) single study (chapter 4) and confirmed by meta-analyses (chapter 5). Extending the neurotrophin 
hypothesis we find that female patients with an anxiety disorder have lower concentrations of BDNF 
relative to female controls and to male patients (chapter 6). This suggests that BDNF might be involved in 
the pathophysiology of anxiety in women. Finally, and also conform expectations was that exposure to 
recent life events such as being fired (in general an etiological risk factor for the development of a 
depressive episode), was associated with a (small) mean decrease in serum BDNF concentrations (chapter 
7). 
     Despite that these findings were confirmative, the meaning of them was not always that clear (e.g., 
reverse causation, to be discussed in a latter part). Furthermore, a part of our data on serum BDNF 
concentrations showed a lack of fit with the expectations from the neurotrophin hypothesis. These non-
confirmative findings are highlighted in the part that follows. 
  
Serum BDNF concentrations - non-confirmative findings 
A first finding that is not contingent on expectations is that depressed patients who were in the early 
remission phase of their depressive episode, and thus largely free of symptoms, had serum BDNF 
concentrations that were lower as compared to those of currently depressed patients (chapter 4). This 
finding does not relate well to the temporal dynamics specified in the neurotrophin hypothesis that low 
neurotrophic support should endanger a person to become depressed (i.e., low BDNF  depression onset). 
In fact it suggests reversed causation, where lower serum BDNF concentrations are a consequence of 
depression (i.e., depression  low BDNF).  
     Other findings reported in chapter 4 and 5 that do not relate well to the neurotrophin hypothesis are 
that BDNF concentrations do not relate to the core clinical features of depression, such as its severity and 
that up-regulation of serum BDNF concentrations in the course of antidepressant treatment is confined to 
some classes of antidepressants. The finding on the lack of a relation between BDNF concentrations and 
clinical characteristics (notable depression symptom severity) does not confirm the logic of the linear 
dynamics of the neurotrophin hypothesis, from which it can be predicted that patients with higher 
symptom severity show particularly low neurotrophic support. Note that chapter 5, through meta-analysis, 
robustly confirms the absence of the association between serum BDNF concentrations and depression 
symptom severity, an association in which the literature had a great deal of belief. The finding of 
antidepressant specific effects on serum BDNF concentrations seems at odds with the prediction of the 
neurotrophin hypothesis that increases in BDNF concentrations are a key mediator for an antidepressant 
response to occur. Because, according to this prediction one might expect that antidepressants that are 
equally efficacious in the treatment of depression would have similar effects on serum BDNF 
concentrations, which they (according to our data but also that of others [Deuschle et al., 2013]) obviously 
don’t have. Another and related finding that is hard to reconcile with the neurotrophin hypothesis is that 
the group of depressed persons who used antidepressants (for a prolonged period and on a frequent base) 
had the highest serum BDNF concentrations alongside the highest symptom severity of depression (see 
chapter 4). This suggests that increases in peripheral BDNF concentrations occur in the course of 
treatment, but these do not parallel clinical effectiveness of antidepressants.  
     What chapter 5 adds regarding the above-mentioned associations is that the literature is less reliable as 
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could be hoped for (e.g., publication bias). In fact, and in contrast to prior data and belief, effect-sizes on 
between groups differences are only small and therefore the evidence for the neurotrophin hypothesis is 
less substantial as was initially thought. The small effect-size estimates further indicate that (changes in) 
serum BDNF concentrations probably are of little clinical use as a diagnostic- or treatment biomarker. 
     In chapter 6 the expectation was that serum BDNF concentrations would be low in the anxious state. 
The data, however, gave little ground to this belief. In male patients with an anxiety disorder there were no 
abnormalities in serum BDNF concentration observed. In female patients with an anxiety disorder we found 
slightly lower serum BDNF concentrations as compared to healthy female. Therefore, the data in this 
chapter may attest that BDNF is involved in the pathophysiology of anxiety disorders per se. And, as 
explained (see the discussion on the relation between serum BDNF concentrations and estrogen), the 
alternations in female patients can easily be a female specific artifact of being anxious without being 
causally involved in anxiety etiology. 
     Finally, chapter 7 attests the prevailing axiom that has been brought forward in explaining depression 
related alternations in BDNF expression: trauma exposure.  
     Clearly, findings that show a lack of fit with the expectations of the neurotrophin hypothesis are 
omnipresent in the studies that make up this thesis. Frankly, none of the expectations that can be derived 
from it could be fully validated. And if confirmative findings were reported, often their respective meaning 
was not that clear (e.g., reverse causation). Maybe these non-confirmative findings by themselves are not a 
sufficient qualification to reject the neurotrophin hypothesis yet together they suggest that the initial idea 
of the neurotrophin hypothesis should not be credited.  
 
The neurotrophin hypothesis: BDNF val66met 
In the chapters 7 through 9 we explored associations between a variant on the gene that codes for BDNF, 
val66met, for which functionality has been shown (in vitro and in vivo; in terms of neurotrophic support). 
We explicitly tested the expectation that the met-allele, the so called risk allele at this locus, is related to 
depression related phenotypes, with the latter being broadly defined from a DSM-IV depression diagnosis 
to impaired cognition and altered brain morphology. An important note is that trauma and stress exposure 
were taken into account in these studies in order to model inter-individual differences in outcomes due to 
these factors and their potential interaction with BDNF val66met. Based on the presumed functionality of 
this polymorphism it was expected that the met allele would be associated with established correlates of 
depression, particularly in the face of trauma- and/or stress exposure.  
 
BDNF val66met - confirmative findings 
A first confirmative finding (chapter 7) was a val66met - trauma interaction effect on serum BDNF 
concentrations. This effect was such that BDNF met carriers had reduced serum BDNF concentrations but 
only when exposed to childhood abuse. In contrast to expectations was that this did not have any effect on 
behavior and the extent to which it is important thus remains to be elucidated. Furthermore, carriers of a 
met allele appeared to have somewhat lower hippocampal volumes relative to val/val homozygotes 
(chapter 8). Finally, hippocampal activity during the retrieval of negative words was different as a function 
of val66met and trauma exposure (chapter 8). These findings may be in line with the expectation that the 
met-allele is a risk allele when depression related phenotypes are taken as outcome.    
     However, also with regard to val66met this thesis reports findings that diverge from the predictions of 
the neurotrophin hypothesis. These inconsistencies are detailed below. 
   
BDNF val66met - non-confirmative findings  
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Findings that were not in line with a priori belief included that val66met is not (directly) associated with 
psychopathology outcomes, cognitive performance, serum BDNF concentrations, or hippocampal activation 
patterns (chapter 7 and 8). Related is that the constellations of events/circumstances that had an effect on 
serum BDNF concentrations and hippocampal encoding activity (the met allele and exposure to childhood 
abuse) were not associated with expected outcomes at the behavioral level (chapter 7 and 8). Finally, and 
maybe most conclusive, chapter 9 shows that that val66met is not associated with hippocampal volume. 
This study in general is noteworthy in that it highlights the deleterious effects of underpowered studies and 
overestimations of effect-sizes that plague the field. Herewith the paper may be relevant beyond the 
val66met – hippocampal volume literature. Given these non-confirmative findings I believe that val66met is 
an invalid model to study BDNF functioning. 
 
Conclusion 
Confidence in a theory increases when it is confirmed by relevant data. Our data (and also that of others) 
show a lack of universal confirmation. Alongside some consistent findings, the data in the prevailing thesis 
largely detail inconsistencies regarding the neurotrophin hypothesis. And where expected associations 
were established (e.g., abnormally low serum BDNF concentrations in the depressed state), the meaning 
often was not that clear (e.g., reverse causation). I therefore conclude, whilst taking limitations into 
account and acknowledging that the results are contingent upon imperfect measurement that the most 
reliable evidence in humans does not corroborate the neurotrophin hypothesis. So, given the data, the final 
words of this thesis are that solid work over novelty shows that the neurotrophin hypothesis should no 
longer be credited in its original form. All that glitters is not gold - back to the drawing table. 
 
Future work – the drawing table  
At the drawing table I could come up with some aspirational goals. The one of these with greatest 
importance is to deepen the understanding of how neurotrophic functioning may be altered in the 
depressed state (i.e., construct validity) and the accompanying functional consequences of this on health 
(i.e., predictive validity). Alongside this, the temporal dynamics as specified in the neurotrophin hypothesis 
(i.e., low BDNF support  depression onset) should be entangled because now reversed causation (i.e., 
depression onset  low BDNF support) in which low BDNF support does not mark the beginning of a 
depressive episode but rather a consequence of it can not be excluded (i.e., construct validity). Further 
challenges on the way to progress include collaboration in data-sharing networks to answer, with rigor, 
some outstanding questions (i.e., statistical validity), to measure beyond single BDNF parameters, to bring 
the preclinical and clinical research more together, and, in parallel, to leave behind the diagnostic 
categories of the DSM in the study of neurotrophic functioning (i.e., all construct validity). Once this can be 
established, progress can be made and the question -- will the neurotrophin hypotehsis sparkle on, long 
after the glitter of the firework is gone -- can definitely be dealt with, maybe in the end accompanied by 


























































NEDERLANDSE SAMENVATTING EN CONCLUSIES 
 
De rol van BDNF in depressie  -- Zal de neurotrofe hypothese nog lang schitteren? 
 
ACHTERGROND 
Neuronale plasticiteit is van essentieel belang voor het functioneren van basale processen als het 
geheugen, leervermogen en emotie regulatie. Het neuronale groeihormoon Brain-Derived Neurotrophic 
Factor (BDNF) induceert en medieert neuronale plasticiteit. Men vermoedt dat inzichten in het ontstaan en 
het verloop van verschillende psychiatrische aandoeningen vergroot kunnen worden door de regulatie van 
BDNF beter te begrijpen. 
     Volgens de neurotrofe hypothese is een laag niveau van BDNF het startpunt van een 
pathophysiologische cascade, die via verstoorde neuronale plasticiteit en atrofie in hersengebieden die 
emotie reguleren, kan leiden tot een depressieve stoornis. Er is toenemend preklinische bewijs voor deze 
hypothese en er wordt veel ondezoek verricht om tot een vertaalslag naar de menselijke depressie te 
komen. Zo toont een aantal humane studies aan dat perifere parameters voor neurotroof functioneren (in 
de vorm van bijvoorbeeld serum BDNF-spiegels) anders worden gereguleerd bij mensen die lijden aan een 
depressieve stoornis. Ook laten enkele studies zien dat genetische varianten, waarvan preklinisch werk 
heeft aangetoond dat ze de expressie van BDNF reguleren, associaties vertonen met aan depressie 
gerelateerde fenotypen.  
      Ondanks positieve geluiden over de neurotrofe hypothese en de mogelijke implicaties die dit model zou 
kunnen bieden om depressieve stoornissen beter te begrijpen, is er ook onzekerheid. De voornaamste bron 
van  onzekerheid komt voort uit een gebrek aan kennis over de fundamentele determinanten van serum 
BDNF-spiegels. Gebrek aan kennis op dit gebied kan immers eenvoudig leiden tot onterechte conclusies uit 
het voornamelijk observationele onderzoek dat tot dusver is uitgevoerd naar de rol van BDNF in depressie. 
Een tweede bron van onzekerheid is dat een reeks klinische vragen vooralsnog onbeantwoord blijft. Met dit 
proefschrift probeer ik  antwoord te geven op enkele vragen met betrekking  tot de neurotrofe hypothese 
en zodoende een verfijnd beeld van perifeer neurotroof functioneren in depressieve (en verwante) 
stoornissen te schetsen. Belangrijk is hierbij de methode van  aanpak. In tegenstelling tot het gros van het 
eerdere onderzoek op deze gebieden wordt gebruikgemaakt van grote groepen en meta-analyses om zo 
associaties betrouwbaar te onderbouwen dan wel te weerleggen.  
     Acht empirische studies vormen het hart van dit proefschrift. In de paragraaf die volgt  vat ik de 
resultaten van deze studies samen (per hoofdstuk) en geef ik kort het belang aan van de desbetreffende 
studies. Het eerste doel van dit proefschrift, het blootleggen van de determinanten van serum BDNF 
spiegels, wordt beschreven in de hoofdstukken 2 en 3. De hoofdstukken 4 - 9 staan in het teken van 
klinische vragen met betrekking tot de neurotrofe hypothese. 
 
RESULTATEN 
Het eerste empirische hoofdstuk van dit proefschrift (hoofdstuk 2) geeft een gedetailleerde beschrijving 
van de determinanten van serum BDNF spiegels. De studie toont aan dat een niet-nuchtere toestand op het 
moment van bloedafname, een later tijdstip van bloedafname en een langere duur van serum opslag  
gepaard gaan met verlaagde serum BDNF-spiegels. Dit in tegenstelling tot roken en leven in een stedelijk 
gebied (in vergelijking tot een meer landelijk gebied), die beide worden geassocieerd met verhoogde BDNF-
spiegels. Tenslotte lijken serum BDNF-spiegels toe te nemen als een functie van leeftijd. 
     Deze paper schetst de determinanten van serum BDNF-spiegels. Dit is een belangrijk uitgangspunt om 
interindividuele verschillen in serum BDNF-spiegels te kunnen begrijpen en is van essentieel belang om tot 
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valide conclusies te komen in onderzoek naar BDNF. 
 
In hoofdstuk 3 is onderzocht of serum BDNF-spiegels seizoensgebonden zijn. Hiertoe werden in eerste 
instantie analyses uitgevoerd om te bepalen of BDNF-spiegels verschilden als een functie van de maand 
waarin het bloed was afgenomen om BDNF in te bepalen. De resultaten tonen uitgesproken 
seizoensgebonden variatie: serum BDNF-spiegels nemen toe in de lente/zomer periode (i.e., de lente 
equinox) en af in de loop van de herfst/winter periode (i.e., de herfst equinox). Verder  bleek dat de lengte 
van de dag en het aantal uren zonneschijn, twee zogeheten zeitgebers (triggers van seizoensgebonden 
variatie) in de weken voor bloedafname positief gecorreleerd zijn aan serum BDNF-spiegels. 
      De bevindingen van deze studie zijn van meerwaarde, omdat ze inzicht verschaffen in de factoren die 
BDNF- expressie reguleren. Daarnaast zijn ze van cruciaal belang bij het ontwerpen en evalueren van 
studies die BDNF spiegels als uitkomst? variabele meenemen. 
 
Het 4de hoofdstuk van dit proefschrift gaat in detail in op het verband tussen serum BDNF-spiegels en 
depressie. De belangrijkste bevinding in dit hoofdstuk is dat serum BDNF-spiegels laag zijn bij depressieve 
patiënten die niet worden behandeld met antidepressiva ten opzichte van gezonde controles en van 
depressieve patiënten die wel worden behandeld met een antidepressivum. Daarnaast laat dit hoofdstuk 
zien dat serum BDNF-spiegels van mensen met een depressie in de remissie-fase vergelijkbaar zijn met die 
van gezonde controles. Verder bleek dat serum BDNF-spiegels niet zijn gerelateerd aan de klinische 
kenmerken van depressie, zoals de ernst van de stoornis. 
     Deze studie laat zien dat lage serum BDNF-spiegels een ‘state’ karakteristiek is van de depressieve 
stoornis, een abnormaliteit die aanwezig is tijdens de daadwerkelijke depressieve episode en die 
normaliseert in de loop van natuurlijke remissie en behandeling met antidepressiva. Van kritisch belang is 
echter dat deze studie ook laat zien dat normalisatie van serum BDNF-spiegels niet noodzakelijkerwijs 
geassocieerd is met een verlichting van de depressieve symptomen. 
 
Hoofdstuk 5 rapporteert de bevindingen van een aantal meta-analyses over verschillen in serum BDNF-
spiegels tussen depressieve patiënten en gezonde controles. De analyses laten zien dat serum BDNF-
spiegels laag zijn bij depressieve patiënten die niet worden behandeld met een antidepressivum in 
vergelijking  tot gezonde controles, en depressieve patiënten die wel waren behandeld met een 
antidepressivum. Deze laatste groep verschilt niet van gezonde controles wat betreft serum BDNF-spiegels. 
Verder is er grote heterogeniteit in uitkomsten tussen studies, waar geen theoretisch relevante verklaring 
(e.g., ernst van de depressie) voor kon worden gevonden. Wel was er evidentie voor enkele ‘artificiële’ 
verklaringen. Zo rapporteren minder betrouwbare studies relatief grote effect-groottes en is er sterk bewijs 
voor publicatie bias. Indien voor dit laatste een statistische correctie werd toegepast dan worden de effect-
groottes over de associaties substantieel kleiner, maar blijven significant. Voor de relatie tussen de ernst 
van de depressie en serum BDNF spiegels geeft de gepoolde data geen consistent bewijs. 
     Deze studie is opmerkelijk, niet zozeer omdat wordt bevestigd dat veranderingen in serum BDNF-
spiegels perifere manifestaties van depressie lijken te zijn, maar eerder doordat het laat zien dat het bewijs 
voor dit idee niet zo sterk is als aanvankelijk werd gedacht. Een belangrijke implicatie van de boodschap in 
dit hoofdstuk is dat kennis met betrekking tot serum BDNF-spiegels waarschijnlijk weinig (directe) klinische 
relevantie heeft. 
 
Hoofdstuk 6 vergelijkt serum BDNF-spiegels tussen patiënten met een angststoornis en gezonde controles. 
Angststoornissen overlappen op een groot aantal dimensies met depressie en hierdoor was de verwachting 
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dat serum BDNF-spiegels abnormaal laag zouden zijn bij patiënten met een angststoornis. Over het geheel 
genomen ondersteunen de bevindingen van deze studie deze verwachting niet, want serum BDNF-spiegels 
lijken vergelijkbaar tussen patiënten en controles. Wel hadden vrouwelijke patiënten met een 
angststoornis lagere serum BDNF-concentraties ten opzichte van gezonde vrouwen, waar dit voor mannen 
niet het geval is. Een laatste bevinding uit deze studie is dat serum BDNF-spiegels niet zijn gerelateerd aan 
de klinische karakteristieken van angst, bijvoorbeeld de duur van de symptomen. 
     De resultaten van deze studie bevestigen niet de verwachting dat serum BDNF spiegels laag zijn in 
mensen met een angststoornis. De studie laat wel iets lagere serum BDNF-spiegels zien bij vrouwelijke 
patiënten met een angststoornis. Deze bevinding kan erop wijzen dat BDNF een rol speelt in de pathologie 
van angst bij vrouwen of, niet onwaarschijnlijk, een vrouwelijke specifiek artefact van angst weerspiegelt. 
 
Hoofdstuk 7 toetst de hypothese dat het BDNF val66met genotype gerelateerd is aan serum BDNF spiegels. 
De studie vindt geen direct bewijs voor deze hypothese, maar wel dat dragers van het met allel lagere 
BDNF spiegels hebben in vergelijking tot mensen die homozygoot zijn voor het val allel wanneer zij zijn 
blootgesteld aan kindermishandeling. Bovendien hebben dragers van het met allel hogere BDNF-spiegels 
dan mensen die homozygoot zijn voor het val allel, wanneer ze zijn niet blootgesteld aan 
kindermishandeling. Daarnaast bevestigt deze studie de neurotrofe hypothese in zijn voorspelling dat 
blootstelling aan recente stressvolle gebeurtenissen wordt geassocieerd met een (kleine) afname in serum 
BDNF-spiegels. 
     Blootstelling aan stress en/of trauma is volgens de neurotrofe hypothese het axioma dat de lagere 
BDNF-spiegels verklaardt in mensen met aan stress gerelateerde psychopathologie. Het belang van dit 
paper is dat het dit idee niet weet te bevestigen. Wel laat deze studie een interessant interactie effect zien 
tussen val66met en kindermishandeling. De mate waarin deze interactie belangrijk is (op verschillende 
niveaus van functioneren) dient in vervolgonderzoek te worden bekeken.  
 
In hoofdstuk 8 is onderzocht of het volume en de functionaliteit van de hippocampus zijn gerelateerd aan 
BDNF val66met. Hiertoe is gebruikgemaakt van structurele en functionele MRI-data. De resultaten van dit 
onderzoek wijzen uit dat dragers van een BDNF met allel kleinere hippocampi hebben ten opzichte val/val 
homozygoten. Verder rapporteert deze studie dat dragers van een met allel verhoogde neurale activiteit 
vertonen in de hippocampus in hun reactie op emotionele beladen woorden. Consistente associaties tussen 
val66met en cognitief functioneren en psychopathologie zijn niet evident in deze studie. 
     De boodschap in dit hoofdstuk is van belang omdat deze het begrip van de veelbesproken associaties 
tussen BDNF val66met met neuronaal functioneren uitdiept. Deze studie, hoewel de bevindingen 
onafhankelijk gerepliceerd dienen te worden, suggereert dat dragers van een met allel abnormale reacties 
vertonen in reactie op emotioneel geladen stimuli. Hierbij dient wel te worden opgemerkt dat de 
gedragseffecten (op bijvoorbeeld cognitief functioneren of psychopathologie) die men zou verwachten 
naast de neurobiologische verschillen niet zijn waargenomen. 
 
Hoofdstuk 9 presenteert een meta-analyse over de relatie tussen BDNF val66met en het volume van de 
hippocampus. De resultaten van deze analyse  suggereren dat  de hippocampus van dragers van een met 
allel kleiner is qua omvang in vergelijking tot die van  val/val homozygoten. Echter, de heterogeniteit in 
uitkomsten tussen studies is aanzienlijk, wat niet kan worden verklaard door demografische, klinische en 
methodologische karakteristieken van de geïncludeerde studies. Wel zijn er sterke aanwijzingen voor 
publicatie-bias en effect-groottes nemen af als een functie van jaar van publicatie. Dit alles duidt erop dat 
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kleinere hippocampi waarschijnlijk niet een biologisch effect van het met allel zijn maar eerder een 
methodologisch artefact. 
      De bevinding dat dragers van een met allel, wat volgens preklinische studies wordt geassocieerd met 
lagere neurotrofe ondersteuning, kleinere hippocampale volumes hebben is in de loop der jaren een pijler 
voor de neurotrofe hypothese geworden (het totale aantal citaties naar de eerste paper over deze relatie 
[Pezawas et al., 2005] is > 500). Deze studie toont echter aan dat dit verband waarschijnlijk een artefact is: 
gebaseerd op studies met een te lage statistische power. 
 
METHODEN 
Voordat ik de belangrijkste discussiepunten en de conclusies van dit proefschrift aan u presenteer, vat ik 
eerst de sterke- en zwakke punten van de studies in dit proefschrift kort samen. Dit is namelijk van groot 
belang bij de interpretatie van de resultaten in dit proefschrift en de manier waarop ik daar betekenis aan 
heb gegeven. 
     Sterk is dat bijna alle resultaten in dit proefschrift gebaseerd zijn op een grote steekproef, wat 
betrouwbare schattingen van effect-groottes biedt (Big Data Notable Fidelity). Een ander sterk punt is dat 
de resultaten in dit proefschrift een hoge mate van validiteit hebben doordat er statistisch is gecontroleerd 
op verstorende factoren, en dat er moderatie- en subgroep analyses zijn uitgevoerd. Daarnaast is in een 
aantal gevallen de betrouwbaarheid van de onderzoeksresultaten getoetst door middel van meta-analyse. 
     Naast deze sterke punten kennen de studies in dit proefschrift ook de nodige beperkingen. Allereerst zijn 
onze conclusies grotendeels afhankelijk van perifere maten (d.w.z. serum BDNF) waar neurotroof 
functioneren een centraal proces betreft. Ten tweede, de resultaten in dit proefschrift zijn gebaseerd op 
voornamelijk cross-sectioneel onderzoek en in geen van de studies is gebruik gemaakt van randomisatie. 
De gerapporteerde bevindingen zijn hierdoor niet voldoende overtuigend om causaliteit aan te tonen. Tot 
slot, de resultaten die worden gerapporteerd in dit proefschrift zijn niet direct te generaliseren naar alle 




Dit proefschrift voegt twee belangrijke elementen aan de wetenschappelijke literatuur toe. Ten eerste 
biedt het een overzicht van de determinanten van serum BDNF-spiegels. Ten tweede levert het 
antwoorden op een aantal belangrijke klinische vragen die voortkomen uit de neurotrofe hypothese. Dit 
tezamen heeft aanzienlijke methodologische en theoretische implicaties die hieronder zullen worden 
samengevat. Ik begin met de bevindingen betreffende de determinanten van serum BDNF-spiegels. 
 
Deel I: determinanten  
Inzicht in de determinanten van een variabele is van vitaal belang om tot valide conclusies te komen. De 
eerste twee hoofdstukken van dit proefschrift beschrijven de resultaten van onze pogingen om inzicht te 
krijgen in de determinanten van serum BDNF-spiegels. 
     Dit proefschrift beschrijft een  aantal variabelen die op systematische wijze  samenhangen met serum 
BDNF-spiegels, waaronde enkele die, wanneer niet op adequate wijze onder controle, gemakkelijk kunnen 
leiden tot niet valide conclusies in het testen van de voorspellingen van de neurotrofe hypothese. Een 
voorbeeld dat dit goed illustreert is het seizoensgebonden effect in serum BDNF-spiegels waar wij over 
rapporteren in hoofdstuk 3. Het is een gegeven dat de prevalentie van depressie hoger is in de winter in 
vergelijking tot de zomer. De sterke seizoen gebondenheid in serum BDNF-spiegels (hoofdstuk 3), samen 
met de hogere prevalentie cijfers van depressie in de winter, suggereert dat het controleren voor seizoen 
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van belang is wanneer men bijvoorbeeld het verschil in serum BDNF spiegels tussen depressieve patiënten 
en gezonde controles wil bepalen. Dit blijkt inderdaad zo te zijn, daar de effect-grootte over deze associatie 
met 40 procent afneemt in analyses die zijn gecontroleerd voor het seizoen waarin de deelnemers zijn 
gesampled.  
     Zoals beschreven heeft onze groep vooruitgang weten te boeken in het begrip van de determinanten 
van serum BDNF-spiegels. De focus lag hierbij op methodologische aspecten, dat wil zeggen: hoe kunnen de 
relaties met onze primaire interesse (i.e., vragen die voortvloeien uit de neurotrofe hypothese) zo zuiver 
mogelijk worden getoetst. De bevindingen die worden gerapporteerd in hoofdstuk 2 en 3 nodigen uit tot 
een perspectief op BDNF gerelateerd onderzoek waarin de basale determinanten zijn 
geïntegreerd/gecontroleerd.  
 
Deel II: de neurotrofe hypothese  
In de hoofdstukken 4 - 7  onderzochten we serum BDNF-spiegels in relatie tot psychiatrische ziektebeelden, 
met name depressie, de karakteristieken en de behandeling ervan. Expliciet getest zijn de volgende 
(vermeende) associaties: (I) patiënten met een depressieve stoornis (en verwante aandoeningen) vertonen 
consistent lage serum BDNF-spiegels, (II) serum BDNF-spiegels zijn gerelateerd aan kenmerken van de 
depressieve stoornis (met name de ernst van de symptomen) en (III) gebruik van antidepressiva en 
risicofactoren voor het ontwikkelen van een depressie (i.e., blootstelling aan trauma en stress) zijn 
gerelateerd aan serum BDNF-spiegels. Een aantal van deze verwachtingen wordt bevestigd in dit 
proefschrift, en vormen het onderwerp van de alinea die volgt.  
 
Bevestigde verwachtingen: de neurotrofe hypothese - serum BDNF-spiegels 
In lijn met de a priori verwachtingen rapporteren we in hoofdstuk 4 en 5 dat serum BDNF-spiegels 
significant verlaagd  zijn bij depressieve patiënten die niet worden behandeld met een antidepressivum ten 
opzichte van gezonde controles en depressieve patiënten die wel worden behandeld met een 
antidepressivum. De resultaten in hoofdstuk 4 en 5 geven verder aan dat serum BDNF-spiegels 
normaliseren in de loop van volledige remissie. De conclusie die hieruit volgt is dat lage serum BDNF-
spiegels een ‘state’ kenmerk zijn van depressie: laag tijdens de actieve fase van de stoornis en 
genormaliseerd wanneer de depressie in volledige remissie is. 
     In overeenstemming met de verwachtingen van de neurotrophe hypothes, lijken serum BDNF-spiegels 
zich in de loop van de behandeling met antidepressiva, te normaliseren, en worden vergelijkbaar aan de 
waarden van die van gezonde controles. Een belangrijke noot hier is dat de hierboven genoemde 
bevindingen robuust zijn: afgeleid van de grootste (en meest betrouwbare) enkelvoudige studie (hoofdstuk 
4) en bevestigd door meta-analyse (hoofdstuk 5). 
     Hoofdstuk 6, kan gezien worden als een extensie van de neurotrofe hypothese naar de angststoornissen, 
aangezien we daar vinden wij dat vrouwelijke patiënten met een angststoornis lage BDNF-spiegels hebben 
ten opzichte van gezonde vrouwen. Dit zou kunnen betekenen dat BDNF een rol speelt in de 
pathofysiologie van angst bij vrouwen. 
     Tenslotte, en mede in lijn der verwachting van de neurotrofe hypothesis is de bevinding in hoofdstuk 7, 
dat blootstelling aan recente stressvolle gebeurtenissen (doorgaans etiologische risicofactoren voor de 
ontwikkeling van een depressie), geassocieerd blijkt te zijn met een (kleine) daling in serum BDNF-spiegels. 
     Ondanks dat de bovengenoemde bevindingen als bevestigingen van de neurotrofe hypothese worden 
gezien, moet worden erkend dat hun betekenis niet altijd even duidelijk is (omgekeerde causaliteit, 
bijvoorbeeld, kan niet  worden uitgesloten [dit wordt in een later deel van deze samenvatting besproken]). 
Daarnaast rapporteren de studies in dit proefschrift een scala aan bevindingen die niet in de pas lopen met 
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de voorspellingen van de neurotrofe hypothese of die hier zelfs haaks op staan. Deze worden kort 
bediscussieerd in de paragraaf die volgt. 
 
Serum BDNF-spiegels – niet bevestigende verwachtingen 
Een eerste bevinding die duidelijk niet in lijn is met de verwachtingen van de neurotrofe hypothese is dat 
depressieve patiënten die in de vroege remissiefase van hun depressieve episode zitten, en dus grotendeels 
vrij van symptomen zijn, serum BDNF-spiegels hebben die lager zijn dan die van huidig depressieve 
patiënten (hoofdstuk 4). Deze bevinding  past niet goed binnen de temporele dynamiek die de neurotrofe 
hypothese specificeert: dat lage BDNF-spiegels, of neurotrofe ondersteuning in het algemeen, een persoon 
kwetsbaar maken om depressief te worden (d.w.z.: laag BDNF → verhoogde kans op depressie). In feite 
suggereert deze bevinding omgekeerde causaliteit,  dat lage serum BDNF-spiegels het gevolg zijn van de 
depressieve episode (d.w.z.: depressie → verlaging van BDNF). 
    Een andere bevindingen die wordt gerapporteerd in hoofdstuk 4 en 5 die niet rijmt met de neurotrofe 
hypothese is de afwezigheid van consistente associaties tussen serum BDNF-spiegels en de klinische 
kenmerken van depressie. Met name het ontbreken van een relatie tussen serum BDNF-spiegels en de 
ernst van de depressie, druist in tegen de logica van de lineaire dynamiek van de neurotrofe hypothese, 
waaruit kan worden afgeleid dat patiënten met een hogere mate van ernst ook een lagere neurotrofe 
ondersteuning hebben. In hoofdstuk 5, waarin een meta-analyse over deze associatie wordt 
gerapporteerd, wordt de afwezigheid van deze vermeende associatie robuust bevestigd. Dit is een 
belangrijke bevinding, aangezien het geloof in het bestaan van deze relatie groot was. 
     Daarnaast rapporteert hoofdstuk 4, evenmin in lijn met de neurotrofe hypothese, dat de normalisatie 
van BDNF-spiegels in de loop van de behandeling met antidepressiva beperkt lijkt tot sommige klassen van 
antidepressiva. Deze bevinding staat op gespannen voet met de voorspelling van de neurotrofe hypothese 
dat een toename in de expressie van BDNF de mediator is voor de klinische response op antidepressiva. 
Deze voorspelling volgend zou men namelijk verwachten dat antidepressiva die klinisch gezien ongeveer 
even effectief zijn in de behandeling van depressie ook gelijke associaties zouden vertonen met serum 
BDNF-spiegels. En deze gelijke associatie hebben zij volgens onze data (hoofdstuk 4), maar ook die van 
anderen, duidelijk niet. Een gerelateerde  bevinding die moeilijk is te rijmen met de neurotrofe hypothese 
is dat de groep van depressieve personen die antidepressiva gebruikt (voor een langere periode en op een 
frequente basis) de hoogste serum BDNF-spiegels hebben maar ook gemiddeld de hoogste ernst van 
depressie (hoofdstuk 4). Dit suggereert dat de verhogingen of normalisatie van serum BDNF-spiegels die 
worden geobserveerd in de loop van de behandeling met antidepressiva niet parallel lopen met de 
klinische effectiviteit van het medicijn. 
     Een belangrijk inzicht  van hoofdstuk 5 is dat de literatuur over de eerder genoemde associaties minder 
betrouwbaar is dan kan worden gehoopt. De redenen hiervoor zijn onder meer publicatie bias. In feite, een 
belangrijke les die hoofdstuk 5 ons brengt is dat in tegenstelling tot wat eerder werd gedacht, dat de effect 
– groottes voor de groepsverschillen met onze interesse slechts klein zijn of zelfs afwezig. Dit impliceert dat 
serum BDNF-spiegels waarschijnlijk niet van enig nut zijn in een rol als diagnostische- of behandeling 
‘biomarker’. 
     De a priori verwachting in hoofdstuk 6, gebaseerd op de neurotrofe hypothese, was dat serum BDNF-
spiegels laag zouden zijn bij mensen die zijn gediagnosticeerd met een angststoornis. De data in dit 
hoofdstuk geeft echter weinig onderbouwing voor deze verwachting, omdat er in het algemeen geen 
verschillen werden gevonden in serum BDNF-spiegels tussen mensen met een angststoornis en gezonde 
controles. Hieruit volgt de conclusie dat BDNF waarschijnlijk niet een rol van betekenis speelt in de 
pathofysiologie van angststoornissen per se. Zoals reeds genoemd vonden we bij vrouwelijke patiënten met 
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een angststoornis enigszins lagere serum BDNF spiegels in vergelijking met gezonde vrouwen. Dit zou 
kunnen wijzen op een specifieke rol van BDNF in de etiologie van angststoornissen bij vrouwen, maar deze 
abnormaliteit kan evengoed een vrouwelijke specifiek artefact van een angststoornis representeren. 
     In hoofdstuk 7 hebben we het in de neurotrofe hypothese heersende axioma getest dat blootstelling 
aan stress en trauma de lagere BDNF spiegels in aan stress gerelateerde stoornissen verklaart. Ook voor dit 
axioma vinden wij geen consistent bewijs. 
     Kortom, bevindingen die niet aansluiten bij de verwachtingen van de neurotrofe hypothese zijn 
alomtegenwoordig in de studies in dit proefschrift. In feite kan geen van de verwachtingen van de 
neurotrofe hypothese volledig worden gevalideerd. En daarnaast, als onze studies enigszins bevestigende 
resultaten opleverden dan was hun betekenis vaak niet duidelijk (omgekeerde causaliteit bijvoorbeeld). 
Misschien zijn deze niet- bevestigende bevindingen  ieder voor zich niet voldoende  om de neurotrofe 
hypothese als niet-valide te bestempelen. Samen suggereren zij echter dat het attribueren van 
gedragsverschillen (zoals depressie) aan verschillen in serum BDNF-spiegels een stap te ver gaat. Daarom 
zal de neurotrofe hypothese in zijn oorspronkelijke vorm niet behouden kunnen worden. 
 
Deel II vervolg: de neurotrofe hypothese - BDNF val66met 
De hoofdstukken 7, 8 en 9 verkenden associaties tussen een variant op het gen dat codeert voor BDNF: 
val66met. Deze variant  is in preklinisch werk (in vitro en in vivo) functioneel gebleken in termen van de 
expressie van BDNF. Uitdrukkelijk hebben wij de verwachting getoetst dat het met allel, het risico allel op 
deze locus, is gerelateerd aan depressie gerelateerde fenotypen, waaronder de DSM-IV depressie diagnose, 
cognitief functioneren en hippocampale morfologie en functionaliteit. Belangrijk is dat de effecten van 
blootstelling aan trauma en stress ook zijn gemodelleerd in deze studies, naast hun potentiële interactie 
effecten met BDNF val66met. De verwachting betreffende dit laatste effect was dat dragers van een met 
allel met name in aanwezigheid van trauma en/of stress blootstelling slecht af zouden zijn betreffende de 
aan depressie gerelateerde fenotypen die wij als uitkomstmaat gekozen hebben (e.g., de ernst van de 
symptomen). 
 
Bevestigende verwachtingen: de neurotrofe hypothese - BDNF val66met 
Een eerste bevinding in hoofdstuk 7 die de neurotrofe hypothese in zekere mate lijkt te bevestigen is een 
val66met - trauma interactie-effect op de serum BDNF-spiegels. Dit effect is zodanig dat dragers van een 
met allel lagere BDNF-spiegels hebben in vergelijking tot val/val homozygoten, maar alleen wanneer zij zijn 
blootgesteld aan trauma in de jeugd. In tegenstelling tot wat was verwacht hadden met drager die 
aangaven getraumatiseerd te zijn geen ander klinisch profiel (bijvoorbeeld de ernst van de depressie was 
vergelijkbaar). De klinische relevantie van dit interactie effect blijft dus vooralsnog onduidelijk. 
     Naast deze intrigerende bevinding rapporteren wij in hoofdstuk 8 lagere hippocampale volumes in 
dragers van een met allel ten opzichte val/val homozygoten. Tenslotte vonden wij in dit hoofdstuk ook dat 
hippocampale activiteit tijdens het ophalen van negatieve woorden uit het geheugen hoger is in dragers 
van een met allel relatief tot dat van val/val homozygoten. Deze bevindingen lijken in overeenstemming 
met de gedachte dat het met allel een risico allel is waar het gaat om aan depressie gerelateerde 
fenotypes. 
     Echter, ook met betrekking tot het val66met polymorfisme worden in dit proefschrift bevindingen 
gerapporteerd die afwijken van de voorspellingen door de neurotrofe hypothese. Deze inconsistenties 
worden in de alinea hieronder beschreven. 
 
Niet bevestigende verwachtingen: de neurotrofe hypothese - BDNF val66met 
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Inconsistent met de neurotrofe hypothese zijn de bevindingen in hoofdstuk 7 en 8 dat val66met niet (direct) 
is gerelateerd aan psychopathologie, cognitief functioneren, serum BDNF-spiegels, noch aan hippocampale 
activiteit. Gerelateerd is dat de constellaties van gebeurtenissen of omstandigheden die een effect op 
serum BDNF-spiegels en hippocampale coderings-activiteit hadden (dat is, het met allel plus blootstelling 
aan trauma) geen effect hadden op uitkomsten op gedragsniveau (hoofdstuk 7 en 8). Ten slotte, en 
misschien wel het meest overtuigend, suggereert de meta-analyse in hoofdstuk 9 dat val66met niet is 
geassocieerd met het volume van de hippocampus. De studie in hoofdstuk 9 is verder opmerkelijk omdat 
het wijst op de verstorende effecten van kleine steekproeven en overschatte effect-groottes. Hiermee is de 
boodschap van dit paper ook relevant voor hersenonderzoek naar de impact van andere kandidaat genen, 
ook buiten het val66met onderzoeksveld om.  
     Gezien deze bevindingen, en andere recente en betrouwbare literatuur concludeer ik dan ook dat het 
bewijs voor BDNF val66met als model voor neurotroof functioneren tanende is. 
 
Conclusie 
Bevestigende onderzoeksbevindingen scheppen vertrouwen in een theorie of hypothese. Dit proefschrift 
brengt, naast enkele resultaten die consistent lijken te zijn met de neurotrofe hypothese, grotendeels 
inconsistenties betreffende het raamwerk van voorspellingen die deze hypothese naar voren brengt. Waar 
wel consistente bevindingen  zijn gevonden (bijvoorbeeld abnormaal lage serum BDNF-spiegels in de 
depressieve toestand), is de betekenis vaak niet duidelijk (bijvoorbeeld omgekeerde causaliteit). Ik 
concludeer derhalve, terwijl ik de beperkingen van het onderzoek in acht neem, dat de neurotrofe 




Op een aantal fronten zijn doelstellingen te formuleren die kunnen leiden tot vooruitgang in het 
onderzoeksveld waar ik de afgelopen jaren in actief ben geweest. De doelstelling die naar mijn mening van 
het grootste belang is, is om beter te begrijpen  wat de lage BDNF-spiegels veroorzaakt bij depressieve 
mensen (construct validiteit) en wat de functionele gevolgen hiervan zijn voor de gezondheid (predictieve 
validiteit). Daarnaast zal de temporele dynamiek zoals die is gespecificeerd in de neurotrofe hypothese 
grondig onderzocht moeten worden. De stand van zaken is nu zo dat omgekeerde causaliteit waarin lage 
neuronale ondersteuning door BDNF niet het begin is van een depressieve episode, maar een gevolg ervan 
(construct validiteit) niet uitgesloten kan worden. Verder zal de aandacht gericht moeten worden op 
grootschalige samenwerkingsverbanden en data-sharing om op solide wijze antwoord te kunnen geven op 
een aantal openstaande vragen (statistische en construct validiteit). Andere uitdagingen zijn onder meer: (I) 
onderzoek waarin meerdere parameters voor neurotroof functioneren en voor gerelateerde biologische 
processen worden gemeten, (II) om het preklinische en klinische onderzoek meer bij elkaar te brengen en 
(III) de brede diagnostische categorieën in de studie van neurotroof functioneren te verlaten (construct 
validiteit). Door dit alles kan vooruitgang worden geboekt en zal de vraag of de neurotrofe hypothese nog 
lang zal schitteren misschien kunnen worden beantwoord, wellicht vergezeld van nuttige informatie voor 








DEUTSCHE ZUSAMMENFASSUNG UND SCHLUSSFOLGERUNGEN 
 
Die Rolle von BDNF in depressive Störungen 
 
HINTERGRUND 
Wo angenommen wird, sind Neurotrophe Faktoren sehr wichtig für das normale Funktionieren der 
neuronalen Plastizität, fur Gedächtnis, Lernen und fur Stimmung. Die Neurotrophine Brain-Derived 
Neurotrophic Factor (BDNF) ist der wichtigste Vermittler von neurotrofe Unterstützung und es wurde 
erklärt, dass durch die Regulierung von BDNF kennen zu lernen das Verständnis von verschiedenen 
psychiatrischen Erkrankungen erhöht werden kann. Nach der Neurotrofe Hypothese entstehen depressive 
Störungen durch abweichende neurotrophe Unterstützung durch BDNF in Hirnregione die Emotionen 
regulieren. Im Laufe der Jahre hat sich diese Hypothese an stabilen Beweise gewonnen. Darüber gibt es 
Grund zu der Überzeugung, dass periphere Maßnahmen (z. B. BDNF-Spiegel im Blut) und bestimmte 
genetische Varianten (z. B. BDNF val66met) als Fenster für neurotrophic Aktion im Gehirn funktionieren 
kann. 
      Allerdings, inmitten einer Menge Aufregung besteht Unsicherheit über die Vorhersagen der 
Neurotrophin Hypothese. Quellen der Unsicherheit betrachten einen Mangel an Wissen über die 
Determinanten von Serum BDNF-Spiegel und wichtige klinische Fragen die bislang unbeantwortet sind. In 
dieser Arbeit richtete ich mich genau auf diese Punkten, um so ein verfeinertes Modell des (peripheren) 
neurotrophischen funktionieren in depressiven (und verwandte) Erkrankungen zu bieten. Eine Kraft von der 
aktuellen Arbeit ist, dass sie is basiert auf große Einzelstudien und Meta-analytische Techniken. 
     Die empirischen Daten, die die Grundlage von dieser Arbeit machen, und eine Diskussion über sie, sind 
in den vorangegangenen Kapiteln dargestellt. Eine Zusammenfassung der Studien und der Hauptpunkte der 
Diskussion wird im folgenden Abschnitt vorgestellt. 
 
ERGEBNISSE 
Im Folgenden werden die Ergebnisse unserer empirischen Studien präsentiert (nach Kapitel) neben der 
Bedeutung, die ich glaube dass sie möglicherweise hatten. Das erste Ziel dieser Arbeit, das abzugrenzen der 
Serum BDNF-Spiegel Determinanten, wird in Kapitel 2 und 3 angegeben. Die Kapitel 4 bis 9 beantworten 
die klinischen Fragen. 
 
TEIL I: Determinanten  
Kapitel 2 bietet eine detaillierte Beschreibung der Determinanten von Serum BDNF-Spiegeln. Es zeigt , bei 
Personen die unbehandelt mit Antidepressiva und frei von einer aktuellen psychiatrischen Krankheit sind, 
dass eine nicht nüchternen Zustand zum Zeitpunkt der Blutprobe, spätere Blutprobe am Tag, eine längere 
Lagerzeit von Blutserum und Binge Trinken alle im Zusammenhang mit abgeschwächten Serum BDNF-
Spiegels sind. Dies im Gegensatz zum Rauchen und das Leben in einem städtischen Gebiet, das mit einem 
erhöhten BDNF-Spiegel verbunden war. Schließlich hatten ältere Probanden höhere Serum BDNF-Spiegels, 
aber dies erwies sich besonders für Frauen (i.e., eine Geschlecht-Alter Interaktionseffekt). 
     Der Hauptgedanke dieser Arbeit ist, dass sie die Determinanten von Serum BDNF-Spiegels skizziert. 
Hiermit bietet sie eine verbesserte Basis, um interindividuelle Unterschiede im Serum BDNF-Spiegels zu 





In Kapitel 3 untersuchten wir saisonalen Regulierung von Serum BDNF-Spiegel. Analysen nach Monat der 
Probenahme zeigten ausgeprägte saisonalen Schwankungen. BDNF-Spiegels im Serum erhöhten sich über 
den Frühjahr-Sommer Zeitraum und verringerte sich über den Herbst-Winter Zeitraum. Die natürliche 
Tageslänge und die Anzahl der Sonnenstunden (wichtigsten Auslöser der Saisonalität im allgemein) in den 
Wochen vor der Blutprobe waren positiv korreliert mit Serum BDNF-Spiegel. 
     Diese Erkenntnisse erhöhen das verstehen von den Faktoren, die BDNF Expression regulieren. Außerdem 
sind die hier berichteten Ergebnisse von entscheidender Bedeutung in der Gestaltung und Auswertung von 
Studien zu BDNF. 
 
TEIL II: der Neurotrophine Hypothese 
Im 4. Kapitel wir das Verständnis über die Zusammenhänge zwischen Serum BDNF-Spiegel und 
Depressionen erhöht. Daten zeigten das Serum BDNF-Spiegel niedriger sind in Antidepressivum freien 
Patienten in Bezug zu Kontrollen und Patienten die mit einem Antidepressivum behandelt wurden sein. 
Serum BDNF-Spiegels von Personen mit eine depressiven Erkrankung in vollständige Remission waren 
vergleichbar mit denen von gesunden Kontrolle Personen. Die Analysen zeigten weiter das BDNF-Spiegel 
nicht zusammenhängen mit der Schweregrad von Depression. 
     Dieses Paper zeigt, dass niedrige Serum BDNF-Spiegel ein Zustand Merkmal für Depression sind, die sich 
im Verlauf der natürlichen Remission und Behandlung mit einem Antidepressivum normalisiert. Wichtig ist, 
dass die Effekt-größen dieser Verbände klein sind und das die Normalisierung der Serum BDNF-Spiegel 
nicht unbedingt mit einer Entlastung von depressiven Symptomen zusammenhängt. 
 
Kapitel 5 berichtet die Ergebnisse von mehreren Meta-Analysen auf Unterschiede im Serum BDNF-Spiegels 
in Antidepressivum freien depressiven Patienten im Vergleich zu gesunden Kontrolle Personen und mit 
Antidepressiva behandelten depressiven Personen. Das Paper zeigt niedrige Serum BDNF-Spiegels in 
Antidepressivum freien Patienten im Verhältnis zu gesunden Kontrollen und Antidepressiva behandelten 
Patienten. Wenn die Analysen für Publikations-bias kontrolliert werden dann scheinen die Effekt-größen 
über diese Verbände klein bis mittel-Groß am besten zu sein. Dieses Paper zeigt ferner, im Gegensatz zu 
früheren Überzeugung das Serum BDNF-Spiegels und die Schwere der Symptome der Depression nicht 
verwandt sind. 
     Dieses Papier ist bemerkenswert, nicht, dass es bestätigt dass Wechsel in Serum BDNF-Spiegels 
peripheren Manifestationen von Depression scheinen zu sein, aber dass es zeigt, dass der Beweis dafür 
wesentlich schwächer ist als ursprünglich angenommen wurde. Eine wichtige Implikation dieser Nachricht 
ist, dass Serum BDNF-Spiegels von wenig klinischen Einsatz sind. 
 
In Kapitel 6 forschen wir Serum BDNF-Spiegels in Patienten mit einer Angststörung und in gesunden 
Kontrollpersonen. Im allgemein fanden wir keine Unterschiede im Serum BDNF-Spiegels bei Patienten und 
Kontrollen. Eine Gender-Diagnose-Interaktion auf Serum BDNF-Spiegels wurde jedoch nachgewiesen. Diese 
Interaktion zeigt das weibliche Patienten mit einer Angststörung, niedrigere Serum BDNF-Spiegels hatten 
im vergleich zu weiblichen Kontrollen. Dies wurde nicht bei Männern beobachtet. Weitere Forschung 
zeigten das Serum BDNF-Spiegel nicht verwandt sind mit den klinischen Charakteristiken von Angst. 
     Angststörungen sind in vielen Aspekten ähnlich an Depression. Um diesen Grund war es zu erwarten, 
dass Serum BDNF-Spiegel niedrig waren bei Patienten mit einer solchen Krankheit. Außer etwas niedriger 
Serum BDNF-Spiegels bei weiblichen Patienten, könnte dieses Paper die Erwartung nicht bestätigen. Dieser 
Befund legt nahe, dass BDNF vielleicht eine Rolle spielt in der Pathophysiologie der Angst bei Frauen, oder, 




Kapitel 7 erforscht das vermuten das BDNF val66met in Relation steht mit Serum BDNF-Spiegeln und ob dies 
abhängig ist von Kindheitstrauma oder andere Formen von Stress. Insgesamt war erfüllt das met Allel 
Träger niedrige Serum BDNF-Spiegel hatte, aber allein  wenn sie zu Missbrauch in der Kindheit ausgesetzt 
werden. Außerdem, wenn nicht zu Missbrauch ausgesetzt, hatte met Allel Träger höhere Serum BDNF-
Spiegels im Vergleich zu val/val Individuen (das ist eine val/met - Missbrauch Interaktionseffekt). Die 
Exposition zu Stressoren in der jüngsten Vergangenheit war mit einer kleinen Reduzierung der BDNF-
Spiegels verbunden. 
     Trauma oder Stressbelastung ist nach der Neurotrophin Hypothese der Erklärung der niedrige BDNF-
Spiegels in Personen mit einen depressive Erkrankung. Dieses Paper kann diese Erklärung nicht bestätigen. 
Außerdem berichtete das Paper eine val66met - Kindheitstrauma Interaktionseffekt auf Serum BDNF-
Spiegels. Die Ausmaß, in welche diese Interaktion wichtig ist (auf verschiedenen Ebenen der Funktion) 
benötigen zukünftige Forschung. 
 
In Kapitel 8 entwirren wir, ob Hippocampusvolumen/funktion und kognitive Leistung abhängig sind von 
Variationen in BDNF val66met. Strukturelle und funktionelle MRI Daten wurden verwendet um diese 
aufzuklären. Unsere Ergebnisse zeigten etwas kleineren Hippocampus-volumen in Träger von einer met 
Allel relativ zu val/val Homozygoten. Für Hippocampus-kodierung Aktivität finden wir ein val66met - Wort 
Valenz Wechselwirkung, so dass Träger eines met Allel erhöhte Aktivität zeigte in Reaktion auf emotional 
beladene Wörter. 
     Diese Ergebnisse, obwohl sie noch  repliziert werden müssen, werfen die Frage auf, ob met Allel Träger 
eine abnormale Gehirnantwort auf emotionale beladen Stimuli zeigen. Neben den neurobiologischen 
Unterschiede beobachtet, konnte aber keine Effekte wurden gefunden auf Verhalten und Kognition. 
 
Kapitel 9 enthält eine Meta-Analyse über die Assoziation zwischen BDNF val66met und das Hippocampus-
volumen. Die Ergebnisse zeigten, dass Träger eines met Allel niedriger Hippocampus-volumen hatten im 
vergeleich zu val/val Homozygoten. Zwischen-Studie Heterogenität in der Effekt-größen war aber sehr 
erheblich, und dies könnte nicht von demographischen, klinischen und methodischen Unterschiede 
zwischen den Studien erklärt werden. Wir fanden starke Hinweise auf Publikations-bias und Effekt-größen 
verringerten sich wesentlich über die Jahre. Diese alle zusammen zeigen dass niedrigere Hippocampus-
volumen keine biologische Wirkung des met Allels sind, sondern ein methodisches Artefakt. 
     Der Erkenntnis der niedrige Hippocampus-volumen in Träger einer met Allel hat sich erfüllt wie eine 
Grundlage für die neurotrophinn Hypothese (gesamte Zitate nach das erste Papier auf dieses Vereins 
[Pezawas et al., 2005] > 500). Die Meta-Analyse zeigt im Gegensatz, dass es nicht existiert und 
wahrscheinlich ein Artefakt ist von Studien mit unzureichende statistische power ist. 
 
METHODEN 
Bevor ich ihnen die Highlights der Diskussion und meine Schlussfolgerungen präsentiere, möchte ich die 
wichtigsten Stärken und Mängel der Methoden, die in dieser Arbeit verwendet wurden berichten, da diese 
bei der Interpretation der Ergebnisse sehr wichtig sind. 
     Eine deutliche hervorstechendes Stärke ist, dass die Studien in dieser Arbeit zureichende statistische 
power haben. Hiermit liefert diese These zuverlässige Schätzungen von wahre Effekt-Größen (Big Data 
Notable Fidelity). Eine weitere Stärke ist, dass eine hohe Validität erreicht wurde durch Anpassung für 
potenzielle Störfaktoren und durch Subgroup- und Moderation Analysen. Außerdem habe ich aktiv versucht 
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festzustellen, wie zuverlässig unsere Forschungsergebnisse waren durch die Durchführung von Meta-
Analysen. 
     Ich bin mir trotzdem sehr bewusst von den Grenzen der Studien in dieser These. Zuerst sind unsere 
Schlussfolgerungen abhängig von periphere Maßnahmen um ein zentrales Prozess, die neuronale 
Plastizität, zu schätzen. Zweitens, diese These erarbeitet meist auf Querschnittsdaten und in keiner der 
Studien wurden die Teilnehmer nach dem Zufallsprinzip zugeordnet. Um diesen Grund sind die berichteten 
Ergebnisse nicht überzeugend genug um Kausalität zu beweisen. Zum Schluss sind die Ergebnisse in dieser 
These nicht (direkt) zu verallgemeinern auf alle Bevölkerungsgruppen, vor allem nicht auf den jungen, alten 
und schwer kranken. 
 
DISKUSSION 
Diese Arbeit hat zwei wichtige Elemente an der Literatur hinzufügen: (I) einen Überblick über die 
Determinanten des Serum BDNF-Spiegels und (II) es löst einige wichtige klinische Fragen in Bezug zu der 
Neurotrofe Hypothese. Zusammen haben diese Resultate erhebliche methodische und theoretische 
Implikationen, die im Folgenden zusammengefasst werden. Ich werde mit den Erkenntnissen über die 
Determinanten des Serum BDNF-Spiegels starten. 
 
Teil I: Determinanten der Serum BDN-Spiegels 
Das Verständnis der Determinanten eine Variable ist wichtig, um in der Forschung zu gültige 
Schlussfolgerungen zu kommen. Die ersten beiden Kapitel dieser Doktor Arbeit sind gewidmet zur 
Definition die Determinanten der Serum BDNF-Spiegels zu kommen. 
     Diese Arbeit beschreibt eine Liste von Variablen die systematisch mit Serum BDNF-Spiegels zugeordnet 
sind. Diese Liste enthält einige Variablen die, wenn nicht gut unter Kontrolle gehalten werden, einfach zum 
ungültige Schlussfolgerungen in die Prüfung der Vorhersagen. Zum beispiell, es ist eine Tatsache, dass die 
Prävalenz der Depression im Winter höher ist als im Sommer. Die starke Saisonalität im Serum BDNF-
Spiegels (Kapitel 3), zusammen mit der höheren Prävalenz der Depression im Winter, deutet darauf hin, 
dass die Kontrolle für die Saison in denen die Probanden wurden getestet, wichtig sein kann, wenn man 
zum Beispiel der Unterschied im Serum BDNF-Spiegels zwischen depressiven Patienten und gesunden 
Kontrollen testet. Unsere Daten zeigen, dass dies in der Tat scheint so ist, da der Effektgröße überdiese 
Assoziation um 40 Prozent sinkt wenn eine für die Saison in denen die Probanden wurden getestet 
korrigiert.  
     Unter anderem aus diesem Grund, laden die Ergebnisse aus Kapitel 2 und 3 ein zu eine Perspektive auf 
BDNF-Forschung, in welchen Determinanten integriert sind. 
 
Teil II: der Neurotrofe Hypothese 
Serum BDNF-Spiegels - bestätigende Ergebnisse 
Im Einklang mit der Neurotrofe Hypothese zeigen Kapitel 4 und 5 das Serum BDNF-Spiegel niedrig sind in 
Antidepressivum freien depressiven Patienten in Bezug auf Kontrollen und depressiven Patienten die mit 
einem Antidepressivum behandelt wurden. Die Daten aus Kapitel 4 und 5 zeigen weiter, dass die Serum 
BDNF-Spiegel von vollständig überwiesen Personen vergleichbar sind mit denen von gesunden Kontrollen. 
So niedrige Serum BDNF-Spiegels sind ein Zustand Merkmal von Depression: niedrig während der 
depressiven Zustand und normiert in voller Remission. Ebenfalls in Übereinstimmung mit was erwartet 
wurde, ist dass Serum BDNF-Spiegel normalisieren im Laufe der Behandlung mit Antidepressiva. Al diese 
Erkenntnisse sind robust, da sie von der größten einzige Studie (Kapitel 4) abgeleitet sind und durch Meta-
Analysen (Kapitel 5) bestätigt wurden. Eine Erweiterung von der Neurotrofe Hypothese aus unsere Arbeit 
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ist das wir finden, dass weibliche Patienten mit einer Angststörung niedrigere BDNF-Spiegels haben im 
Verhältnis zu weiblichen Kontrollen (Kapitel 6). Dies heißt, dass BDNF in der Pathophysiologie von Angst bei 
Frauen beteiligt sein kann. Schließlich, und auch die Erwartungen bestätigend, zeigen wir dass die 
Exposition auf kürzliche belastende Ereignisse, z. B. eine Trennung (im allgemeinen einen ätiologischer 
Risikofaktor für die Entwicklung einer depressiven Erkrankung) im Zusammenhang sind mit einem (kleinen) 
Rückgang des Serum BDNF-Spiegels (Kapitel 7) . 
     Trotz dass diese Ergebnisse bestätigend sind, ist die Bedeutung von ihnen nicht immer klar (z. B. 
umgekehrte Kausalwirkung). Dabei zeigt ein Teil unserer Daten eine mangelnde Anpassung mit den 
Erwartungen aus der Neurotrofe Hypothese. Diese nicht bestätigende Ergebnisse werden diskutiert in der 
nachfolgenden Abschnitt. 
 
Serum BDNF-Spiegel – nicht bestätigende Ergebnisse 
Eine erste Feststellung, die nicht die Erwartungen von der Neurotrofe Hypothese folgt, ist das depressive 
Patienten, die in der frühen Remissionsphase ihrer Episode sind, und damit weitgehend beschwerdefrei 
waren, Serum BDNF-Spiegels hatte die niedriger sind im Vergleich zu den in derzeit depressiven Patienten 
(Kapitel 4). Diese Feststellung bezieht sich nicht gut auf die Erwartung der Neurotrofe Hypothese, dass 
niedrige neurotrofe Unterstützung ein Risiko für die Entwicklung einer Depression ist (d. i., niedriges BDNF 
→ Depression). In der Tat deutet diese Feststellung auf umgekehrten Kausalität, in dem niedrigere Serum 
BDNF Konzentrationen eine Folge sind von Depressionen (d. i., Depression → niedrigen BDNF). 
     Weitere Ergebnisse in Kapitel 4 und 5 , die sich nicht gut auf die Neurotrofe Hypothese beziehen, sind 
das BDNF-Spiegel nicht zu den klinischen Merkmale von eine Depressive Krankheit, wie der Schweregrad, 
verwandt sind und dass die Hochregulierung des Serum BDNF-Spiegels im Verlauf der antidepressiven 
Behandlung nur bei einer beschränkten Anzahl an Antidepressiva ein Effekt zeigt. Die Feststellung, dass 
BDNF-Spiegels und klinischen Merkmale von eine Depressiven Krankheit (bemerkenswerte die Schwere der 
Symptome) nicht Zusammenhängen, folgt nicht der Logik der linearen Dynamik der Neurotrofe Hypothese, 
aus dem es vorhergesagt werden kann das Patienten mit einem höheren Schweregrad der Symptome 
besonders niedrigen neurotrofe Unterstützung zeigen sollten. Bitte beachten Sie, dass in Kapitel 5 dieser 
Arbeit, durch Meta-Analyse, die Abwesenheit von diesem Effekt robust bestätigt war. Die Feststellung von 
spezifischen Auswirkungen der Antidepressiva auf die Serum BDNF-Spiegels scheint im Widerspruch zu der 
Vorhersage der Neurotrofe Hypothese, dass ein erhöhter BDNF-Spiegel ein wichtiger Vermittler für ein 
Antidepressivum Reaktion ist. Nach dieser Vorhersage könnte man erwarten, dass Antidepressiva die in der 
Behandlung von Depressionen genau ebenso wirksam sind, ähnliche Auswirkungen auf die BDNF-Spiegel 
haben würden. Eine weitere und damit verbundene Feststellung die auch schwer mit der Neurotrofen 
Hypothese in Einklang zu bringen ist, ist dass die Gruppe der depressiven Personen die mit Antidepressiva 
behandelt war (für einen längeren Zeitraum und auf einer häufigen Basis) die höchsten BDNF-Spiegeln 
hatten neben dem höchsten Schweregrad der Depression (Kapitel 4). Dies heißt dass Erhöhungen in BDNF-
Spiegels die offensichtlich im Verlauf der Behandlung auftreten, nicht parallel laufen mit die klinische 
Wirksamkeit von Antidepressiva. 
     Etwas das Kapitel 5 addiert zu den oben erwähnten Verbänden ist, dass die Literatur weniger zuverlässig 
ist als wie man hoffen würde (z. B. Publikation-Bias). In der Tat, und im Gegensatz zu früheren Daten und 
Gewissen, sind die Effekt-Größen auf die Unterschiede zwischen den Gruppen nur klein und damit sind 
(Änderungen) in Serum BDNF-Spiegels wahrscheinlich von wenig klinische Verwendung (z. B. als Diagnostik 
Biomarker). 
     In Kapitel 6 war die Erwartung, dass Serum- BDNF-Spiegel sind bei Menschen in einem ängstlichen 
Zustand. Die Daten ergaben jedoch wenig Grund zu dieser Annahme. Bei männlichen Patienten mit einer 
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Angststörung gab es sowieso keine Auffälligkeiten in Serum BDNF-Spiegeln. Bei weiblichen Patienten mit 
einer Angststörung fanden wir etwas niedrigere BDNF-Spiegeln im Vergleich zu gesunden Frauen. Daher 
werden die Daten in diesem Kapitel bezeugen, dass BDNF nicht in der Pathophysiologie der Angststörungen 
per se beteiligt ist. Und wie erklärt (z. B. in die Diskussion über das Verhältnis zwischen BDNF-Spiegels und 
Östrogen), kann die Veränderung bei weiblichen Patienten leicht eine bestimmte weibliche Artefakt 
bedeuten, ohne in die Angst Ätiologie ursächlich beteiligt zu sein. 
     Zu Letzt kann Kapitel 7 die vorherrschende Axiom aus der Neurotrofe Hypothese bestätigten, dass 
Traumata die niedrige BDNF-Expression in der depressive Krankheit erklären.  
     Offenbar, Forschungsergebnisse die eine mangelnde Anpassung mit der Neurotrofe Hypothese hatten 
sind offensichtlich in unsere Studien. Ehrlich gesagt, konnten keine der Erwartungen die aus der Neurotrofe 
Hypothese abgeleitet werden können, voll und ganz bestätigt werden. Und wenn bestätigende Ergebnisse 
berichtet wurden, dann war oft ihrer Bedeutung nicht so klar (z. B. umgekehrte Kausalität). Vielleicht sind 
diese Ergebnisse selbst nicht eine ausreichende Disqualifikation von der Neurotrofe Hypothese doch 
zusammen schlagen sie vor, dass die ursprüngliche Idee nicht eindeutig eingehalten werden kann. 
 
Die Neurotrofe Hypothese: BDNF val66met 
In den Kapiteln 7 bis 9 erforschten wir Assoziationen zwischen einer Variante des Gens das für BDNF  
codiert, val66met. Für die ist Funktionalität gezeigt (in vitro und in vivo) in Bezug auf neurotrofe 
Unterstützung. Wir haben ausdrücklich die Erwartung getestet, dass das met-Allel, das sogenannte Risiko-
Allel an diesem Lokus, im Zusammenhang war mit Depressionen Phänotypen, von einer DSM-IV Depression 
Diagnose bis zur kognitive Funktion und Gehirnmorphologie. Wichtig ist das wir in unseren Studien Trauma 
und Stressbelastung sind enthalten neben deren mögliche Wechselwirkungen mit BDNF val66met. Auf der 
Basis der vermuteten Funktionen in diesem Polymorphismus wurde es erwartet, dass die met Allel mit 
etablierten Korrelate der Depression verbunden werden sein soll, ins besonders im Angesicht der Trauma- 
und Stressbelastung. 
 
BDNF val66met - bestätigende Ergebnisse 
Eine erste bestätigende Erkenntnis (Kapitel 7) war ein val66met - Trauma Interaktions-Effekt auf die Serum 
BDNF-Spiegels. Dieses Effekt war so, dass BDNF met Allel Träger reduzierte Serum BDNF-Spiegel hatten, 
aber nur wenn sie ein Trauma erlebt hatten in der Kindheit. Darüber hinaus schienen Träger eines met 
Allels etwas niedrigere Hippocampus Volumen zu haben, bezogen auf val/val Homozygoten (Kapitel 8). 
Schließlich war die Hippocampus Aktivität in reaktion auf negativen Stimuli anders als Funktion der val66met 
und Trauma-Exposition (Kapitel 8). Diese Ergebnisse sind im Einklang mit der Erwartung dass die met-Allel 
ein Risiko-Allel ist wenn an Depression verbündende Phänotypen als Ergebnis genommen wurde. 
     Trotz dieser Erkenntnisse gibt es in dieser Arbeit die notwendigen Befeindungen die nicht im Einklang 
scheinen zu sein mit den Vorhersagen der Neurotrofe Hypothese. 
 
BDNF val66met - nicht- bestätigende Ergebnisse 
Befindungen die nicht im Einklang sein mit der Neurotrofe Hypothese sind unter anderem dass val66met 
nicht (direkt) mit Psychopathologie, kognitive Leistung, Serum BDNF-Spiegel oder Encoding-Aktivität von 
der Hippocampus verbunden ist  (Kapitel 7 und 8). Dabei scheint die Konstellationen der 
Ereignisse/Umstände, die einen Einfluss auf die Serum- BDNF-Spiegel und Hippocampus Encoding-Aktivität 
hatte (d. h. das met Allel und Exposition zu Missbrauch in der Kindheit) nicht mit den erwarteten Effekten 
auf der Verhalten verbunden waren (Kapitel 7 und 8). Schließlich, und vielleicht am meist schlüssig war die 
Studie in Kapitel 9, welche  überzeugend demonstriert dass das val66met nicht mit Hippocampus Volumen 
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verbunden ist. Das Studium im Kapitel 9 ist auch im allgemeinen wichtig weil es die schädlichen 
Auswirkungen von Überschätzungen der Effekt-Größen (die diese und andere Forschungsfelder quälen) 
unterstreicht. Angesichts dieser nicht-bestätigende Befunde glaube ich, dass val66met kein gültiges Modell 
ist um BDNF Funktion zu erforschen. 
 
Abschluss  
Das Vertrauen in eine Theorie nimmt zu, wenn sie von relevanten Daten bestätigt wird. Neben einigen 
konsistente Ergebnisse, zeigen unsere Daten (und auch die von vieler anderen) eine weitgehend fehlende 
universelle Bestätigung der Neurotrofe Hypothese. Und wo erwartete Ergebnisse gefunden werden, (z. B. 
ungewöhnlich niedrige Serum-BDNF-Konzentrationen im de Depressive Zustand), war die Bedeutung oft 
nicht so klar (z. B. umgekehrte Kausalität). Daraus schließe ich, während Nachteile unserer Studien 
anerkannt werden, dass die neuesten und zuverlässigsten Daten, die Neurotrofe Hypothese in seiner 
ursprünglichen Form nicht bestätigen - zurück an den Zeichentisch. 
 
Zukunft der Arbeit - der Zeichentisch 
Eine von den Zielen mit größter Bedeutung ist, um den Mechanismus des neurotrophen funktionieren im 
depressive Zustand kennen zu lernen (d. h. Konstruktvalidität) neben den funktionellen Konsequenzen auf 
die Gesundheit (d. h. Vorhersagevalidität). Daneben erfordert die zeitliche Dynamik wie die in der 
Neurotrofe Hypothese (d. h. geringe Unterstützung BDNF → Depression) beschrieben ist die nötige 
Forschung, weil nun umgekehrte Kausalität, in dem niedrigen BDNF Unterstützung nicht den Anfang 
markiert von einer depressiven Episode, sondern eine Folge davon ist, nicht ausgeschlossen werden kann 
(d. h. Konstruktvalidität). Weitere Herausforderungen die Notwendig sind um Fortschritte zu machen 
umfassen Zusammenarbeit und gemeinsame Nutzung von Daten um auf robuste Weise einige offene 
Fragen zu beantworten (d. h. statistische Validität), um einzelne BDNF Parameter zu messen, um die 
präklinische und klinische Forschung mehr zusammen zu bringen, und in parallel, die breite diagnostischen 
Kategorien des DSM in der Forschung von neurotrofe funktionieren zu verlassen (d. h. Konstruktvalidität ). 
Sobald dies festgestellt werden kann, können Fortschritte gemacht werden, vielleicht am Ende begleitet 



































































RESUMEN ESPAÑOLES Y CONCLUSIONES 
 
El papel de BDNF en la depresión 
 
INTRODUCCIÓN 
Apoyo neurotrófico es ubicuo en el cerebro donde es de importancia para el funcionamiento normal de la 
plasticidad neuronal, la memoria y la emoción. El neurotrófico Brain-Derived Neurotrophic Factor (BDNF) es 
el principal mediador de apoyo neurotrófico y se ha declarado que la comprensión de varias enfermedades 
psiquiátricas se puede aumentar cuando se entendiendo la regulación de esta hormona. De acuerdo con la 
hipótesis de neurotrofina, trastornos depresivos surgen de soporte neurotrófico aberrante por BDNF en 
áreas del cerebro que regulan la emoción. Con los años, esta hipótesis ha ganado apoya. Además, hay 
motivo para la creencia de que las medidas de periféricos (especialmente BDNF concentraciones en la 
sangre) y ciertas variantes genéticas (notablemente BDNF val66met) pueden servir como ventanas para 
funcionamiento neurotrófico en el cerebro. 
      An medio de una gran expectación, sin embargo, hay dudas con respecto a las predicciones de la 
hipótesis neurotrofina. Fuentes de duda incluye una falta de conocimiento sobre los determinantes de las 
concentraciones séricas de BDNF y muchos preguntas clínicas sin respuesta. En esta tesis me dirigí 
exactamente a este fuentes de duda para crear un modelo (periférica) de funcionar BDNF más refinado en 
trastornos depresivos (y afines). Importante para mencionar es que en el trabajo actual las estimaciones del 
efecto sobre las asociaciones de interés se basan en estudios grandes y técnicas meta-analíticas. 
     Los datos empíricos que forman el corazón de esta tesis y una discusión sobre el se presentan en los 
capítulos anteriores. Un resumen detallado se presentará en la siguiente sección. 
 
RESULTADOS 
A continuación, se presentan los resultados de nuestros estudios empíricos (por capítulo) junto con la 
importancia que creo que pueden tener. El primer objetivo de esta tesis, delinear los determinantes de las 
concentraciones séricas de BDNF, se discribe en el capítulo 2 y 3. Los capítulos 4 a 9 estaban destinados a 
las preguntas clínicas en relación con la hipótesis de neurotrofina. 
 
PARTE I: determinantes  
El capítulo 2 establece una descripción detallada de los determinantes de las concentraciones séricas de 
BDNF. Se nota en las personas que no fueron tratadas con antidepresivos y libre de una enfermedad 
psiquiátrica, que un estado de no-ayuno en el momento de la extracción de sangre, una disminución de 
sangre posterior en el día, y un mayor duración del almacenamiento de sangre se asociaron con 
concentraciones de suero BDNF atenuada. Esto fue en contraste con fumar y vivir en una zona urbana, que 
ambos se asociaron con un aumento de las concentraciones de BDNF. Por último, los sujetos de más edad 
tenían concentraciones de BDNF séricos más altos, pero esto aplican sobre todo a las mujeres (es decir, un 
efecto de la interacción entre  edad y género). 
     La importancia de este trabajo es que da los determinantes de las concentraciones séricas de BDNF. Por 
lo tanto este estudio da una base mejorada para comprender las diferencias interindividuales en las 
concentraciones séricas de BDNF. Además,  el conocimiento de los determinantes es esencial en la 
prevención de inferencias erróneas de los datos. 
 
En el capítulo 3 estudiamos arrastre estacional de las concentraciones séricas de BDNF. Los análisis por 
meses de muestreo mostraron una variación estacional pronunciada. Las concentraciones séricas de BDNF 
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aumentaron linealmente durante el período de primavera-verano (es decir, equinoccio de primavera) y 
disminuyeron linealmente durante el período otoño-invierno (es decir, Equinoccio de Otoño). Análisis 
exploratorios mostraron que la longitud natural del día y el número de horas de sol ambiente (principales 
factores para arrastrar estacionalidad) en las semanas previas a la extracción de sangre se correlacionó con 
las concentraciones séricas de BDNF. 
     Estos resultados se suman a la literatura, ya que ellos dan vías para comprender los factores que regulan 
la expresión de BDNF. Además, los resultados presentados en este documento son de vital importancia en 
el diseño y la evaluación de los estudios sobre el BDNF. 
 
PARTE II: la hipótesis de la depresión neurotrofina 
En el cuarto capítulo se avanza la comprensión de las asociaciones entre las concentraciones séricas de 
BDNF y depresión. Encontramos que concentraciones séricas de BDNF son bajos en los pacientes con 
depresión y libre de antidepresivos respecto a los controles y pacientes con depresión que fueron tratados 
con un antidepresivo. Las concentraciones séricas de BDNF de personas totalmente remitidos fueron 
comparables a los de sujetos sanos. Análisis también muestran que las concentraciones de BDNF no 
estaban relacionados con las características clínicas principales de la depresión, tales como su gravedad. 
     Este trabajo pone de manifiesto que las concentraciones de BDNF sérico son una característica del 
estado de depresión que se normaliza en el remisión natural y el tratamiento con antidepresivos. Además, 
este trabajo muestra que los tamaños del efecto sobre estas asociaciones son pequeñas y que la 
normalización de las concentraciones séricas de BDNF no se asocia necesariamente con un alivio de los 
síntomas depresivos. 
 
Capítulo 5 presenta los resultados de varios meta-análisis sobre las diferencias en concentraciones de BDNF 
en pacientes con depresión no tratados de antidepresivos, sujetos control sanos y personas con depresión 
tratados con antidepresivos. El estudio muestra concentraciones de BDNF sérico bajo en pacientes no 
tratados de antidepresivos en relación con controles sanos y  pacientes tratados con antidepresivos. 
Cuando publicación-bias se contabilizó, los tamaños del efecto se convirtieron en pequeña a mediana. Este 
papel muestra además, en contraste con la creencia previa, que concentraciones de BDNF y la gravedad de 
la depresión no están relacionados. 
     Este trabajo es digno de mención, no en que confirma que alteraciones en las concentraciones de BDNF 
parecen ser manifestaciones periféricas de depresión, pero que muestra que la evidencia de esto es más 
delgada como se pensaba inicialmente. Una implicación importante de este mensaje es que las 
concentraciones del BDNF probablemente son de poca utilidad clínica. 
 
En el capítulo 6 se evaluaron concentraciones de BDNF en  pacientes con un trastorno de ansiedad y en 
controles sanos. Generalmente no encontramos diferencias en las concentraciones séricas de BDNF entre 
pacientes y controles. Una interacción género-diagnóstico sin embargo se detectó que indica que los 
pacientes de sexo femenino con un trastorno de ansiedad tenían menores concentraciones séricas de BDNF 
in relación con los controles de sexo femenino. Esto no se observó en los hombres. Un hallazgo adicional 
fue que los concentraciones de BDNF no estaban relacionados con las características clínicas de la ansiedad. 
     Los trastornos de ansiedad imitan la depresión en gran medida, por lo que se espera que 
concentraciones séricas de BDNF serían bajos en pacientes con esa enfermedad. Este documento no 
confirma eso expectativa, excepto que las concentraciones del BDNF estaban algo inferiores en pacientes 
de sexo femenino. Este hallazgo puede sugerir que el BDNF está implicado en la fisiopatología de la 




El séptimo capítulo se dirigió a la presunta efecto del BDNF val66met en BDNF concentraciones, y si, o está 
efecto es condicionado a la exposición al trauma infantil o otras formas de estrés. En general, portadores 
de una met alelo tenian reducido BDNF concentraciones cuando expuestos al abuso en la niñez. Ademas, 
cuando no expuesto a abusos en la infancia, portadores de una met alelo tenian BDNF concentraciones 
superiores a val/val individuos (es decir, un val/met- abuso en la niñez efecto de la interacción). La 
exposición de estrés recientes se asoció con una pequeña disminución en las concentraciones de BDNF. 
      Trauma o estrés exposición son acordeó a la hipótesis de neurotrofina, el axioma que explique BDNF 
concentraciones reducidos en personas con depresión. Este documento no confirma esta idea. Aquí se hace 
reportar un val/met - abuso efecto de la interacción en las concentraciones séricas de BDNF. El grado en 
que esta interacción puede ser importante (en varios niveles de funcionamiento) será explorado en la 
investigación futura. 
 
Capítulo 8 desentrañar si el volumen y el funcionamiento del hipocampo y el rendimiento cognitivo están 
relacionados con variación en BDNF val66met. MRI datos estructurales y funcionales mostraron volúmenes 
del hipocampo ligeramente más pequeñas en los portadores de un met alelo en relación con los 
homocigotos val/val. Para la actividad del hipocampo codifica encontramos una interacción de valencia de 
estimulos y val66met tales que los portadores de un met alelo se mostraron mayores niveles de actividad en 
respuesta a las palabras emocionales. 
     En este trabajo se promueve la comprensión de la asociación de BDNF val66met con el 
volumen/funcionamiento del hipocampo y el rendimiento cognitivo. Encontramos un pequeño efecto de 
val66met en el volumen del hipocampo. Tambien encontramos que el abuso de la niñez explica diferencias 
individuales en la actividad de la codificación del hipocampo. Este último efecto se manifiesta de forma 
diferente en función de val66met. Estos resultados, aunque en necesidad de replicación, plantear la 
cuestión de si los portadores de un met alelo muestran una respuesta abnormal del cerebro en los 
estímulos emocionales cargados. Este mensaje viene con la noción de que no se observaron efectos en el 
comportamiento junto con las diferencias neurobiológicos. 
 
Capítulo 9 contiene una revisión y meta-análisis de la asociación entre el BDNF val66met y el volumen del 
hipocampo. Los resultados mostraron que los portadores de un met alelo tenían volúmenes del hipocampo 
algo más bajos en relación con los homocigotos val/val. Heterogeneidad entre los estudios en las 
estimaciones del tamaño del efecto fue considerable y esto no se puede explicar por las diferencias 
demográficas, clínicas y metodológicas entre los estudios. Hemos encontrado una fuerte evidencia de 
publicación-bias y los tamaños del efecto se redujeron considerablemente en los últimos años. Todo esto 
llevó a la conclusión de que los volúmenes de hipocampo inferiores no son un verdadero efecto biológico 
del met alelo, sino más bien un artefacto metodológico. 
     La idea de que los volúmenes del hipocampo son bajas en portadores de un met alelo se ha convertido 
en un pilar para la hipótesis neurotrofina (total de citas para el primer artículo sobre esta tema [Pezawas et 
al., 2005] es más de 500). El meta-análisis sobre este tema se muestra que esta asociación es inexistente y 
probablemente un artefacto debido a la utilización de estudios de poca potencia. 
 
MÉTODOS 
Antes de presentar los aspectos más destacados de la discusión y mis conclusiones, presentaré en breve las 
principales fortalezas y limitaciones de los métodos que se he utilizado en esta tesis ya que deben reflejarse 
en estos cuando interpretar los resultados se presente en este Thesis. 
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     Una fortaleza más destacada es que, básicamente todos los estudios en esta tesis son basados en 
estudios de mucha potencia estadistica. Por eso presentamos estimaciones del tamaño del efecto 
confiables (Big Data Notable Fidelity). Otro punto fuerte es un nivel de validez alto por que los resultas se 
logró estaba ajuste para posibles factores de confusión y analysis de subgrupos y moderación. Además, yo 
busqué activamente para determinar el grado de fiabilidad de nuestros resultados a cabo de meta-análisis. 
     También estoy muy consciente de las limitaciones de los estudios en mi tesis. En primer lugar, nuestras 
conclusiones están supeditadas a las medidas de periféricos para medir un proceso central: de la 
plasticidad neuronal. En segundo lugar, esta tesis elaborada principalmente en datos cross-sectional y en 
ninguno de los estudios los sujetos fueron asignados ad random a las condiciones en que se encontraban. 
Por lo tanto los resultados reportados no son suficientemente convincentes para demostrar causalidad. Por 
último, los resultados en este documento no se generalizan (directamente) a todas las poblaciones, en 
particular, no a los jóvenes, los viejos y los enfermos graves. 
 
DISCUSIÓN 
En esta tesis logramos dos cosas importantes: (I) presentamos los determinantes de las concentraciones 
séricas de BDNF y (II) resolvemos algunas preguntas clínicas con respecto a la hipótesis de la neurotrofina. 
En conjunto, estos logros tienen implicaciones metodológicas y teóricas importantes que se resumen a 
continuación. Comenzo con las conclusiones sobre los determinantes de las concentraciones de BDNF. 
 
Parte I: determinantes de los niveles séricos de BDNF 
Comprensión sobre determinantes de una variable es vital para venir a conclusiones válidas. Los dos 
primeros capítulos de esta tesis se describen los resultados de nuestros esfuerzos para comprender los 
determinantes de los niveles séricos de BDNF.  
     En esta tesis se descubre una serie de variables que se asocian sistemáticamente con los niveles séricos 
de BDNF, incluye algunas que cuando no se controlar adecuada, se puede venir fácilmente a conclusiones 
no válidas. Un ejemplo que ilustra esto bien es el efecto estacional de los niveles séricos de BDNF (Capítulo 
3). Es un hecho que la prevalencia de la depresión es mayor en invierno en comparación con el verano. La 
estacionalidad en los niveles séricos de BDNF que nosotros encontramos, junto con la mayor prevalencia de 
depresión en el invierno, sugiere que uno debe controlarse para la temporada cuando se estudia, por 
ejemplo, la diferencia en los niveles séricos de BDNF entre los pacientes deprimidos y controles sanos. 
Nuestros datos muestran que esto parece ser cierto, ya que el tamaño del efecto disminuye por no menos 
de 40 por ciento cuando los análisis están controlada para la temporada en la que se hicieron las 
mediciones. 
     Así, nuestro grupo ha aumentado la comprensión de los factores determinantes de los niveles séricos de 
BDNF. Y claro, todos los hallazgos de Capítulo 2 y 3 invitar a una perspectiva en que estos determinantes 
están integrados. 
 
Parte II: determinantes de los niveles séricos de BDNF 
Las concentraciones séricas de BDNF - observaciones confirmatorias 
En la línea con lo que se esperaba, el capítulo 4 y 5 muestran que las concentraciones séricas de BDNF son 
bajos en los pacientes con depresión no tratados de antidepresivos al respecto a los controles y los 
pacientes con depresión que fueron tratados con un antidepresivo. Los datos de capítulo 4 y 5 además 
indican que las concentraciones séricas de BDNF de personas totalmente remitidos son comparables a los 
de controles sanos. Así, las concentraciones de BDNF sérico bajo son una característica de estado de 
depresión: evidente durante el estado de depresión y normalizó en remisión completa. También en la línea 
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de lo que se esperaba es que las concentraciones séricas de BDNF se normalizan en el curso del 
tratamiento antidepresivo. Todos estos resultados son robustos, ya que se derivan de la estudio más 
grande (capítulo 4) y son confirmados por meta-análisis (capítulo 5). Además, encontraron una extensión 
de la hipótesis de neurotrofina. Es que las pacientes mujeres con un trastorno de ansiedad tienen menores 
concentraciones de BDNF en relación con controles sanos (capítulo 6). Por eso, BDNF podría estar 
implicado en la fisiopatología de la ansiedad en las mujeres. Por último , y también siguiendo la expectativa 
es que la exposición a de estrés recientes, como ser despedido (un factor de riesgo general para una 
enfermedad depresiva), se asoció con una (pequeña) disminución de las concentraciones séricas de BDNF 
(capítulo 7) . 
     Aunque estos resultados eran confirmatoria con el hipótesis de neurotrofina, que exactamente significa 
no siempre eran tan  claro (por ejemplo, los resultados pueden significar la causalidad inversa, para ser 
discutido). Además, una parte de los datos sobre las concentraciones de BDNF no se confirmó a las 
expectativas de la hipótesis de neurotrofinas. Los hallazgos no confirmatorias están el tema de la parte que 
sigue. 
 
Las concentraciones séricas de BDNF – observaciones non confirmatorias  
Una primera constatación que no está en línea con las expectativas que se encontraban en este tesis es que 
los pacientes con depresión en la fase de remisión temprana de su episodio depresivo, y por lo tanto en 
gran medida libres de síntomas, tenían concentraciones séricas de BDNF más bajos en comparación con 
pacientes con una depresión actualmente (capítulo 4). Así, este hallazgo no se refiere a la dinámica 
temporal especificados en la hipótesis de neurotrofina que el apoyo neurotrófico baja debe poner en 
peligro a convertirse en depresión (es decir, bajo el BDNF depresión). De hecho, se sugiere la causalidad 
invertida, donde las concentraciones de BDNF inferiores son una consecuencia de la depresión (es decir, 
depresión  bajo BDNF). 
     Otros hallazgos reportados en el capítulo 4 y 5 que relatan mal con la hipótesis neurotrofina es que 
BDNF concentraciones no se relacionan con las características clínicas de la depresión, tales como su 
gravedad y que la regulación de BDNF en el curso del tratamiento con antidepresivos se limita a algunas 
clases de antidepresivos. El hallazgo sobre la falta de una relación entre las concentraciones de BDNF y las 
características clínicas (notable el gravedad) no confirma la lógica lineal de la hipótesis de neurotrofina, de 
la que se puede predecir que los pacientes con mayor gravedad de los síntomas muestran apoyo 
neurotrófico particularmente baja. Por favor, tenga en cuenta que el capítulo 5, un meta-análisis, confirma 
la ausencia de la asociación entre las concentraciones séricas de BDNF y gravedad de depresión (una 
asociación en la que la literatura tenía mucha fe). El hallazgo de los efectos específicos de antidepresivos en 
las concentraciones del BDNF  contraste con la predicción de la hipótesis de la neurotrofina de que el 
aumento de BDNF es un mediador clave de la respuesta a una antidepresiva. De acuerdo con esta 
predicción se podría esperar que los antidepresivos, que son igualmente eficaces en el tratamiento de la 
depresión, tendrían efectos similares en las concentraciones de BDNF, que (de acuerdo con nuestros datos, 
sino también la de los demás) obviamente no tienen. Otro hallazgo que es difícil de conciliar con la 
hipótesis de neurotrofina es que el grupo de personas con depresión que utilizaron antidepresivos (por un 
período prolongado y sobre una base frecuente) tuvieron los más altos concentraciones de BDNF junto a 
una gravedad de depresión más alta (capítulo 4). El significa de este hallazgo debe ser que los aumentos en 
las concentraciones de BDNF periféricas que ocurren en el curso del tratamiento no van paralela con la 
efectividad clínica de los antidepresivos. 
     Qué capítulo 5 añade con respecto a las asociaciones mencionadas es que la literatura es menos fiable 
como se podía esperar (por ejemplo, el bias de publicación). De hecho, y en contraste con los datos 
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anteriores y de creencias, Los pequeños estimaciones del tamaño indican además que (cambios en) las 
concentraciones séricas de BDNF son de poco uso clínico como, por ejemplo, marcador diagnóstico o 
tratamiento. 
      En el capítulo 6 esperaba que las concentraciones séricas de BDNF serían abnormalmente bajo en el 
estado de ansiedad. Los datos, sin embargo, no apoyó esta creencia. En los pacientes masculinos con un 
trastorno de ansiedad no había observada anormalidades en la concentración sérica de BDNF. Sin embargo, 
nos dimos cuenta de que en las mujeres con un trastorno de ansiedad encontramos concentraciones 
séricas de BDNF ligeramente bajo en comparación con las mujeres sanas. Por lo tanto, los datos de este 
capítulo dan fe en el creencia de que el BDNF no está implicado en la fisiopatología de los trastornos de 
ansiedad. Y, como he explicado (véase la discusión sobre la relación entre las concentraciones séricas de 
BDNF y estrógenos), las alteraciones en las pacientes femenina pueden ser fácilmente un artefacto 
específico de estar ansioso sin estar causalmente implicado en la etiología de la ansiedad. 
     Finalmente, el capítulo 7 atestigua el axioma predominante de que se ha adelantado en la explicación de 
las alternancias en la expresión de BDNF relacionados con la depresión: la exposición al trauma. 
     Claramente, resultados que muestran una falta de ajuste con las expectativas de la hipótesis de 
neurotrofina son omnipresentes en los estudios que componen esta tesis. Francamente, ninguna de las 
expectativas que se pueden derivar de este hipótesis se pudo validar plenamente. Y si nos reportamos 
hallazgos confirmatorias, su respectivo significado no siempre era tan clara (por ejemplo la causalidad 
inversa). Tal vez estos hallazgos no confirmatorias por no son suficiente para rechazar la hipótesis 
neurotrofina todavía sí misma, pero juntos significan en mi opinión que la idea inicial de la hipótesis de 
neurotrofina ya no debe ser acreditado. 
 
La hipótesis de neurotrofina: BDNF val66met 
Los capítulos 7 a 9 exploraron las asociaciones entre una variante en el gen que codifica para el BDNF, 
val66met, para los que funcionalidad se ha demostrado (in vitro e in vivo) en términos de apoyo 
neurotrófico. Pruebamos explícitamente la expectativa de que el met alelo, el llamado alelo de riesgo en 
este lugar, se relaciona con la depresión y fenotipos relatos. Una nota importante es que la exposición al 
trauma y el estrés se han tenido en cuenta en estos estudios con el fin de modelar las diferencias 
interindividuales debido a estos factores y su posible interacción con BDNF val66met. Sobre la base de la 
supuesta funcionalidad de este polimorfismo se esperaba que el met alelo estaría asociados con 
correlaciones establecidas de la depresión, particularmente cuando un persona también estaba expuesto al 
trauma y/o otras formas del estrés 
 
BDNF val66met - observaciones confirmatorias 
Un primer hallazgo confirmatorio (capítulo 7) fue un efecto de interacción entre val66met y trauma en las 
concentraciones séricas de BDNF. Este efecto fue tal que portadores de un met alelo habían 
concentraciones de BDNF reducido, pero sólo cuando se expone al eventos traumaticos. En contraste con 
las expectativas esto no tiene ningún efecto sobre el comportamiento. Por eso el grado en que este 
interaction es importante no se ha dilucidado. Además, portadores de un met alelo parecía tener 
volúmenes del hipocampo algo más bajos en relación con los homocigotos val/val (capítulo 8). Por último, 
la actividad del hipocampo durante la recuperación de estimulas negativas fue diferente en función de 
val66met y la exposición al trauma (capítulo 8). Estos observaciones pueden estar en línea con la 
expectativa de que el alelo met es un alelo de riesgo cuando se toman los fenotipos relacionados con la 
depresión como medido de resultado. 
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     Sin embargo, también en relación con val66met esta tesis reporta resultados que divergen de las 
predicciones de la hipótesis de las neurotrofina. Estas inconsistencias se detallan a continuación . 
 
BDNF val66met - observaciones no confirmatorias 
Los resultados que no estaban en consonancia con la creencia incluidos que val66met no era (directamente) 
asociado con psicopatología, funcionamiento cognitivo, las concentraciones séricas de BDNF, o los patrones 
de activación del hipocampo (capítulo 7 y 8). Además, da cuenta que las constelaciones de 
eventos/circunstancias que tuvieron un efecto sobre las concentraciones séricas de BDNF y la actividad de 
la codificación del hipocampo (el met alelo y la exposición al trauma) no se asociaron con resultados 
esperados a nivel conductual (capítulo 7 y 8). Finalmente, y tal vez más concluyente, capítulo 9 muestra 
que val66met no está asociado con el volumen del hipocampo. Este estudio es importante en general por 
que pone los efectos nocivos de los estudios de poca potencia y sobre-estimaciones de los tamaños del 
efecto. Por eso el papel puede ser relevante más allá del val66met literatura. Dados estos hallazgos no 




La confianza en una teoría aumenta cuando se confirma con datos pertinentes. Junto con algunos hallazgos 
consistentes, nuestros datos (y también la de los demás) muestran en gran falta de confirmación universal 
respecto a la hipótesis de la neurotrofina. Y dónde se establecieron asociaciones esperados (por ejemplo, 
concentraciones de BDNF abnormalmente bajo en el estado de depresión), el significado no era tan clara a 
menudo (por ejemplo, la causalidad inversa). Por lo tanto, llego a la conclusión, teniendo en cuenta las 
limitaciones y reconociendo que los resultados están supeditados a parámetros imperfecta, que la 
evidencia reciente y más confiable en humanos no corrobora la hipótesis neurotrofina y por eso ya no debe 
ser acreditado en su forma original - volver a la mesa de dibujo. 
 
El trabajo futuro - la mesa de dibujo 
En la mesa de dibujo se me ocurrió algunos objetivos importantes. El uno de estos con mayor importancia 
es profundizar la comprensión de cómo el funcionamiento neurotrófico puede ser modificada en el estado 
de depresión (es decir, la validez de constructo) y las consecuencias funcionales de este en la salud (es 
decir, la validez predictiva). Junto a esto, la dinámica temporal como se especifica en la hipótesis de 
neurotrofina (es decir, bajo apoyo BDNF → inicio de la depresión) deben ser atrapados, porque la 
causalidad invertido (es decir, depresión → apoyo bajo BDNF) en la que el apoyo bajo BDNF no marca el 
comienzo de un episodio depresivo, sino más bien una consecuencia ahora no se pueden excluir (es decir, 
la validez de constructo). Otros desafíos en el camino hacia progreso incluyen la colaboración en redes de 
intercambio de datos para resolver, con rigor, algunas cuestiones pendientes (es decir, de validez 
estadística), para medir más allá de los parámetros individuales de BDNF, para llevar la investigación 
preclínica y clínica más juntos, y, en paralelamente, para dejar atrás las categorías diagnósticas del DSM en 
el estudio de neurotrófico funcionamiento (es decir, validez de constructo). Cuando esto se puede 
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APPENDIX I  
Chapter 1 General introduction 








Figure S1. Overview of the breakthroughs in the research into the neurotrofin hypothesis 
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APPENDIX II  
Chapter 3 BDNF concentrations show strong seasonal variation and are correlated with the amount of ambient sunlight 
 
Table S1. P-values for pair-wise comparisons on covariate adjusted serum BDNF concentrations by month of sampling 
 Jan 
n = 249 
Feb 
n = 238 
Mar 
n = 239 
Apr 
n = 228 
May 
n = 229 
Jun 
n = 231 
Jul 
n = 203 
Aug 
n = 211 
Sep 
n = 280 
Oct  
n = 254 
Nov 
n = 292 
Dec 
n = 197 
Jan 1   .19   .01    ↑   .74   .26   .001  ↓   .003  ↓   .001*↓ <.001*↓   .004  ↓ <.001*↓   .003  ↓ 
Feb   .19 1   .21   .35   .02↓ <.001*↓ <.001*↓ <.001*↓ <.001*↓ <.001*↓ <.001*↓ <.001*↓ 
Mar   .01     ↓   .21 1   .03    ↓ <.001*↓ <.001*↓ <.001*↓ <.001*↓ <.001*↓ <.001*↓ <.001*↓ <.001*↓ 
Apr   .74   .35   .03     ↑ 1   .15 <.001*↓   .001  ↓ <.001*↓ <.001*↓   .001  ↓ <.001*↓   .002  ↓ 
May   .26   .02     ↑ <.001*↑   .15 1   .04     ↓   .06   .02     ↓   .001  ↓   .09   .006   ↓   .07 
Jun   .001  ↑ <.001*↑ <.001*↑ <.001*↑   .04    ↑ 1   .92   .78   .27   .69   .59   .87 
Jul   .003  ↑ <.001*↑ <.001*↑   .001  ↑   .06   .92 1   .72   .25   .78   .53   .94 
Aug   .001*↑ <.001*↑ <.001*↑ <.001*↑   .02    ↑   .78   .71 1   .44   .50   .81   .66 
Sep <.001*↑ <.001*↑ <.001*↑ <.001*↑   .001  ↑   .27   .25   .44 1   .12   .56   .22 
Oct    .004  ↑ <.001*↑ <.001*↑   .001  ↑   .09   .69   .78   .50   .12 1   .33   .84 
Nov <.001*↑ <.001*↑ <.001*↑ <.001*↑   .006  ↑   .59   .53   .82   .56   .33 1   .48 
Dec   .003  ↑ <.001*↑ <.001*↑   .002  ↑   .07   .87   .94   .66   .22   .84   .48 1 
* Statistically significant after Bonferroni correction was applied (66 comparisons, critical P value = .00076 ) 
↑ Higher serum BDNF levels in the month indicated in the row relative to the month indicated in the corresponding column 
↓ Lower serum BDNF levels in the month as indicated in the row relative to the month as indicated in the corresponding column 
 
Table S2. Zero-order and partial Pearson’s correlation coefficients with corresponding P-values on the associations between the number weekly 
sunlight hours and serum BDNF concentrations 
 Zero-order correlation P-value Partial correlation 1 P-value 
Number of sunlight hours in the:     
    Week of blood draw  0.03    .08  0.04    .03 
    Week prior to blood draw  0.03    .07  0.04    .04 
    Two weeks prior to blood draw  0.02    .11  0.04    .03 
    Three weeks prior to blood draw  0.04    .01  0.06    .001 
    Four weeks prior to blood draw  0.07 < .0001  0.09 < .0001 
    Five weeks prior to blood draw  0.12 < .0001  0.13 < .0001 
    Six weeks prior to blood draw  0.14 < .0001  0.15 < .0001 
    Seven weeks prior to blood draw  0.15 < .0001  0.16 < .0001 
    Eight weeks prior to blood draw  0.16 < .0001  0.18 < .0001 
    Nine weeks prior to blood draw  0.15 < .0001  0.16 < .0001 
    Ten weeks prior to blood draw  0.12 < .0001  0.13 < .0001 




Figure S1. Mean normalized serum 
BDNF concentrations plotted as a 
function of each consecutive week of 
































Figure S2. Partial Pearson’s correlation 
coefficients (for covariates see the paper) on 
the relation between mean serum BDNF 
concentrations and the hours of sunlight in 
the week of blood draw (wk-0) and the 10 
weeks prior to blood draw (wk-1 to wk-10).  





APPENDIX III  
Chapter 5 Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-
analyses on 179 associations (N = 9,484) 
 
 
Figure S1. Forest plot for random effect meta-analysis on differences in serum BDNF concentrations 
between antidepressant-free and antidepressant treated depressed patients. The sizes of the squares  
are proportional to sample size.     
 
 
Figure S2. Forest plot for random effect meta-analysis on differences in serum BDNF concentrations 
between antidepressant-free and treated depressed patients (within-subjects data only, that is  
treatment studies applying a pre- and post-treatment design). The sizes of the squares are  





Figure S3. Forest plot for random effect meta-analysis on differences in serum BDNF concentrations  
between healthy controls and antidepressant-treated depressed patients. The sizes of the squares  
are proportional to sample size.      
 
 
Figure S4. Forest plot for random effect meta-analysis on the continuous  
relation between serum BDNF concentrations in antidepressant-free  





Figure S5. Forest plot for random effect meta-analysis on the continuous  
relation between serum BDNF concentrations in antidepressant-treated  
depressed persons. The sizes of the squares are proportional to sample size.           
 
 
Figure S6. Forest plot for random effect meta-analysis on the continuous  
relation between serum BDNF concentrations in healthy control subjects.  
The sizes of the squares are proportional to sample size.                                                                                                                                            
 
 
Figure S7. Funnel plot and trim-and-fill estimation showing the typical pattern of publication bias in the meta-analyses on differences in 
serum BDNF concentrations among healthy controls and antidepressant-free depressed patients. White data points depict observed 
associations and black data points imputed values. The white diamond depicts the aggregated point estimate (d = -0.71, 95% CI = -0.89 ― - 
0.53, P < .00000001) and the black diamond the aggregated point estimate after the imputation of 10 studies (d = -0.47, 95% CI = -0.64―-
0.27, P < .000001), resulting in a symmetrical funnel-plot.                                                                                                                                                   
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Figure S8. Funnel plot and trim-and-fill estimation showing the typical pattern of publication bias in the meta-analyses on differences in 
BDNF concentrations among antidepressant-free and treated depressed patients. White data points depict observed associations and black 
data points imputed values. The white diamond depicts the aggregated point estimate (d = -0.56, 95% CI = -0.77 ― - 0.35, P < .000001) and 




Figure S9. Funnel plot and trim-and-fill estimation showing the typical pattern of publication bias in the meta-analyses on differences in 
serum BDNF concentrations in treatment studies that reported on serum BDNF concentrations. White data points depict observed 
associations and black data points imputed values. The white diamond depicts the aggregated point estimate (d = -0.74, 95% CI = -1.04 ― - 
0.45, P < .0000001) and the black diamond the aggregated point estimate after the imputation of 4 studies (d = -0.41, 95% CI = -0.76 ― - 0.06, 
P < .001), resulting in a symmetrical funnel-plot. 
 

















Funnel Plot of Standard Error by Std Paired Difference





















Figure S10. Funnel plot and trim-and-fill estimation showing the typical pattern of publication bias in the meta-analyses on the correlation 
between serum BDNF concentrations and the symptom severity of depression in antidepressant-free depressed patients. White data points 
depict observed associations and black data points imputed values. The white diamond depicts the aggregated point estimate (r = -0.19, 95% 
CI = -0.28 ― - 0.10, P < .00001) and the black diamond the aggregated point estimate after the imputation of 7 studies (r = -0.08, 95% CI = -




















































Funnel Plot of Standard Error by Fisher's Z
203 
 
APPENDIX IV  
Chapter 9 A systematic review and meta-analysis on the association between BDNF val
66
met and hippocampal volume – a genuine 






Table S1. Evaluation of the included records according to the Strenghtening the Reporting of Genetic Association Studies (Little et al., 2009) and 
Strenghtening Reporting of Observational Studies in Epidemiology (von Elme et al., 2007). 
 STREGA and STROBE quality checklist items 
Y; meets the criterion, N; does not meet the criterion, NA; not applicable 
 
Author, year  1  2  3 4 5 6 7 8 9 10 11 Overall quality score 
Pezawas et al., 2004 Y Y Y Y Y Y NA Y N NA Y  7 Y, 2 N, 2 NA  = 0.78 
Szeszko et al., 2005  Y Y Y Y Y Y Y Y Y Y Y 11 Y, 0 N, 0 NA = 1.00 
Agartz et al., 2006 Y Y Y Y Y Y NA N N Y Y  8 Y, 2 N, 1 NA  = 0.80 
Bueller et al., 2006             Y Y Y Y N Y N Y Y Y N  8 Y, 3 N, 0 NA  = 0.73 
Frodl et al., 2007              Y Y Y Y Y N NA Y Y Y N  8 Y, 2 N, 1 NA  = 0.80 
Miyajima et al., 2008 Y Y Y Y Y Y NA Y Y Y NA  9 Y, 0 N, 2 NA  = 1.00 
Takahashi et al., 2008 Y Y Y Y Y Y NA N Y Y NA  9 Y, 1 N, 2 NA  = 0.89 
Chepenik et al., 2009          Y Y Y Y Y Y Y Y Y Y Y 11 Y, 0 N, 0 NA = 1.00 
Dutt et al., 2009              Y Y Y Y Y Y NA N N Y NA  7 Y, 2 N, 2 NA  = 0.78 
Gatt et al., 2009              Y Y Y Y Y Y NA N N Y NA  7 Y, 2 N, 2 NA  = 0.78 
Jessen et al., 2009 Y N Y Y N Y NA N N Y NA  5 Y, 4 N, 2 NA  = 0.56 
Joffe et al., 2009             Y Y Y Y Y Y NA Y Y Y NA  9 Y, 0 N, 2 NA  = 1.00 
Schofield et al., 2009   Y N Y Y Y N NA Y Y Y NA  7 Y, 2 N, 2 NA  = 0.78 
Toro et al., 2009          Y Y Y Y Y Y NA Y Y Y NA  9 Y, 0 N, 2 NA  = 1.00 
Benjamin et al., 2010            Y N Y Y N Y NA N N Y NA  5 Y, 4 N, 2 NA  = 0.56 
Karnik et al., 2010            Y Y Y Y N Y N N Y Y N  7 Y, 4 N, 0 NA  = 0.64 
Koolschijn et al., 2010            Y Y Y Y Y Y NA Y Y Y NA  9 Y, 0 N, 2 NA  = 1.00 
Cole et al., 2011 Y Y Y Y Y Y NA Y Y Y NA  9 Y, 0 N, 2 NA  = 1.00 
Gerritsen et al., 2011           Y Y Y Y Y Y NA N Y Y NA  8 Y, 1 N, 2 NA  = 0.89 
Gonul et al., 2011             Y Y Y Y N Y NA Y Y Y NA  8 Y, 1 N, 2 NA  = 0.89 
Gruber et al., 2011             Y Y Y Y Y Y NA N Y Y NA  8 Y, 1 N, 2 NA  = 0.89 
Kanellopoulos et al., 2011            Y Y Y Y Y Y NA N Y Y NA 8 Y, 1 N, 2 NA   = 0.89 
Richter et al., 2011  Y Y Y Y Y Y NA Y Y Y NA 9 Y, 0 N, 2 NA   = 1.00 
Milan Sanchez et al., 2012 Y Y Y Y Y Y NA N Y Y NA 8 Y, 1 N, 2 NA   = 0.89 
Molendijk  et al., 2012  Y Y Y Y Y Y NA Y Y Y NA 9 Y, 0 N, 2 NA   = 1.00 
Criteria were assessed independently by 2 of the authors. Inconsistencies were evaluated in consensus meetings. Agreement among the raters proved to be 
excellent with Cohen’s Kappa = 0.83, standard error = 0.04. Please contact the corresponding author for information about the actual reason for scoring a yes, a no, 
or a not applicable 
 
STREGA (Little et al., 2009) and STROBE (von Elme et al., 2007) criteria: (1) Clear statement of the objectives and the hypothesis (2) Clear eligibility criteria for study 
participants (3) Clear definition of all variables (4) Replicability of Statistical methods (5) Assessment of Hardy-Weinberg equilibrium (6) Assessment of ethnicity (7) 
Addressing the problem of mixed ethnicities (8) Sufficient descriptive data (9) Statement of genotype frequencies (10) Sample in Hardy-Weinberg equilibrium (11) 





Chapter 10 General discussion: The poll 
 
Two know more than one: a poll 
The conventional option to prove association is observation and experimentation. However, and notwithstanding the fact that 
some experiments have been performed on the relation between peripheral and central BDNF functioning, the literature on this 
topic appears confusing to me. Therefore, I chose to run a poll among experts/researchers from around the world.  
     Through PUBMED I identified the 50 most recently published papers that had BDNF and depression in their title (regardless 
whether it were studies on humans, rats,). From each paper I extracted the email address of the corresponding author and I wrote 
an email to him/her. I asked the following question: What do you think, how relevant are serum BDNF concentrations with regard 
to (human) depression? I prompted them to give a short answer by adding answer options: (A) relevant, will add to our knowledge 
on depression, (B) irrelevant, (C) don’t know yet, but the future probably will tell or (D) I do not believe in a biological basis of 
depression whatsoever. I added that a short explanation could be given but that this was not necessary for my current concerns. 
While doing this I reckoned that a poll like this could yield biased results because all the persons work on the topic and therefore 
their responses could well be overly positive. To overcome this at least a little I set out a second poll. I identified the 50 most 
recently published papers that had cognitive- or interpersonal theory and depression in their title (again regardless their exact 
topic). I asked the corresponding authors of these papers the same question as I asked the BDNF oriented authors and I provided 
them with the same answer categories. A full version of the e-mail and the list of authors that was contacted can be found below. 
     Seventy-two percent (n = 36) of the BDNF oriented researchers and 48 percent (n = 24) of the cognitive/interpersonal-oriented 
researchers responded to my request. This difference in response rate was statistically significant (χ
2
1 = 6.01, P = 0.01). Of the BDNF 
oriented authors who responded, 56 percent (n = 26) agreed with the proposition that peripheral BDNF concentrations are relevant 
parameters for depression, 6 percent (n = 3) disagreed, and 36 percent (n = 13) suggested that for now there is too little knowledge 
on the topic to come to conclusions. The interpersonal/cognitive-oriented authors who responded to the poll were somewhat 
more pessimistic. In this group, 25 percent (n = 6) agreed with the proposition, 25 percent (n = 6) disagreed and 50 percent (n = 12) 
suggested that the future probably would inform us. The pattern of responses between the two groups of authors differed 
significantly (χ
2
2 = 6.44, P = 0.04) such that more of the BDNF oriented authors agreed with the proposition that peripheral BDNF 
concentrations are relevant parameters for depression. The response frequencies of both polls are provided in the Table ↓. 
 
Table. Results from the poll by research orientation 
 Biologically oriented colleagues  Cognitive oriented colleagues  
 n = 50 % n 1 % responders 2 n = 50 % n 1 % responders 2 
A - agree 20 40% 56%    6 12% 25% 
B - disagree   3   6%    9%    6 12% 25% 
C - future will tell 13 26% 36% 12 24% 50% 
D - non-believer   0    0%    0%    0    0%    0% 
No response 14 28%    NA  26 52%    NA 
Abbreviations: NA; Not Applicable 
1
 Percentage of the n = 50 to which I send out the poll 
2 Percentage of the persons that actually responded on the poll  
 
     The main lesson to learn from this poll is that the large majority of researchers either agrees (43 percent) with the proposition 
that serum BDNF concentrations are relevant with regard to depression or expresses the belief that the future will inform us on this 
issue (42 percent). Only 15 percent explicitly disagrees with the notion that serum BDNF concentrations are relevant with regard to 
205 
 
depression. In this sense, the poll was helpful in that most authors see either relevance in the use of serum BDNF concentrations as 
parameters for depression or suggests that more research will bring definite answers. Tentatively, this strengthens the belief that 
serum BDNF concentrations are relevant with regard to depression – but again, a systematic exploration would suit the question 
better and therefore is be very welcome.  
 
The e-mail that was sent out  
 
Topic: Question: BDNF in the periphery, how relevant is that for central processes? 
 
Dear Dr. name corresponding author, dear colleague, 
 
I have a question for you. I’m writing my PhD thesis on serum BDNF concentrations – a topic related to your research interests (attached you can 
find one of our papers on serum BDNF levels in depressed persons). I’m in the middle of wrapping it all together and writing the final thesis 
discussion. Already for a while I noticed debate in the literature on the use of peripheral BDNF levels as a reliable mirror of neurotrophic functioning 
in the central nervous system. For my thesis discussion I wanted to know how other scientists, who work in related fields [but not necessarily the 
exact same], think about this issue. So, I decided to send out a poll to the corresponding authors of the 50 most recent papers that have BDNF in 
their title (regardless the precise topic) to learn about the opinion of the authors on this topic. You happen to be in that group with your paper in 
the Journal in which the paper is published. 
 
My question to you is: What do you think, how relevant are serum BDNF concentrations with regard to (human) depression?  
 
The corresponding letter A, B, C, or D is enough for me as response  
A ‘Relevant, will ad to our knowledge on depression and neuronal plasticity in the brain’ 
B ‘Irrelevant, won’t add a lot to our knowledge on depression and neuronal plasticity in the brain’ 
C ‘Don’t know, maybe the future will tell’  
D ‘I do not believe in a biological basis of depression whatsoever’ 
 
You can add a short explanation if you wish. I’m interested in that but it is not necessary for my current purpose.   
 




Note. Attached you can find one of our papers on serum BDNF concentrations in depressed persons that has been published in Molecular 
Psychiatry. 
 
Authors in the poll -- authors who responded are underlined 
 
BDNF oriented authors 
C Duarte (Portugal), M Miquel (Spain), K Felmingham (New Zealand), K Iqbal (USA), H Scharfman (USA), D Jon (Korea), M Fawzi (Egypt), M Shamsul 
Ola (Saudi Arabia), S Vivekanandhan (India), G Morton (USA), X Zhang (China), F Lotrich (USA), N Perroud (Switzerland), L Ricceri (Italy), J Luykx (the 
Netherlands), R Ting-A-Kee (Canada), G Hasler (Switzerland), R Rodríguez-López (Spain), E Ottem (USA), L-M Wu (China), N Mechawar (Canada), K 
Ressler (USA), X Xiayixiayi (China), M Soleimani (Iran), S Cramer (USA), D Carlino (Italy), D Srivastava (UK), J-M Kim (Korea), G Réus (Brazil), T 
Sakharnova (Russia), E McNay (USA), Y Hung (Taiwan), J Charoenphandhu (Thailand), K Kauppi (Sweden), D Carbone (USA), M Gilbert (USA), D Ron 
(USA), M Dmitrzak-Weglarz (Poland), J Yang (USA), W Umene-Nakano (Japan), S Miller (USA), J-H Chae (Korea), V Stelzhammer (UK), Z-Y Chen 
(China), F Fumagalli (Italy), R Dalle Molle (Brazil), N Cardoner (Spain), T Endres (Germany), C Ernst (Canada), Y Tizabi (USA), E Tongiorgi, (Italy).  
 
Cognitive/inter-personal oriented authors 
P Pössel (USA), F Jollant (Canada), J Johnstone (New Zealand), Melitta Fischer-Kern (UK), P Thoma (Germany), M Constantino (USA), H O’Mahen 
(UK), M van Hees (the Netherlands), J Ogrodniczuk (Canada), M Hochberg (USA), R Auerbach (USA), S Winkeljohn Black (USA), E Sheets (USA), F 
Peters (the Netherlands), M Flynn (USA), K Mclaughln (USA), N Wongpakaran (Thailand), B D'Antono (Canada), J Ehrenreich-May (USA), M 
Constantino (USA), G Stein (USA), A Forsman (Finland), M Power (Scotland), F Renner (the Netherlands), J Stewart (Canada), T Kühnen (Germany), T 
Berger (Switserland), J Jakobsen (Danmark), J McCullough (USA), G Tasca (Canada), L Hides (Australia), L Lemmens (the Netherlands), J Goodman 
(USA), M Serfaty (UK), F Doyle (Ireland), M McKinnon (Canada), L Sockol (USA), S Rueger (USA), D Klein (USA), L Rood (the Netherlands), L 
Wolkenstein (Germany), K Iverson (USA), G Pomaki (Canada), R Trivedi (USA), Pauline Slade (UK), H Teunissen (the Netherlands), C Beevers (USA), S 
Hollon (USA), E Schramm (Germany), D Dozois (Canada).   
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